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A B S T R A C T
Background
Psoriasis is an immune-mediated disease for which some people have a genetic predisposition. The condition manifests in inflammatory
effects on either the skin or joints, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis,
various treatment strategies allow sustained control of disease signs and symptoms. Several randomised controlled trials (RCTs) have
compared the efficacy of the different systemic treatments in psoriasis against placebo. However, the relative benefit of these treatments
remains unclear due to the limited number of trials comparing them directly head to head, which is why we chose to conduct a network
meta-analysis.
Objectives
To compare the efficacy and safety of conventional systemic agents (acitretin, ciclosporin, fumaric acid esters, methotrexate), small
molecules (apremilast, tofacitinib, ponesimod), anti-TNF alpha (etanercept, infliximab, adalimumab, certolizumab), anti-IL12/23
(ustekinumab), anti-IL17 (secukinumab, ixekizumab, brodalumab), anti-IL23 (guselkumab, tildrakizumab), and other biologics (ale-
facept, itolizumab) for patients with moderate to severe psoriasis and to provide a ranking of these treatments according to their efficacy
and safety.
Search methods
We searched the following databases to December 2016: the Cochrane Skin Specialised Register, the Cochrane Central Register of
Controlled Trials (CENTRAL), MEDLINE, Embase, and LILACS. We also searched five trials registers and the U.S. Food and Drug
Administration (FDA) and European Medicines Agency (EMA) reports. We checked the reference lists of included and excluded
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studies for further references to relevant RCTs. We searched the trial results databases of a number of pharmaceutical companies and
handsearched the conference proceedings of a number of dermatology meetings.
Selection criteria
Randomised controlled trials (RCTs) of systemic and biological treatments in adults (over 18 years of age) withmoderate to severe plaque
psoriasis or psoriatic arthritis whose skin had been clinically diagnosed with moderate to severe psoriasis, at any stage of treatment, in
comparison to placebo or another active agent.
Data collection and analysis
Three groups of two review authors independently undertook study selection, data extraction, ’Risk of bias’ assessment, and analyses.
We synthesised the data using pair-wise and network meta-analysis (NMA) to compare the treatments of interest and rank them
according to their effectiveness (as measured by the Psoriasis Area and Severity Index score (PASI) 90) and acceptability (the inverse
of serious adverse effects). We assessed the certainty of the body of evidence from the NMA for the two primary outcomes, according
to GRADE; we evaluated evidence as either very low, low, moderate, or high. We contacted study authors when data were unclear or
missing.
Main results
We included 109 studies in our review (39,882 randomised participants, 68% men, all recruited from a hospital). The overall average
age was 44 years; the overall mean PASI score at baseline was 20 (range: 9.5 to 39). Most of these studies were placebo controlled (67%),
23% were head-to-head studies, and 10% were multi-armed studies with both an active comparator and placebo. We have assessed all
treatments listed in the objectives (19 in total). In all, 86 trials were multicentric trials (two to 231 centres). All of the trials included
in this review were limited to the induction phase (assessment at less than 24 weeks after randomisation); in fact, all trials included in
the network meta-analysis were measured between 12 and 16 weeks after randomisation. We assessed the majority of studies (48/109)
as being at high risk of bias; 38 were assessed as at an unclear risk, and 23, low risk.
Network meta-analysis at class level showed that all of the interventions (conventional systemic agents, small molecules, and biological
treatments) were significantly more effective than placebo in terms of reaching PASI 90.
In terms of reaching PASI 90, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly more
effective than the small molecules and the conventional systemic agents. Small molecules were associated with a higher chance of
reaching PASI 90 compared to conventional systemic agents.
At drug level, in terms of reaching PASI 90, all of the anti-IL17 agents and guselkumab (an anti-IL23 drug) were significantly more
effective than the anti-TNF alpha agents infliximab, adalimumab, and etanercept, but not certolizumab. Ustekinumab was superior
to etanercept. No clear difference was shown between infliximab, adalimumab, and etanercept. Only one trial assessed the efficacy of
infliximab in this network; thus, these results have to be interpreted with caution. Tofacitinib was significantly superior to methotrexate,
and no clear difference was shown between any of the other small molecules versus conventional treatments.
Network meta-analysis also showed that ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab, and ustekinumab out-
performed other drugs when compared to placebo in terms of reaching PASI 90: the most effective drug was ixekizumab (risk ratio
(RR) 32.45, 95% confidence interval (CI) 23.61 to 44.60; Surface Under the Cumulative Ranking (SUCRA) = 94.3; high-certainty
evidence), followed by secukinumab (RR 26.55, 95% CI 20.32 to 34.69; SUCRA = 86.5; high-certainty evidence), brodalumab (RR
25.45, 95% CI 18.74 to 34.57; SUCRA = 84.3; moderate-certainty evidence), guselkumab (RR 21.03, 95% CI 14.56 to 30.38;
SUCRA = 77; moderate-certainty evidence), certolizumab (RR 24.58, 95% CI 3.46 to 174.73; SUCRA = 75.7; moderate-certainty
evidence), and ustekinumab (RR 19.91, 95% CI 15.11 to 26.23; SUCRA = 72.6; high-certainty evidence).
We found no significant difference between all of the interventions and the placebo regarding the risk of serious adverse effects (SAEs):
the relative ranking strongly suggested that methotrexate was associated with the best safety profile regarding all of the SAEs (RR 0.23,
95% CI 0.05 to 0.99; SUCRA = 90.7; moderate-certainty evidence), followed by ciclosporin (RR 0.23, 95% CI 0.01 to 5.10; SUCRA
= 78.2; very low-certainty evidence), certolizumab (RR 0.49, 95% CI 0.10 to 2.36; SUCRA = 70.9; moderate-certainty evidence),
infliximab (RR 0.56, 95% CI 0.10 to 3.00; SUCRA = 64.4; very low-certainty evidence), alefacept (RR 0.72, 95% CI 0.34 to 1.55;
SUCRA = 62.6; low-certainty evidence), and fumaric acid esters (RR 0.77, 95% CI 0.30 to 1.99; SUCRA = 57.7; very low-certainty
evidence). Major adverse cardiac events, serious infections, or malignancies were reported in both the placebo and intervention groups.
Nevertheless, the SAEs analyses were based on a very low number of events with low to very low certainty for just over half of the
treatment estimates in total, moderate for the others. Thus, the results have to be considered with caution.
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Considering both efficacy (PASI 90 outcome) and acceptability (SAEs outcome), highly effective treatments also had more SAEs
compared to the other treatments, and ustekinumab, infliximab, and certolizumab appeared to have the better trade-off between efficacy
and acceptability.
Regarding the other efficacy outcomes, PASI 75 and Physician Global Assessment (PGA) 0/1, the results were very similar to the results
for PASI 90.
Information on quality of life was often poorly reported and was absent for a third of the interventions.
Authors’ conclusions
Our review shows that compared to placebo, the biologics ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab, and
ustekinumab are the best choices for achieving PASI 90 in people with moderate to severe psoriasis on the basis of moderate- to high-
certainty evidence. At class level, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly
more effective than the small molecules and the conventional systemic agents, too. This NMA evidence is limited to induction therapy
(outcomes were measured between 12 to 16 weeks after randomisation) and is not sufficiently relevant for a chronic disease. Moreover,
low numbers of studies were found for some of the interventions, and the young age (mean age of 44 years) and high level of disease
severity (PASI 20 at baseline) may not be typical of patients seen in daily clinical practice.
Another major concern is that short-term trials provide scanty and sometimes poorly reported safety data and thus do not provide
useful evidence to create a reliable risk profile of treatments. Indeed, we found no significant difference in the assessed interventions
and placebo in terms of SAEs. Methotrexate appeared to have the best safety profile, but as the evidence was of very low to moderate
quality, we cannot be sure of the ranking. In order to provide long-term information on the safety of the treatments included in this
review, it will be necessary to evaluate non-randomised studies and postmarketing reports released from regulatory agencies as well.
In terms of future research, randomised trials comparing directly active agents are necessary once high-quality evidence of benefit against
placebo is established, including head-to-head trials amongst and between conventional systemic and small molecules, and between
biological agents (anti-IL17 versus anti-IL23, anti-IL23 versus anti-IL12/23, anti-TNF alpha versus anti-IL12/23). Future trials should
also undertake systematic subgroup analyses (e.g. assessing biological-naïve patients, baseline psoriasis severity, presence of psoriatic
arthritis, etc.). Finally, outcome measure harmonisation is needed in psoriasis trials, and researchers should look at the medium- and
long-term benefit and safety of the interventions and the comparative safety of different agents.
P L A I N L A N G U A G E S U M M A R Y
Systemic (oral or injected) medicines for psoriasis
What is the aim of this review?
The aim of this review was to compare different systemic medicines (oral or injected medicines that work throughout the entire body)
used to treat chronic plaque psoriasis in adults (over 18 years of age), to find out which are the safest and most effective at clearing
psoriasis. We wanted to rank the medicines in order of their safety and how well they work, to help the development of a treatment
pathway for people with chronic plaque psoriasis. We collected and analysed all relevant studies to answer this question and found 109
studies.
Key messages
The results showed that a selection of treatments from the class of biological medicines appear to be themost effective systemicmedicines
for achieving a chronic plaque psoriasis score of PASI (Psoriasis Area and Severity Index) 90, which translates into a 90% improvement
in psoriasis from the beginning of the study. We found no significant difference in serious adverse effects (SAEs) (i.e. serious side effects)
when comparing any of the assessed treatments with placebo. However, as the evidence was of very low to moderate quality, we cannot
be sure of these results.
For some of the interventions, we found low numbers of studies, so more research needs to be conducted to directly compare the
systemic medicines with each other, rather than comparing them with placebo (an inactive substance) (once effect against placebo has
been established by high-quality evidence). In addition, longer-term studies are needed to provide more evidence about the benefit
and safety of systemic medicines and to compare their safety profiles. Indeed, the results of this review are limited to the induction
treatment (i.e. outcomes were measured up to 24 weeks after participants were allocated to their treatment group), which is not an
appropriate treatment option for a chronic disease.
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We rated the certainty of the evidence as ranging from very low (mainly conventional medicines) to high (mainly biological medicines).
We downgraded the certainty of the evidence due to risk of bias (concerns with the study methods) and then for either inconsistent
results or imprecision (inaccuracy).
What was studied in the review?
Psoriasis is characterised by patches of red, flaky skin covered with scales (known as plaques) or other inflammatory effects that are seen
on the skin or joints, or both. Psoriasis is caused by an abnormal response within the immune system in people who may have a genetic
predisposition towards the condition.
Approximately 2% of the population have psoriasis, and 90% of those people have plaque psoriasis. Around 10% to 20% of people
with chronic plaque psoriasis will need to have systemic treatments. Psoriasis impacts on quality of life, including a person’s psychosocial
life.
We compared 19 systemic medicines by identifying studies that compared one or more of these medicines with either placebo or with
another medicine to treat moderate to severe forms of plaque psoriasis in adults who were at any stage of treatment. The medicines
we assessed were conventional systemic treatments (a varied group of treatments that are the oldest treatments given to clear psoriasis),
biologics (treatments that use substances made from living organisms, or synthetic versions, to target the immune system), and small
molecules (which affect molecules inside immune cells). We included studies whose participants may also have had psoriatic arthritis.
The main outcomes we were interested in were achievement of PASI 90 and any serious side effects that were thought to be associated
with the medicines.
We combined all of the studies to allow indirect analysis of the treatments, so we could compare them with each other (network meta-
analysis).
What are the main results of the review?
The 109 studies enrolled 39,882 people (all recruited from a hospital) with moderate to severe psoriasis: 26,902 men and 12,384
women; the overall average age was 44 years, the overall mean PASI score at the start of the study was 20 (range: 9.5 to 39), indicating
a high level of disease severity. Most studies (n = 73) compared the systemic medicine with a placebo treatment, a total of 25 trials
compared systemic treatments with other systemic treatments, and 11 trials compared systemic treatments with systemic treatments
and placebo. Most studies were short-term, and in all, 86 trials were multicentric trials (two to 231 centres).
The outcomes presented here were measured 12 to 16 weeks after the study participants were randomised.
The results showed that compared with placebo, all treatments (assessed in the following groupings: anti-IL17, anti-IL12/23, anti-
IL23, and anti-TNF alpha (i.e. the treatments known as the biologics); small molecule treatments; other biologics; and conventional
systemic agents) were more effective in treating psoriasis when assessed using an index that required 90% improvement (PASI 90).
In relation to the same outcome (PASI 90), the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha appeared to
work better than the small molecules and the conventional systemic agents; and small molecules were associated with a better outcome
compared to conventional systemic agents. (IL is an abbreviation of interleukin; TNF is an abbreviation of tumour necrosis factor -
both are types of cytokine. A cytokine affects the behaviour of a cell.)
In terms of individual drugs, again when assessing the ability to reach PASI 90, all of the anti-IL17 drugs and guselkumab (an anti-IL23
drug) were more effective than the anti-TNF alpha drugs infliximab, adalimumab, and etanercept, but not certolizumab. Ustekinumab
(an IL-12/-23 drug) was better than etanercept. No clear difference was shown between infliximab, adalimumab, and etanercept.
Tofacitinib (a small molecule) was superior to methotrexate (a conventional systemic agent), and no difference was shown between the
other small molecules and the conventional drugs.
Judged against placebo, six biological medicines worked best at clearing psoriasis lesions. These medicines were ranked as follows (most
effective first): ixekizumab, secukinumab (both based on high-certainty evidence), brodalumab, guselkumab, certolizumab (all based
on moderate-certainty evidence), and ustekinumab (high-certainty evidence). Regarding the outcomes PASI 75 and Physician Global
Assessment (PGA) 0/1 (i.e. achieving 75% improvement and achieving a PGA score of 0 or 1), the results were very similar to the
results for PASI 90.
For the risk of serious side effects, there were no clear differences between all of the systemic medicines compared with placebo treatment.
Methotrexate had the best safety profile (based on moderate-certainty evidence), followed by ciclosporin (very low-certainty evidence),
certolizumab (moderate-certainty evidence), infliximab (very low-certainty evidence), alefacept (low-certainty evidence), and fumaric
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acid esters (very low-certainty evidence) (all of these are conventional treatments except for certolizumab, infliximab (anti-TNF alpha
drugs), and alefacept (classed under ’other biologics’). Major adverse cardiac events, serious infections, or malignancies were reported
in both placebo and intervention groups. However, the number of serious side effects was very low, and our conclusions are based on
low to very low- (for just over half of the results) or moderate-certainty evidence, so they should be interpreted with caution. The most
effective treatments (in terms of reaching PASI 90) had the highest numbers of reported side effects; ustekinumab, infliximab, and
certolizumab appeared to have the best compromise between effectiveness and side effects.
For all studies, little information was recorded about quality of life; one third of the medicines studied had no quality of life data.
How up-to-date is this review?
We searched for studies that had been published up to December 2016.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Any systemic treatment compared to placebo for chronic plaque psoriasis (network meta-analysis)
Patient or population: people with chronic plaque psoriasis
Intervention: any systemic treatment
Comparison: placebo
Setting: all the part icipants were recruited f rom a hospital sett ing
Timescale: 12 to 16 weeks af ter randomisat ion
Intervention Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
SUCRA of participants
(studies)b
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placeboa Risk with any sys-
temic treatment
PASI 90
Ixekizumab Moderate RR 32.45
(23.61 to 44.60)
94.3 3268
(4 RCTs)
⊕⊕⊕⊕
High
-
15 per 1000 487 per 1000
(354 to 669)
Secukinumab Moderate RR 26.55
(20.32 to 34.69)
86.5 2707
(7 RCTs)
⊕⊕⊕⊕
High
-
15 per 1000 398 per 1000
(305 to 520)
Brodalumab Moderate RR 25.45
(18.74 to 34.57)
84.3 4109
(5 RCTs)
⊕⊕⊕©
Moderate
Reasons for downgrad-
ing by one level: three
studies contribut ing to
this est imate at high risk
of bias in select ive re-
port ing domain
15 per 1000 382 per 1000
(281 to 520)
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Guselkumab Moderate RR 21.03
(14.56 to 30.38)
77 1502
(3 RCTs)
⊕⊕⊕©
Moderate
Reasons for downgrad-
ing by one level: one
study contribut ing to this
est imate at high risk of
bias in select ive report-
ing domain
15 per 1000 315 per 1000
(218 to 456)
Certolizumab Moderate RR 24.58
(3.46 to 174.73)
75.7 176
(1 RCT)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision: wide
CIs15 per 1000 369 per 1000
(52 to 1000)
Ustekinumab Moderate RR 19.91
(15.11 to 26.23)
72.6 3832
(7 RCTs)
⊕⊕⊕⊕
High
-
15 per 1000 299 per 1000
(227 to 393)
Tildrakizumab Moderate RR 15.63
(2.22 to 110.07)
63.6 355
(1 RCT)
⊕⊕©©
Low
Downgraded one level
due to risk of bias and
one level due to impre-
cision. The single study
contribut ing to this est i-
mate at unclear risk of
bias in both blinding do-
mains; wide CIs
15 per 1000 234 per 1000
(33 to 1000)
Adalimumab Moderate RR 14.87
(10.45 to 21.14)
63.1 3199
(8 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to inconsistency - in-
consistent loops of evi-
dence
15 per 1000 223 per 1000
(157 to 317)
Itolizumab Moderate RR 12.26
(0.76 to 198.53)
56 225
(1 RCT)
⊕⊕©©
Low
Downgraded one level
due to imprecision (wide
CIs) and one level due
to risk of bias (moderate
risk using credibility of
evidence)
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15 per 1000 184 per 1000
(12 to 1000)
Inf liximab Moderate RR 11.18
(5.67 to 22.04)
53.2 (0 RCTs) ⊕©©©
Very low
Downgraded one level
due to risk of bias (cred-
ibility of risk), one level
due to imprecision (wide
CIs) and one level due to
inconsistency (inconsis-
tent loop of evidence)
15 per 1000 168 per 1000
(85 to 331)
Etanercept Moderate RR 10.79
(8.47 to 13.73)
52.6 4954
(12 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to inconsistency
(global inconsistency -
side-split t ing approach)
15 per 1000 162 per 1000
(127 to 206)
Tofacit inib Moderate RR 8.50
(6.23 to 11.60)
42.5 2826
(4 RCTs)
⊕⊕©©
Low
Downgraded one level
due to risk of bias:
two studies at high risk
of bias in incomplete
outcome data domain;
and downgraded one
level due to inconsis-
tency (global approach)
15 per 1000 128 per 1 000
(93 to 174)
Apremilast Moderate RR 7.66
(4.30 to 13.66)
39.7 1775
(4 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to risk of bias: one
study had a slight risk of
bias in select ive report-
ing domain
15 per 1000 115 per 1000
(65 to 205)
Ponesimod Moderate RR 6.60
(1.63 to 26.67)
37.3 326
(1 RCT)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision: wide
CIs15 per 1000 99 per 1000
(24 to 400)
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Alefacept Moderate RR 4.39
(1.38 to 13.94)
25.3 (0 RCTs) ⊕©©©
Very low
Downgraded two levels
due to risk of bias and a
further one level due to
imprecision - study indi-
rect ly contribut ing to the
est imates at high risk of
bias in select ive report-
ing domain; wide CIs
15 per 1000 66 per 1000
(21 to 209)
Fumaric acid esters
(FAEs)
Moderate RR 4.09
(1.88 to 8.88)
21.9 704
(1 RCT)
⊕©©©
Very low
Downgraded two levels
due to risk of bias, and
one level due to impre-
cision - the studies in-
direct ly contribut ing to
this est imate at high risk
of bias in blinding do-
main; wide CIs
15 per 1000 61 per 1000
(28 to 133)
Ciclosporin Moderate RR 3.99
(1.81 to 8.78)
21.3 (0 RCTs) ⊕©©©
Very low
Downgraded two levels
due to risk of bias, and
a further one level due
to imprecision - the sin-
gle study indirect ly con-
tribut ing to this est imate
at high risk of bias in
blinding; wide CIs
15 per 1000 60 per 1000
(27 to 132)
Methotrexate Moderate RR 3.61
(2.01 to 6.48)
20.2 282
(2 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to inconsistency (in-
consistent loop of evi-
dence)
15 per 1000 59 per 1000
(32 to 106)
Acitret in Moderate RR 0.98
(0.06 to 17.24)
9.9 (0 RCTs) ⊕©©©
Very low
Downgraded two levels
due to risk of bias and a
further one level due to
imprecision. The single
study contribut ing to this
est imate at high risk of
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bias in incomplete out-
come data and blinding
domains; wide CIs
15 per 1000 15 per 1000
(1 to 259)
Serious adverse events
Methotrexate Moderate RR 0.23
(0.05 to 0.99)
90.7 282
(2 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision (wide
CIs)17 per 1000 4 per 1000
(1 to 17)
Ciclosporin Moderate RR 0.23
(0.01 to 5.10)
78.2 (0 RCTs) ⊕©©©
Very low
Downgraded two levels
due to risk of bias (cred-
ibility of evidence), and
one level due to impreci-
sion (wide CIs)
17 per 1000 4 per 1000
(0 to 87)
Certolizumab Moderate RR 0.49
(0.10 to 2.36)
70.9 176
(1 RCT)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision (wide
CIs)17 per 1000 8 per 1000
(2 to 40)
Inf liximab Moderate RR 0.56
(0.10 to 3.00)
64.4 (0 RCTs) ⊕©©©
Very low
Downgraded two levels
due to risk of bias, and
one level due to impre-
cision: credibility of evi-
dence; wide CIs
17 per 1000 10 per 1000
(2 to 51)
Alefacept Moderate RR 0.72
(0.34 to 1.55)
62.6 736
(2 RCTs)
⊕⊕©©
Low
Downgraded one level
due to risk of bias (cred-
ibility of evidence), and
one level due to impreci-
sion (wide CIs)
17 per 1000 12 per 1000
(6 to 26)
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Fumaric acid esters
(FAEs)
Moderate RR 0.77
(0.30 to 2.00)
57.7 704
(1 RCT)
⊕©©©
Very low
Downgraded by one level
due to risk of bias and
one level due to impre-
cision: credibility of evi-
dence; wide CIs
17 per 1000 13 per 1000
(5 to 34)
Apremilast Moderate RR 0.84
(0.47 to 1.51)
54.7 2036
(5 RCTs)
⊕⊕©©
Low
Downgraded one level
due to risk of bias and
one level due to impre-
cision: credibility of evi-
dence and wide CIs
17 per 1000 14 per 1000
(8 to 26)
Ustekinumab Moderate RR 0.89
(0.57 to 1.39)
52 4154
(8 RCTs)
⊕⊕©©
Low
Downgraded one level
due to risk of bias and
one level due to impre-
cision - credibility of evi-
dence; wide CIs
17 per 1000 15 per 1000
(10 to 24)
Acitret in Moderate RR 0.99
(0.02 to 49.37)
46.9 (0 RCTs) ⊕©©©
Very low
Downgraded by two lev-
els due to risk of bias and
one level due to impre-
cision: credibility of evi-
dence; wide CIs
17 per 1000 17 per 1000
(0 to 839)
Tofacit inib Moderate RR 0.98
(0.55 to 1.76)
44 2838
(5 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision (wide
CIs)17 per 1000 17 per 1000
(9 to 30)
Etanercept Moderate RR 0.99
(0.65 to 1.51)
43.6 3783
(11 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision (CIs
including one)17 per 1000 17 per 1000
(11 to 26)
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Guselkumab Moderate RR 1.00
(0.49 to 2.04)
42.6 1502
(3 RCTs)
⊕⊕©©
Low
Downgraded one level
due to risk of bias (cred-
ibility of evidence), and
one level due to impreci-
sion (CIs including one)
15 per 1000 15 per 1000
(7 to 31)
Adalimumab Moderate RR 1.02
(0.61 to 1.73)
40.4 3199
(8 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision (CIs
including one)18 per 1000 19 per 1000
(11 to 31)
Brodalumab Moderate RR 1.04
(0.62 to 1.73)
39.8 4109
(5 RCTs)
⊕⊕©©
Low
Downgraded one level
due to risk of bias (cred-
ibility of evidence) and
one level due to impreci-
sion (CIs including 1)
17 per 1000 18 per 1000
(11 to 30)
Tildrakizumab Moderate RR 1.36
(0.07 to 24.94)
37.8 355
(1 RCT)
⊕⊕©©
Low
Downgraded one level
due to risk of bias (cred-
ibility of evidence) and
one level due to impreci-
sion (CIs including 1)
0 per 1000 0 per 1000
(0 to 0)
Ixekizumab Moderate RR 1.12
(0.66 to 1.90)
33.7 3268
(4 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision (CIs
including one)15 per 1000 16 per 1000
(10 to 28)
Secukinumab Moderate RR 1.19
(0.69 to 2.03)
29.9 2707
(7 RCTs)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision (CIs
including one)10 per 1000 12 per 1000
(7 to 20)
Ponesimod Moderate RR 2.59
(0.34 to 19.85)
18.1 326
(1 RCT)
⊕⊕⊕©
Moderate
Downgraded one level
due to imprecision (CIs
including one)
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15 per 1000 39 per 1000
(5 to 296)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; PASIc: Psoriasis Area and Severity Index; RR: risk rat io; SUCRAd : Surface Under the Cumulat ive Ranking
GRADE Working Group grades of evidence
High certainty/quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty/quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that
it is substant ially dif f erent
Low certainty/quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty/quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
a ’Risk with placebo’ is the median placebo-group risk value in the included studies for the assumed risk with placebo.
b ’Number of studies (part icipants)’ is f rom the direct comparisons.
c The Psoriasis Area and Severity Index combines the assessment of the severity of lesions and the area af fected into a single
score in the range of 0 (no disease) to 72 (maximal disease); PASI 90: 90% improvement in the PASI.
d SUCRA was expressed as a percentage between 0 (when a treatment is certain to be the worst) to 100% (when a treatment
is certain to be the best).
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B A C K G R O U N D
Please refer to our glossary (see Table 1).
Description of the condition
Psoriasis is an immune-mediated disease for which a person can
have genetic susceptibility, manifesting in chronic inflammatory
effects on either the skin or joints, or both, with a prevalence rang-
ing from 0.91% (United States) to 8.5% (Norway) (Boehncke
2015; Parisi 2013). The causes of psoriasis are not fully under-
stood. There appears to be interaction between environmental fac-
tors and genetic susceptibility. Genome-wide (or whole genome)
association trials found several candidate genes relating to psoria-
sis (Elder 2010). Various environmental factors, including stress,
injury, and infections, are suspected to trigger or aggravate the
evolution of psoriasis. An inflammatory immune response involv-
ing dendritic cells, T cells, keratinocytes, neutrophils, and the cy-
tokines released from immune cells initiates the pathophysiolog-
ical process (Jariwala 2007; Lowes 2008; Wilson 2007; Zheng
2007).
Diagnosis is made based on clinical findings; skin biopsy is rarely
used to diagnose the disease (Boehncke 2015). Several clinical
types of psoriasis exist: plaque, pustular, inverse, and erythroder-
mic. Plaque psoriasis is the most common form, affecting 90% of
people with psoriasis (Griffiths 2007). Plaque psoriasis typically
appears as raised erythematous and well-demarcated areas of in-
flamed skin covered with silvery white, scaly skin (Griffiths 2007).
The location of the plaques is usually symmetrical on the elbows,
knees, scalp, lower back, and the periumbilical region. For 5% to
25% of people with psoriatic rheumatic disease, their skin is also
involved (Helliwell 2005; Zachariae 2003).
Severity
Chronicity characterises the natural history of plaque psoriasis; this
means that severity varies over time, from minor localised patches
to complete body coverage. The severity of the disease usually
fluctuates around the same level for a particular person (Nijsten
2007), but for each person with this disease, the evolution and
duration of remission is unpredictable. The psoriasis is declared
clear when remission is complete.
More than a dozen outcome instruments are used to assess the
severity of psoriasis and the efficacy of different treatments for
psoriasis (Naldi 2010; Spuls 2010); the Psoriasis Area and Severity
Index (PASI) score is one of these instruments (Schmitt 2005).
The Psoriasis Area and Severity Index combines the assessment of
the severity of lesions and the area affected into a single score in
the range of 0 (no disease) to 72 (maximal disease). Recent clinical
trials evaluating biological therapies that have received secondary
marketing authorisation by the U.S. Food and Drug Adminis-
tration (FDA) and the European Medicines Agency (EMA) used
PASI 75, i.e. 75% improvement in the PASI score, as the primary
end point. However, the PASI has substantial limitations, such as
low-response distribution, no consensus on interpretability, and
low responsiveness in mild disease (Spuls 2010).
Impact and quality of life
Disease severity alone does not determine the burden of psoriasis.
Multiple studies have described an impairment of the quality of life
(QoL); others have focused on an evaluation of the stigma people
experience; and others have studied the impact on psychosocial
life (Kimball 2005).
Impairment of QoL in people with psoriasis, when measured with
the 36-item Short Form Health Survey (SF-36) questionnaire has
been found to be higher than that of people with hypertension,
diabetes, or depression (Rapp 1999).
Many tools exist to measure the QoL of people with psoriasis
and other skin disorders. These measures may be categorised as
psoriasis-specific (Psoriasis Index of Quality of Life (PSORIQoL),
Psoriasis Disability Index (PDI)); skin-specific (Dermatology Life
Quality Index (DLQI), Skindex (a quality-of-life measure for pa-
tients with skin disease)); and generic QoL measures (SF-36).
However,methodological weaknesses exist in the use of QoL ques-
tionnaires, and there is poor reporting of QoL outcomes in ran-
domised clinical trials (Le Cleach 2008). Several case-control stud-
ies reported a higher risk of metabolic syndrome and cardiovascu-
lar comorbidities (Kremers 2007; Naldi 2005).
Description of the intervention
There is currently no cure for psoriasis, but various treatments can
help to control the symptoms; thus, long-term treatment is usually
needed. In daily practice, a treatment strategy needs to be defined,
and this usually involves an induction therapy, e.g. the remission
of the psoriasis flare, and a maintenance therapy, e.g. increasing
the period of remission.
The therapeutic approach to psoriasis includes topical treatments
as a single strategy and a first-line therapy in the management
of minor forms (Mason 2013). Nevertheless, about 20% to 30%
of people with psoriasis have a moderate to severe form requir-
ing a second-line therapy including phototherapy and conven-
tional systemic agents, such as ciclosporin, methotrexate, or ac-
itretin. Among the systemic agents, the choice of drug is not
clear. The NICE 2012 clinical guidelines in the UK had proposed
methotrexate as the first choice of systemic agent. Other countries,
such as France, do not have any available guidelines. Systemic bi-
ological agents, such as the tumour necrosis factor (TNF) antag-
onists (infliximab, etanercept, adalimumab), the monoclonal an-
tibody ustekinumab that targets interleukin-12 and -23 (IL-12/-
23), anti-IL17 drugs (secukinumab or ixekizumab), and more re-
cently new small molecules (apremilast) are “third-line” therapies
(Boehncke 2015). Indeed, there are mandatory reimbursement
criteria that patients must meet before being considered for these
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treatments due to their high costs: moderate to severe psoriasis
after failure, intolerance or contraindication to at least two con-
ventional systemic agents (Nast 2015b).
We used the European S3 guidelines terminology to categorise the
treatments (Nast 2015b).
Oral systemic treatments
Conventional systemic agents
Conventional systemic agents are a heterogeneous group of treat-
ments that are the oldest interventions given to clear psoriasis.
The existing oral systemic pharmacological treatments available
for psoriasis are ciclosporin, methotrexate, acitretin (which is the
retinoid of choice for psoriasis), and fumaric acid esters (FAEs)
which are licensed for psoriasis in Germany and used off-licence
in other countries (Atwan 2015).
Randomised controlled trials against placebo for both induction
and maintenance therapies have demonstrated the efficacy of ci-
closporin for psoriasis (Bigby 2004;Christophers 1992; Ellis 1991;
Flytstrom 2008; Koo 1998; Heydendael 2003; Ho 1999; Mahrle
1995; Meffert 1997; Mrowietz 1995; Shupack 1997). In 2008,
Saurat et al conducted the only randomised trial comparing the ef-
ficacy of methotrexate with placebo (Saurat CHAMPION, 2008).
Randomised trials against placebo have demonstrated the efficacy
of derivatives of vitaminA, the retinoids, in the treatment of plaque
psoriasis (Pettit 1979). Fumaric acid esters are an alternative ther-
apy for people with psoriasis, even though the mechanisms of ac-
tion are not completely understood (Ormerod 2004). A Cochrane
ReviewonFAEs for psoriasis was published in 2015 (Atwan 2015).
Small molecules
Small molecules affect molecules inside immune cells. Recently,
small molecule drugs have been developed and show potential to
treat psoriasis patients not responding to conventional treatments.
These small molecule drugs include apremilast (Papp 2012b), to-
facitinib (Bachelez 2015), and ponesimod (Vaclavkova 2014). To-
facitinib and ponesimod had not been approved for psoriasis at
the time our analyses were done.
Biological therapies
Biological therapies use substances made from living organisms,
or synthetic versions, to target the immune system. In the twen-
tieth century, the development of biological treatments expanded
the therapeutic spectrum of systemic treatments for psoriasis. All
of the biologics have to be given by infusion or subcutaneous in-
jection, and all have had at least one evaluation of their effective-
ness against placebo: alefacept (Krueger 2002; Lebwohl 2003),
etanercept (Leonardi 2003), infliximab (Chaudhari 2001), adal-
imumab (Menter REVEAL, 2008), certolizumab (Reich 2012),
ustekinumab (Lebwohl 2010), secukinumab (Reich 2015), ixek-
izumab (Leonardi 2012), brodalumab (Papp 2012), guselkumab
(Gordon X-PLORE, 2015), tildrakizumab (Papp 2015a), and
itolizumab (Krupashankar 2014). Certolizumab, tildrakizumab,
and itolizumab had not been approved for psoriasis at the time
our analyses were done.
How the intervention might work
Dysregulation of the immune system is a critical event in psoriasis,
and the evolving knowledge of the role of the immune system in
the disease has had a significant impact on treatment development.
Indeed, psoriatic plaque shows marked infiltration by activated T
cells, especially CD4+ cells in the dermis. The activated T cells
produce several important cytokines, namely, interferon (IFN)-c,
TNF alpha (by Th1 and Tc1 cells), IL-17A, and IL-23R (by Th17
and Tc17 cells) (Boehncke 2015).
Oral systemic treatments
Conventional systemic agents
Ciclosporin
Ciclosporin is an immunosuppressive agent (a drug that reduces
the efficacy of the immune system); it acts by inhibiting the initial
phase of the activation of CD4+ T cells, which leads to a block
on the synthesis of interleukin 2 by the complex cyclophilin-ci-
closporin, thus, preventing T cell proliferation that is key to the
pathogenesis of psoriasis (see above) (Ho 1996). This immuno-
suppression is rapid and reversible. Ciclosporin rapidly reduces the
severity of the lesions (over one to three months), but the continu-
ation of treatment is difficult after two years because of the devel-
opment of adverse effects, such as elevated creatinine levels (Maza
2011). A dose of 5.0 mg/kg/day ciclosporin was significantly more
effective than 2.5 mg/kg/day ciclosporin for induction of the re-
mission of psoriasis; however, elevated creatinine was significantly
more likely with 5.0 mg/kg/day ciclosporin than with 2.5 mg/kg/
day ciclosporin (Christophers 1992).
Methotrexate
Methotrexate is an antimetabolite (an inhibitor of a chemical that
is part of normal metabolism), which acts as an antagonist of
folic acid (Montaudie 2011). Low doses of methotrexate exert
anti-inflammatory and immunomodulatory activities (Montaudie
2011). The efficacy of methotrexate cannot be assessed earlier
than three months; its long-term safety profile is good. In clinical
practice, methotrexate is administered orally at 15 to 25 mg/week
(Montaudie 2011).
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Retinoids
Retinoids, including acitretin, are involved in the growth and dif-
ferentiation of skin tissue; they bind to nuclear receptors that be-
long to the large family of steroid hormone receptors (Sbidian
2011). Retinoids modulate many types of proteins, including
epidermal structural proteins, metalloproteinases, and cytokines
(Sbidian 2011). The efficacy of retinoids is evaluated after two
to three months of treatment, but skin side effects (e.g. xerosis,
cheilitis) may limit the ability to increase the dose. Treatment with
retinoids is best avoided in women of childbearing age because of
risks to a developing foetus and the necessity of using contracep-
tion two years after discontinuation of treatment (Sbidian 2011).
People receiving 50 mg/day to 75 mg/day acitretin have signifi-
cantly improved psoriasis compared with those receiving 10 mg/
day to 25 mg/day acitretin (Goldfarb 1988).
FAEs
FAEs are chemical compounds derived from the unsaturated di-
carboxylic acid (Atwan 2015). Oral preparations of FAEs in pso-
riasis were developed containing dimethyl fumarate (DMF) and
salts of monoethyl fumarate (MEF) as main compounds (Atwan
2015). FAEs produce anti-inflammatory effects by preventing the
proliferation of T cells (Atwan 2015).
FAEs are an effective therapy in people with psoriasis (50% to 70%
achieve PASI 75 improvement within four months of treatment).
Tolerance is limited by gastrointestinal side effects and flushing of
the skin (Atwan 2015). Several case-series described rare adverse
events, such as progressive multifocal leukoencephalopathy (Balak
2016). In clinical practice, FAEs are administered orally. People
receive this after a gradual dose incrementation the equivalent of
720 mg of DMF per day.
Small molecules
Small molecule drugs modulate proinflammatory cytokines and
selectively inhibit signalling pathways: phosphodiesterase 4 in-
hibitors (apremilast), Janus kinase (JAK) inhibitors (tofacitinib),
or sphingosine 1-phosphate receptor agonists (ponesimod) (Torres
2015).
Apremilast
Apremilast belongs to the phosphodiesterase 4 (PDE4) inhibitors
family (Torres 2015). By increasing cyclic adenosine monophos-
phate (cAMP) levels, PDE4 inhibitors reduce production of pro-
inflammatory TNF alpha and IFNγ in patients with psoriasis.
Apremilast has recently been approved for psoriasis; its efficacy
seems to be higher than conventional systemic therapy; however,
no randomised controlled trials (RCTs) have assessed apremilast
versus methotrexate or ciclosporin. The safety of the drug should
be detailed in the near future with phase 4 studies. In clinical prac-
tice, apremilast is administered orally at 30 mg twice a day (Torres
2015).
Tofacitinib
Tofacitinib is a Janus kinase (JAK) inhibitor (Torres 2015). JAK
inhibitors targets the Janus kinase (JAK)/signal transducer and
activator of transcription (STAT) pathway, which is pivotal for
the downstream signaling of inflammatory cytokines involved in
psoriasis. Tofacitinib had not been approved for psoriasis at the
time our analyses were done (Torres 2015).
Ponesimod
Ponesimod is a sphingosine 1-phosphate receptor agonist that
causes dose-dependent sequestration of lymphocytes in lymphoid
organs, thus, preventing T cell proliferation, which is key to the
pathogenesis of psoriasis. Ponesimod had not been approved for
psoriasis at the time our analyses were done (Torres 2015).
Biological therapies
Biological therapies have been developed in recent years and tar-
get and prevent T cell proliferation (e.g. alefacept and itolizumab,
a humanised IgG1 (immunoglobulin G1) monoclonal antibody,
which selectively targets CD6) or target cytokines involved in pso-
riasis physiopathology (e.g. anti-TNF alpha, anti-IL12/23, anti-
IL23, anti-IL17).
Alefacept
Alefacept is an immunosuppressive agent (a fusion protein that
blocks the growth of some types ofT cells). Alefacept (either 7.5mg
intravenously (IV) or 15 mg intramuscularly (IM) once a week) is
used to control inflammation in moderate to severe psoriasis with
plaque formation, where it interferes with lymphocyte activation.
This drug was never approved for the European drug market. It
was sold in North America, Switzerland, Israel, and Australia. In
2011, themanufacturersmade a decision to cease sales of alefacept.
This decision was not related to any specific safety concern nor
the result of any FDA-mandated or voluntary product recall (
Heffernan 2010).
Anti-TNF alpha
Two monoclonal antibodies against tumour necrosis factor alpha
(TNF-α) (infliximab, adalimumab) and one recombinant TNF-
α receptor (etanercept) have been developed to inhibit TNF-α
signalling, thus, preventing its inflammatory effects and are ap-
proved in psoriasis (Gisondi 2004). A third, certolizumab, is being
assessed for psoriasis in phase 3 trials.
• Etanercept is a recombinant TNF-α receptor and weakly
immunogenic (provokes only a mild immune response). Its
efficacy is assessed at three months. A 50 mg dose of etanercept is
administered subcutaneously twice weekly for three months
during the induction phase (remission of the psoriasis flare) with
50 mg administered weekly as maintenance therapy (Gisondi
2004).
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• Infliximab is a chimeric antibody that neutralises the action
of TNF-α. Its efficacy is evaluated after six to eight weeks of
treatment. A dose of 5.0 mg/kg infliximab is given as an
intravenous (IV) induction regimen at 0, 2, and 6 weeks
followed by a maintenance regimen of 5.0 mg/kg every 8 weeks.
The presence of a murine sequence at recognition sites can lead
to the development of anti-infliximab antibodies that may
impair the therapeutic effect (Gisondi 2004).
• Adalimumab is a fully humanised antibody with very low
immunogenicity. Its efficacy is estimated after eight and 12 weeks
of treatment. One dose of 80 mg is administered subcutaneously,
followed one week later by a 40 mg subcutaneous dose, which is
administered every two weeks (Mossner 2009). Those receiving
TNF-α blockers are potentially exposed to a greater risk of
infection and require regular monitoring (Tubach 2009).
• Certolizumab is an anti-TNF alpha with a unique structure
that does not contain an Fc (fragment crystallisable) portion as
adalimumab or infliximab does based on the human
immunoglobulin G1 Fc. Therefore, certolizumab does not
display Fc-mediated effects (improving solubility, increasing
drug stability, and decreasing immunogenicity). Certolizumab
had not been approved for psoriasis at the time our analyses were
done (Campanati 2017).
Anti-IL12/23, Anti-IL23, Anti-IL17
Additional monoclonal antibodies have been developed against
pro-inflammatory cytokines: IL-12, IL-23, and IL-17 inhibit the
inflammatory pathway at a different point to the anti-TNF alpha
antibodies (Dong 2017).
• Interleukin-12 and IL-23 share a common domain, p40,
which is the target of ustekinumab (which the FDA has recently
approved) (Savage 2015). A 45 mg subcutaneous dose is
administered initially (90 mg if body weight is over 100 kg),
then 45 mg (or 90 mg) subcutaneously four weeks later, and
thereafter 45 mg (or 90 mg) subcutaneously every 12 weeks
(Savage 2015). Interleukin-23 plays an essential role in skin
inflammation in psoriasis leading to the development of agents
that selectively target the IL-23p19 subunit (Dong 2017). Drugs
targeting the p19 subunit of IL-23 are guselkumab (a fully
human IgG1k monoclonal IL-23 antagonist), tildrakizumab (a
humanised IgG1k monoclonal antibody), and risankizumab
(high affinity humanised IgG1 monoclonal antibody) (Dong
2017). In July 2017, the FDA approved guselkumab for
psoriasis. Guselkumab is given as a 100 mg subcutaneous
injection every 8 weeks, following two starter doses at week 0
and week 4. Risankizumab was assessed after we began the
systematic review and will be added in the next update.
• Interleukin-17 inhibitors include secukinumab (a
recombinant fully human anti-IL17A IgG1k monoclonal
antibody), ixekizumab (a humanised anti-IL17 immunoglobulin
G4 monoclonal antibody), and brodalumab (a human IgG2
monoclonal antibody that decreases the downstream effect of IL-
17 by antagonisng the IL-17RA receptor) (Dong 2017). The
recommended dosage for secukinumab is 300 mg administered
subcutaneously at weeks 0, 1, 2, 3, and 4, and then every 4 weeks
thereafter. Ixekizumab is administered at 160 mg (2 x 80 mg
injections) at weeks 0, 2, 4, 6, 8, 10, and 12, and then every 4
weeks thereafter (Dong 2017).
Why it is important to do this review
To determine the treatment pathway in psoriasis, the efficacy and
safety of each systemic treatment must be determined relative to
other therapies. Several randomised controlled trials (RCTs) have
compared against placebo the efficacy of the different systemic
treatments for psoriasis. However, there are few trials compar-
ing conventional systemic therapies head-to-head, systemic ther-
apies against biological therapies, or biological therapies head-to-
head. Several previous meta-analyses or indirect comparison meta-
analyses have been published (Bansback 2009; Brimhall 2008;
Gomez-Garcia 2017; Gospodarevskaya 2009; Lin 2012; Loveman
2009;Nast 2015;Nelson2008;Reich 2008;Reich 2012a; Schmitt
2008; Signorovitch 2010; Signorovitch 2015; Spuls 1997; Strober
2006; Tan 2011; Turner 2009; Woolacott 2006). However, the
number of studies included in these publications was low, the
searches were not exhaustive, and several trials have been published
since their search dates. Also, the publications did not evaluate
some systemic and biological treatments.
A network meta-analysis enables the best use of the direct and
indirect information available to determine the relative efficacy of
treatments. In other words, a network meta-analysis will help to
highlight the missing key comparisons that are needed to inform
clinical practice.
The plans for this review were published as a protocol ’Systemic
pharmacological treatments for chronic plaque psoriasis’ (Sbidian
2015).
O B J E C T I V E S
To compare the efficacy and safety of conventional systemic agents
(acitretin, ciclosporin, fumaric acid esters, methotrexate), small
molecules (apremilast, tofacitinib, ponesimod), anti-TNF alpha
(etanercept, infliximab, adalimumab, certolizumab), anti-IL12/
23 (ustekinumab), anti-IL17 (secukinumab, ixekizumab, bro-
dalumab), anti-IL23 (guselkumab, tildrakizumab), and other bio-
logics (alefacept, itolizumab) for patients with moderate to severe
psoriasis and to provide a ranking of these treatments according
to their efficacy and safety.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Phase I trials were not eligible because participants, outcomes,
dosages, and schema of administration of interventions are too
different from phase II, III, and IV studies. Cross-over trials were
not eligible (because of the unpredictable evolution of psoriasis
and risk of carry-over bias). Non-randomised studies, including
follow-up studies, were not eligible.
Types of participants
We considered trials that included adults (over 18 years of age)
withmoderate to severe plaque psoriasis (i.e. needed systemic treat-
ment) or psoriatic arthritis whose skin had been clinically diag-
nosed with moderate to severe psoriasis and who were at any stage
of treatment.
Types of interventions
We considered trials that assessed systemic and biological treat-
ments, irrespective of the dose and duration of treatment, com-
pared with placebo or with each other.
Systemic and biological treatments included the following:
• Systemic conventional treatments
◦ FAEs
◦ Acitretin
◦ Ciclosporin
◦ Methotrexate
• Small molecules
◦ Apremilast
◦ Tofacitinib
◦ Ponesimod
• Anti-TNF alpha
◦ Infliximab
◦ Etanercept
◦ Adalimumab
◦ Certolizumab
• Anti-IL12/23
◦ Ustekinumab
• Anti-IL17
◦ Secukinumab
◦ Brodalumab
◦ Ixekizumab
• Anti-IL23
◦ Tildrakizumab
◦ Guselkumab
• Other biologic treatments
◦ Itolizumab
◦ Alefacept
We were interested to compare both the different drugs (n = 19)
and the different classes of drugs (n = 7).
A new anti-IL23 molecule (BI 655066, risankizumab) appeared
after we began this review and was not included in this systematic
review. However, the ongoing studies of risankizumab have been
reported in this review.
Active comparators included the following:
• any of the aforementioned systemic and biological
treatments; or
• additional treatment not of primary interest but used for
the network synthesis, such as topical treatment or phototherapy.
In multi-arm trials, study groups assessing drugs other than those
mentioned above were not eligible. In cases of multi-dose trials,
we grouped together all of the different dose groups as a single arm
and performed sensitivity analysis at dose level.
In our Background section, we have referred to ongoing Cochrane
Reviews that address some of the systemic treatments administered
to adults with plaque psoriasis. We considered these treatments
in our review, and we have liaised with each of these teams to
harmonise our protocols.However, theCochraneReviewonFAEs,
published in 2015, included people with all types of psoriasis and
not only plaque-type psoriasis (Atwan 2015).
Types of outcome measures
Psoriasis is a chronic disease; treatments are symptomatic often
with a return to baseline after discontinuation. In the absence of an
existing defined core outcome set (Spuls 2016), we chose the most
relevant outcomes for patients (COMET). The Psoriasis Area and
Severity Index score (PASI) 75 is themost common outcome mea-
sure used. However, confronted with a debilitating and a socially
and psychologically highly visible disease, a completely “clear or
almost clear” skin is a more stringent test in the induction phase
(remission of the psoriasis flare).
Primary outcomes
1. The proportion of participants who achieved clear or
almost clear skin, that is, at least PASI 90.
2. The proportion of participants with serious adverse effects
(SAE). We used the definition of severe adverse effects from the
International Conference of Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human
Use, which includes death, life-threatening events, initial or
prolonged hospitalisation, and adverse events requiring
intervention to prevent permanent impairment or damage.
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Secondary outcomes
1. Proportion of participants who achieve PASI 75 at
induction phase.
2. Proportion of participants who achieve a Physician Global
Assessment (PGA) value of 0 or 1.
3. Quality of life measured by a specific scale. Available
validated scales are the Dermatology Life Quality Index (DLQI),
Skindex, Psoriasis Disability Index (PDI), or Psoriasis Symptom
Inventory (PSI).
4. The proportions of participants with adverse effects (AE).
5. Proportion of participants with at least one relapse in the
maintenance phase (between 52 to 104 weeks).
Timings
Where possible, we evaluated the outcomes at two different tim-
ings:
• induction therapy (short-term remission) (evaluation less
than 24 weeks after the randomisation); and
• maintenance therapy (long-term remission) (evaluation
between 52 and 104 weeks after the randomisation).
We did not include studies that had timings outside of these time
ranges in our review. All of the outcomes except the proportion
of participants with at least one relapse in the maintenance phase
were recorded during the randomisation phase.
Search methods for identification of studies
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
We searched the following databases up to 15 December 2016:
• the Cochrane Skin Specialised Register using the search
strategy in Appendix 1;
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2016, Issue 11) in the Cochrane Library using the
strategy in Appendix 2;
• MEDLINE Ovid (from 1946) using the strategy in
Appendix 3;
• Embase Ovid (from 1974) using the strategy in Appendix
4; and
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982) using the strategy in
Appendix 5.
Trials registers
We searched the following trials registers up to 22 December 2016
with the following search terms: psoriasis AND one by one each
drug name listed in Types of interventions:
• World Health Organization International Clinical Trials
Registry Platform (ICTRP) (apps.who.int/trialsearch/);
• ISRCTN registry (www.isrctn.com);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov);
• Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au); and
• EU Clinical Trials Register (www.clinicaltrialsregister.eu).
Searching other resources
Previous meta-analyses and systematic reviews
We looked at the search strategies of previous meta-analyses to
improve our search strategies.
References from other studies
We checked the bibliographies of included and excluded studies
for further references to relevant trials.
Unpublished literature
We searched the trial results databases of various pharmaceutical
companies to identify ongoing and unpublished trials. We made
attempts to locate unpublished and ongoing trials through corre-
spondence with authors and pharmaceutical companies (see Table
2).
We searched reviews submitted to the U.S. Food and Drug
Administration and the European Medicines Agency (EMA)
for drug registration (using www.accessdata.fda.gov/scripts/cder/
drugsatfda and www.ema.europa.eu/ema).
Conference proceedings
We handsearched the proceedings of the following conferences
during the periods not included in the Cochrane Skin Specialised
Register:
• The American Academy of Dermatology (AAD) from 2008
to 2009 and from 2012 to 2013;
• The Society for Investigative Dermatology (SID) from
2008 to 2009 and from 2012 to 2013; and
• The European Academy of Dermatology and Venereology
(EADV) from 2008 to 2013.
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Adverse effects
We did not perform a separate search for rare or delayed adverse
effects of the target interventions. However, we examined data on
adverse effects from the included studies we identified.
Data collection and analysis
Selection of studies
Two groups of two review authors (LLC/ES or IGD/GD) inde-
pendently examined each title and abstract to exclude irrelevant
reports. These authors independently examined full-text articles
to determine eligibility. We contacted study authors for clarifica-
tion when necessary and discussed disagreements to reach consen-
sus. We list excluded studies and document the primary reason for
exclusion.
Data extraction and management
Three groups of two review authors (LLC, GD, CH, IGD, CM,
or ES) each extracted the data from published and unpublished
reports independently using a standardised form. We pilot-tested
this form (Data Extraction Form) on a set of included trials. We
extracted the data to populate the ’Characteristics of included
studies’ tables in RevMan Manager 5.3 (Revman 2014).
We extracted the data from the reports of the U.S. Food and Drug
Administration (FDA)when available, if not from theUSNational
Institutes of Health Ongoing Trials Register ClinicalTrials.gov (
www.clinicaltrials.gov), and finally from the published reports.
Outcome data
We extracted (arm-level data) from each included trial; hence, the
total number of participants randomised to each intervention. For
binary outcomes, we also extracted the number of participants (if
available) who:
• reached PASI 90, PASI 75, or PGA 0/1 during the
induction phase;
• had at least one relapse in the maintenance phase; and
• had at least one SAE/one AE during the induction phase.
For quality of life, we extracted from each included trial the mean
change score of the study specific scale from baseline to follow-up.
When PASI 90 and PASI 75 outcomes were not reported and
when the information was available, we extracted the PASI score at
baseline and at the evaluation point (or the percentage reduction
in PASI from baseline to follow up) to calculate the number of
participants who reached PASI 75 and 90.
Regarding the assessment of quality of life, we recorded all spe-
cific quality of life (QoL) scales (Dermatology Life Quality Index
(DLQI), Skindex, Psoriasis Disability Index (PDI), and Psoriasis
Symptom Inventory (PSI)).
Data on potential effect modifiers
We extracted baseline demographic and clinical characteristics of
participants that may have acted as effect modifiers (age, sex, body
weight, duration of psoriasis, severity of psoriasis at baseline, pre-
vious psoriasis treatment). One review author (ES) checked and
entered the data into the RevMan computer software. We con-
tacted the authors of the trials to request missing data (see Table
2).
Assessment of risk of bias in included studies
We used Cochrane’s ’Risk of bias’ (RoB) tool to assess the risk of
bias. Three groups of two review authors each (LLC, GD, CH,
IGD, CM, or ES) independently assessed the risk of bias, and one
author (LLC) resolved any disagreements. For each of the follow-
ing domains and according to the general principles in section 8.4
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), we graded the following ’Risk of bias’ domains as
’low’, ’high’, or ’unclear’.
1. Selection bias
◦ Was the allocation sequence adequately generated? We
considered randomisation adequate (low risk of bias) if the
allocation sequence was generated from a table of random
numbers or was computer-generated. We considered
randomisation inadequate (high risk of bias) if sequences could
be related to prognosis. We considered randomisation unclear if
the paper stated that the trial was randomised, but did not
describe the method.
◦ Was allocation adequately concealed? We deemed
allocation concealment as adequate if the report stated that it was
undertaken by means of sequentially pre-numbered sealed
opaque envelopes or by a centralised system. We considered a
double-blind double-dummy process as at low risk of bias even if
the paper did not describe the method of allocation concealment.
2. Performance and detection bias
◦ Was knowledge of the allocated intervention
adequately prevented during the study? We evaluated the risk of
bias separately for personnel and participants, outcomes
assessors, and each outcome.
3. Attrition bias
◦ Were incomplete outcome data adequately addressed?
We examined if there was imbalance across intervention groups
in numbers or reasons for missing data, type of measure
undertaken to handle missing data, and whether the analysis was
carried out on an intention-to-treat (ITT) basis. We assessed the
use of strategies to handle missing data.
4. Reporting bias
◦ Were reports of the study free of suggestion of selective
outcome reporting? We evaluated if each outcome was measured,
analysed, and reported. We compared outcomes specified in
protocols (if available on the FDA website or ClinicalTrials.gov)
and in material and methods with outcomes presented in the
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results section. We considered reporting bias inadequate if one
specified outcome in protocols was lacking in the main report.
5. Other risk of bias
◦ We did not fulfil the ’other risk of bias’ item as we did
not highlight particular circumstances leading to other risk of
bias from particular trial designs, contamination between the
experimental and control groups, and particular clinical settings.
Overall risk of bias
To summarise the quality of evidence and to interpret the network
results, we used these six RoB criteria (random sequence gener-
ation, allocation concealment, blinding of participants, blinding
of outcome assessor, incomplete outcome data, and selective out-
come reporting) in order to classify each trial.
We would classify the trial as having low risk of bias if we rated
none of the domains above as high risk of bias and two or less as
unclear risk.
We would classify the trial as having moderate risk of bias if we
rated one domain as high risk of bias, one or less domains as unclear
risk, or no domains as high risk of bias but three or less were rated
as unclear risk.
All other cases were assumed to pertain to high risk of bias.
Measures of treatment effect
Relative treatment effects
For each pair-wise comparison and each dichotomous outcome at
each time point, we used risk ratios (RR) with 95% confidence
intervals (CI) as a measure of treatment effect. For continuous
variables (e.g. quality of life scale), we used the standardised mean
difference (SMD) with 95% CI.
Relative treatment ranking - network meta-analysis
For every treatment, we estimated the ranking probabilities of be-
ing at each possible rank for all outcomes. We inferred on treat-
ment hierarchy using the surface under the cumulative ranking
curve (SUCRA) (Salanti 2011). SUCRA was expressed as a per-
centage between 0 (when it is certain a treatment is the worst) to
100% (when it is certain a treatment is the best).
Unit of analysis issues
The primary unit of analysis was the participant. We did not con-
sider studies with non-standard design features that would lead to
clustering (e.g. cross-over trials).
We treated comparisons from trials with multiple intervention
groups as independent two-arm studies in the pair-wisemeta-anal-
yses. At the network meta-analysis stage, we properly accounted
for the within-trial correlation.
Dealing with missing data
We extracted, when possible, both the number of randomised
and analysed participants in each study arm. We contacted trial
authors or sponsors by email to request missing outcome data
(numbers of events and numbers of participants for important
dichotomous clinical outcomes) when these were not available in
study reports that were less than 10 years old (See Table 2). For
the main analysis, we assumed that any participant with missing
outcome data did not experience clearance, whatever the group.
In a sensitivity analysis, we also synthesised the data ignoring the
missing participants (complete case analysis) assuming that they
were missing at random (Mavridis 2014).
Assessment of heterogeneity
We undertook meta-analyses only if we judged participants, in-
terventions, comparisons, and outcomes to be sufficiently similar
(section 9.5.2 of the Cochrane Handbook for Systematic Reviews of
Interventions) (Higgins 2011). Potential sources of heterogeneity
included participants’ baseline characteristics (weight, the dura-
tion of previous treatment, treatment doses, co-interventions, and
duration of treatment). When enough data were available, we in-
vestigated the distributions of these characteristics across studies
and treatment comparisons. The latter allows assessing transitivity,
i.e. whether there were important differences between the trials
evaluating different comparisons other than the treatments being
compared (Salanti 2014). To further reassure the plausibility of
the transitivity assumption, we only included in our analyses tri-
als not involving co-interventions and with a timing of outcome
assessment from 12 to 16 weeks.
In the classical meta-analyses, we assessed statistical heterogeneity
by visual inspection of the forest plots and using theQ-test and the
I² statistic.We interpreted the I² statistic according to the following
thresholds (section 9.5.2 of the Cochrane Handbook for Systematic
Reviews of Interventions; Higgins 2011): 0% to 40% might not be
important; 30% to 60% may represent moderate heterogeneity;
50% to 90% may represent substantial heterogeneity; 75% to
100% represents considerable heterogeneity.
In the network meta-analysis, the assessment of statistical hetero-
geneity in the entire network was based on the estimated het-
erogeneity standard deviation parameter (τ ) estimated from the
network meta-analysis models (Jackson 2014). We inferred on
the presence or absence of important heterogeneity by comparing
the magnitude of τ with the empirical distributions provided in
Turner et al and Rhodes et al (Rhodes 2015; Turner 2012). We
also estimated the prediction intervals to assess howmuch the esti-
mated heterogeneity affects the relative effects with respect to the
additional uncertainly anticipated in future studies (Riley 2011).
Where feasible, we would have investigated the possible sources
of heterogeneity in subgroup analyses and meta-regression.
Although we restricted the risk of important heterogeneity in our
data by considering eligible only studies with a follow-up period
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between 12 and 16 weeks and without co-interventions, we in-
vestigated differences in heterogeneity across the different analy-
ses. Specifically, we observed whether splitting the nodes of the
network and analysing each drug separately reduced the hetero-
geneity estimate. We also ran a series of sensitivity analyses (see
Sensitivity analysis), and we monitored whether heterogeneity be-
came smaller or larger compared to the primary analysis.
Assessment of reporting biases
To assess reporting biases, we used an adaptation of the funnel
plot by subtracting from each study-specific effect size themean of
meta-analysis of the study-specific comparison, which we plotted
against the study standard error (Chaimani 2013). We employed
this ’comparison-adjusted funnel plot’ for all comparisons of an
active treatment against placebo. When we detected funnel plot
asymmetry for the two primary outcomes, we investigated the
presence of small-study effects in the network meta-regression (
Chaimani 2012).
Data synthesis
We conducted pair-wise meta-analyses to synthesise trials com-
paring one of the treatments against placebo or two treatments
against each other. We performed pair-wise meta-analyses for all
outcomes and comparisons, provided that at least two studies were
available, using a random-effects model.
We then employed network meta-analysis to estimate the relative
effects for all possible comparisons between any pair of treatments.
We provided a graphical depiction of the evidence network for all
outcomes to illustrate the network geometry (Chaimani 2017).
We ran network meta-analysis using the approach of multivariate
meta-analysis, which treats the different comparisons that appear
in studies as different outcomes (White 2012).
We interpreted a statistically non-significant P value (e.g. larger
than 0.05) as a finding of uncertainty unless confidence intervals
were sufficiently narrow to rule out an important magnitude of
effect.
We assessed inconsistency (i.e. the possible disagreement between
the different pieces of evidence) locally and globally. Specifically,
we used the loop-specific approach (Bucher 1997) and the side-
splitting method (Dias 2010). We also fit the design by treatment
interaction model to evaluate the presence of inconsistency in the
entire network (Higgins 2012).
We conducted pair-wise meta-analyses using Review Manager 5
(RevMan 5) (Revman 2014), and we performed all other anal-
yses in Stata 14 using the ’network’ (www.stata-journal.com/
article.html?article=st0410) and ’network graphs’ packages (
www.stata-journal.com/article.html?article=st0411).
Subgroup analysis and investigation of heterogeneity
We considered running subgroup analyses and meta-regressions
to investigate potential sources of heterogeneity or inconsistency
(such as weight of participants, duration of psoriasis, baseline
severity, previous systemic treatments), but no sufficient data on
these characteristics were available to perform these additional
analyses.
Sensitivity analysis
To assess the robustness of our results, we performed the following
sensitivity analyses for the two primary outcomes: (1) running the
analysis at dose-level considering that each different drug dose is
a different intervention; (2) excluding trials at high risk of bias;
(3) excluding trials with a total sample size smaller than 50 ran-
domised participants; and (4) analysing only the observed partic-
ipants assuming that missing participants are missing at random.
’Summary of findings’ table
We included a ’Summary of findings’ table in our review. We
downgraded evidence based on the five Grading of Recommenda-
tions, Assessment, Development and Evaluation (GRADE) con-
siderations (study limitations, consistency of effect, imprecision,
indirectness, and publication bias) (Schunemann 2011). We as-
sessed the confidence of the evidence estimates fromnetworkmeta-
analysis, based on an extension of the standard GRADE approach
which is based on the contributions of the direct comparisons to
the estimation in the network meta-analysis (Salanti 2014).
We included an overall grading of the evidence for the two main
outcomes:
• PASI 90 during the induction phase
• Serious adverse effects during the induction phase
We assessed the study limitations by first evaluating the risk of bias
of each direct estimate and then integrating these judgements with
the contribution of each direct estimate to the network estimates.
We assessed inconsistency by considering the networks’ hetero-
geneity (networkmeta-analysis estimate of between-study variance
and prediction intervals) and using both local and global incon-
sistency in the networks.
We assessed imprecision by focusing on the CIs of the network
meta-analysis treatment effect estimates and by examining ranking
probabilities (rankograms).
We assessed indirectness by evaluating the distribution of the po-
tential effect modifiers (baseline demographic and clinical charac-
teristics of participants).
We assessed publication bias by considering the comprehensive
search strategy that we performed and the risk of publication bias
in the specific field. The comparison-adjusted funnel plots that
test the presence of small-study effects in the network assisted our
judgement.
For each outcome, we chose the median placebo-group risk value
in the included studies for the assumed risk with placebo. Accord-
ing to the software GRADEpro 2008 (www.gradepro.org), we as-
signed four levels of certainty of evidence: high, moderate, low, or
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very low. We used this assessment, which two authors (LLC and
ES) conducted, to inform the main text of the discussion section.
R E S U L T S
Description of studies
Results of the search
TheElectronic searches retrieved 4798 records after deduplication.
The searches of other sources identified 622 records from trials
registers and three further records from other sources. We had a
total of 5422 records after removal of duplicates.
After reviewing the titles and abstracts, we discarded 4738 cita-
tions. We examined the full text of the remaining 684 citations:
410 did not meet the inclusion criteria.Within this group, 203 did
not include participants with moderate to severe psoriasis and so
did not meet our inclusion criteria. We have not created ’Charac-
teristics of excluded studies’ tables for this group. We had a further
207 excluded studies (see Characteristics of excluded studies). We
identified 14 trials as studies awaiting classification (reported in 18
references) (see Characteristics of studies awaiting classification).
We identified 34 studies as ongoing (see Characteristics of ongoing
studies).
We included 109 studies, reported in 222 references. For a further
description of our screening process, see the study flow diagram
(Figure 1).
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Figure 1. Study flow diagram
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Included studies
Trial design
All trials used a parallel-group design. The mean sample size was
366 (range: 10 to 1881). In all, 88 trials were multicentric tri-
als (2 to 231 centres) and 15 were single-centre trials (Akcali
2014; Al-Hamamy 2014; Asawanonda 2006; Chaudhari 2001;
Chladek 2005; Dogra 2013; Dogra 2012; Dubertret 1989; Ellis
1991; Gisondi 2008; Gurel 2015; Hunter 1963; Mahajan 2010;
Shehzad 2004; Van Bezooijen 2016); for six trials, single-centre
or multicentric status was not clear (Caproni 2009; Engst 1994;
Goldfarb 1988; Jacobe 2008; Olsen 1989; Yilmaz 2002). All of
the trials recruited participants from a hospital setting. The trials
took place worldwide (n = 37, 33.9%), in Europe (n = 28, 25.7%),
in North America (n = 21, 19.3%), in Asia (n = 17, 15.6%), or in
theMiddle East (n = 1, 0.9%). The location was not stated for five
trials (Caproni 2009; Engst 1994; Goldfarb 1988; Jacobe 2008;
Olsen 1989).
In total, 55 trials out of 109 were multiarm; 40 multiarm trials
assessed the same experimental drug at multiple dose levels; seven
assessed at least two different drugs; eight assessed both the same
experimental drug at multiple dose levels and different drugs.
In total, 15 trials (Al-Hamamy 2014; Asawanonda 2006;
Bissonnette 2013; Gottlieb 2012; Gurel 2015; Jacobe 2008; Lowe
1991; Mahajan 2010; Ruzicka 1990; Saurat 1988; Shehzad 2004;
Sommerburg 1993; Tanew 1991; Van Bezooijen 2016; Yilmaz
2002) had a co-intervention mainly with phototherapy. Only 14
studieswere carried out before the year 2000 (Dubertret 1989; Ellis
1991; Engst 1994; Goldfarb 1988; Hunter 1963; Laburte 1994;
Lowe 1991; Meffert 1997; Nugteren-Huying 1990; Olsen 1989;
Ruzicka 1990; Saurat 1988; Sommerburg 1993; Tanew 1991).
Characteristics of the participants
This review included 109 trials, with a total of 39,882 randomised
participants. We summarise the characteristics of the participants
in the Characteristics of included studies. The participants were
reported to be between 27 and 56.5 years old, with an overall mean
age of 44; there were more men (26,902) than women (12,384).
Age and gender were unreported for, respectively, 743 and 596
participants (eight and nine studies). The overall mean weight was
85.6 (range: 64 to 97), and the overall mean Psoriasis Area and
Severity Index (PASI) score at baseline was 20 (range: 9.5 to 39).
Characteristics of the comparisons
Trials with two parallel arms (the different dose groups were
grouped together in one “arm”)
Intervention versus placebo: 73 trials compared systemic
treatments with placebo
• Twenty-one trials compared systemic conventional
treatments versus placebo
◦ Acitretin (n = 9) (Goldfarb 1988; Gurel 2015; Lowe
1991; Olsen 1989; Ruzicka 1990; Saurat 1988; Sommerburg
1993; Tanew 1991; Yilmaz 2002)
◦ Fumaric acid esters (FAEs) (n = 3) (Nugteren-Huying
1990; Mrowietz BRIDGE, 2016; Van Bezooijen 2016)
◦ Ciclosporin (n = 2) (Ellis 1991; Meffert 1997)
◦ Methotrexate (n = 7) (Al-Hamamy 2014; Asawanonda
2006; Hunter 1963; Gottlieb 2012; Mahajan 2010; Shehzad
2004; Warren METOP, 2017)
• Nine trials compared small molecule treatments versus
placebo
◦ Apremilast (n = 4) (Papp 2012b; Papp 2013b; Papp
ESTEEM-1, 2015; Paul ESTEEM-2, 2015)
◦ Tofacitinib (n = 4) (Krueger 2016; Papp 2012a; Papp
OPT Pivotal-1, 2015; Papp OPT Pivotal-2, 2015)
◦ Ponesimod (n = 1) (Vaclavkova 2014)
• Forty-three trials compared biological treatments versus
placebo
◦ Anti-TNF alpha
⋄ Etanercept (n = 8) (Bagel 2012; Gottlieb 2003;
Gottlieb 2011; Leonardi 2003; Papp 2005; Strober 2011; Tyring
2006; Van de Kerkhof 2008)
⋄ Adalimumab (n = 5) (Asahina 2010; Bissonnette
2013; Gordon 2006; Menter REVEAL, 2008; Cai 2016)
⋄ Infliximab (n = 6) (Chaudhari 2001; Gottlieb
2004; Reich EXPRESS, 2005; Torii 2010; Yang 2012; Menter
EXPRESS-II, 2007)
⋄ Certolizumab (n = 1) (Reich 2012)
◦ Anti-IL12/23
⋄ Ustekinumab (n = 6) (Igarashi 2012; Krueger
2007; Leonardi PHOENIX-1, 2008; Papp PHOENIX-2, 2008;
Tsai PEARL, 2011; Zhu LOTUS, 2013)
◦ Anti-IL17
⋄ Secukinumab (n = 6) (Blauvelt FEATURE,
2015; Langley ERASURE, 2014; Papp 2013a; Paul
JUNCTURE, 2015; Reich 2015; Rich 2013)
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⋄ Ixekizumab (n = 2) (Gordon UNCOVER-1,
2016; Leonardi 2012)
⋄ Brodalumab (n = 3) (Papp AMAGINE-1, 2016;
Papp 2012; Nakagawa 2016)
◦ Anti-IL23
⋄ Guselkumab (n = 0)
⋄ Tildrakizumab (n = 1) (Papp 2015a)
◦ Other biologics
⋄ itolizumab (n = 1) (Krupashankar 2014)
⋄ Alefacept (n = 4) (Ellis 2001; Jacobe 2008;
Krueger 2002; Lebwohl 2003)
Intervention versus active comparators: 25 trials compared
systemic treatments with systemic treatments
• Acitretin versus acitretin (n = 1) (Dogra 2013)
• Acitretin versus ciclosporin (n = 1) (Akcali 2014)
• Ciclosporin versus methotrexate (n = 4) (Flytström 2008;
Heydendael 2003; Piskin 2003, Sandhu 2003)
• Ciclosporin versus ciclosporin (n = 3) (Dubertret 1989;
Engst 1994; Laburte 1994)
• Methotrexate versus methotrexate (n = 2) (Chladek 2005;
Dogra 2012)
• Methotrexate versus FAEs (n = 1) (Fallah Arani 2011)
• Methotrexate versus alefacept (n = 1) (Yan 2011)
• Methotrexate versus infliximab (n = 1) (Barker
RESTORE-1, 2011)
• Acitretine versus etanercept (n = 2) (Caproni 2009; Gisondi
2008)
• Etanercept versus etanercept (n = 3) (Ortonne 2013; Sterry
PRESTA, 2010; Strohal PRISTINE, 2013)
• Etanercept versus infliximab (n = 1) (de Vries PIECE, 2016)
• Etanercept versus ustekinumab (n = 1) (Griffiths ACCEPT,
2010)
• Tofacitinib versus tofacitinib (n = 2) (Asahina 2016;
Bissonnette 2015)
• Secukinumab versus secukinumab (n = 1) (Mrowietz
SCULPTURE, 2015)
• Secukinumab versus ustekinumab (n = 1) (Thaci CLEAR,
2015)
Trials with three parallel arms (the different dose groups
were grouped together in one “arm”)
A total of 11 trials compared systemic treatments with
systemic treatments and placebo.
• Methotrexate versus adalimumab versus placebo (n = 1)
(Saurat CHAMPION, 2008)
• Etanercept versus ixekizumab versus placebo (n = 2)
(Griffiths UNCOVER-2, 2015; Griffiths UNCOVER-3, 2015)
• Etanercept versus secukinumab versus placebo (n = 1)
(Langley FIXTURE, 2014)
• Etanercept versus apremilast versus placebo (n = 1) (Reich
LIBERATE, 2017)
• Guselkumab versus adalimumab versus placebo (n = 3)
(Blauvelt VOYAGE-1, 2016; Gordon X-PLORE, 2015; Reich
VOYAGE-2, 2017)
• Brodalumab versus ustekinumab versus placebo (n = 2)
(Lebwohl AMAGINE-2, 2015; Lebwohl AMAGINE-3, 2015)
• Tofacitinib versus etanercept versus placebo (n = 1)
(Bachelez 2015)
In total, the dataset consisted of 109 studies, which provide in-
formation on 204, 159, and 152 comparisons between 35 differ-
ent drug doses, 20 different drugs, and 8 different drug classes,
respectively (both including placebo). For the sensitivity analyses,
the different drug doses were divided into the following:
• methotrexate, taken orally, ≥ 15 or < 15 mg per week;
• ciclosporin, taken orally, ≥ 3 or < 3 mg/Kg per day;
• acitretin, taken orally, ≥ 35 or < 35 mg per day;
• apremilast, taken orally, 30 mg twice a day or other dosages
per day;
• ponesimod, taken orally, 40 mg per day or other dosages
per day;
• tofacitinib, taken orally, 20 mg per day or other dosages per
day;
• etanercept, subcutaneous (S/C), 25 mg twice a week or
etanercept 50 mg twice a week;
• infliximab, intravenous, 5 mg/kg at week 0, 2, and 4 then
every 6 weeks or other dosages;
• adalimumab, S/C, 80 mg at week 0, 40 mg at week 1 then
40 mg every other week or other dosages;
• secukinumab, S/C, 300 mg at week 0, 1, 2, 3, and 4 then
every 4 weeks or other dosages;
• ixekizumab, S/C, 80 mg every two weeks or other dosages;
• brodalumab, S/C, 210 mg every two weeks or other dosages;
• guselkumab, S/C, 100 mg at week 0 and 4 then every 16
weeks or other dosages.
Alefacept (S/C or intravenous (IV)), FAEs (taken orally), cer-
tolizumab (S/C), itolizumab (IV), ustekinumab (S/C 45 mg or
90 mg according to the weight) and tildrakizumab (S/C) were
grouped in one dosage whatever the dosages.
For each study, we provide details of the dosage in Characteristics
of included studies.
Characteristics of the outcomes
Regarding the efficacy outcomes during induction therapy (eight
to 24 weeks), out of 109 trials, 82 reported PASI 90, 76 reported
on Physician Global Assessment (PGA) 0/1, 93 reported PASI 75,
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and 54 trials reported assessment of change in quality of life. Fifty-
two studies used the dermatology-specific instrument Dermatol-
ogy Life Quality Index (DLQI); two studies used other specific
skin instruments (Skindex). For all of these studies, the investi-
gators provided citations to reports indicating that the tools had
been previously validated.
Out of 109 trials, 73 reported the number of participants with
adverse effects (different from the number of adverse effects), and
85 reported the number of serious adverse effects.
These outcomes were evaluated between eight and 24 weeks: eight
weeks (five studies), 10 weeks (seven studies), 12 weeks (56 stud-
ies), 13 weeks (two studies), 14 weeks (two studies), 15 weeks (one
study), 16 weeks (22 studies), and 24 weeks (10 studies). Timing
of assessment was unknown or not clearly defined for four studies
(Engst 1994; Hunter 1963; Saurat 1988; Shehzad 2004).
No trial assessed the outcome ’Proportion of participants with at
least one relapse in the maintenance phase (between 52 to 104
weeks)’.
Funding
In all, 82 studies declared a source of funding, 79 studies declared a
pharmaceutical company funding, four studies declared a unique
institutional funding (Chladek 2005; de Vries PIECE, 2016;
Flytström 2008; Heydendael 2003), five studies had no funding
source (Akcali 2014; Asawanonda 2006; Fallah Arani 2011; Gurel
2015; Yan 2011), and 21 studies did not report the source of
funding (Al-Hamamy 2014; Caproni 2009; Dogra 2012; Dogra
2013; Dubertret 1989; Engst 1994; Gisondi 2008; Hunter 1963;
Laburte 1994; Mahajan 2010; Meffert 1997; Nugteren-Huying
1990; Piskin 2003; Ruzicka 1990; Sandhu 2003; Saurat 1988;
Shehzad 2004; Sommerburg 1993; Torii 2010; Yang 2012; Yilmaz
2002).
Excluded studies
We excluded 410 full-text reports. The main reason for exclusion
was that the participants did not present with moderate to severe
psoriasis (n = 203): these psoriasis participants were included in
trials assessing the efficacy of our treatments of interest for psoriatic
arthritis or had cutaneous lesions of psoriasis but not moderate to
severe psoriasis. We detail the reason for exclusion of the 207 full-
text reports in Characteristics of excluded studies: we excluded 99
because they assessed another intervention, 45 were not a trial,
three did not include plaque-type psoriasis, and we excluded 60
for other reasons.
For six studies with three arms, one arm was not included as the
intervention was not included in our search:
• Saurat 1988: acitretin versus placebo versus etretinate
(etretinate arm was not included);
• Shehzad 2004: PUVA (psoralen and ultraviolet A) therapy
versus methotrexate (methotrexate only was included);
• Gottlieb 2011; Strober 2011: briakinumab versus
etanercept versus placebo (briakinumab arm was not included);
• Gisondi 2008: etanercept versus acitretin versus etanercept
plus acitretin (etanercept plus acitretin arm was not included);
• Al-Hamamy 2014: narrowband ultraviolet B phototherapy
plus methotrexate versus narrowband ultraviolet B alone and
methotrexate alone (arm with methotrexate alone was not
included).
Thaçi 2002 compared two different dosages of ciclosporin (a fixed
dosage of 200 mg/day and a dosage corresponding to 2.5 mg/kg/
day), and we were unable to classify the fixed dosage group either
in the ciclosporin ≥ 3 mg/kg/day group nor in the ciclosporin <
3 mg/day group for the subgroup meta-analysis.
Studies awaiting classification
We classified 14 trials reported in 18 references as studies awaiting
classification. More details regarding the studies awaiting classifi-
cation are available in Studies awaiting classification and Table 2.
Ongoing studies
We classified 34 trials as ongoing studies. More details are avail-
able in Characteristics of ongoing studies and Table 2. Most of the
ongoing studies compare a biological treatments versus another
biological treatment or versus placebo (n = 13 and n = 14, respec-
tively). Three ongoing studies assess apremilast versus placebo, and
four assess conventional systemic treatments versus conventional
systemic treatments (n = 2) or placebo (n = 2).
Risk of bias in included studies
Figure 2 andFigure 3 summarise ’Risk of bias’ assessments. Regard-
ing the overall risk of bias across studies, 23 trials were at low risk
of bias (Asahina 2016; Bachelez 2015; Blauvelt FEATURE, 2015;
Blauvelt VOYAGE-1, 2016; Cai 2016; Gordon UNCOVER-1,
2016; Griffiths UNCOVER-2, 2015; Griffiths UNCOVER-3,
2015; Langley ERASURE, 2014; Langley FIXTURE, 2014;
Leonardi 2012; Papp PHOENIX-2, 2008; Papp 2012; Papp
2012a; Papp 2012b; Reich 2015; Reich 2012; Reich VOYAGE-2,
2017; Rich 2013; Saurat CHAMPION, 2008; Thaci CLEAR,
2015; Vaclavkova 2014; Warren METOP, 2017). We categorised
almost half of the studies (48/109) as at high risk of bias. Among
the high-risk group, five studies had only one high risk of bias do-
main with all the other dimensions at low risk (Bissonnette 2015;
Lebwohl 2003; Papp 2013a; Papp OPT Pivotal-1, 2015; Reich
LIBERATE, 2017).We categorised the remaining38 studies as un-
clear risk of bias because we assessed one ormore criteria as unclear.
Among the unclear ’Risk of bias’ group, 11 studies had only one
unclear risk of bias with all the other dimensions at low risk (Bagel
2012; Krueger 2016; Leonardi 2003; Leonardi PHOENIX-1,
2008; Menter EXPRESS-II, 2007; Menter REVEAL, 2008; Papp
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AMAGINE-1, 2016; Paul JUNCTURE, 2015; Paul ESTEEM-2,
2015; Reich EXPRESS, 2005; Tyring 2006). Further details of
these assessments are available in the ’Risk of bias’ table corre-
sponding to each trial in the Characteristics of included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
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Figure 3. ’Risk of bias’ graph: review authors’ judgements about each ’Risk of bias’ item presented as
percentages across all included studies
Allocation
The method of sequence generation was not described at all, or
was at best unclear, in 48 trials. The remaining studies (n = 61)
described the method used to generate the allocation sequence in
sufficient detail; therefore, we judged this domain as low risk of
bias for these studies. For allocation concealment, the majority of
studies (n = 56) received a judgement of unclear risk of bias for
this domain because of the absence of reporting the method used
to guarantee concealment. We considered the risk low for the 53
remaining trials.
Blinding
Blinding of participants and personnel was achieved in 74 studies,
whereas 30 studies were at high risk of performance bias. The
remaining five studies were at unclear risk of performance bias.
Blinding of outcome assessment was reported clearly in only 74
of the 109 included studies, whereas 21 studies were at high risk
of detection bias. The risk of detection bias was unclear in the
remaining 14 studies.
Incomplete outcome data
In more than half of the trials (69/109), incomplete outcome
data appeared to have been adequately addressed, and any missing
outcome data were reasonably well balanced across intervention
groups, with similar reasons for missing data across the groups.
However, in 13 studies the reporting of missing outcome data was
largely inadequate because of one ormore of the following reasons:
the high number of withdrawnparticipants, an imbalance between
groups in the number of withdrawn participants, an imbalance
in reasons for missing outcomes, or no intention-to-treat (ITT)
analysis provided. In 27 studies, this domain was as at unclear risk
of bias due to one ormore of the following reasons: the numbers of
participants, reasons, or missing data methods were not reported.
Selective reporting
We considered 14 trials at high risk of selective outcome re-
porting because results for outcomes detailed in the methods
section were not reported in the results section (Akcali 2014;
Engst 1994; Hunter 1963; Jacobe 2008; Lebwohl 2003; Lebwohl
AMAGINE-2, 2015; Lebwohl AMAGINE-3, 2015; Mrowietz
BRIDGE, 2016; Nakagawa 2016; Papp 2013b; Papp 2005; Reich
LIBERATE, 2017; Shehzad 2004; Yan 2011). In all, we consid-
ered 49 studies to be at low risk of bias for this domain as outcome
details in the trial register and in themethods sectionwere reported
in the results section. For other trials (n = 46), we considered the
risk of bias as unclear because we did not find these trials in any
register.
Other potential sources of bias
As detailed in the Methods section, we did not fulfil the ’other
risk of bias’ item as we did not highlight particular circumstances
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leading to other risk of bias from particular trial designs, contam-
ination between the experimental and control groups, and partic-
ular clinical settings.
Effects of interventions
See: Summary of findings for the main comparison Any
systemic treatment compared to placebo for chronic plaque
psoriasis
See: Summary of findings for the main comparison The summary
of findings for the main comparison provides overall estimates
of treatment effects compared with placebo and the certainty of
the available evidence for the two primary outcomes (PASI 90
and serious adverse effects during the induction phase), obtained
through network meta-analysis.
Seven trials provided no usable or retrievable data and did not con-
tribute further to the results of this review (Akcali 2014; Chladek
2005; Engst 1994; Lowe 1991; Piskin 2003; Olsen 1989; Shehzad
2004; see Table 2). The main reason we could not use their
data was that these studies addressed none of our outcomes. Fif-
teen studies, involving 1113 participants (2.8% of the partici-
pants in this review), had a co-intervention and did not con-
tribute further to the results of this review as we could not assess
the specific intervention effect (Al-Hamamy 2014; Asawanonda
2006; Bissonnette 2013; Gottlieb 2012; Gurel 2015; Jacobe
2008; Lowe 1991; Mahajan 2010; Ruzicka 1990; Saurat 1988;
Shehzad 2004; Sommerburg 1993; Tanew 1991; Van Bezooijen
2016; Yilmaz 2002). Twenty-six studies had an outcome assess-
ment before 12 weeks (Akcali 2014; Chaudhari 2001; Goldfarb
1988; Gottlieb 2004; Hunter 1963; Menter EXPRESS-II, 2007;
Meffert 1997;Olsen 1989; Reich EXPRESS, 2005; Ruzicka 1990;
Sommerburg 1993; Saurat 1988; Torii 2010; Yang 2012), or later
than 16 weeks (Al-Hamamy 2014; Asahina 2016; Asawanonda
2006; Bissonnette 2013; Bissonnette 2015; deVries PIECE, 2016;
Engst 1994; Gisondi 2008;Gottlieb 2012; Ortonne 2013; Strohal
PRISTINE, 2013; Van Bezooijen 2016).
In total, 35 studies, involving 4433 participants, were not included
in the classical or network meta-analysis. The interventions of the
35 studies particularly concerned the following:
• infliximab (n = 7) (Chaudhari 2001; de Vries PIECE, 2016;
Gottlieb 2004; Menter EXPRESS-II, 2007; Reich EXPRESS,
2005; Torii 2010; Yang 2012)
• acitretin (n = 8) (Akcali 2014; Goldfarb 1988; Gisondi
2008; Gurel 2015; Lowe 1991; Ruzicka 1990; Saurat 1988;
Sommerburg 1993)
• methotrexate (n = 5) (Asawanonda 2006; Al-Hamamy
2014; Gottlieb 2012; Mahajan 2010; Shehzad 2004)
• ciclosporin (n = 1) (Meffert 1997)
We included a total of 74 studies, involving 35,454 participants
(88.9% participants of this review), in the network meta-analysis
for at least one of the outcomes.
Figure 4 and Figure 5 show the network diagrams for all of the
outcomes included in the review. The size of the nodes is propor-
tional to the total number of participants allocated to each class
level (Figure 4)/drug level (Figure 5) intervention, and the thick-
ness of the lines is proportional to the number of trials evaluating
each direct comparison.
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Figure 4. Network plot for all the outcomes at class-levelThe size of the nodes is proportional to the total
number of participants allocated to each intervention and the thickness of the lines proportional to the
number of studies evaluating each direct comparison.AE: adverse events; PASI: Psoriasis Area and Severity
Index; PGA: Physician Global Assessment; QoL: quality of life; SAE: serious adverse events
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Figure 5. Network plot for all the outcomes at drug-levelThe size of the nodes is proportional to the total
number of participants allocated to each intervention and the thickness of the lines proportional to the
number of studies evaluating each direct comparison.ACI: acitretin; ADA: adalimumab; APRE: apremilast;
BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX:
infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo;
PONE: ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumabAE:
adverse events; PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment; QoL: quality of
life; SAE: serious adverse events
Figure 6 shows the network meta-analysis estimates of all of the
outcomes for each comparisons at class level.
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Figure 6. Relative effects of the class-level intervention as estimated from the network meta-analysis
modelDrugs are reported in order of primary benefit ranking. Each cell contains the risk ratio (RR) (for
dichotomous outcomes: PASI 90, serious adverse events, PASI 75, PGA 0/1, adverse events) or the
standardised mean difference (SMD) (for the quality-of-life outcome), plus the 95% confidence interval, of the
class level in the respective column versus the class level in the respective row. RRs larger than 1 for the lower
triangle and smaller than 1 (or SMDs smaller than zero) for the upper triangle favour the treatment on the
left. Significant results are bolded and underscored.AE: adverse events; PASI: Psoriasis Area and Severity
Index; PGA: Physician’s Global Assessment; QoL: quality of life; SAE: serious adverse events
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Figure 7, Figure 8, and Figure 9 show the network meta-analysis
estimates of all the outcomes for each comparison at drug level.
Figure 7. Relative effects of the intervention as estimated from the network meta-analysis model for
Psoriasis Area and Severity Index (PASI) 90 and serious adverse events (SAEs)Drugs are reported in order of
primary benefit ranking. Each cell contains the risk ratio (RR) and 95% confidence interval for the two primary
outcomes (PASI 90 and SAEs) of the intervention in the respective column versus the class level in the
respective row. RRs larger than 1 for the lower triangle and smaller than 1 for the upper triangle favour the
treatment on the left. Significant results are highlighted in grey.ACI: acitretin; ADA: adalimumab; APRE:
apremilast; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric
acid; IFX: infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO:
placebo; PONE: ponesimod; SECU: secukinumab; τ (Tau): estimated heterogeneity standard deviation
parameter; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumab
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Figure 8. Relative effects of the intervention as estimated from the network meta-analysis model for
Psoriasis Area and Severity Index (PASI 75) and adverse events (AEs)Drugs are reported in order of primary
benefit ranking. Each cell contains the Risk Ratio (RR) and 95% confidence interval for the two secondary
outcomes (PASI 75 and adverse events) of the intervention in the respective column versus the comparator in
the respective row. RRs larger than 1 for the lower triangle and smaller than 1 for the upper triangle favour the
treatment on the left. Significant results are are highlighted in grey.ACI: acitretin; ADA: adalimumab; APRE:
apremilast; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric
acid; IFX: infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO:
placebo; PONE: ponesimod; SECU: secukinumab; τ (Tau): estimated heterogeneity standard deviation
parameter; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumab
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Figure 9. Relative effects of the intervention as estimated from the network meta-analysis model for
Physician’s Global Assessment (PGA 0/1) and quality of life (QoL)Drugs are reported in order of primary
benefit ranking. Each cell contains the risk ratio (RR) and 95% confidence interval (PGA 0/1) or standardized
mean difference (quality of life) of the intervention in the respective column versus the comparator in the
respective row. RRs larger than 1 for the lower triangle and smaller than 1 (or SMDs smaller than zero) for the
upper triangle favour the treatment on the left. Significant results are are highlighted in grey.ACI: acitretin;
ADA: adalimumab; APRE: apremilast; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA:
etanercept; FUM: fumaric acid; IFX: infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX:
methotrexate; PBO: placebo; PONE: ponesimod; SECU: secukinumab; τ (Tau): estimated heterogeneity
standard deviation parameter; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumab
Figure 10 and Figure 11 show all of the relative effects from the
network meta-analyses against placebo with their 95% confidence
and prediction intervals at class and drug level.
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Figure 10. Interval plot. Network meta-analysis estimates of class-level versus placebo for all the
outcomesAE: adverse events; CI: confidence interval; PGA: Physician Global Assessment; PrI: predictive
interval; QoL: Specific quality of life scale; RR: risk ratio; SAE: serious adverse events; SMD: standardised
mean difference
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Figure 11. Interval plot. Network meta-analysis estimates of the interventions versus placebo for all the
outcomesAE: adverse events; CI: confidence interval; PGA: Physician Global Assessment; PrI: predictive
interval; QoL: Specific quality of life scale; RR: risk ratio; SAE: serious adverse events; SMD: standardised
mean differenceACI: acitretin; ADA: adalimumab; APRE: apremilast; BRODA: brodalumab; CERTO:
certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX: infliximab; ITO: itolizumab; IXE:
ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo; PONE: ponesimod; SECU:
secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumab
Figure 12 shows a two-dimensional ranking plot based on surface
under the cumulative ranking curve (SUCRA) values for benefit
(PASI 90) and acceptability (serious adverse events) at class and
drug level. The different colours represent different groups of in-
terventions considering their performance on both outcomes si-
multaneously. Interventions belonging to the same group were as-
sumed to have a similar performance when the two primary out-
comes were considered jointly (Chaimani 2013).
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Figure 12. Ranking plot. Ranking plot representing simultaneously the efficacy (x axis, PASI 90) and the
acceptability (y axis, serious adverse events) of all the interventions (class and drug levels) for patients with
moderate-to-severe psoriasis. Optimal treatment should be characterised by both high efficacy and
acceptability and should be in the right upper corner of this graph.The different colours represent different
groups of interventions considering their performance on both outcomes simultaneously. Interventions
belonging to the same group are assumed having a similar performance when the two primary outcomes are
considered jointlyACI: acitretin; ADA: adalimumab; APRE: apremilast; BRODA: brodalumab; CERTO:
certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX: infliximab; ITO: itolizumab; IXE:
ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo; PONE: ponesimod; SECU:
secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumabPASI: Psoriasis Area and Severity
Index; SAE: serious adverse events; SUCRA: surface under the cumulative ranking curve
Figure 13 and Figure 14 show the ranking for all the outcomes at
class and drug level, respectively.
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Figure 13. Ranking for all the outcomes at class levelAE: adverse events; PASI: Psoriasis Area and Severity
Index; PGA: Physician Global Assessment; QoL: quality of life; SAE: serious adverse events
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Figure 14. Ranking for all the outcomes at drug levelACI: acitretin; ADA: adalimumab; APRE: apremilast;
BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX:
infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo;
PONE: ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumabAE:
adverse events; PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment; QoL: quality of
life; SAE: serious adverse events
1. Primary outcomes
1.1 The proportion of participants who achieved clear or
almost clear skin, e.g. PASI 90
DIRECT EVIDENCE
We report treatment estimates for pair-wise meta-analyses at class
(see Figure 15) anddrug level inAnalysis 1.1; Analysis 1.2; Analysis
1.3; Analysis 1.4; Analysis 1.5; Analysis 1.6; Analysis 1.7; Analysis
1.8; Analysis 1.9; Analysis 1.10; and Analysis 1.11, respectively.
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Figure 15. PASI 90: direct summary effects for comparisons including at least two studies at class
levelAIL12/23: anti-IL12/23; AIL17: anti-IL17; AIL23: anti-IL23, ATA: anti-TNF alpha; CSA: conventional
systemic agents; OB: other biologics; PBO: placebo; SM: small moleculesCI: confidence interval; PASI:
Psoriasis Area and Severity Index; RR: risk ratio
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In terms of reaching PASI 90, anti-IL17 treatments (secukinumab,
ixekizumab, and brodalumab) were more effective than placebo
(risk ratio at class level (RR) 30.02, 95% confidence interval (CI)
21.14 to 42.64). These findings were also confirmed for anti-
IL23 (guselkumab and tildrakizumab) (class-level RR 25.36, 95%
CI 14.80 to 43.43); ustekinumab (RR 22.00, 95% CI 14.90
to 32.48); anti-TNF alpha (etanercept, adalimumab, and cer-
tolizumab) (class-level RR 12.97, 95% CI 9.89 to 17.02); and
small molecules (apremilast, tofacitinib, and ponesimod) (class-
level RR 6.40, 95% CI 4.48 to 9.13). Both infliximab and adali-
mumab were more effective than methotrexate (respectively: RR
2.86, 95% CI 2.15 to 3.80; and RR 3.73, 95% CI 2.25 to 6.19).
Ustekinumab, secukinumab, and ixekizumab were more effec-
tive than etanercept; secukinumab and brodalumab were more
effective than ustekinumab; and guselkumab was more effective
than adalimumab. No significant difference was observed between
etanercept and tofacitinib or apremilast in terms of this outcome
(reaching PASI 90).
NETWORK META-ANALYSES
The PASI 90 outcome was available in 58 trials, involving 31,176
participants (87.9% of the participants in the meta-analysis). This
outcome was reported in two other trials (Nugteren-Huying 1990;
Sandhu 2003); however, the number of randomised participants
was not available. These trialswere added in the complete case anal-
yses. This outcome was also reported in three other trials (Dogra
2012; Dogra 2013; Mrowietz SCULPTURE, 2015), comparing
different dosages of the same drug in each case. These trials were
added to the sensitivity analysis at dose level. PASI 90 was not
reported for the remaining nine trials, and we were not able to ob-
tain missing information from the trial authors (Table 2). Thirty-
nine trials, involving 16,888 participants, were placebo-controlled
trials; seven studies, involving 2048 participants, were head-to-
head comparisons; and 12 studies, involving 12,240 participants,
had both a placebo and at least two active treatments arms.
See Figure 4; Figure 5; Figure 6; Figure 7; Figure 10; Figure 11;
Figure 13; and Figure 14.
Table 3 summarises the main results of both the direct and indi-
rect evidence and the network meta-analysis for PASI 90 at 12 to
16 weeks. The summary relative effects from the network meta-
analysis are presented in league tables for both class-level (Figure
6) and drug-level (Figure 7) analyses.
All of the interventions appeared superior to placebo in terms
of reaching PASI 90. Anti-IL17 treatment was associated with a
higher chance of reaching PASI 90 compared to all of the interven-
tions: versus anti-IL12/23 (risk ratio (RR) 1.33, 95% confidence
interval (CI) 1.19 to 1.49); versus anti-IL23 (RR 1.86, 95% CI
1.54 to 2.26); versus anti-TNF alpha (RR 2.66, 95% CI 2.34 to
3.03); versus small molecules (RR 3.52, 95% CI 2.65 to 4.66);
versus other biologics (RR 6.44, 95% CI 2.44 to 17.04); versus
conventional systemic agents (RR 8.15, 95% CI 6.07 to 10.93)
(Figure 6). In terms of reaching PASI 90, all of the biologic in-
terventions (anti-IL17, anti-IL12/23, anti-IL23, anti-TNF alpha)
appeared significantly superior to the small molecule class of treat-
ments and the conventional systemic class of treatments. Small
molecules were associated with a higher chance of reaching PASI
90 compared to conventional systemic agents (RR 2.31, 95% CI
1.63 to 3.28).
Results of comparisons between each of the drugs are available in
Figure 7. There was no significant difference between the three
anti-IL17 (brodalumab, ixekizumab, and secukinumab) and the
two anti-IL23 (tildrakizumab and guselkumab) monoclonal anti-
bodies in terms of reaching PASI 90. All of the anti-IL17 drugs
(brodalumab, ixekizumab, and secukinumab) and guselkumab (an
anti-IL23) were significantly more effective than three anti-TNF
alpha agents: infliximab, adalimumab, and etanercept. The direct
comparison regarding certolizumab and tildrakizumab only in-
cluded one trial each, so the interpretation of the results regard-
ing certolizumab and tildrakizumab was difficult (related to wide
CIs). Ustekinumab was superior to etanercept (RR 1.85, 95% CI
1.50 to 2.27). No significant difference was shown between the
anti-TNF alpha drugs. Tofacitinib was significantly superior to
methotrexate (RR 2.17, 95% CI 1.13 to 4.20), and no significant
difference was shown between apremilast and the conventional
drugs (versus acitretin: RR 7.81, 95% CI 0.42 to 143.83; versus
fumaric acid: RR 1.87, 95% CI 0.71 to 4.93; versus ciclosporin:
RR 1.92, 95% CI 0.72 to 5.12; versus methotrexate: RR 1.96,
95% CI 0.85 to 4.50).
Ranking class-level analysis (Figure 10; Figure 13; Table 4)
Ranking analysis for PASI 90 performed with SUCRA strongly
suggested that anti-IL17was the best treatment at class level (versus
placebo: RR 30.81, 95% confidence interval (CI) 25.10 to 37.82;
SUCRA = 100; high-certainty evidence), followed by anti-IL12/
23 (versus placebo: RR 23.16, 95% CI 18.70 to 28.68; SUCRA =
85.7; high-certainty of evidence), anti-IL23 (versus placebo: RR
16.53, 95% CI 13.16 to 20.75; SUCRA = 71.3; moderate-cer-
tainty evidence), then anti-TNF alpha (versus placebo: RR 11.58,
95% CI 9.55 to 14.03; SUCRA = 56.4; moderate-certainty ev-
idence). The heterogeneity τ for this network overall was 0.09,
which we considered low heterogeneity.
Ranking drug-level analysis (Figure 11; Figure 14; Table 5)
Ranking analysis for PASI 90 performed with SUCRA strongly
suggested that ixekizumab was the best treatment at drug level
(versus placebo: RR 32.45, 95% CI 23.61 to 44.60; SUCRA =
94.3; high-certainty evidence), followed by secukinumab (versus
placebo: RR 26.55, 95% CI 20.32 to 34.69; SUCRA = 86.5; high
certainty of evidence), brodalumab (versus placebo: RR 25.45,
95% CI 18.74 to 34.57; SUCRA = 84.3; moderate-certainty evi-
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dence), guselkumab (versus placebo: RR 21.03, 95% CI 14.56 to
30.38; SUCRA = 77; moderate-certainty evidence), certolizumab
(versus placebo: RR 24.58, 95% CI 3.46 to 174.73; SUCRA
= 75.7; moderate-certainty evidence), then ustekinumab (versus
placebo: RR 19.91, 95%CI 15.11 to 26.23; SUCRA= 72.6; high-
certainty evidence). The heterogeneity τ for this network overall
was 0.09, which we considered low heterogeneity.
1.2 The proportion of participants with serious adverse
effects
DIRECT EVIDENCE
We report treatment estimates for pair-wise meta-analyses at class (
Figure 16) anddrug level inAnalysis 2.1; Analysis 2.2; Analysis 2.3;
Analysis 2.4; Analysis 2.5; Analysis 2.6; Analysis 2.7; Analysis 2.8;
Analysis 2.9; and Analysis 2.10, respectively.We provide details of
the serious adverse effects in Table 6 (number of serious infections,
number of malignancies, number of major adverse cardiac events
per arm at class level).
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Figure 16. Serious adverse effects: direct summary effects for comparisons including at least two studies at
class levelAIL12/23: anti-IL12/23; AIL17: anti-IL17; AIL23: anti-IL23, ATA: anti-TNF alpha; CSA: conventional
systemic agents; OB: other biologics; PBO: placebo; SM: small moleculesCI: confidence interval; RR: risk ratio;
SAE: serious adverse events
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No significant differences were observed between methotrex-
ate, FAEs, etanercept, adalimumab, certolizumab, ustekinumab,
secukinumab, ixekizumab, brodalumab, guselkumab, tildrak-
izumab, alefacept, apremilast, tofacitinib, ponesimod, and placebo
in terms of the number of paticipants with serious adverse effects
(SAEs). The risk of SAEs was significantly higher for participants
on infliximab compared to methotrexate (RR 2.41, 95% CI 1.04
to 5.59).
There were zero SAEs in the following trials: Fallah Arani 2011
(comparingmethotrexate with FAEs); Flytström 2008 (comparing
ciclosporinwithmethotrexate); andHeydendael 2003 (comparing
ciclosporin with methotrexate).
NETWORK META-ANALYSES
The SAE outcome was available in 60 trials, involving 30,898 par-
ticipants (87.1% of the participants in the meta-analysis). This
outcome was reported in one other trial (Sterry PRESTA, 2010);
however, the number of randomised participants was not available.
This trial was added to the complete-cases analyses. This outcome
was also reported in two other trials (Laburte 1994; Mrowietz
SCULPTURE, 2015), comparing different dosages of the same
drug in each case. These studies were added to the sensitivity anal-
ysis at dose level. SAEs were not reported for the 11 remaining tri-
als, and we were not able to obtain missing information from the
trial authors (Table 2). Forty-two trials, involving 16,822 partici-
pants, were placebo-controlled trials; six, involving 1836 partici-
pants, were head-to-head comparisons, and 12, involving 12,240
participants, had both a placebo and at least two active treatments
arms.
See Figure 4; Figure 5; Figure 6; Figure 7; Figure 10; Figure 11;
Figure 13; and Figure 14.
Table 7 summarised the main results of both direct and indirect
evidences and the network meta-analysis for SAEs at 12 to 16
weeks. We present the summary relative effects from the network
meta-analysis in league tables for both class-level (Figure 6) and
drug-level (Figure 7) analyses. No significant difference was found
between all of the interventions and the placebo regarding the
risk of SAE. Two significant associations were found: anti-IL17
agents and anti-TNF alpha agents had a higher risk of SAE com-
pared with conventional systemic agents (RR 2.31, 95%CI 1.20
to 4.48; RR 2.06, 95% CI 1.13 to 3.75, respectively). The results
are available in Figure 7 for comparison between each drug. Ixek-
izumab, secukinumab, and infliximab were at higher risk of SAE
than methotrexate (RR 4.86, 95%CI 1.03 to 22.88; RR 5.14,
95% CI 1.09 to 24.29; RR 2.41, 95% CI 1.04 to 5.59, respec-
tively).
Ranking class-level analysis (Figure 10; Figure 13; Table 4)
Ranking analysis for SAE performed with SUCRA strongly sug-
gested that conventional systemic treatment was associated with
the best safety profile at class level in terms of serious adverse events
(versus placebo: RR 0.48, 95% CI 0.26 to 0.88; SUCRA = 94.8),
followed by other biologics (versus placebo: RR0.72, 95%CI 0.34
to 1.55; SUCRA = 68.2), anti-IL12/23 (versus placebo: RR 0.89,
95% CI 0.58 to 1.37; SUCRA = 53.9), and then small molecules
(versus placebo: RR 0.95, 95% CI 0.63 to 1.42; SUCRA = 45.4).
The heterogeneity τ for this network overall was 0, which we con-
sidered low heterogeneity.
Ranking drug-level analysis (Figure 11; Figure 14; Table 5)
Ranking analysis for SAE performed with SUCRA strongly sug-
gested that methotrexate was associated with the best safety profile
at drug level in terms of serious adverse events (versus placebo: RR
0.23, 95% CI 0.05 to 0.99; SUCRA = 90.7; moderate-certainty
evidence), followed by ciclosporin (versus placebo: RR 0.23, 95%
CI 0.01 to 5.10; SUCRA = 78.2; very low-certainty evidence),
certolizumab (versus placebo: RR 0.49, 95% CI 0.10 to 2.36;
SUCRA = 70.9; moderate-certainty evidence), infliximab (versus
placebo: RR 0.56, 95%CI 0.10 to 3.00; SUCRA = 64.4; very low-
certainty evidence), alefacept (versus placebo: RR 0.72, 95% CI
0.34 to 1.55; SUCRA = 62.6; low-certainty evidence), and then
the FAEs (versus placebo: RR 0.77, 95%CI 0.30 to 1.99; SUCRA
= 57.7; very low-certainty evidence). The heterogeneity τ for this
network overall was 0, which we considered low heterogeneity.
Placebo had a worse ranking for SAE than conventional systemic
agents, other biologics, anti-IL12/23, and small molecules (see
Table 5). Nevertheless, analyses on serious adverse events were
based on a very lownumber of events andwere reduced to the short
time frame of the trials. Table 6 gives details of the types of SAE;
major adverse cardiac events, serious infections, or malignancies
were reported in both placebo and intervention groups.
1.3 Relationship between PASI 90 and serious adverse events
See Figure 12.
These findings for both efficacy (PASI 90) and acceptability (seri-
ous adverse events) were combined together in a bivariate ranking
plot, where serious adverse events was transformed into accept-
ability by using the inverse values of the corresponding RRs so that
higher values indicate higher acceptability (due to lower SAE): ac-
cordingly, the ideal treatment (highest performance = best efficacy
+ best acceptability) should appear in the upper right corner of the
plot.
At class level, the highly effective treatments had serious adverse
events. However, the anti-IL12/23 treatment group was the class
with the better compromise between efficacy and acceptability.
At drug level, ustekinumab, certolizumab, and infliximab might
be the overall best treatments considering both outcomes jointly.
This result has to be considered with cautioun for certolizumab
and infliximab as only one trial was available for this drug.
47Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2. Secondary outcomes
2.1 Mean difference of quality of life measured by a specific
scale
DIRECT EVIDENCE
We report treatment estimates for pair-wise meta-analyses at class
(Figure 17) and drug level in Analysis 3.1; Analysis 3.2; Analysis
3.3; Analysis 3.4; Analysis 3.5; Analysis 3.6; Analysis 3.7; Analysis
3.8; Analysis 3.9; Analysis 3.10; and Analysis 3.11 respectively.
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Figure 17. Specific quality of life scale: direct summary effects for comparisons including at least two
studies at class levelAIL12/23: anti-IL12/23; AIL17: anti-IL17; AIL23: anti-IL23, ATA: anti-TNF alpha; CSA:
conventional systemic agents; OB: other biologics; PBO: placebo; SM: small moleculesCI: confidence interval;
QoL: specific quality of life scale; SMD: standardised mean difference
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NETWORK META-ANALYSES
The quality of life outcome was available in 39 trials, involving
21,745 participants (61.3% of the participants in this review).
This outcome was reported in one other trial (Krueger 2002);
however, the number of randomised participants was not avail-
able. This trial were added to the complete case analyses. This out-
come was also reported in another trial (Mrowietz SCULPTURE,
2015), comparing different dosages of the same drug. This trial,
Mrowietz SCULPTURE, 2015, was added in the sensitivity anal-
yses at dose level. The quality of life outcome was not reported for
the 35 remaining trials, and we were not able to obtain missing
information from the trial authors (Table 2). Twenty-eight trials,
involving 13,040 participants, were placebo-controlled trials; two,
involving 1080 participants, were head-to-head comparisons; and
nine, involving 7625 participants, had both a placebo and at least
two active treatments arms.
See Figure 4; Figure 5; Figure 6; Figure 9; Figure 10; Figure 11;
Figure 13; and Figure 14.
We present the summary relative effects from the network meta-
analysis in league tables for both class-level (Figure 6) and drug-
level (Figure 9) analyses. All of the interventions appeared superior
to placebo in terms of showing significant improvement on a qual-
ity of life scale. Anti-IL17, anti-IL23, and anti-IL12/23 were asso-
ciated with a higher chance of improving quality of life compared
to small molecules and conventional systemic agents (Figure 6).
These differences were statistically significant for all of the classes.
No significant difference was shown between the different biolog-
ical agents except for anti-IL17 and anti-TNF alpha (anti-IL17
was more favourable than anti-TNF alpha). No significant differ-
ences were shown between the small molecules and the conven-
tional agents. Results of comparisons between each of the drugs
are available in Figure 9.
Ranking class-level analysis (Figure 10; Figure 13; Table 4)
Ranking analysis for quality of life performed with SUCRA
strongly suggested that anti-IL17 was the best treatment at class
level (versus placebo: standardised mean difference (SMD) -1.44,
95% confidence interval (CI) -1.68 to -1.19; SUCRA = 95.4),
followed by anti-IL23 (versus placebo: SMD -1.30 95% CI -1.60
to -0.99; SUCRA = 83.4), anti-IL12/23 (versus placebo: SMD -
1.21 95% CI -1.45 to -0.96; SUCRA = 75.7), then anti-TNF al-
pha (versus placebo: SMD -1.03 95% CI -1.18 to -0.88 SUCRA
= 58.4). The heterogeneity τ for this network overall was 0.27,
which we considered moderate heterogeneity.
Ranking drug-level analysis (Figure 11; Figure 14 Table 5)
Ranking analysis for quality of life performed with SUCRA
strongly suggested that ixekizumab was the best treatment at drug
level (versus placebo: SMD -1.68 95% CI -1.93 to -1.43; SU-
CRA = 99.2), followed by guselkumab (versus placebo: SMD -
1.31 95% CI -1.61 to -1.01; SUCRA = 84.3), ustekinumab (ver-
sus placebo: SMD -1.21 95% CI -1.42 to -1.00; SUCRA = 77.4),
tildrakizumab (versus placebo: SMD -1.23 95% CI -1.77 to -
0.68; SUCRA = 74.9), then etanercept (versus placebo: SMD -
1.11 95% CI -1.29 to -0.93; SUCRA = 67.6). The heterogene-
ity τ for this network overall was 0.22, which we considered low
to moderate heterogeneity. Moreover, six interventions (acitretin,
certolizumab, ciclosporin, fumaric acid, infliximab, secukinumab)
were not included in the ranking at drug level, due to no available
data.
In total, available informationonquality of life was poorly reported
and lacking for a third of the interventions, so has to be considered
with cautious.
2.2 Proportion of participants who achieve a Physician
Global Assessment (PGA) value at 0 or 1
DIRECT EVIDENCE
We report treatment estimates for pair-wise meta-analyses at class
(Figure 18) and drug level in Analysis 4.1; Analysis 4.2; Analysis
4.3; Analysis 4.4; Analysis 4.5; Analysis 4.6; Analysis 4.7; Analysis
4.8; Analysis 4.9; Analysis 4.10; and Analysis 4.11, respectively.
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Figure 18. Physician Global Assessment 0/1: direct summary effects for comparisons including at least two
studies at class-levelAIL12/23: anti-IL12/23; AIL17: anti-IL17; AIL23: anti-IL23, ATA: anti-TNF alpha; CSA:
conventional systemic agents; OB: other biologics; PBO: placebo; SM: small moleculesAE: adverse events; CI:
confidence interval; PGA: Physician Global Assessment; RR: risk ratio
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NETWORK META-ANALYSES
The PGA 0/1 outcome was available in 56 trials, involving
31,030 participants (87.5% of the participants in this review).
This outcome was reported in four other studies (Krueger 2002;
Nugteren-Huying 1990; Sandhu 2003; Sterry PRESTA, 2010);
however, the number of randomised participants was not available.
These trials were added to the complete case analyses. This out-
come was also reported in another trial (Mrowietz SCULPTURE,
2015), comparing different dosages of the same drug. These trials
were added in the sensitivity analysis at dose level. PGA 0/1 was
not reported for the 13 remaining trials, and we were not able to
obtain missing information from the trial authors (Table 2). Forty
trials, involving 16,946 participants, were placebo-controlled tri-
als; four, involving 1844 participants, were head-to-head compar-
isons; and 12, involving 12,240 participants, had both a placebo
and at least two active treatments arms.
See Figure 4; Figure 5; Figure 6; Figure 9 Figure 10; Figure 11;
Figure 13; and Figure 14.
We presented the summary relative effects as estimated from the
network meta-analysis in league tables at class level (Figure 6) and
drug level (Figure 9). All of the interventions appeared superior to
placebo in terms of reaching PGA 0/1, and anti-IL17 monoclonal
antibodies were associated with a better chance in terms of this
outcome compared to the other drug classes (Figure 6). These
differences were statistically significant. All of the interventions
(anti-IL17, anti-IL23, anti-IL12/23, anti-TNF alpha) appeared
significantly superior to the small molecule class of treatments
and the conventional systemic class of treatments. No significant
difference was found between small molecule and conventional
systemic agents. Results of comparisons between each of the drugs
are available in Figure 9.
Ranking class-level analysis (Figure 10; Figure 13; Table 4)
Ranking analysis for PGA 0/1 performed with SUCRA strongly
suggested that anti-IL17was the best treatment at class level (versus
placebo: RR 15.85, 95% confidence interval (CI) 13.08 to 19.20;
SUCRA = 99.9), followed by anti-IL12/23 (versus placebo: RR
11.80, 95% CI 9.67 to 14.39; SUCRA = 83.8), anti-IL23 (versus
placebo: RR 9.93, 95% CI 7.58 to 13.02; SUCRA = 73.1), then
anti-TNF alpha (versus placebo: RR 7.82, 95% CI 6.66 to 9.17;
SUCRA = 57.5). The heterogeneity τ for this network overall was
0.21, which we considered low to moderate heterogeneity.
Ranking drug-level analysis (Figure 11; Figure 14; Table 5)
Ranking analysis for PGA 0/1 performed with SUCRA strongly
suggested that certolizumab was the best treatment at drug level
(versus placebo: RR 35.88, 95% CI 4.86 to 265.07; SUCRA =
90.1), followed by tildrakizumab (versus placebo: RR 27.54, 95%
CI 3.76 to 201.98; SUCRA = 86.3), ixekizumab (versus placebo:
RR 16.11, 95%CI 11.72 to 22.17; SUCRA= 85.9), secukinumab
(versus placebo: RR 15.46, 95% CI 11.19 to 21.37; SUCRA =
84.4), brodalumab (versus placebo: RR 15.31, 95% CI 10.84
to 21.63; SUCRA = 84), then ustekinumab (versus placebo: RR
11.52, 95% CI 9.17 to 14.4; SUCRA = 70.4). The heterogeneity
τ for this network overall was 0.23, which we considered low to
moderate heterogeneity.
2.3 Proportion of participants who achieve PASI 75
DIRECT EVIDENCE
We report treatment estimates for pair-wise meta-analyses at class
(Figure 19) and drug level in Analysis 3.1; Analysis 3.2; Analysis
3.3; Analysis 3.4; Analysis 3.5; Analysis 3.6; Analysis 3.7; Analysis
3.8; Analysis 3.9; Analysis 3.10; and Analysis 3.11, respectively.
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Figure 19. PASI 75: direct summary effects for comparisons including at least two studies at class
levelAIL12/23: anti-IL12/23; AIL17: anti-IL17; AIL23: anti-IL23, ATA: anti-TNF alpha; CSA: conventional
systemic agents; OB: other biologics; PBO: placebo; SM: small moleculesCI: confidence interval; PASI:
Psoriasis Area and Severity Index; RR: risk ratio
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NETWORK META-ANALYSES
PASI 75 outcome was available in 64 trials, involving 32,518 par-
ticipants (91.7% of the participants in this review). This outcome
was reported in two other trials (Krueger 2002; Sterry PRESTA,
2010); however, the number of randomised participants was not
available. These trials were added to the complete case analy-
ses. This outcome was also reported in five other trials (Dogra
2012; Dogra 2013; Dubertret 1989; Laburte 1994; Mrowietz
SCULPTURE, 2015), comparing different dosages of the same
drug in each case. These trials were added in the sensitivity anal-
ysis at dose level. PASI 75 was not reported for the three remain-
ing trials, and we were not able to obtain missing information
from the trial authors (Table 2). Forty-five trials, involving 18,330
participants, were placebo-controlled trials; seven, involving 1948
participants, were head-to-head comparisons; and 12, involving
12,240 participants, had both a placebo and at least two active
treatments arms.
See Figure 4; Figure 5; Figure 6; Figure 8; Figure 10; Figure 11;
Figure 13; and Figure 14.
We present the summary relative effects from the network meta-
analysis in league tables for both class-level (Figure 6) and drug-
level (Figure 8) analyses. All of the interventions appeared superior
to placebo in terms of reaching PASI 75. The anti-IL17 class of
drugs was associated with a higher chance of reaching PASI 75
compared to the other classes (Figure 6). These differences were
statistically significant for all of the classes. All of the interven-
tions (anti-IL17, anti-IL23, anti-IL12/23, anti-TNF alpha) ap-
peared significantly superior to the small molecule class and the
conventional systemic class, and the small molecules appeared sig-
nificantly superior to the conventional systemic agents. Results of
comparisons between each of the drugs are available in Figure 8.
Ranking class-level analysis (Figure 10; Figure 13; Table 4)
Ranking analysis for PASI 75 performed with SUCRA strongly
suggested that anti-IL17was the best treatment at class level (versus
placebo: RR 14.32, 95% CI 12.20 to 16.81; SUCRA = 99.6),
followed by anti-IL12/23 (versus placebo: RR 12.21, 95% CI
10.23 to 14.57; SUCRA = 85.0), anti-IL23 (versus placebo: RR
10.07, 95% CI 8.03 to 12.63; SUCRA = 72.2), then anti-TNF
alpha (versus placebo: RR 8.23 95% CI 7.20 to 9.42; SUCRA
= 57.4). The heterogeneity τ for this network overall was 0.16,
which we considered low heterogeneity.
Ranking drug-level analysis (Figure 11; Figure 14; Table 5)
Ranking analysis for PASI 75 performed with SUCRA strongly
suggested that ixekizumab was the best treatment at drug level
(versus placebo: RR 15.81, 95% CI 12.35 to 20.23; SUCRA =
91.8), followed by secukinumab (versus placebo: RR 14.16, 95%
CI 11.12 to 18.03; SUCRA = 86.7), brodalumab (versus placebo:
RR13.04 95%CI 10.17 to 16.71; SUCRA=82.1), tildrakizumab
(versus placebo: RR 14.51, 95% CI 3.60 to 58.45; SUCRA =
78.3), then ustekinumab (versus placebo: RR 11.84, 95%CI 9.79
to 14.33; SUCRA = 75.2). The heterogeneity τ for this network
overall was 0.16, which we considered low heterogeneity.
Focusing on efficacy outcomes (PASI 90, PASI 75, and PGA 0/1),
the results were identical at class level (Figure 10) and very close
at drug level (Figure 11).
2.4 The proportions of participants with adverse effects
DIRECT EVIDENCE
We report treatment estimates for pair-wise meta-analyses at class
(Figure 20) and drug level in Analysis 6.1; Analysis 6.2; Analysis
6.3; Analysis 6.4; Analysis 6.5; Analysis 6.6; Analysis 6.7; Analysis
6.8; Analysis 6.9; and Analysis 6.10, respectively.
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Figure 20. Adverse effects : direct summary effects for comparisons including at least two studies at class-
levelAIL12/23: anti-IL12/23; AIL17: anti-IL17; AIL23: anti-IL23, ATA: anti-TNF alpha; CSA: conventional
systemic agents; OB: other biologics; PBO: placebo; SM: small moleculesAE: adverse events; CI: confidence
interval; RR: risk ratio
55Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NETWORK META-ANALYSES
Adverse events (AEs) outcome was available in 54 trials, involving
29,699 participants (83.8% of the participants in this review). AEs
were not reported for the 36 remaining trials, and we were not
able to obtain missing information from the trial authors (Table
2). This outcome was also reported in another trial (Mrowietz
SCULPTURE, 2015), comparing different dosages of the same
drug. Mrowietz SCULPTURE, 2015 was added to the sensitivity
analyse at dose level. Thirty-seven trials, involving 15,683 partici-
pants, were placebo-controlled trials; five, involving 1,776 partic-
ipants, were head-to-head comparisons; and 12, involving 12,240
participants, had both a placebo and at least two active treatments
arms.
See Figure 4; Figure 5; Figure 6; Figure 8; Figure 10; Figure 11;
Figure 13; and Figure 14.
We present the summary relative effects from the network meta-
analysis in league tables for both class-level (Figure 6) and drug-
level (Figure 8) analyses. All of the interventions had a more sig-
nificant risk of AEs compared to placebo. Significant associations
were found: anti-IL17 had a higher risk of AE compared with all
the other interventions. Results of comparisons between each of
the drugs are available in Figure 8.
Ranking class-level analysis (Figure 10; Figure 13; Table 4)
Ranking analysis for AEs performed with SUCRA strongly sug-
gested that placebo was associated with the best safety profile re-
garding all the adverse events (SUCRA 94.0). Anti-IL23 was the
best treatment at class level (versus placebo: RR 1.03, 95% CI
0.93 to 1.13; SUCRA = 78.7), followed by anti-IL12/23 (versus
placebo: RR 1.07, 95% CI 1.01 to 1.14; SUCRA = 57.0), then
conventional systemic treatment (versus placebo: RR 1.08, 95%
CI 0.99 to 1.17; SUCRA = 50.8). The heterogeneity τ for this
network overall was 0.05, which we considered low heterogeneity.
Ranking drug-level analysis (Figure 11; Figure 14; Table 5)
Ranking analysis for AE performed with SUCRA strongly sug-
gested that placebo was associated with the best safety profile re-
garding all the adverse events (SUCRA = 88), then tildrakizumab
(versus placebo: RR 0.95, 95% CI 0.76 to 1.19; SUCRA = 86.1),
followed by guselkumab (versus placebo: RR 1.02, 95% CI 0.80
to 1.13; SUCRA = 78.2) and certolizumab (versus placebo: RR
1.00 95% CI 0.80 to 1.23; SUCRA = 78). The heterogeneity τ
for this network overall was 0.04, which we considered low het-
erogeneity.
2.5. Participants with at least 1 relapse in the maintenance
phase (between 52 to 104 weeks)
There were no data available for the maintenance phase.
3. Assessment of heterogeneity and inconsistency
We did not identify important heterogeneity neither in direct
meta-analyses nor in network meta-analysis. The common out-
come-specified network heterogeneity and the prediction inter-
vals suggested the presence of low heterogeneity for all outcomes
except for quality of life, which appeared to have moderate het-
erogeneity. We investigated differences in heterogeneity between
class- and drug-level analysis, and we also investigated differences
in heterogeneity between primary and sensitivity analyses for the
primary outcomes (see 4. subgroup and sensitivity analyses).
The results were very closed.
The distribution of some participant characteristics (age, sex ra-
tio, weight, severity of psoriasis) did not give an indication of im-
portant differences in these characteristics across comparisons (see
Figure 21; Figure 22).
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Figure 21. Distributions of age and sex ratio of participants across comparisonsACI: acitretin; ADA:
adalimumab; APRE: apremilast; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA:
etanercept; FUM: fumaric acid; IFX: infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX:
methotrexate; PBO: placebo; PONE: ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA:
tofacitinib; USK: ustekinumab
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Figure 22. Distributions of weight of participants and PASI score at baseline across comparisonsACI:
acitretin; ADA: adalimumab; APRE: apremilast; BRODA: brodalumab; CERTO: certolizumab; CICLO:
ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX: infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL:
guselkumab; MTX: methotrexate; PBO: placebo; PONE: ponesimod; SECU: secukinumab; TILDRA:
tildrakizumab; TOFA: tofacitinib; USK: ustekinumab
At class-level analysis, the global test for inconsistency was not
significant for all of the outcomes except for PASI 75 (data not
shown). At drug-level analysis, the global test for inconsistencywas
not significant for all of the outcomes but only marginally non-
significant for PASI 90. Results of a global test for inconsistency, at
drug level, are detailed in Figure 23 and Figure 24 for PASI 90 and
SAEs, respectively. The loop-specific and side-splitting approaches
indicated a handful of loops and comparisons with statistically
significant inconsistency (Figure 25; Figure 26). This apparent
inconsistency does not generally exceed however the expected level
of inconsistency that has been suggested by empirical evidence
(Veroniki 2013), which is about 10% of the total number of loops.
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Figure 23. Side-splitting approach and design-by-treatment interaction model for inconsistency for Psoriasis
Area and Severity Index (PASI) 90Treatment codes: A = PBO, B = FUM, C = MTX, D = ACI, E = ALEFACEPT,
F = CICLO, G = IFX, H = ADA, I = ETA, J = USK, K = SECU, L = IXE, M = BRODA, N = CERTO, O = APRE, P =
TOFA, Q = GUSEL, R = TILDRA, S = PONE, T = ITOACI: acitretin; ADA: adalimumab; APRE: apremilast;
BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX:
infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo;
PONE: ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumab
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Figure 24. Side-splitting approach and design-by-treatment interaction model for inconsistency for serious
adverse events (SAEs)Treatment codes: A = PBO, B = FUM, C = MTX, D = ACI, E = ALEFACEPT, F = CICLO,
G = IFX, H = ADA, I = ETA, J = USK, K = SECU, L = IXE, M = BRODA, N = CERTO, O = APRE, P = TOFA, Q =
GUSEL, R = TILDRA, S = PONE, T = ITOACI: acitretin; ADA: adalimumab; APRE: apremilast; BRODA:
brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX: infliximab;
ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo; PONE:
ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumab
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Figure 25. Inconsistency plots for all the outcomes at class-levelInconsistency factor (IF) is calculated as the
risk ratio (RR)/standardised mean difference (SMD) for direct evidence over the RR/SMD for indirect evidence
in the loop with its 95% confidence interval (CI). IF value close to 0 indicates the absence of evidence for
disagreement between direct and indirect evidence.AIL12/23: anti-IL12/23; AIL17: anti-IL17; AIL23: anti-IL23,
ATA: anti-TNF alpha; CSA: conventional systemic agents; OB: other biologics; PBO: placebo; SM: small
molecules
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Figure 26. Inconsistency plots for all the outcomes at drug levelInconsistency factor (IF) is calculated as the
risk ratio (RR)/standardised mean difference (SMD) for direct evidence over the RR/SMD for indirect evidence
in the loop with its 95% confidence interval (CI). IF value close to 0 indicates the absence of evidence for
disagreement between direct and indirect evidence.ACI: acitretin; ADA: adalimumab; APRE: apremilast;
BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX:
infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo;
PONE: ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumab
Possible explanation of this apparent inconsistency could be the
differences between the previous treatment allowed across these tri-
als: for example, participants enrolled in the Saurat CHAMPION,
2008 trial (adalimumab versus methotrexate versus placebo) were
naïve to methotrexate and TNF alpha antagonists whereas partic-
ipants enrolled in the Menter REVEAL, 2008 trial (adalimumab
versus placebo) could have received previous systemic treatment
including methotrexate.
4. Subgroup and sensitivity analyses
Wehad enough data for none of the aforementioned characteristics
that may act as effect modifiers and therefore we were not able
to run subgroup analyses and meta-regressions to investigate their
potential effect on the results.
Results of the sensitivity analyses involving the following were
similar to those of themain analysis for the two primary outcomes:
• excluding studies with less than 50 participants (Figure 27)
(the heterogeneity τ for this subgroup network was 0.08 for PASI
90 and 0 for SAEs, which we considered low heterogeneity);
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Figure 27. Sensitivity analyses - Interval plot. Network meta-analysis results for primary outcomes (PASI 90
and serious adverse events) for trials with at least 50 participants.ACI: acitretin; ADA: adalimumab; APRE:
apremilast; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric
acid; IFX: infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO:
placebo; PONE: ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK:
ustekinumabCI: confidence interval; PASI: Psoriasis Area and Severity Index; RR: risk ratio; SAE: serious
adverse events
• completers (Figure 28) (the heterogeneity τ for this
subgroup network was 0.09 for PASI 90 and 0 for SAEs, which
we considered low heterogeneity);
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Figure 28. Sensitivity analyses - Interval plot. Network meta-analysis results for primary outcomes (PASI 90
and serious adverse events) for the completers.ACI: acitretin; ADA: adalimumab; APRE: apremilast; BRODA:
brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA: etanercept; FUM: fumaric acid; IFX: infliximab;
ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; PBO: placebo; PONE:
ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA: tofacitinib; USK: ustekinumabCI: confidence
interval; PASI: Psoriasis Area and Severity Index; RR: risk ratio; SAE: serious adverse events
• analyses at dose level (Figure 29) (the heterogeneity τ for
this subgroup network was 0.10 for PASI 90 and 0 for SAEs,
which we considered low heterogeneity); and
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Figure 29. Sensitivity analyses - Interval plot. Network meta-analysis results for primary outcomes (PASI 90
and serious adverse events) for all the interventions depending on the dosesMTX ≥ 15/MTX other:
methotrexate ≥ 15 mg per week/methotrexate < 15 mg per week; ALEFACEPT: alefacept all dosages; CICLO
High: ciclosporin ≥ 3 mg/kg/day; ACI ≥ 35: acitretin ≥ 35 mg per day; FUM: fumaric acid esters all dosages;
APRE 30: apremilast 30 mg twice daily; PONE 40: ponesimod 40 mg per day; TOFA 20: tofacitinib 20 mg per
day; ETA 25/ETA 50: etanercept 25 mg twice a week/etanercept 50 mg twice a week; IFX: infliximab 5 mg/kg
week O, 2, 4 every 6 weeks; ADA: adalimumab 80 mg Week 0, 40 mg Week 1 then 40 mg every other week;
CERTO 200/400: certolizumab all dosages; USK 45: ustekinumab 45 mg; SECU 300/SECU other: secukinumab
300 mg every injection/secukinumab other dosages; IXE 200/IXE other: ixekizumab 200 mg per
injection/ixekizumab other dosages; TILDRA 100/200: tildrakizumab all dosages; GUSEL 100: guselkumab 100
mg per injection; BRODA 210: brodalumab 210 mg per injectionCI: confidence interval; PASI: Psoriasis Area
and Severity Index; RR: risk ratio; SAE: serious adverse events
• excluding studies at high risk of bias (Figure 30) (the
heterogeneity τ for this subgroup network was 0.12 for PASI 90
and 0 for SAEs, which we considered low heterogeneity).
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Figure 30. Sensitivity analyses - Interval plot. Network meta-analysis results for primary outcomes (PASI 90
and serious adverse events) for all the interventions excluding studies at high risk of bias.ACI: acitretin; ADA:
adalimumab; APRE: apremilast; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; ETA:
etanercept; FUM: fumaric acid; IFX: infliximab; ITO: itolizumab; IXE: ixekizumab; GUSEL: guselkumab; MTX:
methotrexate; PBO: placebo; PONE: ponesimod; SECU: secukinumab; TILDRA: tildrakizumab; TOFA:
tofacitinib; USK: ustekinumabCI: confidence interval; PASI: Psoriasis Area and Severity Index; RR: risk ratio;
SAE: serious adverse events
5. Reporting bias
The comparison-adjusted funnel plots generally appeared sym-
metrical, and only the graph for quality of life presented some
evidence of small-study effects which might be caused by selective
outcome reporting (Figure 31).
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Figure 31. Funnel plot for network meta-analysis of all the outcomesAE: adverse event; lnRR: Mean effect
size; PASI: Psoriasis Area and Severity Index; QoL: Specific quality of life scale; RR: Risk ratio; SAE: serious
adverse events; SMD: standardised mean difference
6. Grading of the evidence
We graded the evidence for the two primary outcomes, PASI 90
and serious adverse events, for all of the network intervention es-
timates according to the approach proposed by Salanti 2014. We
considered five domains: study limitations (by first evaluating the
risk of bias of each direct estimate (Figure 2) and then by inte-
grating these judgements with the contribution of each direct esti-
mate to the network estimates (Figure 32)), consistency of effect,
imprecision, indirectness, and publication bias.
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Figure 32. Study bias distribution for each primary outcome (PASI 90 and serious adverse events)The
following graphs show how much information (i.e. the percentage contribution of each direct comparison in
the network estimates) comes from low (green), unclear/moderate (yellow) and high (red) risk of bias studies.
Here we have all drugs versus placebo as it is difficult to have all comparisons due to space limitations. To
evaluate the direct comparisons we used the mean level of bias of the included studies in each comparison.We
used the web application CINeMA (CINeMA 2017).The codes of the treatments are A = Placebo, B = Fumaric
acid esters, C = Methotrexate, D = Acitretin, E = Alefacept, F = Ciclosporin, G = Infliximab, H = Adalimumab, I
= Etanercept, J = Ustekinumab, K = Secukinumab, L = Ixekizumab, M = Brodalumab, N = Certolizumab, O =
Apremilast, P = Tofacitinib, Q = Guselkumab, R = Tildrakizumab, S = Ponesimod, T = Itolizumab
For PASI 90, we judged the confidence in the treatment estimate to
be high for ixekizumab, secukinumab, and ustekinumab; moder-
ate for brodalumab, guselkumab (reasons for downgrading: studies
limitations), certolizumab (imprecision), adalimumab (inconsis-
tency), etanercept (inconsistency), apremilast (study limitations),
ponesimod (imprecision), and methotrexate (inconsistency); and
low or very low for all of the other treatments (tildrakizumab,
itolizumab, tofacitinib, infliximab, acitretin, ciclosporin, fumaric
acid esters, alefacept). More detail on the reasons for downgrading
are available in Summary of findings for the main comparison.
For serious adverse events, we judged the confidence in the treat-
ment estimate to be low to very low for almost all of the treatment,
except methotrexate, certolizumab, tofacitinib, etanercept, adali-
mumab, ixekizumab, secukinumab, and ponesimod, which we as-
sessed as moderate certainty (downgrading linked to imprecision
for all “moderate certainty” drugs). More detail on the reasons for
downgrading are available in Summary of findings for the main
comparison.
D I S C U S S I O N
Summary of main results
Our systematic review and meta-analysis compared all drugs and
drugs undergoing phase II/III trials used for moderate to severe
psoriasis in 2017 except a new anti-IL23 molecule (BI 655066,
risankizumab).
In total, this review included 109 studies, involving 39,882 ran-
domised adult participants, which assessed outcomes during the
induction phase (less than 24 weeks after randomisation). In to-
tal, 55 trials were multiarm. Seventy-three trials compared system-
atic treatment against placebo, 25 were head to head trials, and
11 had both active comparator and placebo. Fifteen trials had a
co-intervention mainly phototherapy. Finally, 79 studies declared
pharmaceutical company funding, and 21 studies did not report
the source of funding.
We included 74 studies (without co-intervention and with a tim-
ing of outcome assessment from 12 to 16 weeks after randomisa-
tion (classed as induction therapy)), involving 35,454 participants
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(88.9% participants of this review), in the network meta-analysis.
Conventional systemic treatments, the oldest class-level treatment
(acitretin, ciclosporin, fumaric acid esters, methotrexate); anti-
TNF alpha treatments (etanercept, infliximab, adalimumab, cer-
tolizumab); an anti-IL12/23 treatment (ustekinumab); and anti-
IL17 treatments (secukinumab, ixekizumab, brodalumab) have all
been approved for psoriasis except certolizumab. And except for
apremilast and alefacept, smallmolecule drugs (tofacitinib, ponesi-
mod), anti-IL23 treatments (guselkumab and tildrakizumab), and
other biologics (itolizumab) had not been approved for psoriasis
at the time we conducted our analyses.
All of the assessed interventions appeared superior to placebo in
terms of reaching Psoriasis Area and Severity Index (PASI) 90.
At class level, networkmeta-analysis showed that the biologics anti-
IL17, followed by anti-IL12/23, anti-IL23, and anti-TNF alpha
outperformed the small molecules and the conventional systemic
agents in terms of reaching PASI 90 measured at the twelfth to
the sixteenth week of treatment after randomisation, with small
molecules producing a better outcome than conventional systemic
agents.
The most effective drug for reaching PASI 90 when compared
to placebo was ixekizumab (high-certainty evidence), followed by
secukinumab (high-certainty evidence), brodalumab (moderate-
certainty evidence), guselkumab (moderate-certainty evidence),
certolizumab (moderate-certainty evidence), then ustekinumab
(high-certainty evidence) (see Summary of findings for the main
comparison).
At drug-level, all of the anti-IL17 agents and guselkumab (an anti-
IL23 drug) were significantly more effective in reaching PASI 90
than three anti-TNF alpha agents (infliximab, adalimumab, and
etanercept, but not certolizumab), and ustekinumab was superior
to etanercept. No statistically significant difference was shown be-
tween infliximab, adalimumab, and etanercept. Only one trial as-
sessed the efficacy of infliximab in this network; thus, the results
involving infliximab have to be interpreted with caution. Tofaci-
tinib was significantly superior to methotrexate, and no clear dif-
ference was shown between any of the other small molecules versus
conventional treatments. The results were almost the same for the
other efficacy outcome PASI 75.
No significant difference was found between all of the interven-
tions and the placebo regarding the risk of serious adverse ef-
fects (SAEs). The relative ranking for SAEs strongly suggested that
methotrexate was associated with the best safety profile regard-
ing all the SAEs (moderate-certainty evidence), followed by ci-
closporin (very low-certainty evidence), certolizumab (moderate-
certainty evidence), infliximab (very low-certainty evidence), ale-
facept (low-certainty evidence), then fumaric acid esters (FAEs)
(very low-certainty evidence). Major adverse cardiac events, seri-
ous infections, or malignancies (see Table 6) were reported in both
placebo and intervention groups.
Information on quality of life was often poorly reported and was
absent for a third of the interventions.
Finally, considering both efficacy (PASI 90 outcome) and accept-
ability (SAE outcome), highly effective treatments had also more
SAE than the other treatments, and ustekinumab, infliximab, and
certolizumab appeared to be the better compromise between effi-
cacy and acceptability (bearing in mind the limitations that affect
interpretation of the SAE results, such as the very low number
of events on which the results were based, with just over half of
the treatment estimates being based on low to very low certainty
evidence (the rest moderate)).
Overall completeness and applicability of
evidence
We were able to draw some conclusions on the effectiveness (and
ranking) of the systemic treatment options for moderate to severe
chronic plaque psoriasis during the induction phase. Long-term
efficacy and safety data are lacking. Specific details are listed below.
Participants
Participants in the included studies had a mean age of 44 years
and had moderate to severe psoriasis with an overall mean PASI
score at baseline of 20 (range: 9.5 to 39). This young age and the
high level of disease severity may not be typical of patients seen in
daily clinical practice especially for patients who need a first-line
systemic treatment. In addition, patients selected for randomised
controlled trials (RCTs) generally have few major comorbidities.
Almost all studies including one biological arm excluded patients
with history of infectious diseases or malignancies and signs of
severe renal, cardiac, hepatic, demyelinating, or other disorders.
This may impact the generalisibility of these results for clinical
practice. However, some participants characteristics (such as be-
ing overweight, imbalanced sex ratio in favour of males, presence
of metabolic syndrome) were reflective of a moderate to severe
psoriasis population, comparable to literature data (Wolkenstein
2009).
Interventions
Evidence on 19 treatments included in this review was derived
from 74 trials (searched for up to December 2016). We included
all interventions irrespective of the dose. Thus, we increased the
number of available RCTs per intervention and had more power
to assess SAEs and adverse events (AEs). The number of studies
was still low for the following interventions: certolizumab, tildrak-
izumab, itolizumab, infliximab, ponesimod, acitretin, ciclosporin,
alefacept, fumaric acid, and methotrexate, meaning we must be
cautious of the conclusions drawn for these drugs. In terms of effi-
cacy, the results from the subgroup analysis using a standard dose
for each intervention was similar for PASI 90 (and SAE) compared
to the main analyses, making us confident with the results of the
main analysis.
For drugs just approved or not yet approved for psoriasis, on-
going studies are still investigating guselkumab, tildrakizumab, a
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third anti-IL23 (risankizumab, which will be included in the next
update of this review), certolizumab, tofacitinib, and itolizumab
(Characteristics of ongoing studies). Ponesimod development in
psoriasis is most uncertain and should be excluded from the next
update of this review.
Comparisons
The majority of the studies included in the review were placebo-
controlled (around 70%) as were the identified ongoing stud-
ies. Once the benefit of a treatment has been established against
placebo using high-quality evidence, only head-to-head trials
would be helpful to provide physicians with efficacy estimates be-
tween the different biologics based on stronger evidence than in-
direct comparisons.
Outcomes
Many of the trials included in this review provided evidence for
the proportion of participants who reached PASI 90, PASI 75, or
Physician Global Assessment (PGA) 0/1 or who experienced SAE
or AE. On the other hand, patient-reported outcome (PRO) data
were scanty and poorly reported. Moreover, the heterogeneity of
the scales used for PRO in psoriasis trials required using the stan-
dardised mean difference in the network. So, from a clinical point
of view, the interpretation of the results was difficult: a significant
result for PRO between two drugs did not mean that the result
was clinically useful for the patients.
Timing
All of the included trials assessed the efficacy of the different treat-
ments during the induction treatment phase (less than 24 weeks,
with evidence in the network meta-analysis (NMA) assessed 12 to
16 weeks after randomisation). This is an unwelcome finding for
a chronic disease. The trials were designed to detect differences in
the severity of psoriasis in response to therapy over short periods
of treatment and are often underpowered and of insufficient du-
ration to detect rare or long-term adverse events. Therefore, it is
of interest to conduct studies taking into account the induction
of remission but also the long-term management (long-term re-
mission) and the long-term safety of the drug. In order to provide
long-term information on the safety of the treatments included in
this review, it will be necessary to also evaluate non-randomised
studies and postmarketing reports released from regulatory agen-
cies.
Quality of the evidence
Overall, we judged the confidence in the treatment estimate for
PASI 90 to be high or moderate for anti-IL17 agents, anti-IL12/
23 agents, anti-IL23 agents, anti-TNF alpha agents (except inflix-
imab), methotrexate, and apremilast. We judged the confidence
in treatment estimate for PASI 90 as low or very low certainty for
most of the comparisons involving conventional systemic agents
(except for methotrexate), infliximab, other biologics, and tofaci-
tinib; we downgraded the certainty of the evidence due to risk of
bias and then either for inconsistency or imprecision. We judged
the confidence in the treatment estimate for SAEs to be low to
very low certainty for half of the treatment estimates, moderate
for the others; we downgraded the certainty of the evidence due
to imprecision and risk of bias.
Risk of bias
The risk of bias in included studies appeared to be globally moder-
ate to low (Figure 2; Figure 3). However, some limitations should
be discussed.
1. There was variation in how well the studies took measures
to blind investigators and participants: a third of trials in this
systematic review were considered at high or unclear risk of
performance bias (35 out of 109). This is an important point to
highlight as the outcomes used for assessing efficacy were
subjective. However, the proportion of trials at high risk of
blinding used in the network meta-analyses decreased to 15%
(13 out of 74).
2. The reporting of missing outcome data was largely
inadequate in a few studies. Since we chose a likely scenario that
any participant with missing outcome data did not experience
clearance for the overall analyses, the risk of overestimating
efficacy due to how we reported missing data was minimised.
3. Finally, a few trials were considered at high risk of selective
outcome reporting. However, we chose a stringent definition of
studies at high risk of selective outcome reporting: we considered
reporting bias inadequate if one specified outcome in protocols
was lacking in the main report. A large proportion of included
trials did not report the PRO outcomes in the main report but
only in slicing publications (see Included studies). We extracted
outcomes of interest both in main and slicing publications, but
this disadvantaged trials that did not report all of the specified
outcomes in the main report.
Indirect comparison and network meta-analyses as standard pair-
wise meta-analyses provide “observational” evidence since the
treatments being compared have not been randomised across stud-
ies. However, we considered carefully the assumption underpin-
ning the validity of indirect comparisons to reassure a sufficiently
coherent evidence base (Cipriani 2013). The limitations of this
review are reflected by the GRADE evaluations.
Heterogeneity (i.e. variation in effect modifiers within
comparisons) and inconsistency (imbalance in effect
modifiers between comparisons)
70Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
No evidence of the presence of heterogeneity either in direct com-
parisons or in the entire networks was found except in relation
to the quality of life outcome (poorly reported, few studies per
comparisons). There was no global inconsistency for the two pri-
mary outcomes, and the global test for inconsistency was signifi-
cant only for PASI 75 at the class-level analysis. According to the
local tests, for each outcome, a handful of loops and comparisons,
which does not exceed the expected level of inconsistency from
empirical evidence (Veroniki 2013), appeared to have important
inconsistency. Thus, we downgraded the strength of evidence for
inconsistency for methotrexate, adalimumab, etanercept, inflix-
imab, and tofacitinib.
Imprecision
The number of studies was low for the following interventions
(one to two studies per interventions): certolizumab, tildrak-
izumab, itolizumab, infliximab, ponesimod, acitretin, ciclosporin,
alefacept, fumaric acid, and methotrexate. We downgraded the
strength of evidence for imprecision for all of these interventions
for the two primary outcomes.
Indirectness or transitivity assumption
Wedid not find any evidence that important variables, such as age,
sex, weight, and duration and severity of psoriasis, varied across
comparisons (see Characteristics of included studies and Figure
31 and Figure 32). However, several comparisons had only one
or two studies, and the lack of data did not allow us to check
the distributions of previous treatments across comparisons; thus,
transitivity cannot be assessed statistically properly.
Several participant characteristics have changed in newer trials,
such as participants’ exclusion criteria. However, most of the in-
cluded trials were conducted after 2000, minimising the variabil-
ity across trial participant characteristics. The location of the trial
could also create some differences between participants as the re-
sponse of treatment could be related to genetic background (Chiu
2014). To further reassure the plausibility of the transitivity as-
sumption, we only included in our analyses trials not involving co-
interventions. Moreover, the trials were also fairly similar in terms
of outcome assessment (less than 24 weeks). As a consequence, we
excluded from the meta-analyses most of the trials assessing inflix-
imab efficacy. Indeed, timing of efficacy outcome assessments was
from 8 to 10 weeks for infliximab trials. However, as differences in
response rates of biologics for the treatment of psoriasis have been
reported in several meta-analyses published to date mainly related
to the primary endpoint times, we assumed the importance of a
similar timing of outcome assessment between trials (Puig 2014).
Thus, the possibility of intransitivity seems to be unlikely even if
it could not be totally excluded.
Publication bias
Weassessed publicationbias considering the comprehensive search
strategy we performed and the risk for publication bias in the
specific field. The comparison-adjusted funnel plot for all placebo-
controlled trials for all the outcomes did not indicate any evident
risk of publication bias for the two primary outcomes.
Potential biases in the review process
We performed a wide search for trials, including five trials reg-
isters and databases of each company when available, and we
searched the U.S. Food and Drug Administration and the Euro-
peanMedicines Agency (EMA) databases and abstract proceedings
of seven congresses up to a maximum of 10 years. We did not ap-
proach pharmaceutical companies for additional data when their
databases were not open access, and it is possible that additional
data from this source could contribute to this review. The prob-
ability that we missed a trial is low considering our wide search
and is supported by the absence of small-study effects (testing by
the comparison-adjusted funnel plots). However, the fact that 14
studies have not yet been incorporated may be a source of poten-
tial bias.
Study selection, data extraction, and ’Risk of bias’ assessments were
done in duplicate and independently, andwe reached consensus by
discussing any discrepancies. Some published trial reports did not
provide enough details to extract outcomes and adequately assess
risk of bias, especially studies performed before 2000 (e.g. before
the International Committee of Medical Journal Editors issued
the requirement of trial registration for publication). However, we
contacted the authors of the trials to request missing data, but we
cannot avoid some biased assessment in the review process due to
incomplete reporting of trial details, results, or both.
We had some departures from the protocol plans (see Differences
between protocol and review). After protocol publication, we
added five biological drugs either approved for psoriasis or for
which there were ongoing phase 3 trials. We chose to keep only
PASI 90 as the primary efficacy outcome and not a composite out-
come including PASI and Physician Global Assessment (PGA).
Indeed, PASI 90 and PGA do not reflect the same measures (see
Agreements and disagreements with other studies or reviews). To
minimise inconsistency, we assessed the primary outcome between
the twelth and the sixteenth week rather than less than 24 weeks.
Agreements and disagreements with other
studies or reviews
We searched in MEDLINE Ovid (from 1946) using the strat-
egy “Psoriasis” AND “Meta-analysis” for already published net-
work meta-analyses. Seven network meta-analyses were system-
atically reviewed and have compared the short-term efficacy of
treatments for moderate to severe psoriasis (Gomez-Garcia 2017;
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Gupta 2014; Jabbar-Lopez 2017; Lin 2012; Reich 2012a; Schmitt
2014; Signorovitch 2015).
We compared our findings with the four most recent network
meta-analyses (Gomez-Garcia 2017; Jabbar-Lopez 2017; Schmitt
2014; Signorovitch 2015). Schmitt 2014 included 48 trials, in-
volving 16,696 participants, assessing both conventional systemic
(ciclosporin, methotrexate, acitretin, FAEs) and biologic treat-
ments (infliximab, adalimumab, etanercept, alefacept, and ustek-
inumab). Signorovitch 2015 included 15 trials, involving 7388
participants, assessing only anti-TNF alpha agents (infliximab,
adalimumab, etanercept) and anti-IL12/23 drugs (ustekinumab).
Gomez-Garcia 2017 included 27 trials, involving 10,629 partici-
pants, assessing three anti-TNF alpha agents (infliximab, etaner-
cept, and adalimumab), one anti-IL12/23 agent (ustekinumab),
and one anti-IL17 agent (secukinumab). Jabbar-Lopez 2017 in-
cluded 41 trials, involving 20,561 participants, assessing the same
drugs as Gomez-Garcia 2017, plus ixekizumab (another anti-IL17
agent) and methotrexate.
Thus, compared to previous reviews, we included more interven-
tions and consequently more trials (n = 109) and participants (n =
39,882). Regarding the overlapping period, we also includedmore
trials than the other meta-analyses. Indeed, we performed a larger
search in terms of the number of databases used, including trials
registers and other resources (unpublished literature), irrespective
of the date or language limitations.
Schmitt 2014 and Signorovitch 2015 chose PASI 75 as primary
outcome during the induction phase (less than 16 weeks); how-
ever, data on PASI 90 were also available. Gomez-Garcia 2017
presented both PASI 75 and PASI 90 results. Finally, Jabbar-Lopez
2017 chose a composite outcome: PASI 90 or Physician Global
Assessment (PGA) 1. We chose PASI 90 as our primary efficacy
outcome because complete clearance seems the less subjective out-
come and themost relevant regarding patient expectation in short-
term assessment (induction phase). The composite outcome used
by Jabbar-Lopez 2017 did not reflect complete or almost com-
plete clearance. Indeed, PGA 1 is highly correlated to PASI 75 and
not PASI 90, which could lead to a classification bias (Robinson
2012).
Jabbar-Lopez 2017 presented their results using number needed
to treat (NNT). Although NNT is an easily understandable and
very usefulmeasure for patients and clinicians, it can bemisleading
in a network meta-analysis since it requires the assumption of a
common average control group risk applying to all studies. This is
a rather strong assumption particularly in networks involving also
head-to-head studies without a control group as here.
Infliximab was the best drug in terms of reaching PASI 75 in the
network meta-analyses of Schmitt 2014 and Signorovitch 2015.
Adalimumab and ustekinumab were more likely to reach PASI
75 than etanercept. These last results are partly confirmed by our
review: ustekinumab was more effective at reaching both PASI
75 and 90 than etanercept; however, no significant difference was
shown between adalimumab and etanercept, as in the most recent
network meta-analyses from Gomez-Garcia et al (Gomez-Garcia
2017) and Jabbar-Lopez et al (Jabbar-Lopez 2017). Infliximab was
also the most effective drug in Gomez-Garcia 2017, without sig-
nificant difference between infliximab and secukinumab. Inflix-
imab was ranked in third place after ixekizumab and secukinumab
in Jabbar-Lopez 2017, without significant difference between in-
fliximab and secukinumab. Our findings did not find such effi-
cacy for infliximab. To prevent inconsistency in our networkmeta-
analaysis, we chose to include trials assessing outcomes between
12 to 16 weeks. Thus, only one trial, Barker RESTORE-1, 2011,
which compared infliximab versus methotrexate, was taken into
account for this intervention. Regarding the four previous network
meta-analyses, two did not assess inconsistency (Schmitt 2014 ;
Signorovitch 2015), and two reported significant global and local
inconsistency for PASI 75, which preclude interpretation of their
results (Gomez-Garcia 2017; Jabbar-Lopez 2017).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In terms of achieving PASI 90 with induction therapy (evaluation
between 12 to 16 weeks after the randomisation), we found the
following results.
• At class level, all of the assessed interventions (conventional
systemic agents, small molecules, and biological treatments)
showed significant superiority compared with placebo.
• The biologic treatments anti-IL17, anti-IL12/23, anti-
IL23, and anti-TNF alpha showed significant superiority
compared with small molecules and the conventional systemic
agents, with small molecules achieving better results than
conventional systemic agents.
• All of the anti-IL17 agents and the anti-IL23 guselkumab
were significantly more effective than all of the anti-TNF alpha
agents except for certolizumab (i.e. infliximab, adalimumab, and
etanercept), and the anti-IL12/23 ustekinumab was superior to
the anti-TNF alpha etanercept.
• When compared with placebo, in order of highest efficacy,
the following biological agents are the best choices: ixekizumab
(high-certainty evidence), secukinumab (high-certainty
evidence), brodalumab (moderate-certainty evidence),
guselkumab (moderate-certainty evidence), certolizumab
(moderate-certainty evidence), and ustekinumab (high-certainty
evidence).
• Tofacitinib was superior to methotrexate, and no difference
was shown between the other small molecules and the
conventional drugs.
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Regarding the other efficacy outcome (PASI 75), the results were
very similar to the results for PASI 90.
In terms of serious adverse events, there was no significant differ-
ence between all of the assessed interventions andplacebo.The sur-
face under the cumulative ranking curve (SUCRA) strongly sug-
gested that methotrexate had the best safety profile regarding the
serious adverse events (SAEs) (moderate-certainty evidence), fol-
lowed by ciclosporin (very low-certainty evidence), certolizumab
(moderate-certainty evidence), infliximab (very low-certainty ev-
idence), alefacept (low-certainty evidence), and FAEs (very low-
certainty evidence). Major adverse cardiac events, serious infec-
tions, or malignancies were reported in both placebo and inter-
vention groups. Nevertheless, analyses on SAE events were based
on a very low number of events with a low to very low certainty
for just over half of the treatment estimates in total, moderate for
the others. Thus, the results have to be considered with caution.
Considering both efficacy (PASI 90 outcome) and acceptabil-
ity (SAE outcome), highly effective treatments also had more
SAEs than the other treatments: ustekinumab, infliximab, and cer-
tolizumab appeared to be the better compromise between efficacy
and acceptability.
Information on quality of life was often poorly reported and was
absent for a third of the interventions.
Conservative interpretation is warranted with regard to the results
for conventional systemic agents, as well as ponesimod, tildrak-
izumab, infliximab, certolizumab, alefacept, and itolizumab as
these drugs have been evaluated in few trials. The evidence is lim-
ited to a selected trial population (participants were young (mean
age of 44 years) and had a high level of disease severity (with an
overall mean score of PASI 20 at baseline)) and to the induction
treatment phase (for the NMA results, measurement was done 12
to 16 weeks after randomisation, but all results were measured less
than 24 weeks after randomisation), which is not relevant enough
for a chronic disease, which would require long-term treatment.
Our main results (i.e. superiority of efficacy of the biologic treat-
ments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha
compared with small molecules and the conventional systemic
agents, with small molecules achieving better results than conven-
tional systemic agents) do not reflect the way patients are man-
aged in “real-life”. Currently, biological treatments have been po-
sitioned as third-line therapies by regulatory bodies, with manda-
tory reimbursement criteria that patients must meet before being
considered for these treatments (moderate to severe disease after
failure, intolerance or contraindication to conventional systemic
agents). Recently, the same restrictions were applied to apremilast.
Such decisions were based on the lack of long-term safety knowl-
edge but also taking into account economic consideration. In this
review, we found insufficient evidence to evaluate long-term sa-
fety, and we did not address economic considerations; thus, the
question of the choice of the first-line treatment for moderate to
severe psoriasis is still debated.
The first choice in conventional systemic agents is still in question
as the limited number of trials assessing conventional systemic
agents did not allow us to draw robust conclusions; this is also true
for some small molecule treatments and biological treatments.
Implications for research
From a clinical point of view, we need drugs that can be admin-
istered long term to provide continuous effective control, because
continued remission after successful treatment is as important as
successful induction of remission. Moreover, treatment should be
easy to use, well accepted by patients, have minimal drug to drug
interactions, and should have minimal monitoring requirements
because convenience is also an important issue when dealing with
chronic diseases that require prolonged treatments. Finally, the
cost of the drug should be affordable by most patients and by any
national health service.
Specific questions and issues in the management of psoriasis still
remain unmet:
• Which conventional systemic agents have the best benefice/
risk balance?
• Which patients are candidates for small molecule treatment?
• Which treatments work for subgroups of patients (age,
psoriasis severity, previous treatment, psoriatic arthritis)?
• Adjustment of therapy for patients with stable low disease
activity.
• Add-on therapy or switching for patients who failed with a
systemic treatment.
• Long-term safety data for all the treatments.
1. Future trials need to ensure the following.
• Participants: enough information about participants is
needed to enable systematic subgroup analyses for biological-
naïve patients (or conventional systemic agent-naïve); future
trials also need to provide an adequate description of data
regarding other important potential effect modifiers such as
previous systemic treatments, whether participants are
overweight/obese, the duration of a participant’s psoriasis,
baseline psoriasis severity (efficacy differences could be expected
for patients with PASI at 10 and patients with PASI at 40); and
presence of psoriatic arthritis.
• Interventions: high-quality trials assessing the efficacy of
conventional systemic agents are needed.
• Comparators: once the benefit of a treatment has been
established against placebo, only head-to-head trials would be
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helpful to provide physicians efficacy estimates between the
different biologics with a stronger evidence than indirect
comparisons. Thus, head-to-head comparisons are lacking
between the conventional systemic agents and small molecules
and against themselves. More head-to-head comparisons
between biological agents are also needed (anti-IL17 versus anti-
IL23, anti-IL23 versus anti-IL12/23, anti-TNF alpha versus
anti-IL12/23).
• Outcomes: outcome measure harmonisation is needed for
psoriasis as it has been done for eczema by the COMET (Core
Outcome Measures in Effectiveness Trials) Initiative.
• Timing assessment strategy: all of the trials included in
this review were limited to the induction phase (less than 24
weeks). Long-term efficacy data is critical for chronic diseases.
Placebo-controlled long-term trials would not be ethical due to
the suffering it would entail for the people in the placebo group.
However, long-term studies comparing different drugs would be
ethical and informative. Such long-term trials could also assess
the adjustment of therapy for patients with stable cleared
psoriasis.
2. New trial designs are needed such as pragmatic trials that per-
mitted dose adjustment once in remission, switching, and addi-
tional treatments (i.e. adding two or more systemic treatments)
as per normal clinical practice. All of this unmet medical need
evidence would improve the management of the condition.
3. Finally, evidence-based decision making and management
of chronic plaque psoriasis request both efficacy AND safety
data. As we already know, the limitations of network meta-anal-
ysis and in the same way the limitations of randomised clinical
trials (included in these meta-analyses) means we cannot reliably
interpret the significance of rare events given their current design.
Actually, these studies are designed to detect differences in the
severity of psoriasis in response to therapy over short periods of
treatment and are often underpowered and of insufficient duration
to detect rare or long-term adverse events. One way to counter this
is to include observational cohort studies/registries in a network
observational meta-analysis.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Akcali 2014
Methods RCT, active-controlled, open-label trial
Date of study: January 2008-January 2009
Location: Gaziantep, Turkey (1 centre)
Participants Randomised: 55 participants (mean age 39 years, 33 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 10)
Exclusion criteria
None
Dropouts and withdrawals
• 9/55(16.4%)
• AEs: 5
• Other reason: 4
Interventions Intervention
A. Acitretin (n = 25), orally, 0.3-0.5 mg/kg/d
Control intervention
B. Cyclosporin (n = 21), orally, 3 mg/kg/d
Outcomes Assessment at 8 weeks
Primary outcome of the trial
• Not stated
Outcomes of the trial
• PASI score
• Adverse effects
Notes Funding source:
Quote (p 1121): “No specific grant”
Declarations of interest:
Quote (p 1121): “The authors declare that there are no conflicts of interest.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p1119): “Patients were stratified
into one of two groups via a computer-gen-
erated randomisation schedule”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
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Akcali 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not stated that it was a blinded
trial. Acitretin has visible side effects (muco
cutaneous dryness)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no independent assessor. Not
stated that it was a blind trial. Acitretin has
visible side effects
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 55, analysed 46
Management of missing data: not stated
Selective reporting (reporting bias) High risk Comment: no primary or secondary out-
comes stated. No protocol available
Al-Hamamy 2014
Methods RCT, active-placebo controlled, open-label trial
Date of study: February 2010-October 2011
Location: Baghdad, Iraq (1 centre)
Participants Randomised: 120 participants (mean age 41 years, 41 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA > 10%)
• Age ≥ 18 and ≤ 60 years
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency, past history of malignant
tumours
• Had received conventional systemic treatments in the 4 past weeks
• Had received biologics (anti-TNFα)
• Had uncontrolled diabetes
Dropouts and withdrawals
• 7 (6%)
No more statements regarding time and reasons of follow-up
Interventions Intervention
A. Methotrexate + NBUVB (n = 38), 20 mg/week + 45 mJ/cm2, 3 times/week
Control intervention
B. NBUVB (n = 38), 45 mJ/cm2, 3 times/week
C. Methotrexate (n = 37), 20 mg/week
Outcomes Assessment at 6 months
Primary outcomes of the trial
• PASI 90
Secondary outcomes of the trial
• Number of weeks for achieving clearance
• Total cumulative dose of UVB
• Relapses (PASI returning at 50% of original score for 1 year)
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Notes Funding: not stated
Declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (page 1531): ”three groups ran-
domly...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Comment: No description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not stated that it was a blind
trial, probably not blind
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no independent assessor. Not
stated that it was a blind trial, probably not
blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 120, analysed 113
Management of missing data: not stated
Selective reporting (reporting bias) Unclear risk Comment: no protocol available. The out-
comes mentioned in the methods section
appeared to have been reported
Asahina 2010
Methods RCT, active, placebo-controlled, double blind
Date of study: September 2005-December 2006
Location: 42 centres in Japan
Participants Randomised: 169 participants (mean age 45 years, 143 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA > 10)
• Age > 20 years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency, past
history of malignancy
• Had received biologics
• Had an active infection
Dropouts and withdrawals
• 22 (13%) (A/B/C/D)
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Asahina 2010 (Continued)
• 10 AEs (2/3/2/3)
• 10 withdrawals of consent (2/4/2/2)
• 1 worsening disease (D)
• 1 prohibited medication (C)
Interventions Intervention
A. Adalimumab (n = 38), 40 mg, SC, eow
B. Adalimumab (n = 43), 40 mg, SC, 2 injections, week 0, 1 injection eow (week 2)
C. Adalimumab (n = 41), 80 mg, SC, eow
Control
D. Placebo (n = 46), 0.8 mL, SC, eow
Outcomes Assessment at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• -PASI 50
• -PASI 90
• -PGA clear or minimal
• -DLQI
• -SF36
Notes Funding: support by Abbott (Quote p309)
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p301): “Patients were randomised.
..”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p301): “Adalimumab40mg/0.8mL
and Placebo 0.8 mL were supplied two-vial
cartons (Adalimumab+Adalimumab, Adal-
imumab+placebo, Placebo+Placebo)”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no specific description of the
method used to guarantee blinding of out-
come assessment however considering that
this was a placebo-controlled trial with no
known systematic AEs we considered the
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Asahina 2010 (Continued)
risk as low
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 169, analysed 169
Management ofmissing data: quote (p302)
: “Patients without evaluation at week 16
were considered non-responders for the
primary analysis”
Comment: the report provided sufficient
detail about the management of missing
data to permit a clear judgment
Selective reporting (reporting bias) Unclear risk Comment: no protocol available. The out-
comes mentioned in the methods section
appeared to have been reported
Asahina 2016
Methods RCT, active-controlled, double blind
Date of study: March 2012-January 2014
Location: 16 centres in Japan
Participants Randomised: 95 participants, 94 treated (mean age 49 years, 78 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, PGA 3-4 or BSA ≥ 10),
age ≥ 20 years,
• Patients were to be considered candidates for systemic therapy or phototherapy
for psoriasis (either treatment-naive or -experienced)
Exclusion criteria
• Not plaque-type psoriasis
• Inability to discontinue systemic, topical or phototherapies, concomitant oral or
injectable corticosteroids
• Active infection, history of disseminated herpes zoster or disseminated herpes
simplex or recurrent localized dermatomal herpes zoster, a history of infection
requiring hospitalization or parenteral microbial therapy
• Any uncontrolled significant medical condition
Dropouts and withdrawals
• 6/95 (6.3%); tofacitinib 5 mg twice/d group (0), tofacitinib 10 mg twice-daily
group (6)
• Not received study medication; tofacitinib 10 mg twice-daily group (1)
• AEs: tofacitinib 10 mg twice-daily group (1)
• Lack of efficacy: tofacitinib 10 mg twice-daily group (1)
• Withdrawal consent: tofacitinib 10 mg twice-daily group (1)
• Other reason:tofacitinib 10 mg twice-daily group (2)
Interventions Intervention
A. Tofacitinib (n = 43), orally, 5 mg twice daily
Control intervention
B. Tofacitinib (n = 44), orally, 10 mg twice daily
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Outcomes Assessment at 16 weeks
Primary outcomes of the trial
• PASI 75 and PGA rating of clear or almost clear
Secondary outcomes of the trial
• PASI 50
• PASI 90
• Itch severity item score
• Mean DLQI score
• AEs
Notes Funding source:
Quote (p878): “This study was sponsored by Pfizer Inc. Medical writing support under
the guidance of the authors was provided by Kate Silverthorne, Ph.D., at Complete
Medical Communications and was funded by Pfizer Inc”
Declarations of interest:
Quote (p878): “A. A., A. I., S. I., H. S. and M. O. have received consultancy fees from
Pfizer Inc. Y. S., Y. T., S. T. and M. N. are employees of Pfizer Japan Inc. T. E. has
nothing to disclose.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p870): “Patients were randomized
1:1 to tofacitinib 5 or 10 mg b.i.d. using a
computer-generated randomization sched-
ule”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p870): “patients were registered by
the investigator in a central randomized
management system”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p870): “Tofacitinib was supplied as
5 mg tablets with a corresponding match-
ing placebo. Patients and study staff were
unable to determine from the packag-
ing which treatment group the patient
was assigned to. Patients, investigators,
study teams, the contract research organi-
zation and the sponsor remained blinded
throughout the study period ”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p870): “Tofacitinib was supplied as
5 mg tablets with a corresponding match-
ing placebo. Patients and study staff were
unable to determine from the packag-
ing which treatment group the patient
was assigned to. Patients, investigators,
study teams, the contract research organi-
zation and the sponsor remained blinded
throughout the study period ”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned n = 95, 94 received at
least 1 dose of study drug, 87hadmoderate-
severe psoriasis (study population) and 12
had psoriatic arthritis
Management of missing data: Quote (page
871): “The full analysis set included all ran-
domized patients who received one ormore
dose of study drug...Missing values were
treated as non-responders (non-responder
imputation).”
Table 2: 87 analysed participants
Comment: done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01519089)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Asawanonda 2006
Methods RCT, active placebo-controlled, double blind
Date of study: not reported
Location: Bangkok, Thailand, Asia
Participants Randomised: 24 participants (mean age 40 years (methotrexate) 48 years (placebo), 15
male)
Inclusion criteria
• Participants with moderate-severe plaque type psoriasis (BSA ≥ 20)
Exclusion criteria
• Pregnancy, immunosuppression, alcohol abuse
Dropouts and withdrawals
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Asawanonda 2006 (Continued)
• 4 (17%)
• Time and reasons: conflicts in schedule (1 methotrexate group, 3 placebo group)
Interventions Intervention
A. Methotrexate (n = 11), 15 mg/week, orally
Control
B. Placebo (n = 13), orally
Co-intervention: phototherapy UVB
Outcomes Assessment at 24 weeks
Primary outcomes of the trial
• PASI 90
Secondary outcomes of the trial
• Time to relapse after clearance
Notes Funding: (quote 1013) no funding source
Declarations of interest: (quote 1013) “None identified”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 1014): “randomized by way of
randomization cards”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1014): “to receive either MTX
or placebo, which were identical in appear-
ance”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1015): “PASI scores were given
by a investigator blinded to the treatment
assignment”
Comment: probably done, placebo-con-
trolled
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 24, analyzed 24
Management of missing data:
Comment: no more precision regarding
methods for dealing with missing data
Selective reporting (reporting bias) Unclear risk Comment: no protocol available. The out-
comes mentioned in the methods section
appeared to have been reported
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Bachelez 2015
Methods RCT, active placebo-controlled, double blind
Date of study: 29 November 2010-13 September 2012
Location: 122 worldwide excluding the USA and Canada
Participants Randomised: 1106 participants (mean age 46 years, 458 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, PGA 3-4 or BSA ≥ 10),
age ≥ 18 years, failed to respond to, had a contraindication to, or were intolerant to at
least one conventional systemic treatment
Exclusion criteria
• Not plaque-type psoriasis
• Active infection, and any uncontrolled significant medical condition
• Had previously been treated or had a contraindication to etanercept, had
previously not responded to treatment with any tumor necrosis factor inhibitors, had
previously participated in studies involving tofacitinib
Dropouts and withdrawals
• 86/1106 (7.8%); tofacitinib 5 mg group (24), tofacitinib 10 mg twice-daily group
(26), etanercept group (23), placebo group (13)
• Not received study medication; tofacitinib 5 mg twice-daily group (1), tofacitinib
10 mg twice-daily group (2), etanercept group (1), placebo group (1)
• AEs: tofacitinib 5 mg twice-daily group (3), tofacitinib 10 mg twice-daily group
(11), etanercept group (12), placebo group (4)
• Lack of efficacy: tofacitinib 5 mg twice-daily group (5), tofacitinib 10 mg twice-
daily group (2), etanercept group (2), placebo group (3)
• Lost to follow-up: tofacitinib 5 mg twice-daily group (1), tofacitinib 10 mg twice-
daily group (2), etanercept group (2), placebo group (2)
• Withdrawal consent: tofacitinib 5 mg twice-daily group (6), tofacitinib 10 mg
twice-daily group (4), etanercept group (2), placebo group (2)
• Other reason:tofacitinib 5 mg twice-daily group (8), tofacitinib 10 mg twice-daily
group (5), etanercept group (4), placebo group (1)
Interventions Intervention
A. Tofacitinib (n = 330), orally, 5 mg twice daily
Control intervention
B. Tofacitinib (n = 332) orally, 10 mg twice daily
C. Etanercept (n = 336) SC, 50 mg twice weekly
D. Placebo (n = 108)
Outcomes Assessment at 12 weeks
Primary outcomes of the trial
• PASI 75 and PGA rating of clear or almost clear
Secondary outcomes of the trial
• PASI 50
• PASI 90
• Itch severity item score
• Mean DLQI score
• AEs
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Notes Funding source:
Quote (p 555): “This study was designed and funded by Pfizer Inc. Study investigators
gathered the data, which were maintained in a database by Pfizer.”
Declarations of interest:
Quote (p 560): “HB has provided consultancy services for AbbVie, Amgen, Boehringer,
Celgene, Janssen, Leo Pharma, Lilly, Novartis, MSD, Pfizer, and Sandoz. He has also
acted as an adviser for AbbVie, Amgen, Boehringer, Celgene, Janssen, Leo Pharma, Lilly,
Novartis, Pfizer, and Sandoz; has served on speaker’s bureaus for AbbVie, Amgen, Cel-
gene, Janssen, Leo Pharma, Lilly, Novartis, and Pfizer; and has received a research grant
fromPfizer. PCMvdK has provided consultancy services for Celgene, Centocor, Almirall,
Amgen, Pfizer, Philips, Abbott, Ely Lilly, Galderma,Novartis, JanssenCilag, Leo Pharma,
Sandoz, and Mitsubishi. He has also done clinical trials for Basilea, Pfizer, Ely Lilly, Am-
gen, AbbVie, Philips Lighting, JanssenCilag, and Leo Pharma. RS has served on speaker’s
bureaus for Pfizer, Schu lke and Mayr, Lohmann & Rauscher, Meda Pharmaceuticals,
Menarini Pharmaceuticals, Stockhausen, and Smith & Nephew; has had consulting
agreements with Pfizer, Novartis, Lohmann & Rauscher, Urgo, Chemomedica, Schu
lke & Mayr, and Pantec Biotechnologies; and has received research and educational
grants from Stockhausen, 3M-Woundcare, Smith & Nephew, Lohmann & Rauscher,
Enjo Commercials, Urgo, Chemomedica, and Schu lke & Mayr. FV has been a princi-
pal investigator, member of a scientific advisory board, or speaker for AbbVie, Janssen,
Eli Lilly, Merck, Novartis, and Pfizer. SC has been a consultant and/or speaker for Pfizer,
AbbVie, Novartis, Merck, and Janssen-Cilag. JPa, JPr, PG, HT, MT, HV, and RW are
employees of Pfizer Inc. AK, J-HL, and VY declare no competing interests.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (page 553): “A computer-generated
randomization schedule was used to assign
patients to the treatment groups”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 553-4): “The study site con-
tacted an interactive voice response system
or web-based interactive response system..
.”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 553): “For this randomised, dou-
ble-blind, double-dummy, placebo-con-
trolled, parallel-group phase 3 study”
Comment: the report provided sufficient
detail about the measures used to blind
study participants and personnel from
knowledge of which intervention a partici-
pant received, to permit a clear judgement
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 553): “Double Blind (Subject,
Caregiver, Investigator, Outcomes Asses-
sor), Patients and study personnel were
masked to treatment assignment: the study
drug packaging was labelled.... ”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 1106, 1101 received at
least 1 dose of study drug
Management of missing data: Quote (page
554): “The primary analysis population for
efficacy was the full analysis set, which was
defined as all patients who received at least
one dose of study drug... We judged pa-
tientswithmissing values for all binary end-
points to be non-responders in efficacy as-
sessments”
Table 2: 1101 analysed participants
Comment: done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01241591)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Bagel 2012
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: North America
Participants Randomised: 124 participants (median age 39 years (etanercept) and 42 years (placebo)
, 69 male)
Inclusion criteria
• Participants with moderate-severe psoriasis: ≥ 30% of scalp surface area affected
(PASI > 10, BSA > 10)
• Age > 18 years
Exclusion criteria
• Had past history of malignant tumours in the past 5 years, had an active
infection, had a significant medical problem
Dropouts and withdrawals
• 26/124 (21%)
• Not received study treatment: etanercept (3), placebo (0)
• AEs: etanercept (5), placebo (0)
• Withdrawal of consent: etanercept (1), placebo (5)
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Bagel 2012 (Continued)
Interventions Intervention
A. Etanercept (n = 62), SC, 50 mg, twice a week
Control intervention
B. Placebo (n = 62), SC, twice a week
Outcomes Assessment at 12 weeks
Primary outcomes of the trial
• % change in PSSI score
Secondary outcomes of the trial
• % change in PSSI score at 24 weeks for group B
• Proportion PSSI at 12 weeks
• Participant satisfaction
• AEs
• PASI 50/75/90 improvement through 24 weeks
• Proportion PGA 0 or 1
• Mean PASI improvement from baseline
Notes Funding: Amgen Inc
Declarations of interest (quote p86): “Dr Bagel receives a salary as founder of the Psoriasis
Treatment Center of Central New Jersey. He has received speaker honoraria from Leo
Pharma, Galderma, Centocor, Abbott, and Amgen. He has also been compensated as
a consultant for Galderma and has served as an investigator for Centocor, Abbott, and
Amgen. Dr Lynde has received research grants and honoraria from Amgen, Abbott,
Merck, Ortho Biotech, Leo Pharma, and Galderma, for whom he has served as an
advisory board member, consultant, and speaker. He has also served as an investigator
for Amgen, Abbott, Merck, Ortho Biotech, and Leo Pharma. Dr Tyring has received
a research grant and honoraria from Amgen, for whom he has served as a consultant,
investigator, and speaker. He has also served as an investigator and/or speaker for Abbott,
Leo Pharma,Galderma,GSK,Novartis,Merck, Epiphany, Inhibitex, AiCuris, and Pfizer.
Dr Kricorian, Yifei Shi, and Dr Klekotka are employees of Amgen Inc. and have received
Amgen stock/stock options.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p87): “Each patient provided writ-
ten informed consent and received a unique
identification number and randomised as-
signment from an Interactive Web Re-
sponse System”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p87): “Each patient provided writ-
ten informed consent and received a unique
identification number and randomised as-
signment from an Interactive Web Re-
sponse System”
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Bagel 2012 (Continued)
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p87): “patients and clinicians were
blinded throughout the study as to treat-
ment assignments.”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote:“patients
and clinicians were blinded throughout the
study as to treatment assignments.”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 124, analysed 124
Dropouts and withdrawals
• 26/124 (21%)
• Not received study treatment;
etanercept (3), placebo (0)
• AEs; etanercept (5), placebo (0)
• Withdrawal of consent; etanercept
(1), placebo (5)
Quote (p89): “included in ITT efficacy
analysis”
Management of missing data:
Quote (p88): “Last observation carried for-
ward imputation was used for missing val-
ues”
Comment: probably done
Selective reporting (reporting bias) Unclear risk Comment: no protocol available. The out-
comes mentioned in the methods section
appeared to have been reported except for
QoL
Barker RESTORE-1, 2011
Methods RCT, active-controlled, open-label trial
Date of study: September 2005-June 2008
Location: 106 centres in Europe
Participants Randomised: 868 participants (mean age 43 years, 586 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA > 10)
• Age ≥18 years and ≤ 75
• Non-response to topical treatment
Exclusion criteria
• Immunosuppression, kidney insufficiency, liver insufficiency
• Had received conventional systemic treatments (methotrexate)
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Barker RESTORE-1, 2011 (Continued)
• Had received biologics
• Had an active infection
• Had uncontrolled cardiovascular disorder
• Had past history of malignant tumours
Dropouts and withdrawals
• 71/868 (8%)
• Infliximab (58), methotrexate (13)
Reasons not stated at week 16
Interventions Intervention
A. Infliximab (n = 653), IV, 5 mg/kg, weeks 0, 2, 6, 14, 22
Control intervention
B. Methotrexate (n = 215), orally, 15 mg/week for 22 weeks
Outcomes Assessment at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 90
• PGA 0/1 (Physician Global Assessment)
• PASI 50
• DLQI
• SF36
Notes Funding: financial support for this study was provided by Schering-Plough Research
Institute, now Merck, Sharp & Dohme Corporation, Whitehouse Station, NJ, U.S.A
Declarations of interest: (Quote Appendix 1): “J.B. has served as a consultant and/or
paid speaker for, and/or participated in clinical trials sponsored by companies that man-
ufacture drugs used for the treatment of psoriasis including Abbott, Celgene, Cento-
cor, Janssen-Cilag, Johnson and Johnson, Merck, Novartis, Pfizer, Schering-Plough and
Wyeth. M.H. has served as a consultant and/or paid speaker for, and/or has participated
in clinical trials sponsored by Abbott, Amgen, Essex, Janssen, Leo, Medac, Novartis,
Pfizer, Schering-Plough and Wyeth. G.W. has no conflicts of interest to disclose. J.-P.O.
has been a consultant for Schering-Plough, Abbott, Merck-Serono, Centocor, Wyeth,
Janssen-Cilag,Meda-Pharma, Pierre-Fabre andGalderma.H.Z. is an employee ofMerck,
Sharp & Dohme. H.v.H. was an employee of Merck, Sharp & Dohme at the time of
the RESTORE1 study and during the preparation of this manuscript. K.R. has served
as a consultant and/or paid speaker for, and/or participated in clinical trials sponsored
by Abbott, Celgene, Centocor, Janssen-Cilag, Leo, Medac and Merck.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p1110): “At each eligible subject’s
baseline visit, study centres telephoned the
Interactive Voice REsponse Syste .... for
randomisation“
Comment: probably done
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Barker RESTORE-1, 2011 (Continued)
Allocation concealment (selection bias) Low risk Quote (p1110): “At each eligible subject’s
baseline visit, study centres telephoned the
Interactive Voice REsponse Syste .... for
randomisation”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p1110): “open-label trial”
Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p1110): “open-label trial”
Comment: no blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 868, analysed 868
Quote (p1110-11): “Primary and sec-
ondary efficacy analyses were based on the
ITT population, the ITT population in-
cluded all randomised patients. At week 16,
patientswhodroppedout early or hadmiss-
ing data for PASI 75 ... were considered
nonresponders”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00251641)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Bissonnette 2013
Methods RCT, placebo-controlled, single blind
Date of study: May 2009-June 2011
Location: Montréal, Quebec, Canada (5 centres)
Participants Randomised: 30 participants (median age 56 years (adalimumab) and 57 years (placebo)
, 23 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA>5)
• Age ≥ 18 years and ≤ 80
• Non-response to topical treatment
Exclusion criteria
• Immunosuppression, kidney insufficiency
• Had an active infection, had uncontrolled cardiovascular disorder, had
uncontrolled diabetes, had uncontrolled hypertension, had past history of malignant
tumours
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Dropouts and withdrawals
• 2/30 (7%)
• Discontinued intervention (1, placebo group)
• Death myocardial infarction (1, adalimumab group)
Interventions Intervention
A. Adalimumab (n = 20), SC, 80/40 mg, eow
Control intervention
B. Topical treatment, phototherapy or no treatment (n = 10)
Outcomes Assessment at 16 weeks
Primary outcomes of the trial
• The change in the average of max TBR values of carotid arteries
Secondary outcomes of the trial
• PASI 75 at week 16
• Change in average of max TBR of vessels
• Change in the most diseased segment T
Notes Funding: Abbott laboratories
Declarations of interest: (quote p 89) “Dr Bissonnette and Dr Bolduc have been in-
vestigators, advisors and/ or consultants and received grants and/or honoraria from Ab-
bott, Amgen, Astellas, Novartis, Janssen Ortho, Pfizer, Celgene, and Tribute. Drs Tardif,
Harel, Pressacco, and Guertin have no conflicts of interest to declare.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p84): “were randomised a con-
cealed computer generated code created by
the sponsor”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p84): “were randomised a con-
cealed computer generated code created by
the sponsor”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (83-4): “single-blind (cardiologist
and all staff involved in vascular imaging
and analysis were blinded to treatment as-
signment)”
Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (83-4): “single-blind (cardiologist
and all staff involved in vascular imaging
and analysis were blinded to treatment as-
signment)”
Comment: probably done; however, no
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Bissonnette 2013 (Continued)
statement regarding secondary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 30, analysed 30
Quote (p84): “For all end points, the anal-
ysis was conducted on the ITT population,
... for the PASI 75 end point,... a nonre-
sponder imputation method was used”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00940862)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Bissonnette 2015
Methods RCT, placebo-controlled, double blind
Date of study: 20 August 2010-14 May 2014
Location: 65 centres in Europe, North and South America, and Australia
Participants Randomised: 674 participants (mean age 46 years, 458 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, PGA 3-4 or BSA ≥ 10),
age ≥ 18 years
Exclusion criteria
• Past history of malignant tumours and active infection
Dropouts and withdrawals
• 72/674(10.7%): tofacitinib 5 mg twice-daily group (39), tofacitinib 10 mg twice-
daily group (41)
• Not received study medication: tofacitinib 5 mg twice-daily group (5), tofacitinib
10 mg twice-daily group (3)
• Death: tofacitinib 5 mg twice-daily group (1), tofacitinib 10 mg twice-daily group
(0)
• AEs: tofacitinib 5 mg twice-daily group (7), tofacitinib 10 mg twice-daily group
(9)
• Lack of efficacy: tofacitinib 5 mg twice-daily group (6), tofacitinib 10 mg twice-
daily group (7)
• Lost to follow-up: tofacitinib 5 mg twice-daily group (6), tofacitinib 10 mg twice-
daily group (7)
• Withdrawal consent: tofacitinib 5 mg twice-daily group (12), tofacitinib 10 mg
twice-daily group (0)
• Other reason: tofacitinib 5 mg twice-daily group (2), tofacitinib 10 mg twice-
daily group (8)
Interventions Intervention
A. Tofacitinib (n = 338), orally, 10 mg twice daily
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Control intervention
B. Tofacitinib (n = 336), orally, 5 mg twice daily
Outcomes Assessment at 24 weeks
Primary outcomes of the trial
• PASI 75 and PGA rating of clear or almost clear
Secondary outcomes of the trial
• Median time to PASI 75 response
• Median time to PGA rating of clear or almost clear response
• Percentage of participants achieving both a PASI 50-75 response and DLQI ≤ 5
• Percentage of participants with PGA response of clear or almost clear
• Mean change From baseline-A in PASI score
• Percentage of participants achieving at least a 90% reduction in PASI relative to
baseline-A (PASI 90)
• Mean DLQI score
• AEs
Notes Funding source:
Quote (p 1395 & 1400): “This study was sponsored by Pfizer Inc. Pfizer conducted the
data analysis and the authors interpreted the data and collaborated in the manuscript
preparation. All authors have access to the study data.”
Declaration of interest: (quote: Appendix 1): “R.B. has received honoraria, grants or
worked as a consultant for AbbVie, Amgen, Apopharma, Astellas, Celgene, Eli Lilly,
Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer and Tribute. L.I. has served as a
consultant and/or paid speaker for, and/or participated in clinical trials sponsored by,
AbbVie, Almirall, Amgen, Celgene, Centocor, Eli Lilly, Janssen-Cilag, LEO Pharma,
MSD, Novartis, Pfizer and UCB. H.S. has served as a principal investigator and con-
sultant for Pfizer, Celgene, Janssen, Amgen, Novartis, Eli Lilly and Merck. C.E.M.G
has received grant/research support and/or received honoraria from AbbVie, Actelion,
Biotest, Celgene, Eli Lilly, Incyte, Janssen, LEOPharma,MSD, Novartis, Pfizer, Sandoz,
Stiefel U.K., Trident, Zymogenetics and UCB. P.F. has served as a consultant for Gal-
derma, LEO/Peplin, Ascent, Clinuvel, Aspen, Janssen-Cilag, Eli Lilly, AustralianUltravi-
olet Services, Novartis, Wyeth/Pfizer,Mayne Pharma, MedyTox and Roche. He has also
served on advisory boards/speaker’s bureaus and/or as a clinical trial investigator for CSL,
Galderma, 3M/iNova/Valeant, LEO/Peplin, Ascent, Clinuvel, GSK/Stiefel, Abbott/Ab-
bVie, BiogenIdec, Janssen-Cilag, Merck Serono, ScheringPlough/MSD, Wyeth/Pfizer,
Amgen, Novartis, Eli Lilly, Celgene, Roche, Aspen, Actelion, Sanofi Aventis, MedyTox,
Shape and BMS.He has received travel grants fromGalderma, LEO/ Peplin, BiogenIdec,
Merck Serono, Ascent, Abbott/Abbvie, Schering-Plough/MSD, Janssen-Cilag, Wyeth/
Pfizer, Novartis and Roche. R.R. is a consultant, investigator and/or speaker for AbbVie,
Eli Lilly, Galderma, Janssen-Cilag, LEO Pharma, Novartis and Pfizer. M.B., S.T.R., H.
T., J.P., H.V., L.M., P.G. and R.W. are employees of Pfizer Inc.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (page 1398): “A computer-gener-
ated central randomisation schemawas im-
plemented using an automated web/tele-
phone sytem.”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (page 1398): “A computer-gener-
ated central randomisation schemawas im-
plemented using an automated web/tele-
phone sytem.”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1398, Clini-
cal.gov, NCT01186744): “Masking: Dou-
ble Blind (Subject, Caregiver, Investigator,
Outcomes Assessor) ”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1397): “Masking: Double Blind
(Subject, Caregiver, Investigator, Out-
comes Assessor) ”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 674, analysed 662
Dropouts and withdrawals:
Tofacitinib 5 mg twice-daily group (39),
tofacitinib 10 mg twice-daily group (41)
Imbalanced numbers for withdrawal con-
sent: tofacitinib 5 mg twice-daily group
(12), tofacitinib 10 mg twice-daily group
(0)
Management of missing data: Quote (page
1398): “Efficacy analysis was performed
on the full analysis set comprising patients
who were randomised and received one or
more doses of the study drug” (page 1400)
“666 patients with moderate-severe psori-
asis were randomised to the initial period
and received study medication”. However
only 662 patients were analysed for the out-
comes
Comment: we judged this as a high risk of
bias
Selective reporting (reporting bias) Low risk Comment: the protocol for the study
was available on ClinicalTrials.gov (NCT-
NCT01186744)
The pre-specified outcomes and those
mentioned in the methods section ap-
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peared to have been reported
Blauvelt FEATURE, 2015
Methods RCT, active/placebo-controlled, double blind
Date of study: May 2012-January 2013
Location: 32 centres in the USA/Germany/France/Estonia/India/Switzerland
Participants Randomised: 177 participants (mean age 45 years (secukinumab 300 mg), 46 years
(secukinumab 150 mg), 47 years (placebo), 117 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, Investigator’s Global
Assessment, IGA ≥3, BSA ≥ 10)
• Age ≥ 18 years
• Non-response to topical treatment
• Non-response to phototherapy
• Non-response to systemic treatment
Exclusion criteria
• Pregnancy, Immunosuppresion, Kidney insufficiency, Liver insufficiency,
• Had received biologics (IL17)
• Had uncontrolled cardiovascular disorder
• Had uncontrolled hypertension
• Past history of malignant tumours
Dropouts and withdrawals
• 7/177(4%), secukinumab 300 group (3), secukinumab 150 group (1), placebo (3)
• AEs: secukinumab 300 group (1), secukinumab 150 group (0), placebo (1)
• Lost to follow-up: secukinumab 300 group (2), secukinumab 150 group (1),
placebo (0)
• Withdrew consent: secukinumab 300 group (0), secukinumab 150 group (0),
placebo (2)
Interventions Intervention
A. Secukinumab (n = 59), SC, 300 mg, weeks 1, 2, 3, 4, 8, 12
B. Secukinumab (n = 59), SC, 150 mg, weeks 1, 2, 3, 4, 8, 12
Control intervention
C. Placebo (n = 59), SC, weeks 1, 2, 3, 4, 8, 12
Outcomes Assessment at 12 weeks
Primary outcomes of the trial
• PASI 75 and IGA 0-1
Secondary outcomes of the trial
• Usability of the pre-filled syringe as assessed by observer rating of successful,
hazard-free self-injection and subject rating of acceptability by the SIAQ
• PASI 90/100 over time
• IGA 0/1 over time
AEs
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Notes Funding: Novartis Pharmaceuticals, Basel, Switzerland.
Declarations of interest (quote p 484): “A.B. has served as a scientific consultant and
clinical study investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Janssen,
Lilly, Merck, Novartis, Pfizer and Sandoz. J.C.P. has served as a consultant, investigator,
speaker or advisory board member for Abbott, Biogen-Idec (formerly Biogen), Cen-
tocor, Essex Pharma, Galderma, Janssen-Cilag/Janssen-Ortho, Merck-Serono (formerly
Serono), MSD, Novartis, Pfizer andWyeth, and has received unrestricted research grants
from Biogen-Idec and Wyeth. A.B.G. has served as scientific consultant and/or clinical
study investigator for Abbott, Abbvie, Actelion, Akros Pharma, Amgen, Astellas Pharma,
Beiersdorf, BMS, Canfite, Celgene, Coronado BioSciences, CSL Behring, GSK, Im-
mune Control, Incyte, Janssen-Ortho, Lerner Medical Devices, Lilly ICOS,Merck, No-
vartis, Novo Nordisk, Pfizer, Teva, UCB, Vertex Pharmaceuticals and Xenoport. K.K.
has served as a study investigator for Celgene, Hexal, Mitsubishi and Novartis. H.S. has
served as a study investigator, consultant and speaker for Novartis. M.R.-M. has served
as a study investigator for Novartis. V.S., R.P., C.P. and S.C. are full-time employees of
Novartis. C.P. and S.C. own stock in Novartis”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 486): “were randomised via in-
teractive response technology to one of the
treatment arms...using a validate system
that automated the random assignment of
subject numbers to randomisation num-
bers”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 486): “were randomised via in-
teractive response technology to one of the
treatment arms...using a validate system
that automated the random assignment of
subject numbers to randomisation num-
bers”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p486): “Subjects, study manage-
ment team, investigator staff, persons per-
forming the assessments and data analysts
were blinded...”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p486): “Subjects, study manage-
ment team, investigator staff, persons per-
forming the assessments and data analysts
were blinded...”
Comment: probably done
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 177, analysed 177
Dropouts and withdrawals
• 7/177(4%), secukinumab 300 group
(3), secukinumab 150 group (1), placebo
(3)
• AEs: secukinumab 300 group (1),
secukinumab 150 group (0), placebo (1)
• Lost to follow-up: secukinumab 300
group (2), secukinumab 150 group (1),
placebo (0)
• Withdrew consent: secukinumab
300 group (0), secukinumab 150 group
(0), placebo (2)
Management of missing data: quote (sup-
plemental appendix) “Missing values were
imputed as non-response for all efficacy
analyses regardless of the reason of missing
data”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01555125)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Blauvelt VOYAGE-1, 2016
Methods RCT, active placebo-controlled, double blind
Date of study: December 2014-April 2016
Location: 101 centres worldwide
Participants Randomised: participants (mean age 44 years, 608 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, IGA ≥ 3, BSA ≥ 10), age
≥ 18 years
• Exclusion criteria
• Had a history or current signs of a severe, progressive, or uncontrolled medical
condition
• Had current or history of malignancy, except nonmelanoma skin cancer, within 5
years.
• History or symptoms of active TB
• Had previously received guselkumab or adalimumab
Dropouts and withdrawals
• 24/837 (2.9%): guselkumab (7), adalimumab (10), placebo group (7)
• AEs: guselkumab (4), adalimumab (2), placebo group (2)
• Lack of efficacy: guselkumab (0), adalimumab (1), placebo group (2)
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• Lost to follow-up: guselkumab (1), adalimumab (1), placebo group (1)
• Withdrawal consent: guselkumab (0), adalimumab (4), placebo group (2)
• Non compliance: guselkumab (2), adalimumab (1), placebo group (0)
• Protocol violation: guselkumab (0), adalimumab (1), placebo group (0)
Interventions Intervention
A. Guselkumab (n = 334), SC, 100 mg, weeks 0 and 4, then every 8 weeks
Control intervention
B. Adalimumab (n = 329), 80 mg week 0, then 40 mg week 1, and every 2 weeks
C. Placebo (n = 174)
Outcomes Assessment at 16 weeks
Primary outcomes of the trial
• PASI 90 and IGA clear or almost clear
Secondary outcomes of the trial
• PASI 50/75
• Mean Dermatology Life Quality Index (DLQI) Score
• NAPSI (Nail Psoriasis Severity Index)
• Scalp specific IGA
• fingernail PGA
• AEs
Notes Funding source:
Quote (p 405): “Supported by Janssen Research & Development LLC, Spring House,
PA.”
DEclarations of interest
Quote (p 405): “Dr Blauvelt has served as a scientific adviser and clinical study investi-
gator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Genentech, GSK,
Janssen, Eli Lilly, Merck, Novartis, Pfizer, Regeneron, Sandoz, Sanofi-Genzyme, Sun,
UCB, and Valeant, and as a paid speaker for Eli Lilly. Dr Papp has received honoraria or
clinical research grants as a consultant, speaker, scientific officer, advisory board member,
and/or steering committee member for AbbVie, Akesis, Akros, Allergan, Alza, Amgen,
Anacor, Artax, Astellas, AstraZeneca, Baxalta, Baxter, Biogen, Boehringer Ingelheim,
Bristol-Myers Squibb,CanFite,Celgene,Celtic, Cipher,Dermira,DowPharmaceuticals,
Eli Lilly, Ferring Pharmaceuticals, Formycon, Forward Pharma, Funxional Therapeutics,
Fujisawa, Galderma, Genentech, Genexion, Genzyme, Gilead, GSK, Janssen, Kyowa
HakkoKirin, Leo, Lypanosys,Medimmune,Meiji Seika Pharma,Merck (MSD),Merck-
Serono, Mitsubishi Pharma, Mylan, Novartis, NovImmune, Pan Genetics, Pfizer, Re-
generon, Roche, Sanofi-Aventis, Stiefel, Takeda, UCB, Vertex, and Valeant. Dr Griffiths
has received honoraria and/or grants as an investigator, speaker, and/or advisory board
member for AbbVie, Eli Lilly, Janssen, Leo, Novartis, Pfizer, Sandoz, and Sun Pharma.
Dr Kimball has received honoraria as a consultant for AbbVie, BMS, Dermira, Eli Lilly
ICOS LLC, Merck, and Novartis; and received grants and/or funding for research or the
residency/fellowship program as a principal investigator for AbbVie, Amgen, Boehringer
Ingelheim, Dermira, Janssen, Merck, and Novartis. Drs Randazzo, Wasfi, Shen, and Li
are all employees of Janssen Research & Development LLC (subsidiary of Johnson &
Johnson) and own stock in Johnson & Johnson.”
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p3): “Patients were randomised us-
ing a permuted block method Central ran-
domisation was implemented using an in-
teractiveWorldWideWeb response system
(Perceptive Informatics, East Windsor, NJ)
.”
Comment: clearly defined
Allocation concealment (selection bias) Low risk Quote (p3): “Central randomisation was
implemented using an interactive World
Wide Web response system (Perceptive In-
formatics, East Windsor, NJ).”
Comment: clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 3): “To maintain the blind,
matching placebos were used.”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p3): “To maintain the blind,
matching placebos were used.”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 837, 837 analysed
Management of missing data: quote (page
3): “Patients who discontinued study agent
because of lack of efficacy or anAE of pso-
riasis worsening or who started a protocol-
prohibited psoriasis treatment were consid-
ered nonresponders (binary end points) or
had baseline values carried over (continu-
ous end points). Other patients with miss-
ing datawere considered nonresponders for
binary end points (nonresponder imputa-
tion) and had last observation carried for-
ward for continuous end points (and all
PSSD end points).”
Comment: done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT02207231)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
129Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cai 2016
Methods RCT, placebo-controlled, double blind
Date of study: 14 August 2012-21 December 2013
Location: China
Participants Randomised: 425 participants (mean age 43 years, 310 men)
Inclusion criteria
• 18 years of age and older
• Moderate-severe disease (PASI ≥ 10, PGA ≥ 3)
• Had failed to respond to or were intolerant to previous systemic therapy
Exclusion criteria
• Had previous exposure to a biologic treatment
• Received other systemic therapies for psoriasis within 28 days of baseline
• Severe uncontrolled or progressive medical conditions
• Had a history of demyelinating disease or certain infections or cardiovascular
events
• Had certain malignancies or abnormal laboratory results
• Had active TB, had immune deficiency or was immunocompromised
Dropouts and withdrawals
• 7/425 (1.6%)
• AEs: adalimumab (2)
• Withdrawal of consent adalimumab (1), placebo (1)
• Others (3)
Interventions Intervention
A. Adalimumab (n = 338), SC, 40 mg, week 0, 2 injections, eow 1 injection
Control intervention
B. Placebo (n = 87), SC
Outcomes Assessment at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA0/1, AE, PASI 50/90
Notes Funding source:
Quote (p 2): “Abbvie Inc participated in the study design, study research, collection,
analysis and interpretation of data”
Declarations of interest:
Quote (p 2): “L Cai, J Gu, J Zheng, M Zheng, GWang, L-Y Xi, F Hao, X-M Liu, Q-N
Sun, Y Wang, W Lai, H Fang, Y-T Tu, Q Sun, J Chen and X-H Gao were investigators
for this study, and J-Z Zhang was the principal investigator for this study; all declare
no financial, professional or personal relationships that might be perceived as a conflict
of interest. Y Gu and HD Teixeira receive a salary as employees of AbbVie and may
also receive stock, stock options and/or stock grants. MM Okun is a former AbbVie
employee.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (p 2 & Appendix): “The randomi-
sation schedule was prepared by the Statis-
tics Department of AbbVie, US. Random-
ization was performed using an adequate
block size.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 2 & Appendix): “An interac-
tive voice/web response system determined
patient randomisation. The randomisation
schedule was prepared by the Statistics De-
partment of AbbVie, US. Randomization
was performed using an adequate block
size.“
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 2 & Appendix): “Patients in
Period A were randomised 4:1 to receive
adalimumab 40 mg every-other-week (fol-
lowing a single 80 mg dose), or match-
ing placebo...All AbbVie personnel with
direct oversight of the conduct and man-
agement of the trial (with the exception
of the drug supply team), the investiga-
tor, study-site personnel and the patient re-
mained blinded to each patient’s treatment
throughout the 12 week blinded period of
the study.”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 2 & Appendix): “Patients in Pe-
riod A were randomised 4 : 1 to receive
adalimumab 40 mg every-other-week (fol-
lowing a single 80 mg dose), or match-
ing placebo...All AbbVie personnel with
direct oversight of the conduct and man-
agement of the trial (with the exception
of the drug supply team), the investiga-
tor, study-site personnel and the patient re-
mained blinded to each patient’s treatment
throughout the 12 week blinded period of
the study.“
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned: 425, analysed 425
(ITT)
Quote (p 3): “Efficacy was analysed in
Period A for all randomised patients [in-
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tent-to-treat (ITT A Population)]... Miss-
ing data were handled using non-respon-
der imputation (NRI) for categorical vari-
ables and last-observation-carried-forward
(LOCF) for continuous variables.”
Comment: ITT analyses
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01646073)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Caproni 2009
Methods RCT, active-controlled
Date of study: not stated
Location: not stated
Participants Randomised: 60 participants (age range 28-67 years (etanercept), 32-65 years (acitretin)
, 24 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 10, BSA ≥ 10)
Exclusion criteria
• Pregnancy
• Had an active infection
• Past history of malignant tumours
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Etanercept (n = 30), SC, 50 mg, twice a week, 12 weeks
Control intervention
B. Acitretin (n = 30), orally, 0.4 mg/kg/day, 12 weeks
Outcomes Assessment at 12 weeks
Primary and secondary outcomes of the trial
• Not stated
Outcomes of the trial
• Mean PASI at baseline and at 12 weeks
• PASI 75, PASI 50
Notes Funding: not stated
Declarations of interest: not stated
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 211): “Patients were randomly
assigned to one of the two groups”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: probably open-label trial, term
“blind” not used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: probably open-label trial, term
“blind” not used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no description of the method
used to manage the missing data. No ITT
analyses mentioned
Selective reporting (reporting bias) Unclear risk Comment: no primary or secondary out-
comes stated
Chaudhari 2001
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: single centre, New Jersey, USA
Participants Randomised: 33 participants (age mean 35 years (infliximab 10), 51 years (infliximab
5), 45 years (placebo), 23 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 5)
• Non-response to topical treatment
Exclusion criteria
• Immunosuppression
• Had received biologics
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 3/33 (9%)
• Time and reasons: worsening psoriasis (n = 1 from infliximab 10 mg/kg group),
mild rash (n = 1 from infliximab 5mg/kg group), lack improvement disease (n = 1 from
placebo group)
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Interventions Intervention
A. Infliximab (n = 11), IV, 5 mg/kg , weeks 0, 2, 6, 10
Control intervention
B. Infliximab (n = 11), IV, 10 mg/kg , weeks 0, 2, 6, 10
C. Placebo (n = 11), IV, 20 mL, weeks 0, 2, 6, 10
Outcomes Assessment at 10 weeks
Primary outcomes of the trial
• PGA good, excellent or clear
Secondary outcomes of the trial
• PASI 75
Notes Funding : Y Johnson and Johnson, Centocor Inc
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 1843): ”...were randomly as-
signed... bymeans of a lock-of-six randomi-
sation scheme“
Comment: probably done
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1843): ”Placebo was supplied in
a identical manner except that it did not
contain IFX...The infliximab infusion so-
lution was given by investigators unaware
of treatment assignment...“
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1843): ”All assessments were
done in a masked manner“
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 33, analysed 33
Dropouts and withdrawals
• 3/33 (9%)
• Time and reasons: worsening
psoriasis (n = 1 from infliximab 10 mg/kg
group), mild rash (n = 1 from infliximab
5mg/kg group), lack improvement disease
(n = 1 from placebo group)
Management of missing data: quote (p
1844): ”The primary analysis was done ac-
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cording to ITT, all randomised patients
were included
Comment: probably done
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Chladek 2005
Methods RCT, active-controlled
Date of study: not stated
Location: Prague, Czech Republic
Participants Randomised: 41 participants (mean age 50 years (A), 46 years (B), 44 years (C), 41
years (D), 24 male)
Inclusion criteria
• Not stated
Exclusion criteria
• Not stated
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Methotrextate (n = 12), 7.5 mg/week, 2.5-2.5-2.5 at 12 h, for 13 weeks
Control intervention
B. Methotrextate (n = 12), 15 mg/week, 5-5-5 at 12 h, 13w
C. Methotrextate (n = 7), 7.5 mg/week, once a week, for 13 weeks
D. Methotrextate (n = 10), 15 mg/week, once a week, 13 weeks
Outcomes Assessment at 13 weeks
Primary or secondary outcomes of the trial
• Not stated
Outcomes of the trial
• Red cell concentrations of methotrexate
• PASI weeks 1, 5, 9, 13
Notes Funding: Czech Ministry of Education
Declarations if interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 247): “were randomly assigned”
Comment: no description of the method
used to guarantee random sequence gener-
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Chladek 2005 (Continued)
ation
Allocation concealment (selection bias) Unclear risk Quote (p 247): “were randomly assigned”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: probably open-label trial, term
“blind” not used
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: probably open-label trial, term
“blind” not used
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no description of the method
used to manage the missing data. No ITT
analyses mentioned
Selective reporting (reporting bias) Unclear risk Comment: no primary or secondary out-
comes stated
de Vries PIECE, 2016
Methods RCT, active-controlled,
Date of study: April 2009 and June 2011
Location: 5 centres in The Netherlands
Participants Randomised: 50 participants
Inclusion criteria
• 18-75 years
• Moderate to severe chronic plaque type psoriasis defined as PASI) ≥ 10 and/or
BSA ≥ 10 and/or PASI ≥ 8 plus a Skindex-29 score ≥ 35
• Patients must have had unsuccessful treatment with or were contraindicated and/
or intolerant to UV therapy, and methotrexate or cyclosporine
Exclusion criteria
• Pregnant, breastfeeding
• Malignancy in the previous 10 years
• Active/chronic infections including TB
• Demyelinating disease
• Congestive heart failure
• Severe liver function disorders >2 times and/or kidney function disorders >1.5
times upper limit of the parameters
Dropouts and withdrawals
• 15/50 (30%)
• False inclusion: infliximab (0), etanercept (2)
• AEs: infliximab (1), etanercept (3)
• Injection fear: infliximab (0), etanercept (1)
• Switch to etanercept: infliximab (3), etanercept (not applicable)
• Switch to infliximab: infliximab (not applicable), etanercept (3)
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• No response: infliximab (0), etanercept (1)
• Lost To follow-up: infliximab (1), etanercept (0)
Interventions Intervention (n = 48)
A. Infliximab (n = 25), IV, 5 mg/kg, weeks 0, 2, 6, 15, 22
Control intervention
B. Etanercept (n = 23), SC, 50 mg twice weekly
Outcomes Assessment at 24 weeks
Primary outcomes of the trial
PASI 75
Secondary outcomes of the trial
QoL scale, Global assessment, treatment satisfaction
Notes Funding source quote (p 1): ”study was funded by a program grant from theNetherlands
Organization for ScientificResearch-Medical Sciences (NWO-MW;project 152001006)
.“
Declaration of interest: ”A.C.Q. de Vries: none reported; H.B. Thio: has been a con-
sultant and invited speaker for Biogen/Idec, Janssen, Abbvie, Pfizer, MSD, Leopharma,
Teva and Novartis. He has received educational grants from Abbvie, Janssen, Pfizer and
Biogen/Idec.;W.J.A. de Kort:medical advisor forNovartis; B.C.Opmeer: none reported;
H.M. van der Stok: Involved in performing clinical trials with Abbvie, Pfizer, Novar-
tis, Janssen, BioClinic, AMGEN and LeoPharma.; E.M.G.J. de Jong: received research
grants for the independent research fund of the department of dermatology of Univer-
sity Medical Centre St Radboud Nijmegen, the Netherlands from AbbVie, Pfizer, and
Janssen. Has acted as consultant and/or paid speaker for and/or participated in research
sponsored by companies that manufacture drugs used for the treatment of psoriasis in-
cluding AbbVie, Janssen, MSD, and Pfizer.; B. Horvath: Unrestricted Educational Grant
from AbbVie, IIS Studies by Janssen, AbbVie, Performing clinical trial Novartis, Solenne
B.V., Consultancies: Abbvie, Janssen, Philips, Galderma.; J.J.V.Busschbach: none re-
ported; T.E.C. Nijsten: received research grants for the independent research fund of the
department of dermatology of Erasmus MC, Rotterdam, the Netherlands from AbbVie,
Leo Pharma, MSD, Pfizer, and Janssen. Has acted as consultant and/or paid speaker for
and/or participated in research sponsored by companies that manufacture drugs used
for the treatment of psoriasis including AbbVie, Leo Pharma, Galderma, Janssen, MSD,
and Pfizer. ; Ph.I. Spuls: consultancies in the past for Leopharma, AbbVie and Novartis.
In the past an independent research grant from Schering Plough and from Leopharma.
Involved in performing clinical trials with many pharmaceutical industries that manu-
facture drugs used for the treatment of psoriasis.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 4 & 8): “...was a multi-cen-
tre, single-blind, investigator initiated, ran-
domised controlled trial comparing inflix-
imab and etanercept in the treatment of
moderate to severe chronic plaque type pso-
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de Vries PIECE, 2016 (Continued)
riasis... Adequate generation of an unpre-
dictable allocation sequence and conceal-
ment of allocation was achieved by us-
ing a secure online internet facility (the
TEN-ALEA Clinical Trial Data Manage-
ment System, provided by the Trans Eu-
ropean Network http://www.tenalea.com/
) performed in the coordinating centre by
the main investigators. The sequence was
generated in random block sizes of two and
four to ensure it was unknown and not
predictable by the investigators involved in
randomising participants.”
Comment: done
Allocation concealment (selection bias) Low risk Quote (p 4 & 8): “...was a multi-cen-
tre, single-blind, investigator initiated, ran-
domised controlled trial comparing inflix-
imab and etanercept in the treatment of
moderate to severe chronic plaque type pso-
riasis... Adequate generation of an unpre-
dictable allocation sequence and conceal-
ment of allocation was achieved by us-
ing a secure online internet facility (the
TEN-ALEA Clinical Trial Data Manage-
ment System, provided by the Trans Eu-
ropean Network http://www.tenalea.com/
) performed in the coordinating centre by
the main investigators. The sequence was
generated in random block sizes of two and
four to ensure it was unknown and not
predictable by the investigators involved in
randomising participants.“
Comment: done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 4 & 8): “...was a multi-cen-
tre, single-blind, investigator initiated, ran-
domised controlled trial comparing inflix-
imab and etanercept in the treatment of
moderate to severe chronic plaque type pso-
riasis...”
Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p 8): “Efficacy outcomes were car-
ried out by trained assessors who were
blinded to treatment allocation.”
Comment: no clear descriptionofmeasures
taken to guarantee the blinding of investi-
gators
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 50, analysed 48
Quote (p 8& 9): “Missing data on primary
endpoint were imputed using last observa-
tion carried forward. Analyses were carried
out according to intention-to-treat (ITT)
principle, apart from the longer term data
where a per protocol analysis (PPA) was
performed”
Comment: probably done
Selective reporting (reporting bias) Unclear risk The trial was prospectively registered on the
Dutch Trial Register: www.trialregister.nl/
trialreg/index.asp; NTR 1559
The pre-specified outcomes mentioned in
the methods section appeared to have been
reported
Dogra 2012
Methods RCT, active-controlled, double blind
Date of study: August 2008-September 2009
Location: Chandigarh, India
Participants Randomised: 60 participants (mean age 37 years, 48 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 10)
• Age ≥ 18 years ≤ 65
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had uncontrolled cardiovascular disorder
• Had uncontrolled diabetes
• had uncontrolled hypertension
Dropouts and withdrawals
• 9/60 (15%): methotrexate 10 group (5), methotrexate 25 group (4)
• 4 lost to follow-up: methotrexate 10 group (3), methotrexate 25 group (1)
• 4 withdrawn due to side effects: methotrexate 10 group (1), methotrexate 25
group (3)
• 1 refused to participate further in the study: methotrexate 10 group (1),
methotrexate 25 group (0)
Interventions Intervention
A. Methotrexate (n = 30), orally, 10 mg/week, for 12 weeks
Control intervention
B. Methotrexate (n = 30), orally, 25 mg/week, for 12 weeks
Outcomes Assessment at 12 weeks
Primary outcomes of the trial
• Change in PASI score
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Secondary outcomes of the trial
• PASI 75
• AEs
Notes Funding: none declared
Declarations of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 730): “The randomisation list
was generated using a random number ta-
ble, and the code was kept by an investi-
gator who was not directly involved in the
study”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 730): “The randomisation list
was generated using a random number ta-
ble, and the code was kept by an investi-
gator who was not directly involved in the
study. All tablets were supplied in sealed
envelopes bearing the code for any particu-
lar patient according to the randomisation
list”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 730-31): “Double blind study,
…, the 10 mg group was also given an oral
placebo tablet in addition to the MTX to
give an equal number of tablets in both
groups. The placebo tablets were identi-
cal in appearance to the MTX tablets in
colour, texture, size, shape and markings.
All tabletswere supplied in sealed envelopes
bearing the code for any particular patient
according to the randomisation list”
Comment: clearly described
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 730-31): “Double blind study,
…, the 10 mg group was also given an oral
placebo tablet in addition to the MTX to
give an equal number of tablets in both
groups. The placebo tablets were identi-
cal in appearance to the MTX tablets in
colour, texture, size, shape and markings.
All tabletswere supplied in sealed envelopes
bearing the code for any particular patient
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Dogra 2012 (Continued)
according to the randomisation list”
Comment: clearly described
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 60, analysed 51
Dropouts and withdrawals
• 9/60 (15%): methotrexate 10 group
(5), methotrexate 25 group (4)
• 4 Lost to follow-up: methotrexate 10
group (3), methotrexate 25 group (1)
• 4 withdrawn due to side effects:
methotrexate 10 group (1), methotrexate
25 group (3)
• 1 refused to participate further in the
study: methotrexate 10 group (1),
methotrexate 25 group (0)
Management of missing data: no ITT anal-
yses
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Dogra 2013
Methods RCT, active-controlled, double blind
Date of study: March 2008-March 2009
Location: Chandigarh, India
Participants Randomised: 61 participants (mean age 37 years, 51 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 10)
• Age ≥ 18 years ≤ 65
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had uncontrolled cardiovascular disorder
• Had uncontrolled diabetes
• had uncontrolled hypertension
Dropouts and withdrawals
• 13/61 (21%): acitretin 25 group (5), acitretin 35 group (4), acitretin 50 group (4)
• 10 lost to follow-up: acitretin 25 group (4), acitretin 35 group (2), acitretin 50
group (4)
• 3 severe disease exacerbation: acitretin 25 group (1), acitretin 35 group (2)
Interventions Intervention
A. Acitretin (n = 20), orally, 25 mg/day, for 12 weeks
Control intervention
B. Acitretin (n = 20), orally, 35 mg/day, for 12 weeks
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C. Acitretin (n = 21), orally, 50 mg/day, for 12 weeks
Outcomes Assessment at 12 weeks
Primary outcomes of the trial
• Change in PASI score
Secondary outcomes of the trial
• PASI 75
• % complete clearance
• Time taken to achieve those parameters
• AEs
Notes Funding (quote e305): none declared
Declarations of interest (quote e305): none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p e306): “Randomization list was
generated using random number table and
codewas keptwith a study coordinatorwho
was not directly involved in assessment of
endpoint”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p e306): “Randomization list was
generated using random number table and
codewas keptwith a study coordinatorwho
was not directly involved in assessment of
endpoint”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (p e306): “double blind”
Comment: no description of the method
used to guarantee blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p e306): “double blind” “Random-
ization list was generated using random
number table and code was kept with a
study coordinator who was not directly in-
volved in assessment of endpoint”
Comment: no description of the method
used to guarantee blinding of outcome as-
sessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 61, analysed 48
Dropouts and withdrawals:
• 13/61(21%): acitretin 25 group (5),
acitretin 35 group (4), acitretin 50 group
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(4)
• 10 lost to follow-up: acitretin 25
group (4), acitretin 35 group (2), acitretin
50 group (4)
• 3 severe disease exacerbation:
acitretin 25 group (1), acitretin 35 group
(2)
Not ITT analyses
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Dubertret 1989
Methods RCT, active-controlled
Date of study: July 1987-January 1988
Location: Paris
Participants Randomised: 37 participants (mean age, sex ratio: not stated)
Inclusion criteria
• Participants with moderate-severe psoriasis: widespread psoriasis (PASI > 18)
Exclusion criteria
• Not stated
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Cyclosporin (n = 18), orally, 2.5 mg/kg/d
Control intervention
B. Cyclosporin (n = 19), orally, 5 mg/kg/d
Outcomes Time to Assessment for the primary outcome: not stated
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• Not stated
Notes Funding: not stated however one out of four authors was a staff member of Sandoz
pharmaceutical company
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (p 136): “The patients were ran-
domised...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 136): “The patients were ran-
domised...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not specified as blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: not specified as blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 37, analysed 37
Dropouts and withdrawals
Not stated
Management of missing data: no descrip-
tion of the method used to guarantee man-
agement of missing data
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Ellis 1991
Methods RCT, active, controlled, double blind
Date of study: not stated
Location: single-centre (University of Michigan Medical Center, Ann Arbor)
Participants Randomised: 85 participants (mean age 46 years (cyclosporine 3), 42 years (cyclosporine
5), 46 years (cyclosporine 7.5), 43 years (placebo), 66 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 25)
• Non-response to phototherapy
• Non-response to conventional systemic treatment
• Failure to at least 1 line
Exclusion criteria
• Pregnancy
Dropouts and withdrawals
• Not stated
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Interventions Intervention
A. Ciclosporin (Sandimmun) (n = 15), orally, 7.5 mg/kg, 8 weeks
Control intervention
B. Ciclosporin (Sandimmun) (n = 20), orally, 5 mg/kg, 8 weeks
C. Ciclosporin (Sandimmun) (n = 25), orally, 3 mg/kg, 8 weeks
D. Vehicle (Sandimmun oral olive oil) (n = 25), orally, 8 weeks
Outcomes Assessment at 8 weeks
Primary or secondary outcomes not stated
Outcomes
• Target lesions
• PASI
• Urinary creatinine clearance
• Blood count
• Blood pressure
Notes Funding (p 277): Sandoz research Institute, the Babcock Dermatologic Endowment
(Ann Arbor) and a Clinical research centre grant (M01-RR-00042) from the National
Institutes of Health
Declarations of interest: not stated (p 277) ”Drs Ellis and Voorhees are consultants to
Sandoz Pharmaceuticals corporation (the manufacturer of cyclosporine)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 278): “patients were assigned
numbers in consecutive order; each num-
ber had been preassigned to one of four
treatments groups by means of a computer
generated random code in blocks 17”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 278): “The preparation of cy-
closporine and vehicle were identical …pa-
tients were blinded to their treatment”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 278): “Other physician who were
blinded to group assignment and labora-
tory findings evaluated the patient”
Comment: probably done
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 85, analysed not stated
Dropouts and withdrawals
not stated
Quote (p 279): “In the primary, intention-
to-treat analysis”
Management of missing data: no descrip-
tion of the method used to guarantee man-
agement of missing data
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Ellis 2001
Methods RCT, active placebo-controlled, double blind
Date of study: 14 May 1998-22 February 1999
Location: 22 centres in USA
Participants Randomised: 229 participants (mean age 45 years, 163 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 10)
• Age ≥ 18 years ≤ 70
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency,
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 32/229 (14%): alefacept 0.025 (6), alefacept 0.075 (7), alefacept (9), placebo (10)
• 5 lost to follow-up: alefacept 0.025 (2), alefacept 0.075 (0), alefacept (2), placebo
(1)
• 9 withdrawals: alefacept 0.025 (0), alefacept 0.075 (1), alefacept (5), placebo (3)
• 4 AEs: alefacept 0.025 (1), alefacept 0.075 (3), alefacept (0), placebo (0)
• 2 lab abnormalities: alefacept 0.025 (1), alefacept 0.075 (3), alefacept (0), placebo
(0)
• 8 worsening: alefacept 0.025 (2), alefacept 0.075 (1), alefacept (0), placebo (5)
• 4 other: alefacept 0.025 (1), alefacept 0.075 (1), alefacept (1), placebo (1)
Interventions Intervention
A. Alefacept (n = 57), IV, 0.025 mg/kg, once a week, 12 weeks
Control intervention
B. Alefacept (n = 55), IV, 0.075 mg/kg, once a week, 12 weeks
C. Alefacept (n = 58), IV, 0.150 mg/kg, once a week, 12 weeks
D. Placebo (n = 59), IV, once a week, 12 weeks
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Outcomes Assessments at 14 weeks
Primary or secondary outcomes of the trial
• Not stated
Outcomes of the trial
• Mean change PASI
• PGA clear/almost clear
• PASI 75
• PASI 50
Notes Funding (p 254) : “supported by Biogen and a grant from the National Institutes of
Health ... at the university of Utah”
Declarations of interest (p 254): “A patent on the use of alefacept (LFA3TIP) for the
treatment of psoriasis has been assigned to Biogen and the University of Michigan;
neither Dr. Ellis nor Dr. Krueger has a financial interest in the patent. Dr. Ellis and
Dr. Krueger are consultants to Biogen, as well as to other companies that manufacture
treatments for psoriasis.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 249): “Randomization scheme
was generated before the study, with a block
size of four at each center”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 249): “Randomization scheme
was generated before the study, with a block
size of four at each center”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 249): “Double blind... all prepa-
rations were identical in appearance”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: no specific description of the
method used to guarantee blinding of out-
come assessment however considering that
this is a placebo-controlled trial with no
known systematic AEs we considered the
risk as low
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote (p 250): “were conducted according
to the intention-to-treat principle”
Dropouts and withdrawals
• 32/229 (14%); alefacept 0.025 (6),
alefacept 0.075 (7), alefacept (9), placebo
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(10)
• no imbalance in reasons
Comment: no description of the method
used to guarantee missing data manage-
ment, number of participants analysed not
stated
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Engst 1994
Methods RCT, active-controlled, open-label trial
Date of study: not stated
Location: not stated
Participants Randomised: 22 participants (mean age 45.9 years, 18 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI > 16)
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency,
• Had an active infection
• Had uncontrolled cardiovascular disorder
• Had past history of malignant tumours
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Ciclosporin A (n = 10), orally, 1.25 mg/kg/d (increase to 2.5 if PASI > 50% of initial
PASI), 12 months
Control intervention
B. Ciclosporin A, (n = 12), orally, 2.5 mg/kg/d (increase to 5 if PASI > 50% of initial
PASI), 12 months
Outcomes Assessment period: not stated but longer than 16 weeks
Primary or secondary outcomes of the trial: not stated
Outcomes of the trial
• PASI score
• Blood pressure
• Blood count
• Urine samples
Notes Funding: not stated
Declarations of interest: not stated
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 189): “Patients enrolled in the
study were randomised...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 189): “Patients enrolled in the
study were randomised...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not blinded (open-label)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: not blinded (open-label)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts and withdrawals
• Not stated
Management of missing data: no descrip-
tion of the method used to guarantee man-
agement of missing data, ITT analyses not
mentioned
Selective reporting (reporting bias) High risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section were not reported in re-
sults section
Fallah Arani 2011
Methods RCT, active-controlled, open-label trial
Date of study: October 2006-February 2009
Location: Rotterdam/Eindhoven
Participants Randomised: 60 participants (mean age 41 years (methotrexate) and 43 years (fumarate)
, 36 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 10)
Exclusion criteria
• Pregnancy, Immunosuppression, kidney insufficiency, liver insufficiency,
• Had an active infection
• Had uncontrolled cardiovascular disorder
• Had uncontrolled diabetes
Dropouts and withdrawals
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• 9/60 (15%): methotrexate group (5), fumarate group (4)
• Time and reasons
◦ found ineligible: methotrexate group (2), fumarate group (3)
◦ withdrew consent: methotrexate group (1), fumarate group (0)
◦ non-appearance: methotrexate group (2), fumarate group (1)
Interventions Intervention
A. Methotrexate (n = 30), orally, 15 mg/week, Weinstein schema 15 mg weekly in 3
equal doses of 5 mg each 12 h apart, 16 weeks
Control intervention
B. Fumarate (n = 30), orally, 720 mg, 30 mg followed by 120 mg and max 720 mg after
week 9, 16 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI decreased
Secondary outcomes of the trial
• PASI decreased at 4, 16, 20 weeks
• AEs
Notes Funding source (p 855): none
Declarations of interest (p 855): “none declared”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 856): “patients were randomly
assigned ... randomisation was performed
centrally according to a computered-gener-
ated randomisation list”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 856): “Only the research nurse,
who had no contact with the patients be-
fore randomisation had insight into the al-
location schedule”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 856): “could not be blinded be-
cause treatment intake differed in both
groups”
Comment: not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p 857): “by the same trained asses-
sors (one trained physician and a research
nurse in consensus in each site)”
Comment: not specified whether “trained
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assessors” were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 60, analysed 51
Management of missing data: Quote (p
857): “Analysis was by Intention-to-treat..
.”
Comment: ITT analysis not performed
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Flytström 2008
Methods RCT, active-controlled, open-label trial
Date of study: Feb 2002-Feb 2005
Location: multicentre (n = 5), Sweden
Participants Randomised: 84 participants (mean age: 48 years (methotrexate), 46 years (ciclosporin)
; 55 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• Age ≥18
• Non response to topical treatment
• Non-response to phototherapy
• One previous treatment line allowed
• Exclusion criteria
• Pregnancy, immunodepression, kidney insufficiency, liver insufficiency
• Had uncontrolled hypertension
• Had past history of malignant tumours
Dropouts and withdrawals
• 16/84 (19%): methotrexate group (4), ciclosporin group (12)
• 7 with exclusion criteria: methotrexate group (2), ciclosporin group (5)
• 7 consent withdrawal: methotrexate group (2), ciclosporin group (5)
• 2 ineligible: ciclosporin group
Interventions Intervention
A. Methotrexate + folic acid (n = 41), orally, 7.5 mg/kg /week (5 mg folic acid except
days of methotrexate), 12 weeks
Control intervention
B. Ciclosporin (n = 43), orally, 3 mg/kg, divided into 2 doses, 12 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI
Secondary outcomes of the trial
• DLQI
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• SF-36
• VAS for patient assessment
Notes Funding (p121): “Financial support from the Swedish Psoriasis Association and the
Welander foundation”
Declarations of interest (p116): “none declared”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 117): “Randomization was per-
formed with the use of computer-gener-
ated random numbers, numbers by calling
a central telephone number”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 117): “Randomization was per-
formed with the use of computer-gener-
ated random numbers, numbers by calling
a central telephone number”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p 117): “Blinded assessors per-
formed the PASI at baseline and monthly
thereafter”
Comment: no description of method used
to guarantee no communication between
care givers or participants and assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 84, analysed 68
Management of missing data: not ITT
analysis
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
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Gisondi 2008
Methods RCT, active-controlled, investigator-blinded pilot trial
Date of study: Feb 2002-Feb 2005
Location: Verona, Italy
Participants Randomised: 60 participants (mean age 55 years (acitretin); 55 years (etanercept), 53
years (acitretin + etanercept), 33 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• Age ≥ 18
Exclusion criteria
• Fertile women, Kidney insufficiency (severe disorder), Liver insufficiency (severe
disorder),
• Had received biologics
• Had an active infection (HIV, Hepatitis B & C, latent TB)
• Had demyelinating diseases
• Has uncontrolled cardiovascular disorder (severe heart failure)
• Had past history of malignant tumours
Dropouts and withdrawals
• 4/60 (6.6%): acitretin group (4), etanercept group (0), acitretin + etanercept
group (0)
• Inefficacy of the treatment: acitretin group (4)
Interventions Intervention
A. Etanercept (25mg) and acitretin (0.4 mg/kg) (n = 18), SC (etanercept) and orally
(acitretin), twice a week (etanercept) and once a day (acitretin), 24 weeks
Control intervention
B. Acitretin (n = 20), orally, 0.4 mg/kg, once a day, 24 weeks
C. Etanercept (n = 22), SC, 25 mg, twice a week, 24 weeks
Outcomes Assessments at 24 weeks
Primary outcomes of the trial
≥ PASI 75 improvement from baseline
Secondary outcomes of the trial
• PASI 50
• BSA
• Number of participants reporting significant changes (e.g. > 3 times the normal
value for AST and ALT and > double the normal value for cholesterol and triglycerides)
Notes Funding: not stated
Declarations of interest (p 1345): “PG has received lecture fees from Merck-Serono,
Schering-Plough, Wyeth. GG has received consultation and lecture fees from Abbott,
Janssen-Cilag, Merck-Serono, Schering-Plough, Wyeth.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Gisondi 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Quote (p 1346): “Randomization was per-
formedwith the use of computer-generated
random numbers and block size of four pa-
tients”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 1346): “Randomization was per-
formedwith the use of computer-generated
random numbers and block size of four pa-
tients”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 1346): “The PASI assessor was
blinded concerning the group allocation of
the patient”
Comment: acitretin provide visible AEs
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 60, analysed 60
Management of missing data, quote (p
1346): “An ITT analysis was performed”
Comment: no description of the method
used to manage the missing data
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Goldfarb 1988
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: not stated
Participants Randomised: 38 participants (mean age 45-48 years, 31 male)
Inclusion criteria
• BSA 10-70
Exclusion criteria
• No women of childbearing potential
Dropouts and withdrawals
• 0/38 (0%)
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Goldfarb 1988 (Continued)
Interventions Intervention
A. Acitretin (n = 10), orally, 10-25 mg/day, 8 weeks
B. Acitretin (n = 16), orally, 50-75 mg/day, 8 weeks
Control intervention
C. Placebo (n = 12), orally, daily, 8 weeks
Outcomes Assessments at 8 weeks
Primary outcomes of the trial
• Not stated
Outcomes of the trial
• Percentage of skin involvement with psoriasis
• Overall scaling, erythema, thickness, and global extent of the disease on a 0
through 6 scale
• Improvement range from worse/unchanged/fair/good/excellent
• AEs
Notes Funding sources, quote (p 655): “Supported in part by Hoffman-La Roche Inc., Nutley,
NJ, and the Babcock Dermatologic Endowment”
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 656): “21 patients were randomly
and equally divided into 4 groups”
Comment: no description of the method
used to generate the sequence generation
Allocation concealment (selection bias) Unclear risk Quote (p 656): “21 patients were randomly
and equally divided into 4 groups”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 656): “we have studied 38 pa-
tients in a double-blind fashion”
Comment: visible side effect of acitretin
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 656): “we have studied 38 pa-
tients in a double-blind fashion”
Comment: visible side effect of acitretin
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 38, analysed 38
No mention of how the missing data were
managed
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available.
The pre-specified outcomes mentioned in
the methods section appeared to have been
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Goldfarb 1988 (Continued)
reported
Gordon 2006
Methods RCT, placebo-controlled, double-blind trial
Date of study: March 2003-June 2004
Location: Multicentre (n = 18) in USA, Canada
Participants Randomised: 148 participants (mean age 44 years, 99 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 5)
• Age ≥ 18
• Non-response to topical treatment
Exclusion criteria
• Pregnancy
• Had received biologics (anti-TNF)
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 8/148 (5%)
• Time and reasons:
◦ did not receive the treatment: adalimumab weekly (0), adalimumab eow (1),
placebo (0)
◦ AE: adalimumab weekly (2), adalimumab eow (2), placebo (1)
◦ lack of efficacy: adalimumab weekly (0), adalimumab eow (0), placebo (1)
◦ abnormal lab value: adalimumab weekly (1), adalimumab eow (0), placebo
(0)
Interventions Intervention
A. Adalimumab (n = 46), SC, 40 mg, 12 weeks, week 0: 2 injections, 1 injection eow
B.Adalimumab, (n = 50), SC, 40 mg, 12 weeks, week 0, week 1: 2 injections, 1 injection
weekly
Control intervention
C. Placebo (n = 52), SC, 12 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 50
• PASI 100
• PGA
• DLQI
Notes Funding, quote (p 598): “Supported by Abbott Laboratories”
Declarations of interest (p 598): “DrGordon has received research support and honoraria
and is a consultant for Abbott. Dr Langley is an investigator and has received research
funding to conduct research studies with Abbott. Dr Leonardi is a consultant and speaker
for Abbott. Dr Menter has received honoraria and is a consultant for Abbott. Dr Kang
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Gordon 2006 (Continued)
is an ad-hoc consultant for Abbott. Dr Heffernan is a consultant for and has received
research funding from Abbott. Drs Zhong, Hoffman, and Okun and Ms Lim are full-
time employees of Abbott.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 699): “Patients were centrally
randomised...”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 699): “Patients were centrally
randomised...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 599): “Tomaintain blinding, pre-
filled syringes were identically labelled and
all patients received the same number of in-
jections at the same time points”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 599): “Tomaintain blinding, pre-
filled syringes were identically labelled and
all patients received the same number of in-
jections at the same time points”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 148, analysed 147
Dropouts and withdrawals
• 8/148 (5%)
• Time and reasons:
◦ did not receive the treatment:
adalimumab weekly (0), adalimumab eow
(1), placebo (0)
◦ AE: adalimumab weekly (2),
adalimumab eow (2), placebo (1)
◦ lack of efficacy: adalimumab
weekly (0), adalimumab eow (0), placebo
(1)
◦ abnormal lab value:
adalimumab weekly (1), adalimumab eow
(0), placebo (0)
Management of missing data, quote (p
601): “modified intent-to-treat analysis... a
patient with missing data was counted as a
nonresponder at that visit”
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Comment: few lost to follow-up, well-bal-
anced number and reasons between groups
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Gordon UNCOVER-1, 2016
Methods RCT, placebo-controlled, double blind
Date of study: November 2011-June 2014
Location: multicentre (104) in Europe, Australia, North America
Participants Randomised: 1296 participants (mean age 45 years, 883 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency, past
history of malignant tumours, active infection, uncontrolled cardiovascular disorder,
uncontrolled diabetes, uncontrolled hypertension
• Had received anti IL17
Dropouts and withdrawals
• 66/1296 (5%);
• Ixekizumab 4-week group (24), ixekizumab 2-week group (18), placebo (24)
• AEs: ixekizumab 4-week group (10), ixekizumab 2-week group (10), placebo (6)
• Protocol violation: ixekizumab 4-week group (6), ixekizumab 2-week group (0),
placebo (3)
• Participant decision: ixekizumab 4-week group (6), ixekizumab 2-week group (5),
placebo (6)
• Lost to follow-up: ixekizumab 4-week group (0), ixekizumab 2-week group (2),
placebo (1)
• Investigator decision: ixekizumab 4-week group (1), ixekizumab 2-week group (1)
, placebo (1)
• Lack of efficacy: ixekizumab 4-week group (1), ixekizumab 2-week group (0),
placebo (7)
Interventions Intervention
A. Ixekizumab (n = 432), SC, 80 mg, 2 injections week 0, 1 injection monthly
Control intervention
B. Ixekizumab (n = 433), SC, 80 mg, 2 injections week 0, 1 injection eow
C. Placebo (n = 431), SC
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PGA 0-1
• PASI 75
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Gordon UNCOVER-1, 2016 (Continued)
Secondary outcomes of the trial
• PASI 90
• DLQI
• NAPSI
• AEs
Notes Funding source:
Quote (p 346): “The trials were sponsored by Eli Lilly and were designed by the scientific
steering committee and Eli Lilly personnel. The site investigators collected the data, Eli
Lilly personnel performed the data analyses, and all the authors had access to the data.”
Declarations of interest (p 355): ”Disclosure forms provided by the authors are available
with the full text of this article at NEJM.org.“ Gordon received grants and personal fees
from Abbvie, Amgen, Celgene, Eli Lilly, Novartis; and personal fees from Pfizer and
Medac
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (supplemental appendix): “Patients
were assigned to treatment groups as de-
termined by a computer-generated random
sequence ..”
Comment: clearly defined
Allocation concealment (selection bias) Low risk Quote (supplemental appendix): “Patients
were assigned to treatment groups as de-
termined by a computer-generated ran-
dom sequence using an interactive voice re-
sponse system (IVRS). Site personnel con-
firmed that they had located the correct as-
signed investigational product package by
entering a confirmation number found on
the package into the IVRS”
Comment: clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 346): “double-blind, placebo-
controlled”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 346): “double-blind, placebo-
controlled”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 1296, analysed 1296
Management of missing data:
Quote (p 348): “Unless otherwise specified,
all analyses of efficacy during the induction
period were performed according to the in-
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Gordon UNCOVER-1, 2016 (Continued)
tention-to-treat principle. Missing values
for the PASI and the sPGA score were im-
puted conservatively as nonresponses, re-
gardless of the reason for the missing data”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01474512)
The pre-specified outcomes mentioned in
the protocol and in the methods section
appeared to have been reported
Gordon X-PLORE, 2015
Methods RCT, active placebo-controlled, double blind
Date of study: October 2011-August 2013
Location: multicentre (n = 31), Europe & North America
Participants Randomised: 293 participants (mean age 47 years, 207 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency, past
history of malignant tumours, active infection, uncontrolled cardiovascular disorder,
uncontrolled diabetes, uncontrolled hypertension
• Had received adalimumab or guselkumab
Dropouts and withdrawals
• 20/293 (6.8%);
• 1 not treated (guselkumab 200)
• AEs: guselkumab 5 (0), guselkumab 15 (0), guselkumab 50 (1), guselkumab 100
(1), guselkumab 200 (4), adalimumab (3), placebo (2)
• Lack of efficacy: guselkumab 5 (0), guselkumab 15 (0), guselkumab 50 (0),
guselkumab 100 (0), guselkumab 200 (0), adalimumab (0), placebo (1)
• Lost to follow-up: guselkumab 5 (1), guselkumab 15 (0), guselkumab 50 (1),
guselkumab 100 (0), guselkumab 200 (0), adalimumab (1), placebo (0)
• Other: guselkumab 5 (2), guselkumab 15 (0), guselkumab 50 (1), guselkumab
100 (1), guselkumab 200 (0), adalimumab (0), placebo (0)
Interventions Intervention
A. Guselkumab (n = 41), SC, 5 mg weeks 0, 4, 16
Control intervention
B. Guselkumab (n = 41), SC, 15 mg weeks 0, 4, 16
C. Guselkumab(n = 42), SC, 50 mg weeks 0, 4, 16
D. Guselkumab (n = 42), SC, 100 mg weeks 0, 4, 16
E. Guselkumab (n = 42), SC, 200 mg weeks 0, 4, 16
F. Adalimumab (n = 43), SC, 40 mg 2 injections week 0, 1 injection week 1, 1 injection
160Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gordon X-PLORE, 2015 (Continued)
eow
G Placebo (n = 42), SC (100 mg weeks 0, 4, 16)
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PGA 0-1
Secondary outcomes of the trial
• PASI 90
• PASI 75
• DLQI
Notes Funding source:
Quote (p 137): “This study was sponsored by Janssen Research and Development.
Janssen supplied the study agents and collected and analysed the data. All the authors
had full access to the data”
Declarations of interest (p 144): “Disclosure forms provided by the authors are available
with the full text of this article at NEJM.org.” Gordon received grants and personal fees
from Abbvie, Amgen, Celgene, Eli Lilly, Novartis; and personal fees from Pfizer and
Medac. Reich received personal fees from Celgene, Centocor/Janssen, Forward Pharma,
GSK, Janssen Cilag, LEO Pharma, Lilly Medoc, MSD, Novartis, Ocean Pharma, Pfizer,
Regeneron, Takeda, Vertex
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 137): “patients were ran-
domised…”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 137): “patients were ran-
domised…”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 137, p 143): “double-blind…
Adalimumab was not administered in a
blinded, placebo-controlled manner”, “An-
other potential issue was to use of a blinded
efficacy evaluator at each site instead of the
administration of ADA in a blinded man-
ner”Quote (p 553-4): “Double Blind (Sub-
ject, Caregiver, Investigator, Outcomes As-
sessor ), Patients and study personnel were
masked to treatment assignment: the study
drug packaging was labelled.... ”
Comment: adalimumab group was not
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Gordon X-PLORE, 2015 (Continued)
double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 137): “to ensure objectivity, all
efficacy assessment were performed by an
evaluator at each study site who was un-
aware of the study group”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 293, analysed 293
Dropouts and withdrawals
• 20/293 (6.8%);
• 1 not treated (guselkumab 200)
• AEs: guselkumab 5 (0), guselkumab
15 (0), guselkumab 50 (1), guselkumab
100 (1), guselkumab 200 (4),
adalimumab(3), placebo (2)
• Lack of efficacy: guselkumab 5 (0),
guselkumab 15 (0), guselkumab 50 (0),
guselkumab 100 (0), guselkumab 200 (0),
adalimumab (0), placebo (1)
• Lost to follow-up: guselkumab 5 (1),
guselkumab 15 (0), guselkumab 50 (1),
guselkumab 100 (0), guselkumab 200 (0),
adalimumab (1), placebo (0)
• Other: guselkumab 5 (2),
guselkumab 15 (0), guselkumab 50 (1),
guselkumab 100 (1), guselkumab 200 (0),
adalimumab (0), placebo (0)
Management of missing data:
Quote (p 138): “PatientswithmissingPGA
or PASI score at week 16 were categorized
as not having had a response”
Comment: low number of withdrawals,
balanced number and reasons between
groups
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01483599)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
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Gottlieb 2003
Methods RCT, placebo-controlled, double blind
Date of study: August 2000-January 2001
Location: multicentre (locations not specified)
Participants Randomised: 112 participants (mean age 47 years, 70 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 10), age ≥ 18 years
• Had previously received phototherapy or systemic psoriasis therapy at least once
Exclusion criteria
• Quote p 1628) ”Patients were excluded if they had guttate, erythrodermic, or
pustular psoriasis; other skin conditions; or other significant medical conditions that
might interfere with evaluations of the effect of study medications on psoriasis“
Dropouts and withdrawals
• 19/112 (17%): etanercept 4/57 (7.0%), placebo 15/55 (27.3%)
• Time and reasons:
◦ etanercept: AE (1), lack of efficacy (3)
◦ placebo: AE (4), lack of efficacy (9), lost to follow-up (1), patient refusal (1)
Interventions Intervention
A. Etanercept (n = 57), SC, auto-administered, 25 mg twice a week, 24 weeks
Control intervention
B. Placebo (n = 55), SC, auto-administered, twice a week, 24 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
At 4, 8, 12, 24 weeks
• PASI 50
• PASI 75
• PASI 90
• DLQI
• PGA
• Safety
• Participant global assessment of psoriasis
Notes Funding source, quote (p 1631): ”This study was sponsored by Immunex Corp, a sub-
sidiary of Amgem, Inc.)
Declarations of interest not stated except “Dr Zitnik is an employee of Amgen” (p1627)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 1628): “Patients ... were to be
randomised in block of 6 with equal al-
location between the treatment group...
Patients were assigned numbers based on
randomisation tables verified by Immunex
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Pharmaceutical Planning”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 1628): “Patients ... were to be
randomised in block of 6 with equal al-
location between the treatment group...
Patients were assigned numbers based on
randomisation tables verified by Immunex
Pharmaceutical Planning, after which the
Immunex Clinical Distribution Depart-
ment shaped blind-labelled vials of study
drug to the pharmacies”
Comment: we don’t know whether the in-
vestigators were blinded or the numbers of
participants per block. This probably was
a centralized randomisation; however, it’s
not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1628): “... performed blinded la-
belling and packaging of the study drug. ..
. multicenter, randomised, double-blind”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1628): “... performed blinded la-
belling and packaging of the study drug. ..
. multicenter, randomised, double-blind”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 112, 112 participants
analysed for the primary endpoint
Dropouts and withdrawals
• Etanercept 4/57 (7.0%), placebo 15/
55 (27.3%)
• Time and reasons:
◦ etanercept: AE (1), lack of
efficacy (3)
◦ placebo: AE (4), lack of efficacy
(9), lost to follow-up (1), patient refusal
(1)
Management of missing data:
Quote (1628): “Patients were analysed on
an intent-to-treat basis... If a patient dis-
continued treatment before the end of the
study, the last observation was carried for-
ward for efficacy analyses”
Comment: high rate of withdrawal in
placebo group and imbalanced reasons for
withdrawal
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Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Gottlieb 2004
Methods RCT, placebo-controlled, double blind
Date of study: 2001-2003
Location: 24 centres in USA
Participants Randomised: 249 participants (mean age 44 years, 174 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Pregnancy, past history of malignant tumours, active infection
Dropouts and withdrawals after a 30-week study period
• 85/249 (34%)
Reasons
• AE: infliximab 3 mg (7), infliximab 5 mg (3), placebo (1)
• Lack of efficacy: infliximab 3 mg (11), infliximab 5 mg (5), placebo (26)
• Other reasons: infliximab 3 mg (12), infliximab 5 mg (10), placebo (10)
Interventions Intervention
A. Infliximab (n = 99), IV, 3 mg/kg, weeks 0, 2, 6, for 10 weeks
Control intervention
B. Infliximab (n = 99), IV, 5 mg/kg, weeks 0, 2, 6, for 10 weeks
C. Placebo (n = 51), IV, equivalent, weeks 0, 2, 6, for 10 weeks
Outcomes Assessments at 10 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI
• PGA
• DLQI
• AEs
Notes Funding source, quote (534): “Supported by Centocor Inc”
Declarations of interest (p 534): “DrsGottlieb andMenter have received research support
from and served as consultants for Centocor Inc. Drs Baker, Bala, Dooley, Evans, Guzzo,
and Marano, and Ms Li, are employees of Centocor Inc. ”
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 535): “Randomisation was car-
ried out using adaptive treatment alloca-
tion and was stratified by the investiga-
tional site”
Comment: no description of the method
used to generate random sequence
Allocation concealment (selection bias) Unclear risk Quote (p 535): “Randomissation was car-
ried out using adaptive treatment alloca-
tion and was stratified by the investiga-
tional site”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 535): “Patients and investigators
were unaware of treatment assignments.
Double blind was achieved andmaintained
by using an independent pharmacist or staff
member to prepare all study infusion”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 535): “Patients and investigators
were unaware of treatment assignments.
Double blind was achieved andmaintained
by using an independent pharmacist or staff
member to prepare all study infusion”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 249 randomised, 249 analysed
Methods for dealing with missing data:
Quote (p 536): “All randomised patients
were included in the efficacy analysis at
week 10... Patients who discontinued..
. were considered to have not achieved
the dichotomous end points or were as-
signed the baseline value for continuous
end points after the event occurrence”
Comment: done
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
166Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Gottlieb 2011
Methods RCT, placebo-controlled, double blind
Date of study: June 2008-March 2009
Location: 33 centres in the USA
Participants Randomised: 209 participants (mean age 43.5 years, 145 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PGA ≥ 3, PASI ≥ 12, BSA ≥ 10),
age ≥ 18 years
Exclusion criteria
• Previous exposure to either etanercept or ABT-874
Dropouts and withdrawals
• 12/209 (5.7%): etanercept 7, placebo 5
• Time and reasons:
◦ Etanercept: AE (4), lost to follow-up (1), protocol violation (1), Other (1)
◦ Placebo: AE (0), lost to follow-up (4), protocol violation (1)
Interventions Intervention
A. Etanercept (n = 141), SC, auto-administered, 50 mg twice a week, 11 weeks
Control intervention
B. Placebo (n = 68), SC, auto-administered, twice a week
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75/PGA 0/1
Secondary outcomes of the trial
At 4, 8, 12 weeks
• PASI 50
• PASI 75
• PASI 90
• DLQI (Dermatology Life Quality Index)
• PGA
• Safety
• Patient global assessment of psoriasis
Notes Funding source, quote (Appendix 1): “Abbott Laboratories funded this study and partic-
ipated in the study design, data collection, data management, data analysis and prepara-
tion of the manuscript. All of the authors had full access to the data and were involved in
the analysis of data, development and revision of the manuscript, and decision to submit
the manuscript for publication. The corresponding author takes responsibility for the
integrity of the data and the accuracy of the data analysis..)”
Declarations of interest, quote (Appendix 1): “A.B.G. has been a consultant or served
on an advisory board for Amgen, Centocor, Celgene, Bristol Myers Squibb, Beiersdorf,
Abbott, TEVA, Actelion, UCB, Novo Nordisk, Immune Control, DermiPsor, Incyte,
PureTech, Magen Biosciences, Cytokine Pharmasciences, Alnylam, Ono, Pfizer, Scher-
ing, Canfite, Schering, UCB, BIND Biosciences and Merck, and has received research/
educational grants (paid to Tufts Medical Center) from Centocor, Amgen, Immune
Control, Abbott, Novo Nordisk, UCB and Novartis. C.L. has been an investigator for
Abbott, Allergan, Altana, Alza, Amgen, Astellas, Celgene, Centocor, Genentech, Bristol
Myers, Eli Lilly, Galderma, Genzyme, Pfizer, Incyte, CombinatoRx, 3M Pharmaceuti-
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cals, Perrigo Israel Pharmaceutical, ScheringPlough, RTL, Novartis, Vitae and Wyeth;
has served on an advisory board and has been a speaker for Abbott, Amgen and Centocor;
and has been a consultant for Abbott, Amgen, Centocor and Pfizer. F.K. has been an
investigator for Abbott, Centocor, Amgen, Wyeth, Novartis and Merck; and has served
on an advisory board and has been a speaker for Abbott, Centocor, Amgen, Eisai, Astel-
las and Wyeth. S.M. has been an investigator for Abbott, Amgen, Celgene, Centocor,
Graceway and Novo Nordisk; and has been a speaker for Abbott. M.O. and D.A.W. are
employees of Abbott.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 653): “Patients were randomised.
..”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 653): “Patients were randomised”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 653): “Patients enrolled in the
placebo arm received SC injections match-
ing active treatment to maintain the blind.
To maintain the blind, all patients received
two SC injections at weeks 0 and 4 and
one SC injection at week 8, consisting of
either briakinumab or matching placebo,
depending on the treatment arm. In ad-
dition, each patient also received two SC
injections biweekly, 3 days apart, week 0
through week 11, consisting of either etan-
ercept or matching placebo, depending on
the treatment arm.”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 653): “Patients enrolled in the
placebo arm received SC injections match-
ing active treatment to maintain the blind.
To maintain the blind, all patients received
two SC injections at weeks 0 and 4 and
one SC injection at week 8, consisting of
either briakinumab or matching placebo,
depending on the treatment arm. In ad-
dition, each patient also received two SC
injections biweekly, 3 days apart, week 0
through week 11, consisting of either etan-
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ercept or matching placebo, depending on
the treatment arm.”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 209, analysed 209
Management of missing data:
Quote (p 654): “The primary efficacy anal-
ysis consisted of four comparisons per-
formed in the intent-to-treat population (i.
e. all randomised patients),…,Nonrespon-
der imputation was used to handle missing
data.”
Comment: done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00691964)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Gottlieb 2012
Methods RCT, placebo-controlled, double blind
Date of study: November 2010-December 2011
Location: Multicentre in Boston/USA
Participants Randomised: 478 participants (methotrexate: mean age 43 years & 153 male; placebo:
mean age 45 years & 167 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (author assessment ≥ 6 months or
PASI ≥ 10 or BSA ≥ 10%), age ≥ 18 years
• Non-response to topical treatment
Exclusion criteria
• Kidney insufficiency, liver insufficiency
• Had received biologics
• Had received conventional systemic treatments
Dropouts and withdrawals
• 61/478 (12.8%)
• Methotrexate 28/239 (11.7%); placebo 33/239 (13.8%)
• Time and reasons :
◦ Methotrexate: AE (10), lost to follow-up (5), ineligibility (4),
noncompliance (4), full consent withdrawn (4)
◦ Placebo: AE (5), lost to follow-up (9) ineligibility (2), noncompliance (7),
disease progression (3), full consent withdrawn (5), other (2
Interventions Intervention
A. Methotrexate (n = 239), orally, 15 mg/week 7.5 mg-10 mg to a maximum of 15 mg,
24 weeks + etanercept, SC, 50 mg x 2/weeks, S1-S12 and 50 mg/week, S12-S24, 24
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weeks
Control intervention
B. Placebo (n = 239), orally, 24 weeks + etanercept, SC, 50 mg x 2/weeks, S1-S12 and
50 mg/week, S12-S24, 24 weeks
Outcomes Assessments at 24 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 75 at 12 weeks
• PASI 50 at 12 weeks
• PASI 50 at 24 weeks
• PASI 90 at 12 weeks
• PASI 90 at 24 weeks
• PGA at 12 weeks and 24 weeks
• BSA at 12 and 24 weeks
• AEs
• Change of laboratory assessment
Notes Funding source, quote (p 649): “This study was funded by Immunex Corporation, a
wholly owned subsidiary of Amgen Inc, and by Wyeth, which was acquired by Pfizer...”
Declarations of interest (Appendix): “A.B.G. is a consultant and/or advisory boardmem-
ber for Abbott, Actelion, Amgen, Astellas, Beiersdorf, Bristol-Myers Squibb, Can-Fite,
Celgene, Centocor (Janssen), Dermipsor, Incyte, Lilly, Merck, Novartis, Novo Nordisk,
Pfizer, TEVA, and UCB and is a recipient of research/educational grants paid to Tufts
Medical Center by Abbott, Amgen, Celgene, Centocor (Janssen), Immune Control,
Novartis, Novo Nordisk, Pfizer, and UCB. R.G.L. has served as an investigator, on the
scientific advisory board, and speaker for Abbott, Amgen, Centocor, and Pfizer, and as
an advisor and investigator for Celgene, Novartis, and Johnson & Johnson. B.E.S. has
served as an advisor, consultant, investigator, and speaker for Abbott, Amgen, and Cen-
tocor, and as an advisor, consultant, and investigator for Celgene, Novartis, Maruho,
and Pfizer. K.A.P. has been a consultant, advisory board member, and investigator for
Abbott, Amgen, Celgene, Centocor, Janssen-Ortho,MedImmune, Merck, Pfizer, Scher-
ing-Plough, and Wyeth (Wyeth was acquired by Pfizer in October 2009); has consulted
for Astellas and UCB; and has served as a speaker for Abbott, Amgen, Celgene, Janssen-
Ortho, Pfizer, Schering-Plough, and Wyeth. P.K., K.C., E.H.Z.T., M.H., and G.K. are
employees and stockholders of Amgen Inc.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 650): “This was a randomised...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
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Allocation concealment (selection bias) Unclear risk Quote (p 650): “This was a randomised...
study”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 650): “double-blinded placebo-
controlled”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 650): “double-blinded placebo-
controlled”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 478, analysed 478
Management of missing data:
Quote (p 651): “Efficacy analyses were per-
formed using the ITT set (all randomised
patients)... Missing postbaseline data were
imputed using last observation carried for-
ward for primary analyses of all efficacy
endpoints...”
Comment: done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01001208)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Griffiths ACCEPT, 2010
Methods RCT, active-controlled, open-label trial
Date of study: 26 March 2007-15 January 2009
Location: 67 centres in Manchester/UK
Participants Randomised: 903 participants (mean age 45 years, 613 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• Authors’ assessment > 6 months, PASI ≥ 12, PGA > 3, BSA > 10%
• Age ≥ 18 years
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Had received biologics
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
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• 24/903 (2.7%)
• Ustekinumab 45 mg (8): AE (2), lost to follow-up (2), other (4)
• Ustekinumab 90 mg (5): AE (1), lost to follow-up (2), other (2)
• Etanercept (11): AE (5), lost to follow-up (1), other (5)
Interventions Intervention
A. Ustekinumab (n = 209), SC, 45 mg, weeks 0-4, 4 weeks
Control intervention
B. Ustekinumab (n = 347), SC, 90 mg, weeks 0-4, 4 weeks
C. Etanercept (n = 347), SC, 50 mg x 2/weeks, 12 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• Number of participants PGA 0/1 at week 12
• PASI 90 at weeks 8-12
• Difference PASI at week 12 and 12 weeks after retreatment on recurrence of
psoriasis
• AEs
Notes Funding, quote (p 127): “Supported by Centocor Research and Development.”
Declarations of interest (p 127) “Dr. Griffiths reports receiving consulting and lecture
fees from Abbott, Janssen-Cilag, Merck Serono, Novartis, Schering-Plough, and Wyeth
and grant support from Merck Serono; Dr. Strober, receiving consulting and lecture
fees from Centocor, Johnson & Johnson, Amgen, and Abbott Laboratories and grant
support from Amgen and Abbott Laboratories; Dr. van de Kerkhof, receiving consulting
fees from Schering-Plough, Celgene, Centocor, Almirall, UCB,Wyeth, Pfizer, Soffinova,
Abbott, Actelion,Galderma,Novartis, Janssen-Cilag, and Leo Pharma;Dr.Ho, receiving
advisory-board and lecture fees from Schering, Abbott, Janssen-Ortho, Pfizer, Amgen,
and Wyeth and grant support from Centocor, Abbott, Amgen, and Wyeth; Dr. Menter,
receiving advisory-board, consulting, and lecture fees from Abbott, Amgen, Astellas,
Biogen Idec, Celgene, Centocor, Genentech,Warner Chilcott, andWyeth;Drs. Yeilding,
Guzzo, Xia, and Dooley and Ms. Li, being employees of Johnson & Johnson and having
equity and holding stock options in Johnson & Johnson; Dr. Zhou, being an employee
of Johnson & Johnson, having equity and holding stock options in Johnson & Johnson,
and having equity in Wyeth; Dr. Fidelus-Gort, being a former employee of Johnson
& Johnson and having equity and holding stock options in Johnson & Johnson; and
Dr. Goldstein, receiving consulting fees from Centocor. No other potential conflict of
interest relevant to this article was reported.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 119): “We randomly assigned...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
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Allocation concealment (selection bias) Unclear risk Quote (p 119): “We randomly assigned...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 119): “Patients were aware of
their treatment assignment”, ... “All study
personnel, except those who dispensed or
administered a study agent remained un-
aware of the treatment assignments“
Comment: high risk for participants and
unclear risk for personnel (no description
of means used to avoid communication be-
tween participants and personnel and very
difficult to avoid)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p 119): “All study personnel, ex-
cept those who dispensed or administered a
study agent remained unaware of the treat-
ment assignments”
Comment: no description of the method
used to assess the primary outcome
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 903 participants underwent randomisa-
tion, 903 were analysed
Comment: methods for dealing with miss-
ing data not specified
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00454584)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Griffiths UNCOVER-2, 2015
Methods RCT, active, placebo-controlled, double blind
Date of study: 10 May 2012-7 May 2015
Location: 118 centres in Europe, Australia, North America
Participants Randomised: 1224 participants (mean age 45 years, 821 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency, past
history of malignant tumours, active infection, uncontrolled cardiovascular disorder,
uncontrolled diabetes, uncontrolled hypertension
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• Had received etanercept and anti IL17
Dropouts and withdrawals
• 63/1224 (5%)
• Ixekizumab 4-week group (19), ixekizumab 2-week group (9), etanercept group
(25), placebo (10)
• AEs: ixekizumab 4-week group (5), ixekizumab 2-week group (4), etanercept (5),
placebo (1)
• Protocol violation: ixekizumab 4-week group (5), ixekizumab 2-week group (2),
etanercept (4), placebo (2)
• Participant decision: ixekizumab 4-week group (6), ixekizumab 2-week group (2),
etanercept (8), placebo (1)
• Lost to follow-up: ixekizumab 4-week group (2), ixekizumab 2-week group (0),
etanercept (5), placebo (1)
• Investigator decision: ixekizumab 4-week group (0), ixekizumab 2-week group (1)
, etanercept (0), placebo (1)
• Absence of efficacy: ixekizumab 4-week group (1), ixekizumab 2-week group (0),
etanercept (3), placebo (3)
Interventions Intervention
A. Ixekizumab (n = 347), SC, 80 mg, 2 injections week 0, 1 injection monthly
Control intervention
B. Ixekizumab (n = 351), SC, 80 mg, 2 injections week 0, 1 injection eow
C. Etanercept (n = 358), SC, 50 mg 1 injection twice weekly
D. Placebo (n = 168), SC
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PGA 0-1
• PASI 75
Secondary outcomes of the trial
• PASI 90
• DLQI
• AEs
Notes Funding source:
Quote (p 543): “The funder Eli Lilly. Data were collected by investigators, gathered by
Parexel International, and analysed by the funder”. agents and collected and analysed
the data. All the authors had full access to the data”
Declarations of interest, Quote (p 550-551): ”CEMG has received grants and personal
fees from Eli Lilly, Abbvie, Janssen, Novartis, Sandoz, Pfizer, and GlaxoSmithKline; per-
sonal fees from Actelion, Amgen, and UCB Pharma; grants from LEO Pharma and
Merck Sharp & Dohme; and is president of the International Psoriasis Council. KR
has received personal fees from AbbVie, Amgen, Biogen, Celgene, Forward Pharma,
Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer,
Regeneron, and Takeda. ML is an employee of the Mount Sinai Medical Center which
receives research funds from AbGenomics, AbbVie, Amgen, Anacor, Aqua, Canfite Bio-
pharma, Celgene, Clinuvel, CoronadoBiosciences, Ferndale, Lilly, JanssenBiotech, LEO
Pharmaceuticals, Merz, Novartis, Pfizer, Sandoz, and Valeant. PvdK has received grants
from Celgene, Centocor, Allmiral, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novar-
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tis, Janssen Cilag, and Leo Pharma; and has served as a speaker for Amgen, a consul-
tant for Sandoz and Mitisibishu, and a speaker and consultant for Celgene, AbbVie,
Eli Lilly, Galderma, Novartis, Janssen Cilag, and Leo Pharma. CP has received grants
and personal fees from Amgen, Abbvie, Celgene, Eli Lilly, Novartis, Janssen, Pfizer, and
Leo Pharma. KP has received honoraria as consultant and/or scientific officer and/or
advisory board and/or steering committee member and/or acted as a paid speaker and/
or participated in clinical trials and/or received clinical research grants sponsored by
3M, Abbott/AbbVie, Akesis, Akros, Allergan, Alza, Amgen, Anacor, Apotex, Astellas,
Baxter, Berlex, Biogen, Boehringer Ingelheim, Celgene, Celtic, Centocor, Cipher, Der-
mira, Dow Pharma, Eli Lilly, Forward Pharma, Fujisawa, Funxional Therapeutics, Gal-
derma, Genentech, Genexion, GlaxoSmithKline, Isotechnika, Janssen, Janssen Biotech,
Johnson & Johnson, Kataka, Kirin, Kyowa, Leo Pharma, Lypanosys, Medical Minds,
Medimmune, Merck, Mitsubishi, Novartis, NovImmune, Pan Genetics, Pfizer, Roche,
Regneron, Merck-Serono, Stiefel, Takeda, UCB, Vertex, Wyeth/Pfizer, and Xoma. AM
has served as an advisory board member and/or consultant and/or investigator and/or
speaker and/or received compensation in the form of grants and/or honoraria from Ab-
bVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Thera-
peutics, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Merck, Novartis, Pfizer,
Symbio and Maruho, Syntrix, Wyeth, and XenoPort. GSC, JE, LZ, RJS, SB, DKB,
OOO, MPH, and BJN were employees of and hold stock in Eli Lilly & Co during the
conduct of this study. “
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 542): “randomly assigned”, “An
interactive voice response system”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 542): “An interactive voice re-
sponse system was used to assign double-
blind investigational product to every pa-
tient. Site personnel confirmed that they
had located the correct assigned investiga-
tional product package by entering a confir-
mation number found in the package into
to IVRS”
Comment: clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 542): “Patients, investigators and
study personnel were masked to the treat-
ment allocation. A double-dummy design
was used”
Comment: clearly defined
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 542): “Patients, investigators and
study personnel were masked to the treat-
ment allocation. A double-dummy design
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was used”
Comment: clearly defined
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 1224, analysed 1224
Management of missing data:
Quote (p 543): “All missing data were
imputed using non-responder imputation
(NRI)”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01597245)
One pre-specified outcome in the proto-
col missing from the results section (assess-
ment of efficacy at 60 weeks); however, as
we assessed outcomes at induction phase
(between 8-24 weeks), we judged that the
risk of selective reporting was low
Griffiths UNCOVER-3, 2015
Methods RCT, active, placebo-controlled, double blind
Date of study: 18 July 2012-18 January 2016
Location: 101 in Europe, Asia, North and South America
Participants Randomised: 1346 participants (mean age 46 years, 918 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency, past
history of malignant tumours, active infection, uncontrolled cardiovascular disorder,
uncontrolled diabetes, uncontrolled hypertension
• Had received etanercept and anti IL17
Dropouts and withdrawals
• 71/1346 (5%)
• Ixekizumab 4-week group (10), ixekizumab 2-week group (13), etanercept group
(26), placebo (22)
• AEs: ixekizumab 4-week group (9), ixekizumab2-week group (8), etanercept (4),
placebo (2)
• Protocol violation: ixekizumab 4-week group (8), ixekizumab2-week group (7),
etanercept (3), placebo (1)
• Participant decision: ixekizumab 4-week group (4), ixekizumab2-week group (4),
etanercept (2), placebo (3)
• Lost to follow-up: ixekizumab 4-week group (2), ixekizumab2-week group (0),
etanercept (2), placebo (3)
• Investigator decision: ixekizumab 4-week group (1), ixekizumab2-week group (1),
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etanercept (2), placebo (1)
• Absence of efficacy: ixekizumab 4-week group (2), ixekizumab2-week group (1),
etanercept (0), placebo (0)
Interventions Intervention
A. Ixekizumab (n = 386), SC, 80 mg, 2 injections week 0, 1 injection monthly
Control intervention
B. Ixekizumab (n = 385), SC, 80 mg, 2 injections week 0, 1 injection eow
C. Etanercept (n = 382), SC, 50 mg 1 injection twice weekly
D. Placebo (n = 193), SC
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PGA 0-1
• PASI 75
Secondary outcomes of the trial
• PASI 90
• DLQI
• AEs
Notes Funding source: quote (p 543): “The funder Eli Lilly.Datawere collected by investigators,
gathered by Parexel International, and analysed by the funder”. agents and collected and
analysed the data. All the authors had full access to the data”
Declarations of interest: quote (p 550-551): ”CEMG has received grants and personal
fees from Eli Lilly, Abbvie, Janssen, Novartis, Sandoz, Pfizer, and GlaxoSmithKline; per-
sonal fees from Actelion, Amgen, and UCB Pharma; grants from LEO Pharma and
Merck Sharp & Dohme; and is president of the International Psoriasis Council. KR
has received personal fees from AbbVie, Amgen, Biogen, Celgene, Forward Pharma,
Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer,
Regeneron, and Takeda. ML is an employee of the Mount Sinai Medical Center which
receives research funds from AbGenomics, AbbVie, Amgen, Anacor, Aqua, Canfite Bio-
pharma, Celgene, Clinuvel, CoronadoBiosciences, Ferndale, Lilly, JanssenBiotech, LEO
Pharmaceuticals, Merz, Novartis, Pfizer, Sandoz, and Valeant. PvdK has received grants
from Celgene, Centocor, Allmiral, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novar-
tis, Janssen Cilag, and Leo Pharma; and has served as a speaker for Amgen, a consul-
tant for Sandoz and Mitisibishu, and a speaker and consultant for Celgene, AbbVie,
Eli Lilly, Galderma, Novartis, Janssen Cilag, and Leo Pharma. CP has received grants
and personal fees from Amgen, Abbvie, Celgene, Eli Lilly, Novartis, Janssen, Pfizer, and
Leo Pharma. KP has received honoraria as consultant and/or scientific officer and/or
advisory board and/or steering committee member and/or acted as a paid speaker and/
or participated in clinical trials and/or received clinical research grants sponsored by
3M, Abbott/AbbVie, Akesis, Akros, Allergan, Alza, Amgen, Anacor, Apotex, Astellas,
Baxter, Berlex, Biogen, Boehringer Ingelheim, Celgene, Celtic, Centocor, Cipher, Der-
mira, Dow Pharma, Eli Lilly, Forward Pharma, Fujisawa, Funxional Therapeutics, Gal-
derma, Genentech, Genexion, GlaxoSmithKline, Isotechnika, Janssen, Janssen Biotech,
Johnson & Johnson, Kataka, Kirin, Kyowa, Leo Pharma, Lypanosys, Medical Minds,
Medimmune, Merck, Mitsubishi, Novartis, NovImmune, Pan Genetics, Pfizer, Roche,
Regneron, Merck-Serono, Stiefel, Takeda, UCB, Vertex, Wyeth/Pfizer, and Xoma. AM
has served as an advisory board member and/or consultant and/or investigator and/or
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speaker and/or received compensation in the form of grants and/or honoraria from Ab-
bVie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Thera-
peutics, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Merck, Novartis, Pfizer,
Symbio and Maruho, Syntrix, Wyeth, and XenoPort. GSC, JE, LZ, RJS, SB, DKB,
OOO, MPH, and BJN were employees of and hold stock in Eli Lilly & Co during the
conduct of this study. “
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 542): “randomly assigned” ”An
interactive voice response system“
Comment: probably done”
Allocation concealment (selection bias) Low risk Quote (p 542): “An interactive voice re-
sponse system was used to assign double-
blind investigational product to every pa-
tient. Site personnel confirmed that they
had located the correct assigned investiga-
tional product package by entering a confir-
mation number found in the package into
to IVRS”
Comment: clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 542): “Patients, investigators and
study personnel were masked to the treat-
ment allocation. A double-dummy design
was used”
Comment: clearly defined
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 542): “Patients, investigators and
study personnel were masked to the treat-
ment allocation. A double-dummy design
was used”
Comment: clearly defined
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 1346, analysed 1346
Management of missing data:
Quote (p 543): “All missing data were
imputed using non-responder imputation
(NRI)”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01646177)
One pre-specified outcome in the proto-
col missing from the results section (assess-
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Griffiths UNCOVER-3, 2015 (Continued)
ment of efficacy at 60 weeks); however, as
we assessed outcomes at induction phase
(between 8-24 weeks), we judged that the
risk of selective reporting was low
Gurel 2015
Methods RCT, placebo-controlled, single blind
Date of study: not stated
Location: one centre, Turkey
Participants Randomised: 50 participants (mean age 43 years, 25 male)
Inclusion criteria
• Moderate-severe type plaque psoriasis BSA > 10%
Exclusion criteria
• Pregnancy
• Had uncontrolled cardiovascular disorder
• Kidney or liver insufficiencies
• Had past history of malignant tumours
• Had received conventional systemic treatments
Dropouts
No participants lost to follow-up
Interventions Intervention
Acitretine (0.3-0.5 mg/kg/day, 25 mg) (n = 25)
Control intervention
Placebo (n = 25)
Co-invervention NBUVB
Outcomes Assessment at 12 weeks
Primary outcome
• Not stated
Outcomes:
• Change in PASI scores from baseline
• Change in self-PASI scores from baseline
• Skindex 30
Notes Funding: none
Declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description
Allocation concealment (selection bias) Unclear risk No description
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Gurel 2015 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 3): “The physicians were not
blinded”
Comment: high risk of performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 3): “An independent assessor who
is not from the team performed the out-
come assessment.”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomized 50, analysed 50, no loss to fol-
low-up during the 12 weeks
Comment: probably done
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Heydendael 2003
Methods RCT, active-controlled, open-label trial
Date of study: October 1998-June 2000
Location: multicentre (> 1) in Amsterdam/the Netherlands
Participants Randomised: 88 participants, mean age 40 years, 57 male
Inclusion criteria
• Participants with moderate-severe psoriasis, PASI>8,
• Age ≥18
• Non-response to topical treatment
• Non-response to phototherapy
• Number of allowed previous treatment line: 2
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency, high-risk liver function
abnormalities, hepatitis B
• Had received methotrexate or ciclosporin
• Had an active infection
• Had uncontrolled diabetes (Insulino dependent)
• Had uncontrolled cardiovascular disorder
• Had uncontrolled hypertension
• Had past history of malignant tumours
Dropouts and withdrawals
• 3/88 (3.4%)
• Methotrexate group (1): withdrew consent (1)
• Ciclosporin group (2): ineligible (2)
Interventions Intervention
A. Methotrexate (n = 44), orally, 15 mg/week until 4 weeks then increase up to 22.5 mg
if reduction from baseline PASI < 25%, 3 divided doses with 12-h interval, 12 weeks
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Control intervention
B. Ciclosporin (n = 44), orally, 3 mg/kg until 4 weeks then increase up to 5 mg/kg if
reduction from baseline PASI < 25%, 2 divided doses, 12 weeks
Outcomes Assessments at weeks 16 weeks
Primary outcomes of the trial
• PASI
Secondary outcomes of the trial
• Side effects
• SF36
Notes Funding sources, quote (p 664): “Supported by a grant (OG 97-009) from the Dutch
Health Authorities”
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 660): “Randomisation was per-
formed centrally with the use of computer-
generated random numbers and block size
of eight patients”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 660): “Randomisation was per-
formed centrally with the use of computer-
generated random numbers and block size
of eight patients”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p 660): “The score of the PASI ...
was determined... by trained assessors who
were unaware of the treatment assignment”
Comment: no description of method used
to guarantee no communication between
care givers or participants and assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 88 randomised, 85 analysed
Quote (p 660-1): “If a patientmissed a visit,
we used the score from the previous visit”
Comment: few lost to follow-up, well-bal-
anced number and reasons between groups
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Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Hunter 1963
Methods RCT, placebo-controlled, double-blind trial
Date of study: not stated
Location: 1 centre in London
Participants Randomised: 41 participants (no description of the study population)
Inclusion criteria
• Participants with moderate-severe psoriasis
Exclusion criteria
• Not stated
Dropouts and withdrawals
• included (41) analysed (36)
Interventions Intervention
A. Methotrexate (n = 19), orally, 2.5 mg every day for 1 week and 1 week after
Control intervention
B. Placebo (n = 17), orally, every day for 1 week and 1 week after
Outcomes Assessments not clearly stated (reported at 4 weeks)
Primary outcomes of the trial
• Not stated
Outcomes of the trial
• Scale:
◦ 0 = no improvement
◦ 1 = definite improvement
◦ 2 = marked improvement
◦ 3 = complete clearing
Notes Funding: not stated
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee random sequence gener-
ation
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1 & 2): “Control tablet of iden-
tical appearance... thus neither physician,
patient nor pharmacist was aware whether
drug or control had been dispensed”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1 & 2): “Control tablet of iden-
tical appearance... thus neither physician,
patient nor pharmacist was aware whether
drug or control had been dispensed”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 41 randomised participants and 38 anal-
ysed
Comment: no description of the method
used to manage missing data
Not ITT analyses
Selective reporting (reporting bias) High risk No pre-specified outcomes mentioned in
the methods section
Igarashi 2012
Methods RCT, placebo-controlled, double-blind trial
Date of study: March 2008-March 2010
Location: 35 centres in Japan
Participants Randomised: 160 participants (age median 45 years, 126 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• Authors’ assessment > 6 months, PASI ≥ 12, BSA > 10%
• Age > 20 years
• Non-response to topical treatment
• Non-response to phototherapy
• Number of allowed previous treatment line: 2
Exclusion criteria
• Pregnancy
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 10/160 (6.2%)
• Withdrawn before treatment (2)
• Ustekinumab 45 mg group (64): discontinued (0)
• Ustekinumab 90 mg group (62): discontinued (4)
• Placebo (32): discontinued (4)
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Interventions Intervention
A. Ustekinumab (n = 64), SC, 45 mg, weeks 0-4, every 12 weeks, 64 weeks
Control intervention
B. Ustekinumab (n = 62), SC, 90 mg, weeks 0-4, every 12 weeks, 64 weeks
C. Placebo (n = 32), SC , weeks 0-4, every 12 weeks, 64 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• Proportion of participants with PGA 0/1 at week 12
• Change in DLQI from baseline at 12 weeks
• Improvement from baseline to week 12 through 64 in NAPSI and joint pain, as
measured by the change in VAS
Notes Funding source, quote (p 242): ”This study was supported by Janssen pharmaceutical
KK, a part of the Johnson & Johnson family of companies
Declarations of interest (p 242): “Igarashi has served as a consultant and speaker for
Janssen Pharmaceutical K.K.; H. Nakagawa has served as a consultant for Abbott Japan
and Tanabe Mitsubishi, and as a consultant and speaker for Janssen Pharmaceutical K.
K.; M. Song is an employee of Centocor Research & Development, Inc., a division of
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., and owns stock
in Johnson & Johnson; T. Kato and M. Kato are employees of Janssen Pharmaceutical
K.K. and own stock in Johnson & Johnson.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 244): “randomised”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 244): “randomised”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 243): “double-blind placebo-
control”
Comment: used a placebo without visible
side effect
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 243): “double-blind placebo-
control”
Comment: used a placebo without visible
side effect
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 160 randomised, 157 analysed (2 did not
received a dose of the drug and 1 was ex-
cluded in the placebo group due to lack of
efficacy data after receiving a single dose)
Methods for dealing with missing data
Quote (p 244): “Efficacy analyses were
based on all randomised patients with ef-
ficacy data after randomisation... Patients
who discontinued the study... were consid-
ered as treatment failures”
Comment: few lost of follow-up, well-bal-
anced number and reasons between groups
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available
The pre-specified outcomes mentioned in
the methods section appeared to have been
reported
Jacobe 2008
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: not stated
Participants Randomised: 16 participants (mean age 50 years, 11 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (authors’ assessment)
Exclusion criteria
• Not stated
Dropouts and withdrawals
• 1/16 (6%)
• Non compliance before initiating treatment (1)
Interventions Intervention
A. Alefacept (n = 8), IM, 15 mg, once a week, 12 weeks
Control intervention
B. Placebo (n = 8), IM, once a week, 12 weeks
Co-intervention: UVB 3 times/week, 12 weeks
Outcomes Assessments at 12 weeks
Primary or secondary outcomes of the trial
• Unclear
Outcomes of the trial
• -PASI
Notes Funding source (p 1068): ”Biogen/IDECprovided alefacept andNBUVB for this study“
Declarations of interest (p 1068): ”none reported“
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 1067): ”randomised... study“
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 1067): ”randomised... study“
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1067) ’double-blind study...
placebo”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no description of the method
used to guarantee blinding of outcome as-
sessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomized (16), analysed (15)
Comment: no description of the method
used to manage the missing data, no ITT
analyses
Selective reporting (reporting bias) High risk Comment: no pre-specified outcomes
mentioned in the methods section except
PASI score. In the results section, safety, bi-
ological data are reported
Krueger 2002
Methods RCT, placebo-controlled, double blind
Date of study: 21 November 1999-22 March 2001
Location: 51 centres in USA/Canada
Participants Randomised: 553 participants analysed (mean age 45 years, 387 male) out of 569
patients randomised
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 10)
• Age ≥ 16
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Pregnancy
• Had an active infection
Dropouts and withdrawals
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• 79/569 (10%)
• 16 excluded from analysis: 7 at 1 site because of poor compliance and 9 who were
not dosed
• 9 lost to follow-up: alefacept (3), placebo (6)
• 13 disease worsening: alefacept (8), placebo (5)
• 8 AEs: alefacept (7), placebo (1)
• 29 by request: alefacept (10), placebo (19)
• 4 other; alefacept (3), placebo (1)
Interventions Intervention
A. Alefacept (n = 367), IV, 7.5 mg, once a week, 12 weeks
Control intervention
B. Placebo (n = 186), IV, once a week, 12 weeks
Outcomes Assessments at 14 weeks
Primary or secondary outcomes of the trial
• PASI 75
Outcomes of the trial
• PGA clear or almost clear
• PASI 50
• AEs
Notes Funding source, quote (p 821): “This study was funded by Biogen, Inc, Cambridge,
Massachusetts”
Declarations of interest p 821): “A patent on the use of alefacept for the treatment
of psoriasis has been assigned to Biogen and the University of Michigan. None of the
authors have a financial interest in the patent. Gerald G. Krueger, MD, Kim A. Papp,
MD, and Charles N. Ellis, MD, are consultants to Biogen, as well as to other companies
that have and are developing treatments for psoriasis.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 822): “ This was a randomised...
”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 822): “ This was a randomised...
”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 823): “... The active drug
and placebo were visually indistinguishable
from each other, and the injection vol-
ume was consistent. Physician who had no
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contact with the patient, … A pharmacist
who had no contact with the patient….
The physician and the pharmacist were in-
structed not to communicate any informa-
tion to the examining physicians….”
Comment: use of a placebo with no major
side effects
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 823): “An examining physician
administered the study drug”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 569 included/557 analysed (comment: 16
participants excluded, 7 because of poor
compliance and 9 were not dosed)
Quote (p 825): “Analyses of efficacy end
points ... were based on the intent-to-treat
population, which included patients who
were randomised had a baseline assessment
and had at least 1 injection”
Methods for dealing with missing data: not
stated
Comment: not modified ITT (7 partic-
ipants excluded because of poor compli-
ance) however 7/557 low rate
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Krueger 2007
Methods RCT, placebo-controlled, double-blind trial
Date of study: June 2003-March 2005
Location: 46 centres in Utah, USA
Participants Randomised: 320 participants
Ustekinumab 12/23 45 mg (64) (mean age 46 years; 38 male)
Ustekinumab 12/23 90 mg (64) (mean age 46 years; 47 male)
Ustekinumab 12/23 45 mg 4-weekly (64) (mean age 45 years; 39 male)
Ustekinumab 12/23 90 mg 4-weekly (64) (mean age 44 years; 52 male)
Placebo (64) (mean age 44 years; 46 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• Authors’ assessment > 6 months, PASI ≥ 12, BSA > 10%
• Age ≥ 18
Exclusion criteria
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• Had received biologics (ustekinumab 12/23)
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 32/320 (8.8%)
• Ustekinumab 12/23 45 mg (7) (received no treatment (1) unsatisfactory
therapeutic effect (2) AE (5))
• Ustekinumab 12/23 90 mg (4) (received no treatment (1), other (3))
• Ustekinumab 12/23 45 mg 4-weekly (3) (AE (2), withdrew consent (1))
• Ustekinumab 12/23 90 mg 4-weekly (4) (unsatisfactory therapeutic effect (1), AE
(1), withdrew consent (1), other (1))
• Placebo (13) (unsatisfactory therapeutic effect (6), lost to follow-up (1), withdrew
consent (2), other (4))
Interventions Intervention
A. Ustekinumab 12/23 (n = 64), SC, 45 mg, 45 mg 1 dose, 1 week
Control intervention
B. Ustekinumab 12/23 (n = 64), SC, 90 mg, 45 mg 1 dose, 1 week
C. Ustekinumab 12/23 (n = 64), SC, 45 mg, 45 mg/week, 4 weeks
D. Ustekinumab 12/23 (n = 64), SC, 90 mg, 45 mg/week, 4 weeks
E. Placebo (n = 64), SC
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• Proportion of participants achieving ≥ PASI 75
Secondary outcomes of the trial
• Safety
• PGA
• DLQI
Notes Funding source (p 590): “Supported by Centocore, Malvern, PA”
Declarations of interest (p 590-1): “Dr. Krueger reports receiving fees as a consultant
or advisory board member for Abbott, Almirall, Alza, Amgen, Astellas, Boehringer In-
gelheim, Barrier Therapeutics, Bristol-Myers Squibb, Centocor, Connetics, and Genen-
tech; Dr. Langley, for Centocor, Abbott, and Amgen/Wyeth; Dr. Leonardi, for Abbott,
Amgen, Centocor, and Genentech; and Dr. Lebwohl, for Abbott, Amgen, Astellas, Cen-
tocor, Connetics, Galderma, Genentech, Novartis, PharmaDerm, and Warner Chilcott.
Dr. Krueger reports receiving lecture fees from Abbott, Amgen, Boehringer Ingelheim,
Centocor, and Connetics; Dr. Langley, from Abbott and Amgen/ Wyeth; Dr. Leonardi,
from Abbott, Amgen, Centocor, and Genentech; and Dr. Lebwohl, from Abbott, Astel-
las, Amgen, Centocor, Connetics, Galderma, Genentech, PharmaDerm, and Warner
Chilcott. Dr. Krueger reports receiving stipends for a clinical research fellowship from
Amgen and Centocor; Dr. Langley, grant support from Centocor, Abbott, and Amgen/
Wyeth;Dr. Leonardi, educational grants from Amgen and Genentech; andDr. Lebwohl,
grants fromAbbott, Amgen, Astellas, Centocor, Connetics, Galderma,Genentech, Phar-
maDerm, and Warner Chilcott. Drs. Yeilding, Guzzo, Wang, and Dooley report being
employees of Centocor. Dr. Krueger reports owning stock options from ZARS Pharma;
Drs. Yeilding, Guzzo, and Dooley report holding stock and stock options in Johnson &
Johnson; and Dr. Wang reports being a stockholder in Johnson & Johnson. No other
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potential conflict of interest relevant to this article was reported.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 581): “Patients ... were randomly
assigned”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 581): “Patients ... were randomly
assigned”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 581): “This placebo-controlled,
double-blind...phase 2 study”
Comment: placebo controlled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 581): “This placebo-controlled,
double-blind...phase 2 study”
Comment: no specific description of the
method used to guarantee blinding of out-
come assessment however considering that
this is a placebo-controlled trial with no
known systematic AEs we considered the
risk as low
Incomplete outcome data (attrition bias)
All outcomes
Low risk 320 included/320 analysed
Quote (p 582): “Efficacy data from all pa-
tients who underwent randomisation were
analysed... Missing values at week 12 were
replaced with the most recently available
values for all efficacy variables, missing data
at other time points were not imputed”
Comment: done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00320216)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
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Methods RCT, placebo-controlled, double blind
Date of study: March 2013-November 2013
Location: 6 centres in the USA
Participants Randomised: 12 participants (mean age 45.5 years, 8 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency, past
history of malignant tumours, active infection, uncontrolled cardiovascular disorder,
uncontrolled diabetes, uncontrolled hypertension
Dropouts and withdrawals
• 1/12 (1%);
• Lost to follow-up: tofacitinib (1)
Interventions Intervention
A. Tofacitinib (n = 9), orally, 10 mg twice daily
Control intervention
B. Placebo (n = 3)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PGA 0-1
• PASI 75
Secondary outcomes of the trial
• AEs
Notes Funding source:
Quote (p 1079): “This study was sponsored by Pfizer Inc. Both Pfizer Inc and non-
Pfizer Inc authors have participated in the study design, data collection, data analysis,
and open scientific discussion of the data; its interpretation; and the development of
the associated manuscript. The views and opinions expressed within the manuscript are
those of all authors and do not necessarily represent those of the funding organization.
Medical writing support was funded by Pfizer Inc.”
Declarations of interest (p 1079) : “J. Krueger received research funding from Novartis,
Pfizer Inc, Janssen, Lilly, Merck, Kadmon, Dermira, Boehringer, BMS, and Paraxel
during the conduct of the study; grants paid to institutions from Amgen, Innovaderm
andKyowa; and personal fees fromSerono, BiogenIdec,Delenex, AbbVie, Sanofi, Baxter,
Xenoport, and Kineta. M. Suárez-Fariñas receives research funding and speakers’ fees
from Pfizer. J. D. Clark, H. Tan, R. Wolk, S. T. Rottinghaus, M. Z. Whitley, H. Valdez,
D. von Schack, S. P. O’Neil, P. S. Reddy, and S. Tatulych are employees of Pfizer Inc.
The rest of the authors declare that they have no relevant conflicts of interest.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (p 1079): “Patients were ran-
domised 3:1 to receive 10 mg of oral tofac-
itinib or placebo twice daily for 12 weeks
by using an automated Web or telephone
randomization system”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 1079): “Patients were ran-
domised 3:1 to receive 10 mg of oral tofac-
itinib or placebo twice daily for 12 weeks
by using an automated Web or telephone
randomisation system”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1079): “This was a phase 2, ran-
domised, placebo-controlled, double-blind
study carried out in 6 centers”
Comment: placebo-controlled, probably
done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1079): “This was a phase 2, ran-
domised, placebo-controlled, double-blind
study carried out in 6 centers”
Comment: placebo controlled, probably
done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 12, analysed 11
Management of missing data:
Quote: not mentioned
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01710046)
The pre-specified outcomes in the protocol
or those mentioned in the methods section
have been reported in the results section
Krupashankar 2014
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: 20 centres in India
Participants Randomised: 331 participants (mean age 37 years, 65 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 10, BSA ≥ 10)
• Age > 18 years
• Intolerance, contraindication, or inadequate response to systemic therapy; and
192Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Krupashankar 2014 (Continued)
requiring ≥ 15 mg/week of methotrexate
Exclusion criteria
• Had an active infection (active tuberculosis)
Dropouts and withdrawals
• 26/225 (11.5%);
• Lost to follow-up (10), withdrawn (7), disease worsening (7), AEs (5)
Interventions Intervention
A. Itolizumab (n = 91,) IV, 0.4 mg/kg for 4 weeks, then 1.6 mg/kg once a week for 4
weeks, then eow to 12 weeks
Control intervention
B. Itolizumab (n = 91), IV, 1.6 mg/kg for 4 weeks, then 1.6 mg/kg once a week for 4
weeks, then eow to 12 weeks
C. Placebo (n = 43), IV
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA
• SF36
• DLQI
• Histopatholgy
• Safety
Notes Funding source (p 484): “Biocon limited funded this study and supplied the drug”
Comment: Biocon Limited designed, performed, analysed and wrote the paper (medical
writing)
Declarations of interest (p 484): “Drs Krupashankar, Dogra, Kura, Saraswat, Leelavathy,
Sumathy, Shah, Gopal, Narayana Rao, Srinivas, Bhat, Shetty, Manmohan, Sai Krishna,
Padmaja, Pratap, Garg, Gupta, Pandey, and Khopkar were investigators who conducted
the clinical trial described in this manuscript and collected the trial data; they received
honoraria from the study sponsor. Dr Montero is a part-time employee of Biocon Re-
search Limited. Drs Ramakrishnan, Nair, and Ganapathi are employees of Biocon Re-
search Limited.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 485): “This was a 52-week phase
3, double-blind, randomised, placebo-con-
trolled...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 485): “This was a 52-week phase
3, double-blind, randomised, placebo-con-
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trolled...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 485): “Tomaintain blind dummy
infusion was given”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 485): “Tomaintain blind dummy
infusion was given”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 225 randomised, 220 analysed (not dosed
(2), withdrawn the day after the first infu-
sion (2), lost to follow-up (1))
Quote (p 486): “The full analysis set intent-
to-treat population contained randomised
patients who received at least 1 infusion
and had at least 1 visit after enrollement, .
.., Missing values were imputed using last
observation carried forward”
Comment: few lost to follow-up, well-bal-
anced number and reasons between groups
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Laburte 1994
Methods RCT, active-controlled, open-label trial
Date of study: not stated
Location: 27 centres worldwide
Participants Randomised: 251 participants (mean age 41 years, 176 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 18)
Exclusion criteria
• Kidney insufficiency
• Had past history of malignant tumours
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Ciclosporin A (n = 119), orally, 2.5 mg/kg/d, 12 weeks
Control intervention
B. Ciclosporin A (n = 132), orally, 5 mg/kg/d, 12 weeks
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Outcomes Period assessments: 12 weeks
Primary or secondary outcomes of the trial:
• PASI 75
• PASI < 8
Outcmes of the trial
• Overall assessment score
• Nails, pruritus, severity, arthropathy
• Safety
Notes Funding and declarations of interest: not stated but the first author was employed by
Sandoz Pharma Ltd
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 367): “... was an open randomised
study in parallel group”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 367): “... was an open randomised
study in parallel group”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 367): “... was an open randomised
study in parallel group”
Comment: no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 367): “... was an open randomised
study in parallel group”
Comment: no blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Management of missing data: no descrip-
tion of the method used to guarantee man-
agement of missing data
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
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Langley ERASURE, 2014
Methods RCT, placebo-controlled, double-blind trial
Date of study: June 2011-April 2013
Location: 88 centres worldwide (Erasure)
Participants Randomised: 738 participants mean age 45 years, 509 male
Inclusion criteria
• Participants with moderate-severe psoriasis
• PASI ≥ 12, IGA 3-4, BSA ≥ 10%
• Age ≥ 18
• Non response to topical treatment
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Immunosuppression,
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 38/738 (5.1%)
• AEs: secukinumab 300 (3), secukinumab 150 (5), placebo (4)
• Lack of efficacy: secukinumab 300 (1), secukinumab 150 (1), placebo (0)
• Withdrew consent: secukinumab 300 (1), secukinumab 150 (9), placebo (8)
• Lost to follow-up: secukinumab 300 (0), secukinumab 150 (0), placebo (3)
• Protocol deviation: secukinumab 300 (1), secukinumab 150 (0), placebo (1)
• Became pregnant: secukinumab 300 (1), secukinumab 150 (0), placebo (0)
Interventions Intervention
A. Secukinumab 300 (n = 245), SC, 300 mg, weeks 0, 1, 2, 3, 4 and every 4 weeks, 12
weeks
Control intervention
B. Secukinumab 150 (n = 245), SC, 150 mg, weeks 0, 1, 2, 3, 4 and every 4 weeks, 12
weeks
C. Placebo (n = 248), SC, weeks 0, 1, 2, 3, 4 and every 4 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
• IGA score at 0 or 1
Secondary outcomes of the trial
• PASI 50, PASI 75, PASI 90, PASI 100
• Response of 0 or 1 on the modified IGA at each study visit until week 52
• Score of 0 or 1 on the DLQI at weeks 12 and 52
Notes Funding source, quote (p 326): “funded by Novartis Pharmaceuticals”
Declarations of interest (p 337): “Disclosure forms provided by the authors are available
with the full text of this article at NEJM.org.” Langley received personal fees from Eli
Lilly, Leo, Novartis, Janssen, Amgen, AbbVie, Celgene, Merck, Pfizer
Risk of bias
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Langley ERASURE, 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (protocol and Appendix): “Ran-
domization numbers were generated by
the Interactive Response Technology (IRT)
provider using a validated system, which
automated the random assignment of sub-
ject numbers to randomisation numbers...
”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (protocol and Appendix): “Ran-
domization numbers were generated by
the Interactive Response Technology (IRT)
provider using a validated system, which
automated the random assignment of sub-
ject numbers to randomisation numbers...
”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (protocol and Appendix): “Subjects,
investigator staff, persons performing the
assessments, and data analysts were blinded
to the identity of the treatment from the
time of randomisation until primary objec-
tive analyses“
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (protocol and Appendix): “Subjects,
investigator staff, persons performing the
assessments, and data analysts were blinded
to the identity of the treatment from the
time of randomisation until primary objec-
tive analyses”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 738 included/738 analysed
Quote (p 329): “The analyses of the effi-
cacy end points included all the patients
who underwent randomisation according
to the treatment assigned at randomisation.
.. Missing values ... were conservatively im-
puted as nonresponses, regardless the rea-
son of missing data”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
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ClinicalTrials.gov (NCT01365455)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Langley FIXTURE, 2014
Methods RCT, active, placebo-controlled, double-blind trial
Date of study: June 2011-June 2013
Location: 231 centres worldwide (Fixture)
Participants Randomised: 1306 participants, mean age 44 years, 929 male
Inclusion criteria
• Participants with moderate-severe psoriasis
• PASI ≥ 12, IGA 3-4, BSA ≥ 10%
• Age ≥ 18
• Non-response to topical treatment
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Immunosuppression
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 73/1306 (5.6%)
• AEs: sekunimab 300 (4), sekunimab 150 (2), etanercept (6), placebo (2)
• Lack of efficacy: sekunimab 300 (0), sekunimab 150 (0), etanercept (2), placebo
(9)
• Withdrew consent: sekunimab 300 (5), sekunimab150 (5), etanercept (5),
placebo (10)
• Physician decision: sekunimab 300 (1), sekunimab 150 (2), etanercept (0),
placebo (2)
• Protocol deviation: sekunimab 300 (5), sekunimab 150 (3), etanercept (3),
placebo (0)
• Other: sekunimab 300 (0), sekunimab 150 (0), etanercept (5), placebo (2)
Interventions Intervention
A. Sekunimab 300 (n = 327), SC , 300 mg, weeks 0, 1, 2, 3, 4 and every 4 weeks, 12
weeks
Control intervention
B. Sekunimab 150 (n = 327), SC, 150 mg, weeks 0, 1, 2, 3, 4 and every 4 weeks, 12
weeks
C. Etanercept 50 (n = 326), SC, 50 mg/week twice a week, 12 weeks
D. Placebo (n = 326), SC, weeks 0, 1, 2, 3, 4 and every 4 weeks, 12 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
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Langley FIXTURE, 2014 (Continued)
• and a IGA score at 0 or 1
Secondary outcomes of the trial
• PASI 50, PASI 75, PASI 90, PASI 100
• Response of 0 or 1 on the modified IGA at each study visit until week 52
• Score of 0 or 1 on the DLQI at weeks 12 and 52
Notes Funding source, quote (p 326): “funded by Novartis Pharmaceuticals”
Declarations of interest (p 337): “Disclosure forms provided by the authors are available
with the full text of this article at NEJM.org.” Langley received personal fees from Eli
Lilly, Leo, Novartis, Janssen, Amgen, AbbVie, Celgene, Merck, Pfizer.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (protocol and Appendix): ”Ran-
domization numbers were generated by
the Interactive Response Technology (IRT)
provider using a validated system, which
automated the random assignment of sub-
ject numbers to randomisation numbers...
“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (protocol and Appendix): “Subjects,
investigator staff, persons performing the
assessments, and data analysts were blinded
to the identity of the treatment from the
time of randomisation until primary ob-
jective analyses” “Randomization numbers
were generated by the Interactive Response
Technology (IRT) provider”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (protocol and Appendix): “Subjects,
investigator staff, persons performing the
assessments, and data analysts were blinded
to the identity of the treatment from the
time of randomisation until primary objec-
tive analyses
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (protocol and Appendix): “Subjects,
investigator staff, persons performing the
assessments, and data analysts were blinded
to the identity of the treatment from the
time of randomisation until primary objec-
tive analyses
Comment: probably done
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote (p 329): “The analyses of the effi-
cacy end points included all the patients
who underwent randomisation according
to the treatment assigned at randomisation.
.. Missing values ... were conservatively im-
puted as nonresponses, regardless the rea-
son of missing data” 1306 included/1306
analysed
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01358578)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Lebwohl 2003
Methods RCT, placebo-controlled, double blind
Date of study: 23 March 2000-05 January 2001
Location: 64 centres in Europe, USA and Canada
Participants Randomised: 507 participants (mean age 45 years, 333 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 10)
• Age ≥ 18 years
Exclusion criteria
• Pregnancy, immunosuppression
• Had an active infection
• had past history of malignant tumours
Dropouts and withdrawals
• 62/507 (12.2%)
• AE (10): alefacept 10 (4), alefacept 15 (2), placebo (4)
• Worsening (13): alefacept 10 (5), alefacept 15 (2), placebo (6)
• Request (25): alefacept 10 (8), alefacept 15 (6), placebo (11)
• Laboratory (1): alefacept 10 (1), alefacept 15 (0), placebo (0)
• Lost to follow-up (2): alefacept 10 (0), alefacept 15 (2), placebo (0)
• Other (11): alefacept 10 (3), alefacept 15 (3), placebo (5)
Interventions Intervention
A. Alefacept 10 (n = 173), IM, 10 mg once a week, 12 weeks
Control intervention
B. Alefacept 15 (n = 166), IM, 15 mg once a week, 12 weeks
C. Placebo (n = 168), IM, 0.9 mL once a week, 12 weeks
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Outcomes Assessments at 12 weeks
Primary or secondary outcomes of the trial
• Not clearly identified
Outcomes of the trial
• PASI 50
• PASI 75
• PGA clear/almost clear
• Side effects
Notes Funding source, quote (p 725): “Support for this research and data monitoring and
analysis were provided by Biogen Inc.”
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 720): “The present multicen-
ter, randomised...ICT Inc..., a contract re-
search organization, was responsible for pa-
tient randomisation and tracking and study
inventory”
Comment: unlikely to introduce selection
bias
Allocation concealment (selection bias) Low risk Quote: “a contract research organization,
was responsible for patient randomisation
and tracking and study inventory” “Un-
blinded pharmacist prepared, coded… and
maintained drug accountability”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 720): ”Unblinded pharmacist
prepared, coded… and maintained drug
accountability”
Comment: placebo-controlled, probably
done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 720): “All efficacy measures were
assessed ... by a dermatologist blinded to
treatment”
Comment: placebo-controlled, probably
done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 507 included/507 analysed
Quote (p 721): “Statistical analyses for ef-
ficacy measures were based on the intent-
to-treat population composed of those pa-
tients who were randomised, had at least 1
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injection and had a baseline assessment”
Comment: no description of the method
used tomanagemissing data however num-
ber and reasons for withdrawal well-bal-
anced between groups
Selective reporting (reporting bias) High risk Comment: no protocol was available.
No pre-specified primary outcome
Lebwohl AMAGINE-2, 2015
Methods RCT, active/placebo-controlled, double blind
Date of study: August 2012-September 2014
Location: 142 centres worldwide
Participants Randomised: 1831 participants (mean age 45 years, 1258 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, PGA 3-5, BSA ≥ 10),
age 18-75 years
Exclusion criteria
• Pregnancy
• Active infection, past history of malignant tumours, active infection, kidney or
liver insufficiency, uncontrolled cardiovascular disorder, uncontrolled diabetes,
uncontrolled hypertension
• Had Crohn’s disease
• Had used ustekinumab and/or anti-IL17 biologic therapy
Dropouts and withdrawals
• 55/1831 (3%): brodalumab 140 group (22), brodalumab 210 group (15),
ustekinumab 45/90 group (9), placebo group (9)
• Ineligibility determined: brodalumab 140 group (3), brodalumab 210 group (0),
ustekinumab 45/90 group (0), placebo group (0)
• AEs: brodalumab 140 group (4), brodalumab 210 group (3), ustekinumab 45/90
group (2), placebo group (0)
• Lost to follow-up: brodalumab 140 group (2), brodalumab 210 group (3),
ustekinumab 45/90 group (2), placebo group (2)
• Death; brodalumab 140 group (0), brodalumab 210 group (1), ustekinumab 45/
90 group (0), placebo group (0)
• Full consent withdrawal: brodalumab 140 group (11), brodalumab 210 group (2)
, ustekinumab 45/90 group (3), placebo group (5)
• Other: brodalumab 140 group (2), brodalumab 210 group (6), ustekinumab 45/
90 group (2), placebo group (3)
Interventions Intervention
A. Brodalumab (n = 610), SC, 140 mg (2 injections week 0, 1 injection eow)
Control intervention
B. Brodalumab (n = 612), SC, 210 mg (2 injections week 0, 1 injection eow)
C. Ustekinumab (n = 300), SC, 45/90 mg (week 0, week 4 and every 12 weeks)
D. Placebo (n = 309), orally (same drug administration)
202Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lebwohl AMAGINE-2, 2015 (Continued)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75 & PGA0/1 (brodalumab compared to placebo)
• % of participants who had a 100% reduction in PASI score
Secondary outcomes of the trial
• Improvement in PASI
• PGA score
• Participant-reported outcome
• AEs
Notes Funding source:
Quote (p 1319) “Amgen funded both studies. ... and Amgen conducted the data analyses.
All the authors interpreted the data”
Declarations of interest (p 1327): “Disclosure forms provided by the authors are available
with the full text of this article at NEJM.org.” Dr. Lebwohl reports grant support from
Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis
outside the submitted work
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (protocol): “The randomisation lists
will be generated by Amgen using a per-
muted block design within each strata...via
an interactive voice response system”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (protocol): “The randomisation lists
will be generated by Amgen using a per-
muted block design within each strata...via
an interactive voice response system”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (protocol, cf 6. Treatment proce-
dure): “This is a double dummy procedure.
..”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (protocol, cf 6. Treatment proce-
dure): “This is a double dummy procedure.
..”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 1831, analysed 1831
Dealing with missing data
Quote (protocol & p 1321) “...with miss-
ing data imputed as indicatingno response”
Comment: well described
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Selective reporting (reporting bias) High risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT0178603)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared tohave been reported except for par-
ticipant-reported outcome
Lebwohl AMAGINE-3, 2015
Methods RCT, active/placebo-controlled, double blind
Date of study: September 2012-August 2014
Location: 142 centres worldwide (no sites that were included in the AMAGINE-2 study)
Participants Randomised: 1881 participants (mean age 45 years, 1288 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, PGA 3-5, BSA ≥ 10),
age 18-75 years
Exclusion criteria
• Pregnancy
• Active infection, past history of malignant tumours, active infection, kidney or
liver insufficiency, uncontrolled cardiovascular disorder, uncontrolled diabetes,
uncontrolled hypertension
• Had Crohn’s disease
• Had used ustekinumab and/or anti-IL17 biologic therapy
Dropouts and withdrawals
• 65/1881 (3.4%): brodalumab 140 group (25), brodalumab 210 group (16),
ustekinumab 45/90 group (10), placebo group (14)
• Ineligibility determined: brodalumab 140 group (3), brodalumab 210 group (0),
ustekinumab 45/90 group (1), placebo group (2)
• AEs: brodalumab 140 group (4), brodalumab 210 group (4), Usk 45/90 group
(1), placebo group (0)
• Lost to follow-up: brodalumab 140 group (5), brodalumab 210 group (5),
ustekinumab 45/90 group (3), placebo group (1)
• Full consent withdrawl: brodalumab 140 group (7), brodalumab 210 group (5),
ustekinumab 45/90 group (3), placebo group (7)
• Other: brodalumab 140 group (6), brodalumab 210 group (2), ustekinumab 45/
90 group (2), placebo group (4)
Interventions Intervention
A. Brodalumab (n = 629), SC, 140 mg (2 injections week 0, 1 injection eow)
Control intervention
B. Brodalumab (n = 624), SC, 210 mg (2 injections week 0, 1 injection eow)
C. Ustekinumab (n = 313), SC, 45/90 mg (week 0, week 4 and every 12 weeks)
D. Placebo (n = 315), orally (same drug administration)
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Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
• PGA 0/1 (brodalumab compared to placebo)
• % of participants who had a 100% reduction in PASI score
Secondary outcomes of the trial
• Improvement in PASI
• PGA score
• Participant-reported outcome
• AEs
Notes Funding source:
Quote (p 1319) “Amgen funded both studies. ... and Amgen conducted the data analyses.
All the authors interpreted the data”
Declarations of interest (p 1327): ”Disclosure forms provided by the authors are available
with the full text of this article at NEJM.org.“ Dr. Lebwohl reports grant support from
Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis
outside the submitted work
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (protocol): “The randomisation lists
will be generated by Amgen using a per-
muted block design within each strata..
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (protocol): “The randomisation lists
will be generated by Amgen using a per-
muted block design within each strata...via
an interactive voice response system”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (protocol, cf 6. Treatment proce-
dure): “This is a double dummy procedure.
..”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (protocol, cf 6. Treatment proce-
dure): ”This is a double dummy procedure.
..”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 1881, analysed 1881
Dealing with missing data
Quote (protocol & p 1321) “...with miss-
ing data imputed as indicatingno response”
Comment: well described
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Selective reporting (reporting bias) High risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01708629)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared tohave been reported except for par-
ticipant-reported outcome
Leonardi 2003
Methods RCT, placebo-controlled, double-blind trial
Date of study: December 2001-April 2002
Location: 47 centres in USA
Participants Randomised: 672 participants (mean age 45 years, 672 male)
Inclusion criteria
• Participants with moderate-severe stable plaque psoriasis, BSA > 10%
• Age ≥ 18
• Quote (p 2015) “Had previously received phototherapy or systemic psoriasis
therapy at least once or had been candidate to such therapy”
Exclusion criteria
• Had received biologics treatments
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 103/672 (15.3%)
• Not received any treatment: etanercept LD (9), etanercept MD (5), etanercept
HD (4), placebo (2)
• AEs: etanercept LD (8), etanercept MD (7), etanercept HD (5), placebo (8)
• Loss to follow-up: etanercept LD (4), etanercept MD (4), etanercept HD (3),
placebo (3)
• Lack of efficacy: etanercept LD (6), etanercept MD (2), etanercept HD (3),
placebo (6)
• Patient refusal: etanercept LD (3), etanercept MD (4), etanercept HD (1),
placebo (4)
• Protocol violation: etanercept LD (3), etanercept MD (4), etanercept HD (0),
placebo (1)
• Death: etanercept LD (1), etanercept MD (1), etanercept HD (0), placebo (0)
• Unknown/other: etanercept LD (1), etanercept MD (0), etanercept HD (1),
placebo (0)
Interventions Intervention
A. Etanercept LD (n = 169), SC auto-administered, 25 mg, once/week, 12 weeks
Control intervention
B. Etanercept MD (n = 167), SC auto-administered, 25 mg, twice/week, 12 weeks
C. Etanercept HD (n = 168), SC auto-administered, 50 mg, twice/week, 12 weeks
D. Placebo (n = 168), SC, 12 weeks
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Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 50
• PASI 90
• DLQI
• PGA
• Safety
• Patient global assessment of psoriasis
Notes Funding source, quote (p 2021): “Supported by Immunex, Seattle, a wholly-owned
subsidiary of Agen, Thousand Oaks, Calif ”
Declarations of interest (p 2021): “Drs. Leonardi, Powers, Goffe, and Gottlieb report
having served as consultants for Amgen, and Drs. Leonardi, Goffe, and Gottlieb report
having served as paid lecturers for Amgen. Dr. Gottlieb reports having served as a con-
sultant and paid lecturer for Johnson & Johnson, Genentech, and Biogen; Dr. Leonardi
reports having served as a consultant and paid lecturer for Johnson & Johnson and
Genentech; Dr. Powers reports having served as a consultant for Genentech and Biogen;
and Dr. Goffe reports having served as a consultant and paid lecturer for Biogen. Dr.
Zitnik and Ms. Wang report owning equity in Amgen.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 2016): “Patients underwent cen-
tral randomisation with the use of a per-
muted block randomisation list, with equal
allocation to each of the four treatment
groups”
Comment: probably done
Allocation concealment (selection bias) Low risk Comment: no description of the method
used to guarantee the allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 2015): “Double-blind... Etan-
ercept ... was supplied to patients in sy-
ringes, each containing the contents of one
reconstituted vial of etanercept or match-
ing placebo...All patients received two in-
jections per dose of study”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 2015): “Double-blind... Etan-
ercept ... was supplied to patients in sy-
ringes, each containing the contents of one
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reconstituted vial of etanercept or match-
ing placebo...All patients received two in-
jections per dose of study”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 672 randomised participants, 652 analysed
(20 participants did not receive the treat-
ment and were excluded from the analyses)
Comment: modified ITT but number of
participants not receiving treatment and
not included in the analysis low and com-
parable between groups
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Leonardi 2012
Methods RCT, placebo-controlled, double-blind trial
Date of study: April 2010-May 2011
Location: 23 centres internationally
Participants Randomised: 142 participants (mean age 46 years, 81 male)
Inclusion criteria
• Participants with moderate-severe psoriasis, PASI ≥ 12, PGA 3-5, BSA ≥ 10
• Age ≥ 18
Exclusion criteria
• Pregnancy
• Had an active infection
Dropouts and withdrawals
• 13/142 (9%) :
• Placebo (4) (AE (4), withdrew (1) efficacy lack (2))
• Ixekizumab 10 mg (6) (AE (2), protocol violations (2), lost to follow-up (1),
efficacy lack (1))
• Ixekizumab 25 mg (1) (AE (1))
• Ixekizumab 75 mg (1) (withdrawal (1))
• Ixekizumab 150 mg (1) (withdrawal (1))
Interventions Intervention
A. Placebo (n = 27), SC, 0, 2, 4, 8, 12, 16 weeks, 16 weeks
Control intervention
B. Ixekizumab (n = 28), SC, 10 mg, 0, 2, 4, 8, 12, 16 weeks, 16 weeks
C. Ixekizumab (n = 30), SC, 25 mg, 0, 2, 4, 8, 12, 16 weeks, 16 weeks
C. Ixekizumab (n = 29), SC, 75 mg, 0, 2, 4, 8, 12, 16 weeks, 16 weeks
C. Ixekizumab (n = 28), SC, 150 mg, 0, 2, 4, 8, 12, 16 weeks, 16 weeks
208Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Leonardi 2012 (Continued)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• % reduction of PASI
• PASI 90/PASI 100
• PGA
• NAPSI
• PSSI
Notes Funding source, quote (p 1190): “Funded by Eli Lilly”
Declarations of interest (p 1198): “Disclosure forms provided by the authors are available
with the full text of this article at NEJM.org.” Leonardi received personal fees from
Abbott, Amgen, Certocor, Eli Lilly and Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (protocol p 44): “... from the central
randomisation center using an IVRS”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (protocol p 44): “... from the central
randomisation center using an IVRS”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (protocol p 22): “The investigators
and patients are blinded while the sponsor
is unblinded to study assignment”
Comment: placebo-controlled trial, no sys-
tematic AE for the drug, probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (protocol p 22): “The investigators
and patients are blinded while the sponsor
is unblinded to study assignment”
Comment: placebo-controlled trial, no sys-
tematic AE for the drug, probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Included 142/141 analysed (1 in the
placebo group who did not have any post-
baseline assessment)
Quote (protocol p 62 & p 1192): “All ef-
ficacy and health outcome analyses will be
conducted on all patients who received any
amount of study drug and have any post-
baseline efficacy assessment....Missing data
for the primary timepoint at week 12 will
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be imputed by the last observation carried
forward method”
Comment: m-ITT and 1 participant out of
142 was not included in the analyses
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01107457)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Leonardi PHOENIX-1, 2008
Methods RCT, placebo-controlled, double-blind trial
Date of study: December 2005-September 2007
Location: 48 centres in USA, Canada, Belgium
Participants Randomised: 766 participants (mean age 45 years, 531 male)
Inclusion criteria
• Participants with moderate-severe psoriasis, authors’ assessment > 6 months, PASI
≥ 12, BSA > 10%
• Age ≥ 18
Exclusion criteria
• Had received conventional systemic treatments
• Had received biologics (IL12/23)
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 23/766 (3%) :
• Ustekinumab 45 (1) (other 1)
• Ustekinumab 90 (10) (lack of efficacy (1), adverse event (2) other (7))
• Placebo (12) (lack of efficacy (3), adverse event (6) other (3))
Interventions Intervention
A. Ustekinumab (n = 255), SC, 45 mg, weeks 0-4 and every 12 weeks, 40 weeks
Control intervention
B. Ustekinumab (n = 256), SC, 90 mg, weeks 0-4 and every 12 weeks, 40 weeks
C. Placebo (n = 255), SC, weeks 0-4, 40 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA cleared or minimal at 12 weeks
• Change of DLQI from baseline at 12 weeks
• PASI 90 at week 12
• Side effects
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Notes Funding source, quote (p 1665): Centocor Inc.
Declarations of interest (p 1673): “CLL has served as a consultant for Abbott, Amgen,
Centocor, and Genentech, as an investigator for Abbott, Allergan, Altana, Alza, Am-
gen, Astellas, Celgene, Centocor, Genentech, Bristol Myers, Eli Lilly, Fujisawa, Gal-
derma, CombinatoRx, 3M Pharmaceuticals, Perrigo Isreal Pharamceutical, Schering-
Plough, Serono, RTL, Novartis, Vitae, and Wyeth, and as a speaker for Abbott, Am-
gen, Centocor, Genentech, and Warner Chilcott. ABK has served as an investigator and
consultant for Abbott, Amgen, and Centocor and has been a study steering committee
member, speaker, and fellowship funding recipient from Centocor. KAP has served as
a consultant and advisory board member for Abbott, Alza, Amgen, Celgene, Centocor,
Johnson and Johnson, Isotechnika, Janssen Ortho Biotech, Medimmune, MerckSerono,
and Wyeth. KBG has served as a consultant for Abbott, Amgen, Astellas, Centocor, and
Genentech and has received grant support fromAbbott, Astellas, andCentocor. NY,CG,
YW, SL, and LTD are employees of Centocor and own stock in Johnson and Johnson.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 1667-68): “...via a centralised in-
teractive voice response system”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 1667-68): “...via a centralised in-
teractive voice response system”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1666-67): “This phase 3, dou-
ble-blind, placebo-controlled... Patients re-
ceived placebo injections as needed to pre-
serve the blind. The study sponsor was
unblinded to treatment... Site monitors,
investigators, site personnel involved in
the study conduct, and patients remained
blinded until week 76”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1666-67): “This phase 3, dou-
ble-blind, placebo-controlled... Patients re-
ceived placebo injections as needed to pre-
serve the blind. The study sponsor was
unblinded to treatment... Site monitors,
investigators, site personnel involved in
the study conduct, and patients remained
blinded until week 76”
Comment: probably done
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Leonardi PHOENIX-1, 2008 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Included 255/256/255
Analysed 255/256/255
Quote (p 1668): “Efficacy data fromall ran-
domised patients were analysed according
to the assigned treatment group.... Patients
who discontinued study treatment... were
deemed to be treatment failures”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00267969)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Lowe 1991
Methods RCT, placebo-controlled, double-blind trial
Date of study: not stated
Location: 2 centres in Santa Monica and New York City, USA
Participants Randomised: 34 participants, age range 20-75 years, 24 male
Inclusion criteria
• Participants with moderate-severe psoriasis
• BSA 20-80
• ≥ 6 months duration
Exclusion criteria
• Had received conventional systemic treatments or phototherapy for 4 weeks or
topical therapy for 2 weeks
Dropouts and withdrawals
• Not specified
Interventions Intervention
A. Acitretin (n = 16), orally, 50 mg, daily, 12 weeks
Control intervention
B. Placebo (n = 18), orally, daily, 12 weeks
Co-intervention:
UVB (phototherapy)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI
Secondary outcomes of the trial
• Side effects
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Notes Funding source (p 591): “Supported by Roche dermatologics, Nutley, New Jersey and
the Skin Research Foundation of California, Santa Monica, California”
Declarations of interest; not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 592): “Patients receiving UVB
phototherapy were randomly assigned”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 592): “Patients receiving UVB
phototherapy were randomly assigned”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 592): “were randomly assigned to
either acitretin or placebo”
Comment: no more precision however ad-
verse effects of acitretin such as cheilitis are
visible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 592): “were randomly assigned to
either acitretin or placebo... the same ob-
server who was unaware of patient group
examined the patients throughout the in-
vestigation”
Comment: no more precision however ad-
verse effects of acitretin such as cheilitis are
visible
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 34 included / 34 analysed (Table 2)
Comment: no description of the method
used to manage the missing data or to per-
form the analyses
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
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Mahajan 2010
Methods RCT, placebo-controlled, double-blind trial
Date of study: January 2007-September 2007
Location: 1 centre in Chandighar, India
Participants Randomised: 40 participants (mean age 37 years, 29 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• BSA > 10%
• Age 18-60 years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency
• Had uncontrolled diabetes
Dropouts and withdrawals
• 11/40 (28%)
• 3 withdrawn (disease exacerbation)
• 4 lost to follow-up (acitretin (3), placebo (1))
• 4 alternative therapy
Interventions Intervention
A.Methotrexate 0.5mg/kg + folic acid, (n = 20), orally 5mg/dDay-1; Day+1 +NBUVB
3/week max 1200 mJ/cm2
Control intervention
B. Placebo + folic acid (n = 20), orally, 5 mg/d Day-1; Day+1 + NBUVB 3/week max
1200 mJ/cm2
Outcomes Assessments at 6 months
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI at 4-12 weeks
• Relapse (return of PASI at 50 weeks to baseline)
Notes Funding source: not stated
Declarations of interest (p 595): “not declared”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 596): “... were randomised byway
of random number table”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 596): “... were randomised byway
of random number table”
Comment: no description of the method
used to guarantee allocation concealment
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 596): “patient-blinded study”
Comment: not double blind
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 596): “patient-blinded study”
Comment: not double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 20/20 included; 20/20 analysed
Quote (p 596):“Intention to treat principle
was followed for the analysis of the obser-
vations”
Comment: no description of the method
used to manage the missing data
Selective reporting (reporting bias) Low risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Meffert 1997
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: 17 centres in Germany
Participants Randomised: 128 participants
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI 8 to 25)
• Age 18-70 years
Exclusion criteria
• Pregnancy, leucopenia, kidney insufficiency, liver insufficiency
• Had uncontrolled hypertension
Dropouts and withdrawals
• 15/128 (12%) :
• Protocol violation(6)
• Lack efficacy(4)
• AE (5)
Interventions Intervention
A. Ciclosporin (n = 43), orally, 1.25 mg/kg/d, 10 weeks
Control intervention
B. Ciclosporin (n = 41), orally, 2.5 mg/kg/d, 10 weeks
C. Placebo (n = 44), orally, 10 weeks
Outcomes Assessments at 10 weeks
Primary outcomes of the trial
• PASI
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Secondary outcomes of the trial
• PASI 25
• PASI 50
• PASi 75
Notes Funding source not stated however 3 out of 4 authors from Sandoz pharmaceuticals
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 77): “patients were randomised”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (p 77): “double blind study period”
Comment: no description of the method
used to guarantee blinding regarding the
need of hypertension and renal func-
tion surveillance and modification in ci-
closporin groups
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p 77): “double blind study period”
Comment: no description of the method
used to guarantee blinding, regarding the
need of hypertension and renal func-
tion surveillance and modification in ci-
closporin groups
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 128 included/120 analysed
Comment: methods for dealing with miss-
ing data not specified, not ITT analyses
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
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Menter EXPRESS-II, 2007
Methods RCT, placebo-controlled, double-blind trial
Date of study: not stated
Location: 63 centres in Europe, USA, Canada
Participants Randomised: 835 participants (mean age 44 years, 551 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• PASI ≥ 12, BSA ≥ 10
• No history of serious infection, lymphoproliferative disease, or active TB
Exclusion criteria
• Had received biologics
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 62/835 (7.4%)
• Inflximab 5 mg/kg (17) (AE (12), other (4), lost to follow-up (1))
• Infliximab 3 mg/kg (21) (AE (13), other (7), low effect (1))
• Placebo (24) (AE (4), other (9), lost to follow-up (1), low effect (10))
Interventions Intervention
A. Infliximab (n = 313), IV, 3 mg/kg, weeks 0, 2, 6; 10 weeks
Control intervention
B. Infliximab (n = 314), IV, 5 mg/kg, weeks 0, 2, 6; 10 weeks
C. Placebo (n = 208), IV, weeks 0, 2, 6; 10 weeks
Outcomes Assessments at 10 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 50/90
• DLQIAE
• PGA
Notes Funding (p 31. e1) by Centocor, Inc, Malvern, Penn, and Schering-Plough, Kenilworth,
NJ
Declarations of interest (appendix): “DrMenter has received consulting, research, and/or
speaking support from Abbott Laboratories, Allergan Inc, Allermed, Amgen Inc, Astralis
Inc, Berlex Inc, Biogen Idec Inc, Centocor Inc, Cephalon, Collagenex Pharmaceuticals,
CombinatoRx, Connetics Corp, Corixa Corporation, Dermik Laboratories, Doak Der-
matologics, Dow, Ferndale Laboratories Inc, FujisawaHealthcare Inc, Galderma,Genen-
tech Inc, Genzyme, GlaxoSmithKline, Ligand Pharmaceuticals, Medicis, Med-Immune
Inc, Novartis Pharmaceuticals, Otsuka Pharmaceutical Inc, Protein Design Labs, QLT
USA, Regeneration Pharma AG, Roche Laboratories, Serono, Sinclair, Synta Pharma,
Thermosurgery, 3M Pharmaceuticals, Vertex, XOMA, and Zars Inc. Dr Feldman has
received consulting, research, and/or speaking support from Amgen, Centocor, and Bio-
gen. Dr Papp’s support is as follows: Abbott: Investigator, Consultant; Amgen: Investiga-
tor, Consultant, Speaker, Advisory Boards; Centocor: Investigator, Consultant, Speaker,
Senior Medical Officer for Canada (non-compensatory), Advisory Boards; Genentech:
Investigator, Consultant, Speaker, Senior Medical Officer for Canada (non-compen-
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Menter EXPRESS-II, 2007 (Continued)
satory), Advisory Boards; Serono: Investigator, Consultant, Speaker, Advisory Boards;
Schering: Investigatory, Consultant, Speaker, Advisory Boards; and Wyeth: Speaker, Ad-
visory Boards. Dr Weinstein has received consulting, research, and/or speaking support
from Allergan, Amgen, Centocor, Biogen, Genentech, Valeant, Collagenex, Combina-
toRx, Fujisawa, Abbott, andQLT. Dr Gottlieb has received research support from and/or
is a consultant and/or speaker for Amgen, Inc, BiogenIdec, Inc, Centocor, Inc, Genen-
tech, Inc, Abbott Labs, Ligand Pharmaceuticals, Inc, Beiersdorf, Inc, Fujisawa Health-
care, Inc, Celgene Corp, Bristol Myers Squibb, Inc, Warner Chilcott, Paradigm, Wyeth
Pharmaceuticals, Schering-Plough Corp, Eisai, Roche, Sankyo,Medarex, Kemia, Celera,
TEVA, Actelion, and Amarill. At the time of the study, DrGottlieb was affiliatedwith the
Clinical Research Center, University of Medicine and Dentistry of New Jersey, Robert
Wood Johnson Medical School, New Brunswick, NJ. Dr Guzzo, Dr Dooley, Ms Li, and
Ms Arnold are employees of Centocor, Inc. Mr Evans was an employee of Centocor, Inc
at the time this study was conducted and is currently an employee of Scios, Inc.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 31; e2): “Randomizations were
performed by ClinPhone (Lawrenceville,
NJ), allocating patients using a minimiza-
tion algorithm with a biased coin assign-
ment by means of an interactive voice re-
sponse system”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 31; e2): “Randomizations were
performed by ClinPhone (Lawrenceville,
NJ), allocating patients using a minimiza-
tion algorithm with a biased coin assign-
ment by means of an interactive voice
response system” “Patients, investigators,
and all study staff except pharmacists were
blinded to treatment assignments”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 31. e2): “Patients, investigators,
and all study staff except pharmacists were
blinded to treatment assignments... to re-
ceive IFX 3mg/Kg or 5mg/Kg or placebo”“
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 31. e2): ”Patients, investigators,
and all study staff except pharmacists were
blinded to treatment assignments... to re-
ceive IFX 3mg/Kg or 5mg/Kg or placebo“”
Comment: placebo-controlled, probably
done
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 835 included / 835 analysed
Quote (p 31.e3/4): “For patients who dis-
continued... these patients were considered
as notmeeting the respective end-points re-
gardless of the observed data”
Comment: ITT
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Menter REVEAL, 2008
Methods RCT, placebo-controlled, double-blind trial
Date of study: December 2004-August 2007
Setting: 81 centres (67+14)) in USA, Canada
Participants Randomised: 1212 participants (mean age 44 years, 803 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• PASI ≥ 12, PGA moderate severity, BSA ≥ 10
• Age ≥ 18 years
Exclusion criteria
• Pregnancy
• Had an active infection
Dropouts and withdrawals
• 74/1212 (6%)
• 4/10 AEs
• 9/6 withdrew consent
• 8/6 lost to follow-up
• 17/2 unsatisfactory effect
• 5/1 others
Interventions Intervention
A. Adalimumab (n = 814), SC, 40 mg, week 0: 2 injections, week 1: eow, 16 weeks
Control intervention
B. Placebo, SC (n = 398), week 0: 2 injections/week 1: eow, 16 weeks
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA
• PASI 90
• PASI 100
• Safety
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Notes Funding source quote (p 106): “Supported by Abbott Laboratories
Declarations of interest (p 106): ”DrMenter has received research support and/or lecture
honoraria from Abbott, Amgen, Astellas, Biogen, Centocor, Genentech, and Wyeth. Dr
Tyring has received research support from, has consulted for, and is part of the speak-
ers’ bureaus for Abbott. Dr Gordon has received research support and honoraria from
Abbott, Amgen, and Centocor. Dr Kimball is an investigator, speaker, and consultant
for Abbott, Amgen, Biogen, Centocor, and Genentech. Dr Leonardi is a consultant
for Abbott, Amgen, Centocor, and Genentech and is an investigator for Abbott, Al-
lergan, Altana, Amgen, Astellas, Biogen, Bristol Myers, Centocor, Fujisawa, Galderma,
Genentech, Serono, CombinatoRx, 3M Pharmaceuticals, Schering Plough, RTL, and
Vitae; he also received an educational grant from Amgen and Genentech, and is part of
the speakers’ bureaus for Abbott, Amgen, Centocor, Genentech, and Warner Chilcott.
Dr Langley is a scientific advisory board member, investigator, and speaker for Abbott,
Amgen, Astellas, Centocor, Norvartis, and Wyeth. Dr Strober serves on the advisory
boards of, has received honoraria from, and is an investigator for Abbott, Amgen, Astel-
las, Centocor, Genentech, and Wyeth, and is part of the speakers’ bureaus for Abbott,
Amgen, Astellas, Genentech, and Wyeth. Dr Kaul, Ms Gu, and Dr Okun are employees
of Abbott Laboratories. Dr Papp is a consultant for and has received honoraria and travel
grants from Abbott, Alza, Amgen, Astellas, Celgene, Centocor, Genentech, Isotechnika,
Johnson and Johnson, Serono, Schering-Plough, and UCB.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 107): ”Randomization schedules
were generated by one of our data manage-
ment departments before study inception”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 107): ”Patients were randomised
by centre via an interactive voice response
system”. “ADA and placebo-filled syringes
were identically labelled and packaged, and
self-administrated by patients”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 107): “Double-blind, placebo-
controlled... ADA and placebo-filled sy-
ringes were identically labelled and pack-
aged, and self-administrated by patients”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 107): “Double-blind, placebo-
controlled... ADA and placebo-filled sy-
ringes were identically labelled and pack-
aged, and self-administrated by patients”
Comment: probably done
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Incomplete outcome data (attrition bias)
All outcomes
Low risk 1212 included/1212 analysed
Quote (p 109): “The primary efficacy anal-
yses were conducted on ITT population...
a patient with missing data for a visit... had
the last observation carried forward”
Comment: probably done
Selective reporting (reporting bias) Unclear risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT002377887)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared tohave been reported except for par-
ticipant-reported outcome
Mrowietz BRIDGE, 2016
Methods RCT, active-controlled, double blind
Date of study: November 2012-November 2015
Setting: 57 centres in Austria, Germany, the Netherlands and Poland
Participants Randomised: participants (mean age, male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Failed therapy with fumaric ester
• Baseline leucocyte counts < 3 x 109 cells L1 and/or lymphocyte counts < 1 x 109
cells L1
• Pregnant or breastfeeding women
Dropouts and withdrawals
• 254/704 (36%);
• Not treated: Dimethyl Fumarate (DMF) (1), DMF + salt of monoethyl fumarate
(MEF) (3), placebo (1)
• AEs: DMF (64), DMF + MEF (70), placebo (6)
• Lack of efficacy: DMF (12), DMF + MEF (9), placebo (20)
• Withdrew consent: DMF (13), DMF + MEF (11), placebo (7)
• Lost to follow-up: DMF (5), DMF + MEF (5), placebo (5)
• No compliance: DMF (3), DMF + MEF (7), placebo (1)
• Other: DMF (6), DMF + MEF (5), placebo (0)
Interventions Intervention
A. Dimethyl fumarate (DMF) (n = 280), orally, maximum daily dose of 720 mg DMF
Control intervention
B. DMF + salt of monoethyl fumarate (n = 286), orally, maximum daily dose of 720 mg
DMF
C. Placebo (n = 138)
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Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
• PGA 0/1
Secondary outcomes of the trial
• PASI 90
• DLQI
• AEs
Notes Funding source: Quote (p 1) “This research was funded by Almirall S.A.”
Declarations of interest (p 1): “U.M. has been an advisor and/or received speaker hon-
oraria and/or received grants and/or participated in clinical trials for the following
companies: Abbott/AbbVie, Almirall Hermal, Amgen, Biogen, Boehringer Ingelheim,
Celgene, Centocor, Foamix, Forward Pharma, Galderma, Janssen, LEO Pharma, Lilly,
Medac, Miltenyi Biotec, MSD, Novartis, Pfizer, Teva, UCB, VBL and XenoPort. J.
C.S. receives advisory board/consulting fees from AbbVie, Biogen, Biogenetica Inter-
national Laboratories, Egis Pharmaceuticals, Fresenius, LEO Pharma, Lilly, Novartis,
Pierre Fabre, Polpharma, Sandoz and Toray Corporation; and receives speaker fees from
AbbVie, Actavis, Adamed, Astellas, Berlin-Chemie Menarini, Fresenius, Janssen-Cilag,
LEO Pharma, Mitsubishi Tanabe Pharma, Novartis, Pierre Fabre, Takeda and Vichy,
and clinical trial funding from AbbVie, Actelion, Almirall, Amgen, GlaxoSmithKline,
Janssen-Cilag, Merck, Mitsubishi Tanabe Pharma, Novartis, Regeneron and Takeda. P.
V.K. declares consultancy fees for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
Abbott, Lilly, Galderma, Novartis, Janssen-Cilag, LEO Pharma, Sandoz and Mitsubishi
Tanabe Pharma and carries out clinical trials for Basilea, Pfizer, Lilly, Amgen, AbbVie,
Philips Lighting, Janssen-Cilag and LEO Pharma. R.L.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 2): “Randomisation was per-
formed by the investigators using an inter-
active web-based response system.”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 2): “Randomisation was per-
formed by the investigators using an inter-
active web-based response system. The ran-
domisation sequence was kept concealed
from the investigators during the trial.”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 2): “Treatment was uptitrated
over the first 9 weeks, with placebo or up
to a maximum daily dose of 720 mg DMF
in the LAS41008 or Fumaderm® groups”
Comment: probably done
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Mrowietz BRIDGE, 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 2): “Treatment was uptitrated
over the first 9 weeks, with placebo or up
to a maximum daily dose of 720 mg DMF
in the LAS41008 or Fumaderm® groups”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 704, analysed 671
Management of missing data:
Quote (p 4): “All statistical analyses were
based on the full analysis set (FAS) and
the per protocol set (PPS). As the results
of both were consistent, data are presented
here only for the FAS. A last-observation-
carried-forward approach was used to han-
dle
missing data for the PASI- and PGA-de-
rived end points.”
DMF/DMF + MEF/placebo
Randomized 280/286/138
Safety set analysis 279/283/137 (not
treated patients excluded)
Full set analysis 267/273/131 (not ex-
plained)
Comment: not ITT analysis
Selective reporting (reporting bias) High risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01726933)
Some pre-specified outcomes and those
mentioned in themethods section asDLQI
had not been reported
Mrowietz SCULPTURE, 2015
Methods RCT, active-controlled, double blind
Date of study: August 2011-March 2013
Setting: 133 centres in North and South America, Europe and Asia
Participants Randomised: 966 participants (mean age 46 years, 635 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Immunosuppression, active infection, uncontrolled cardiovascular disorder,
uncontrolled diabetes, uncontrolled hypertension, had past history of malignant
tumours
• Had received anti IL17 drug
Dropouts and withdrawals
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Mrowietz SCULPTURE, 2015 (Continued)
• 38/966 (4%);
• AEs: secukinumab 300 (9), secukinumab 150 (8)
• Lack of efficacy: secukinumab 300 (0), secukinumab 150 (1)
• Withdrew consent: secukinumab 300 (8), secukinumab 150 (6)
• Lost to follow-up: secukinumab 300 (3), secukinumab 150 (2)
• Protocol deviation: secukinumab 300 (0), secukinumab 150 (1)
Interventions Intervention
A. Secukinumab (n = 482), SC, 150 mg weeks 0, 1, 2, 3 then monthly
Control intervention
B. Secukinumab (n = 484), SC, 300 mg weeks 0, 1, 2, 3 then monthly
Outcomes Assessments at 52 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 50/75/90 week 12
• IGA 0/1
• DLQI
• AEs
Notes Funding source: quote (p 27) “Study funded by Novartis Pharma...Novartis conducted
data analyses, and all authors had access to data”
Declarations of interest (p 27): “The authors received writing and editorial support from
Barry Weichman and Jinling Wu in the preparation of the manuscript from BioScience
Communications, New York, NY, supported by Novartis. Dr Mrowietz has served as
advisor and/or received speaker honoraria and/or received grants and/or participated in
clinical trials for Abbott/AbbVie, Almirall, Amgen, BASF, Biogen Idec, Celgene, Cen-
tocor, Eli Lilly, Forward Pharma, Galderma, Janssen, Leo Pharma, Medac, MSD, Mil-
tenyi Biotech, Novartis, Pfizer, Teva, VBL, and Xenoport. Dr Leonardi has served as
consultant and/or investigator and/or participated in a speaker’s bureau for AbbVie,
Amgen, Celgene, Dermira, Eli Lilly, Galderma, Janssen, Leo Pharma, Merck, Novartis,
Pfizer, Sandoz, Stiefel, and UCB. Dr Girolomoni has received advisory/speaker hono-
raria and/or research funding from AbbVie, Almirall, Boehringer Ingelheim, Celgene,
Dompe, Eli Lilly, Galderma, Janssen, Leo Pharma, Merck Serono, Maruho, MSD, No-
vartis, and Pfizer. Dr Toth has served as investigator for Novartis, Amgen, Eli Lilly, John-
son & Johnson, Abbott, Celgene, Merck, Galderma, and Leo Pharma. Dr Morita has
served as consultant and/or paid speaker for and/or participated in psoriasis clinical tri-
als sponsored by AbbVie, Mitsubishi Tanabe, Janssen, Novartis, Eli Lilly, Kyowa-Kirin,
Leo Pharma, Maruho, and MSD. Dr Szepietowski has served as advisor and/or received
speakers honoraria and/or participated in clinical trials for Abbott/AbbVie, Actavis, Am-
gen, BASF, Astellas, Berlin-Chemie/Menarini, Biogenetica International Laboratories,
Centocor, Fresenius, Janssen, Leo Pharma, Mitsubishi Tanabe, Novartis, Pierre-Fabre,
Takeda, Toray Corporation, and Vichy. Dr Regnault, Ms Thurston, and Dr Papavassilis
are employees of and/or own stock in Novartis. Dr Balki has no conflicts of interest to
declare.”
Risk of bias
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Mrowietz SCULPTURE, 2015 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 28): “were randomised”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 28): “administered via 2 150-mg
SC injections or one 150-mg SC and one
placebo SC injection respectively”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 28): “administered via 2 150-mg
SC injections or one 150-mg SC and one
placebo SC injection respectively”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 966, analysed 966
Management of missing data:
Quote (p 29): “Missing values for PASI or
IGA 2011 modified version responses were
imputed as non response regardless of the
reason for missing data”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01406938)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Nakagawa 2016
Methods RCT, active/placebo-controlled, double blind
Date of study: October 2012- March 2013
Setting: multicentre (56) in Japan
Participants Randomised: 151 participants (mean age 45 years, 120 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10), age 20-70
years
Exclusion criteria
• Past history of malignant tumours, active infection, uncontrolled cardiovascular
disorder
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Nakagawa 2016 (Continued)
• Had received anti IL17 (RA) treatment
Dropouts and withdrawals
• 6/151 (4%); brodalumab 70 group (2), brodalumab 140 group (0), brodalumab
210 group (0), placebo group (4)
• AEs: brodalumab 70 group (1)
• Full consent withdrawal: brodalumab 70 group (1), placebo group (1)
• Symptoms worsening: placebo group (1)
Interventions Intervention
A. Brodalumab (n = 39), SC, 70 mg, 2 injections week 0, 1 injection eow
Control intervention
B. Brodalumab (n = 37), SC, 140 mg, 2 injections week 0, 1 injection eow
C. Brodalumab (n = 37), SC, 210 mg, 2 injections week 0, 1 injection eow
D. Placebo (n = 38), orally (same drug administration)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• % improvement in PASI
Secondary outcomes of the trial
• PASI 75
• PGA 0/1
• PASI 90/100
• AEs
Notes Funding source:
Quote (p 51) “The study was supported by Kyowa Hakko Kirin Co., Ltd.”
Declarations of interest (p 51): “H. Nakagawa is a consultant and/or received research
grants and/or speaker honoraria from for Kyowa Hakko Kirin Co., Ltd., AbbVie, Mit-
subishi-Tanabe Pharma, Janssen Pharmaceutical K.K., Novartis Pharma K.K., Eli Lilly
Japan K.K., LEO Pharma Maruho Corporation Limited and MSD K.K.H. Niiro has
no conflict of interest to declare. K. Ootaki is an employee of Kyowa Hakko Kirin Co.,
Ltd.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 45): “were randomised to re-
ceive…”
Comment: not stated
Allocation concealment (selection bias) Unclear risk Quote (p 45): “were randomised to re-
ceive…”
Comment: not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (p 51): “double-blind…”
Comment: not stated
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Nakagawa 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No description of themethod used to guar-
antee blinding of outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 151, analysed 151
Comment: no supplementary explanation
regarding the management of missing data
Selective reporting (reporting bias) High risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01748539)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared tohave been reported except for par-
ticipant-reported outcome
Nugteren-Huying 1990
Methods RCT, active/placebo-controlled, double blind
Date of study: not stated
Setting: multicentre in the Netherlands
Participants Randomised: 39 participants (mean age 44 years, 27 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 10)
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had uncontrolled cardiovascular disorder
Dropouts and withdrawals
• 5/39 (12.8%)
• Time and reason: not stated
Interventions Intervention
A. Dimethylfumarate (n = 12), orally, 120 mg, gradual increase 1-6 tablets, once a day,
16 weeks
Control intervention
B. Octyl hydrogen fumarate (n = 10), orally, 284 mg, gradual increase 1-6 tablets, once
a day, 16 weeks
C. Placebo (n = 12), orally, once a day, 16 weeks
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• BSA
Secondary outcomes of the trial
• Score of infiltration and scaling
• Side effects
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Nugteren-Huying 1990 (Continued)
Notes Funding source: not stated
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 331): “The patients were ran-
domly assigned...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 331): “The patients were ran-
domly assigned...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 331): “The double-blind treat-
ment lasted 16 weeks for each patients...
All tablets (provided by Fumapharm AG,
Muri, Switzerland) had the same appear-
ance, size and colour”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 331): “The double-blind treat-
ment lasted 16 weeks for each patients...
All tablets (provided by Fumapharm AG,
Muri, Switzerland) had the same appear-
ance, size and color”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 39, analysed 34
Comment: no description of the method
used to perform analyses of the primary
outcome and to manage missing data
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
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Olsen 1989
Methods RCT, placebo-controlled, double-blind trial
Date of study: not stated
Setting: not stated
Participants Randomised: 15 participants, age range 23-72 years, 11 male
Inclusion criteria
• Moderate-severe psoriasis
• BSA ≥ 10
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
Dropouts and withdrawals
• 3/15 (20%)
• Disease flare-up (n = 3)
Interventions Intervention
A. Acitretin (n = 10), orally, 25/50 mg, daily, 8 weeks
Control intervention
B. Placebo (n = 5), orally, daily, 8 weeks
Outcomes Assessments at 8 weeks
Primary outcomes of the trial
• Not clearly defined
Secondary outcomes of the trial
• Body surface area
• Scale
• Side effects
Notes Funding by Hoffman-La Roche Inc
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 681): “Patients were assigned to.
.. in a random, double-blind fashion”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 681): “Patients were assigned to.
.. in a random, double-blind fashion”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 681): “Patients were assigned to.
.. in a random, double-blind fashion”
Comment: visible adverse effects of ac-
itretin such as cheilitis were visible
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Olsen 1989 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 681): “Patients were assigned to.
.. in a random, double-blind fashion”
Comment: visible adverse effects of ac-
itretin such as cheilitis were visible
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 15 included / Number of patients analysed
not stated
Comment: no description of the methods
used to perform the efficacy analyses and
to manage the missing data
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section were reported
Ortonne 2013
Methods RCT, active-controlled, open-label study
Date of study: 21 September 2007-August 2009
Setting: 17 centres in Austria, France, Greece and Italy
Participants Randomised: 72 participants randomised, 69 analysed (mean age 46 years, 50 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• PASI ≥ 10, PGA moderate or severe, BSA > 10, DLQI > 10
• Age 18-70 years
• Overall NAPSI > 14
Exclusion criteria
• TB infection; recent serious infection within 1 month of etanercept
administration or active infection at screening; or known history of HIV infection.
• Prior exposure to any biologic treatment was prohibited
Dropouts and withdrawals
• 12/72 (17%), BIW/QW group (7), QW/QW group (5)
• AEs: BIW/QW group (2), QW/QW group (1)
• Participants’ request or withdrawal request: BIW/QW group (1), QW/QW group
(4)
• Death: BIW/QW group (1)
• Other: BIW/QW group (3)
Interventions Intervention
A. Etanercept twice-a-week/once-a-week group (n = 38), 50 mg SC twice a week for 12
weeks then 50 mg once a week to week 24
Control intervention
B. Etanercept once-a-week/once-a-week group (n = 34), 50 mg SC injections once a
week for the full 24-week treatment period
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Ortonne 2013 (Continued)
Outcomes Assessments at 24 weeks
Primary outcomes of the trial
• NAPSI
Secondary outcomes of the trial
• NAPSI 50/75
• PASI 50/75
• PGA0/1
• DLQI
• AEs
Notes Funding source, quote (p 1080): “TWyeth Research, which was acquired by Pfizer in
October 2009, sponsored this clinical trial and was responsible for the collection and
analysis of data. Editorial medical writing assistance was funded by Pfizer Inc.”
Declarations of interest (p 1080):“ J.P.O. has been an investigator or consultant for Scher-
ing-Plough, Abbott, Merck-Serono, Centocor, Pfizer, Janssen-Cilag, Meda-Pharma,
Pierre-Fabre, Galderma and Leo-Pharma. C.P. has been an investigator or consultant for
Abbott, Amgen, Celgene, Janssen Cilag, Leo Pharma, Novartis and Pfizer Inc. E.B. has
no conflicts of interest. V.M., G.G., Y.B. and J.M.G. are employees of Pfizer Inc.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 1081): “Patients were ran-
domised by the investigator or other autho-
rized person using an automatic online en-
rolment system in a 1:1 ratio”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 1081): “Patients were ran-
domised by the investigator or other autho-
rized person using an automatic online en-
rolment system in a 1:1 ratio”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 1081): “This was a multicen-
ter, multinational, randomised, open-label
study”
Comment: not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 1081): “This was a multicen-
ter, multinational, randomised, open-label
study”
Comment: not blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 72 included/69 analysed
Quote (p 1082): “All efficacy analyses
were based on the modified intent-to treat
(mITT) population, which was defined
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Ortonne 2013 (Continued)
as all patients who had received one or
more doses of ETN and had baseline and
post baseline data...The MMRM and GEE
models have been developed for the anal-
ysis of longitudinal categorical data and to
handle missing data without any imputa-
tion; this kind of model is preferred to the
last-observation carried forward approach
for analysis of longitudinal data”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment: The protocol for the study was
available on ClinicalTrials.gov
(NCT00581100)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Papp 2005
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: 50 centres in USA, Canada & Western Europe
Participants Randomised: 611 participants (mean age 45 years, male 382 out of 583 participants
who received 1 dose)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 10, BSA ≥ 10%, age ≥ 18
years)
• Non-response to topical treatment
• Only 1 previous systemic treatment allowed
Exclusion criteria
• Kidney insufficiency, liver insufficiency
• Had received biologics (antiTNF)
• Had an active infection
Dropouts and withdrawals
• 52/611 (8.5%)
• Placebo (26): refusal (7) eligibility (6) lost to follow-up (6) AE (2) lack efficacy (4)
protocol requirement (1)
• Etanercept 25 (13): refusal (5) eligibility (4) AE (3) lack efficacy (1)
• Etanercept 50 (13): refusal (5) eligibility (2) lost to follow-up (3) AE (2) lack
efficacy (1)
Interventions Intervention
A. Etanercept (n = 204), SC, 25 mg twice a week, 12 weeks
Control intervention
B. Etanercept (n = 203), SC , 50 mg twice a week, 12 weeks
C. Placebo (n = 204), SC, twice a week, 12 weeks
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Papp 2005 (Continued)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• Proportion of participants with PGA score of 0 or 1 at Week 12
• PASI 50 at Week 12
• PASI 90 at Week 12
• Percentage improvement from baseline at week 12 to PASI
• AEs
• QoL
Notes Funding source, quote (p 1304): ”This study was supported by Immunex Corporation
(Seattle, WA, U.S.A)“
Declarations of interest: (p 1304) S.T. has received research support from Amgen; C.E.
M.G. has been a paid consultant for Wyeth and Amgen; A.M.N and R.Z. are both full-
time employees of Amgen.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 1305): “Patients were randomly
assigned (using an Interactive Voice Re-
sponse system) to receive placebo or etan-
ercept)
Comment: not stated
Allocation concealment (selection bias) Low risk Quote (p 1305): ”Patients were randomly
assigned (using an Interactive Voice Re-
sponse system) to receive placebo or etan-
ercept)
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1305): “ the patients, study site
personnel and all sponsor representatives
remained blinded to the initial randomisa-
tion treatment groups...”
Comment: placebo-controlled, probably
done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1305): “ the patients, study site
personnel and all sponsor representatives
remained blinded to the initial randomisa-
tion treatment groups...”
Comment: placebo-controlled, probably
done
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Papp 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 611 randomised participants, 583 analysed
(28 participants did not receive the treat-
ment and were excluded from the analy-
ses). Sensitivity analysis (Table 2) were per-
formed with the 611 randomised partici-
pants
Management ofmissing data: quote “In the
analyses, missing post baseline efficacy data
were imputed using last observation car-
ried forward. In addition, a sensitivity anal-
ysis was performed on the binary efficacy
endpoints to evaluate the robustness of the
primary analysis. This sensitivity analysis
included all randomised patients. In addi-
tion, rather than using LOCF imputation
patients with missing data at a given visit
were assumed to have not met the response
criteria for that endpoint”
Comment: the main result (primary out-
come) was not an ITT analysis
Selective reporting (reporting bias) High risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported except for the results of participant-
reported endpoints summarized in a sepa-
rate publication
Papp 2012
Methods RCT, placebo-controlled, double-blind trial
Date of study: December 2009-April 2010
Location: 23 centres worldwide
Participants Randomised: 198 participants (mean age 42 years, 107 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• PASI ≥ 12, BSA > 10%
• Age 18-70 years
Exclusion criteria
• Pregnancy, immunosuppression
• Had past history of malignant tumours
Dropouts and withdrawals
• 10/198 (5%)
• Brodalumab 70: ineligible (1)
• Brodalumab 140: decision (1)
• Brodalumab 210: (3): deviation (1) consent withdrawn (1) decision (1)
• Brodalumab 280: (2): ineligible (1), AE (1)
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Papp 2012 (Continued)
• Placebo (3): ineligible (1), consent withdrawn (2)
Interventions Intervention
A. Brodalumab 70 (n = 39), SC, 70 mg, day 1-weeks 1, 2, 4, 6, 8, 10, 10 weeks
Control intervention
B. Brodalumab 140 (n = 39), SC, 140 mg, day 1 and weeks 1, 2, 4, 6, 8, 10, 10 weeks
C. Brodalumab 210 (n = 40), SC, 210 mg, day 1 and weeks 1, 2, 4, 6, 8, 10, 10 weeks
D. Brodalumab 280 (n = 42), SC, 280 mg, day 1 and weeks 1, 2, 4, 6, 8, 10, 10 weeks
E. Placebo (n = 38), SC, day 1 and weeks 1, 2, 4, 6, 8, 10, 10 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI75
Secondary outcomes of the trial
• PASI 50/90/100 at week 12
• BSA
• PGA
• DLQI
• AEs
Notes Funding source, quote (p 1182): “The study was funded by Amgen”
Declarations of interest (p 1188-89): “Dr. Papp reports receiving consulting fees from
Abbott, Amgen, Astellas, Celgene, Centocor, Eli Lilly, Galderma, Graceway Pharma-
ceuticals, Janssen, Johnson & Johnson, Merck, Norvartis, Pfizer, and UCB, lecture fees
from Abbott, Amgen, Astellas, Celgene, Centocor, Galderma, Janssen, LEO Pharma,
Merck, Novartis, Pfizer, and Stiefel, and grant support from Abbott, Amgen, Astellas,
Celgene, Centocor, Eli Lilly, Galderma, Glaxo-SmithKline, Graceway Pharmaceuticals,
Janssen, Johnson & Johnson, Medimmune, Merck, Novartis, Pfizer, Stiefel, and UCB;
Dr. Leonardi, receiving consulting fees from Abbott, Amgen, Centocor, Eli Lilly, and
Pfizer, lecture fees from Abbott and Amgen, and investigator fees from Abbott, Am-
gen, Celgene, Centocor, Galderma, GlaxoSmithKline, Incyte, Maruho, Novartis, Novo
Nordisk, Pfizer, Schering-Plough (now Merck), Sirtris, Stiefel, Vascular Biogenics, and
Wyeth (now Pfizer); Dr. Menter, receiving consulting fees fromAbbott, Amgen, Astellas,
Centocor, Galderma, Genentech, and Wyeth, lecture fees from Abbott, Amgen, Cento-
cor, Galderma, and Wyeth, and fees for expert testimony from Galderma; Dr. Krueger,
receiving consulting fees from Centocor, Eli Lilly, and Pfizer and grant support from
Amgen, Centocor, Eli Lilly, Merck, and Pfizer; and Drs. Krikorian, Aras, Li, Russell,
Thompson, and Baumgartner being full-time employees of Amgen. No other potential
conflict of interest was relevant to this article was reported.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (protocol p 30): “Randomization:
IVRS will be used to randomise subjects
into the study. The randomisation list will
be generated by Amgen using a permuted
block design within each of 4 strata based
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Papp 2012 (Continued)
on BMI at baseline, and participation in
the PK study”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (protocol p 30): “Randomization:
IVRS will be used to randomise subjects
into the study
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (protocol p 24 & 50): “double-
blind placebo controlled... Subjects ran-
domised to active drug will receive addi-
tional placebo injections as necessary to
maintain the blind”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (protocol p 39): “PASI assessments
will be performedby a blinded assessor. The
blinded assessor will be a healthcare pro-
fessional who has been certified as trained
with the standard PASI”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 198 included/198 analysed
Quote (p 1183): “The analyses of efficacy
endpoints were performed on data from
all patients who underwent randomisation
(full set analysis), according to the inten-
tion-to-treat principle... Missing data were
handled bymeans of the baseline-value-car-
ried-forward method or the imputation of
no response”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00307437)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Papp 2012a
Methods RCT, placebo-controlled, double blind
Date of study: July 2008-August 2009
Location: 42 centres in USA, Canada
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Papp 2012a (Continued)
Participants Randomised: 197 participants (tofacitinib 2 mg (49) mean age 46 years, 29 male;
tofacitinib 5 (49) mean age 44 years, 29 male; tofacitinib 15 (49) mean age 44 years, 31
male; placebo (n = 50) mean age 44 years, 36 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 13, BSA ≥ 15%), age ≥ 18
• Number of allowed previous biologic treatments: any
Exclusion criteria
• Had an active infection
• Had past history of malignant tumour (with the exception of adequately treated
or excised basal cell or squamous cell carcinoma, or cervical carcinoma in situ)
Dropouts and withdrawals
• 48/197 (24%);
• Tofacitinib 2 mg (11): AE (1), lack efficiency (2), lost to follow-up (4), decision
(3), other (1)
• Tofacitinib 5 mg (11): AE (2), lack efficiency (3), lost to follow-up (2), decision
(4)
• Tofacitinib 15 mg (6): AE (3), lack efficiency (1), other (1), decision (1)
• Placebo (20): AE (3), lack efficiency (9), lost to follow-up (1), decision (7)
Interventions Intervention
A. Tofacitinib (n = 49), orally, 2 mg, twice a day, 12 weeks
Control intervention
B. Tofacitinib, (n = 49), orally, 5 mg, twice a day, 12 weeks
C. Tofacitinib (n = 49), orally, 15 mg, twice a day, 12 weeks
D. Placebo (n = 50), orally, twice a day, 12 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• Safety
• Proportion of participants achieving a PASI 50 response (weeks 2, 4, 8, 12, 14
and 16)
• Proportion of participants achieving a PASI 90 response week 12
• Actual and change from baseline in PASI and PASI component scores baseline/
day 1 and weeks 2, 4, 8, 12, 14 and 16
• Proportion of participants with PGA of clear/almost clear, weeks 2, 4, 8, 12, 14
and 16
• Proportion of participants achieving a PASI 75 response (weeks 2, 4, 8, 14 and 16)
Notes Funding source, quote (p 668): ”This study was funded by Pfizer Inc“
Declarations of interest (appendix): ”K.A.P. has been a principal investigator, an advisor
or consultant, a Scientific Officer, member of a Scientific Advisory Board and a speaker
for the following groups: Abbott, Amgen, Astellas, Celgene, Centocor-Ortho Biotech,
Incyte, Isotechnika, Janssen, Lilly, Medimmune, Merck, Pfizer Inc. and Novartis. A.
M. has been on the Advisory Board, been a consultant to, been an investigator for,
been a speaker for, obtained a research grant from, or obtained honoraria from the
following groups: Abbott, Allergan, Amgen, Astellas, Asubio, Celgene, Centocor,DUSA,
Eli Lilly, Galderma, Genentech, Novartis, Novo Nordisk, Pfizer Inc., Promius, Stiefel,
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Syntrix Biosystems, Warner Chilcott and Wyeth. B.S. has been a principal investigator,
an advisor or consultant, or a speaker for the following groups: Abbot, Amgen, Celgene,
Centocor-Ortho Biotech, Janssen, Pfizer Inc., Maruho and Novartis. R.G.L. has been
an investigator, served as a principal investigator or on the Advisory Board, or been a
speaker for the following groups: Abbott, Amgen, CentocorOrtho Biotech, Pfizer Inc.,
Novartis and Celgene. R.W., S.K., H.T., P.G. and M.B. are employees of Pfizer Inc. J.A.
H. was a full-time employee of Pfizer Inc. during the conduct and reporting of the study
and now works at Novartis Pharma AG, Basel, Switzerland. “
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 669): ”A computer-generated
central randomisation schema was imple-
mented in an automated web telephone
system.“
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 669): ”A computer-generated
central randomisation schema was imple-
mented in an automatedTreatment identi-
ficationwas concealed by use of study drugs
that were identical in labelling, packaging,
appearance and odour“
web telephone system.”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 669): “Patients, investigational
site staff, the Pfizer study team and data an-
alysts were blinded to treatment from the
time of randomisation until database lock..
. Treatment identification was concealed by
use of study drugs that were identical in la-
belling, packaging, appearance and odour”
Comment: probably one
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 669): “Patients, investigational
site staff, the Pfizer study team and data an-
alysts were blinded to treatment from the
time of randomisation until database lock..
. Treatment identification was concealed by
use of study drugs that were identical in la-
belling, packaging, appearance and odour”
Comment: probably one
Incomplete outcome data (attrition bias)
All outcomes
Low risk 197 included / 195 analysed
Quote (p 670): “The full analysis set in-
cluded all randomised patients who re-
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ceived one or more doses of investiga-
tional drug...This population ... represents
a modified intent-to-treat analysis... Pa-
tients with missing values had the missing
values imputed but last observation carried
forward.... As a sensitivity analysis the pa-
tients [with missing values] were also con-
sidered nonresponders (NRI)”
Comment: mITT and two patients out of
197 not analysed
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00678210)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Papp 2012b
Methods RCT, active/placebo-controlled, double blind
Date of study: September 2008-October 2009
Location: 35 centres in Canada and USA
Participants Randomised: 352 participants (mean age 44 years, 221 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10%)
• Age ≥ 18 years
Exclusion criteria
• Had a history of, or present, significant disease, including Mycobacterium TB or
HIV infection
• Had a positive screening test for hepatitis B or C
• Pregnant or breastfeeding
Dropouts and withdrawals
• 65/352 (11%) at 16w;
• Apremilast 30 twice daily: (18): AE (10), lack efficacy (2), withdrew consent (4),
lost to follow-up (1), Other (1)
• Apremilast other (31): AE (9), lack efficacy (5), withdrew consent (8), protocol
violation (7), other (2)
• Placebo (16): AE (5), lack efficacy (4), withdrew consent (2), death (1), lost to
follow up (2), protocol deviation (1), other (1)
Interventions Intervention
A. Apremilast (n = 88), orally, 30 mg, twice a day, 16 weeks
Control intervention
B. Apremilast (n = 176), orally, 10-20 mg twice a day, 16 weeks
C. Placebo (n = 88), orally, twice a day 16 weeks
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Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA 0 or 1
• PASI 50/90
• DLQI
• SF36
Notes Funding source quote (p 738): “Funding Celgene Corporation”
Declarations of interest quote (p 745): “KP has served as an investigator for Abbott,
Amgen, Celgene, Centocor, Galderma, Incyte, Isotechnika, Janssen, Lilly, Medimmune,
Merck,Novartis, and Pfizer; an adviser for Abbott, Amgen, Astellas, BMS, Celgene, Cen-
tocor, Galderma, Incyte, Isotechnika, Janssen, Johnson & Johnson, Lilly, Medimmune,
Merck, Novartis, Pfizer, and UCB; and a speaker for Abbott, Amgen, Astellas, Celgene,
Centocor, Isotechnika, Janssen, Novartis, and Pfizer. JCC has served as an investigator
for Celgene, Centocor, Novartis, and Pfizer; as a speaker for Centocor and Abbott; and
as an adviser for Pfizer, Abbott, and Novartis. LR has been a paid investigator for doing
clinical trials for Amgen, Genentech, Abbott, Centocor, Basilea, Leo, Isotechnika, Stiefel,
GSK, Galderma, 3-M, Serono, Novartis, Astellas, UCB, Celgene, Johnson & Johnson,
and Pfizer. HS has served as an investigator for Abbott, Centocor, Celgene, Amgen,
and Pfizer; as a speaker for Abbott and Centocor; and as an adviser for Centocor. RGL
has served as an investigator for Abbott, Centocor, Celgene, Amgen, Pfizer, Johnson
& Johnson/Ortho Biotech, and Novartis; as a speaker for Abbott, Centocor, Amgen,
Pfizer, Johnson & Johnson/Ortho Biotech, and Novartis; and as an adviser for Abbott,
Centocor, Celgene, Amgen, Pfizer, Johnson & Johnson/Ortho Biotech, and Novartis.
RTM has served as an investigator for Abbott, Centocor, Celgene, Amgen, Novartis,
Lilly, Pfizer, Allergan, and Galderma; as a speaker for Centocor and Amgen; and as an
adviser for Centocor. CH and RMD are employees of Celgene Corporation.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 739): “Eligible patients were ran-
domly assigned in a 1:1:1:1 ratio to oral
apremilast 10 mg twice daily, apremilast
20 mg twice daily, apremilast 30 mg twice
daily, or placebo, with a permuted-block
randomisation list generated by an inter-
active voice response system (ClinPhone,
East Windsor, NJ, USA).”
Comment: clearly described
Allocation concealment (selection bias) Low risk Quote (p 739): “Eligible patients were ran-
domly assigned in a 1:1:1:1 ratio to oral
apremilast 10 mg twice daily, apremilast
20 mg twice daily, apremilast 30 mg twice
daily, or placebo, with a permuted-block
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randomisation list generated by an inter-
active voice response system (ClinPhone,
East Windsor, NJ, USA).”
Comment: clearly described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 739): “Treatment was double-
blind for the first 16 weeks of the 24-week
treatment phase.”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 739): “Treatment was double-
blind for the first 16 weeks of the 24-week
treatment phase.”
Comment: probably done, placebo-con-
trolled
Incomplete outcome data (attrition bias)
All outcomes
Low risk 352 included / 352 analysed
Quote (p 740): “Efficacy data were assessed
by intention to treat. Missing data were
handled with the last-observation carried-
forward method.”
Comment: number of lost to follow-up and
reasons comparable across group
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00773734)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Papp 2013a
Methods RCT, placebo-controlled, double blind trial
Date of study: March 2010-February 2011
Location: 19 international centres
Participants Randomised: 125 participants (mean age 46 years, 91 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• PASI ≥ 12, IGA ≥ 3, BSA ≥ 10%
• Age ≥ 18 years
• Non-response to topical treatment
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Pregnancy
Dropouts and withdrawals
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• 47/125 (38%) at 36 weeks: secukinumab 25 (15): secukinumab 75 (10);
secukinumab 225 (4); secukinumab 450 (7); placebo (11)
• Unsatisfactory therapeutic effect: secukinumab 25 (4); secukinumab 75 (6);
secukinumab 225 (2); secukinumab 450 (0); placebo (6)
• Withdrew consent: secukinumab 25 (8); secukinumab 75 (2); secukinumab 225
(1); secukinumab 450 (2); placebo (3)
• Administrative problems: secukinumab 25 (1); secukinumab 75 (1); secukinumab
225 (0); secukinumab 450 (2); placebo (1)
• Lost to follow-up: secukinumab 25 (1); secukinumab 75 (0); secukinumab 225
(1); secukinumab 450 (2); placebo (0)
• AEs: secukinumab 25 (1); secukinumab 75 (1); secukinumab 225 (0);
secukinumab 450 (1); placebo (0)
• Death: secukinumab 25 (0); secukinumab 75 (0); secukinumab 225 (0);
secukinumab 450 (0); placebo (1)
Interventions Intervention
A. Secukinumab (n = 29), SC, 25 mg, 0, 4, 8 weeks, 12 weeks
Control intervention
B. Secukinumab (n = 26), SC, 3 x 25 mg, 0, 4, 8 weeks, 12 weeks
C. Secukinumab (n = 21), SC, 3 x 75 mg, 0, 4, 8 weeks, 12 weeks
D. Secukinumab (n = 27), SC, 3 x 150 mg, 0, 4, 8 weeks, 12 weeks
E. Placebo (n = 22), SC, 0, 4, 8 weeks, 12 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• IGA 12 weeks
• PASI 50/90 12 weeks
• Time to relapse
• Effect on PASI over time
• ECG
• AE
Notes Funding source (p412): “Novartis Pharm AG, Basel, Switzerland”
Declarations of interest (Appendix): “K.A.P. has received honoraria for lecturing at in-
dustry-sponsored meetings and has received industry funding for presentations and con-
sultation at national and international meetings; he has also received research grants
from and been a paid consultant to Novartis and other pharmaceutical companies; has
served as a scientific officer for pharmaceutical and biotechnology corporations; and is a
participant on clinical, scientific and corporate advisory boards. R.G.L. has been a mem-
ber of scientific advisory boards and served as a clinical investigator for Abbott, Amgen,
Celgene, CentocorJohnson & Johnson, Eli Lilly, Fujisawa, Novartis and Pfizer, and has
served as a speaker for Abbott, Amgen, CentocorJohnson & Johnson, Fujisawa and No-
vartis. B.S. has consulted for Novartis and several other pharmaceutical companies; he
has been a member of an advisory board for Novartis and several other pharmaceutical
companies. S.H., H.J.T., C.P. and H.B.R. are full-time employees of and own stock in
Novartis. M.A., D.R.B. and P.K. declare no conflicts of interest.”
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 414): “The randomisation num-
bers were generated by an interactive voice
response provider using a validated auto-
mated system”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 414): “The randomisation num-
bers were generated by an interactive voice
response provider using a validated auto-
mated system”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 413 & 414): “Double-blind,
placebo controlled...Patients, investigator
staff, persons performing the assessments
and data analysts were blinded ... remained
blind until final database lock”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 413 & 414): “Double-blind,
placebo controlled...Patients, investigator
staff, persons performing the assessments
and data analysts were blinded ... remained
blind until final database lock”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
High risk 125 included/125 analysed
Quote (p 415): “The full analysis set con-
sisted of all patients who were randomised.
.. The missing score was imputed by carry-
ing forward the last non missing post base-
line PASI”
Comment: very high number of with-
drawals (38%)
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01071252)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
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Methods RCT, active/placebo-controlled, double blind
Date of study: April 2006-May 2007
Location: multicentre (30) in Canada, the Czech Republic, and Germany
Participants Randomised: 260 participants (mean age 46 years, 163 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA > 10%)
• Age ≥ 18 years
Exclusion criteria
• History of clinically significant medical or psychiatric diseases
• Pregnancy or lactation
• History of active Mycobacterium TB infection
• HIV, hepatitis B or C, history of malignancy within 5 years of screening or
evidence of skin conditions
• Current erythrodermic, guttate or pustular psoriasis
Dropouts and withdrawals
• 47/260 (18%) at 12w;
• Apremilast (28): AE (8), lack efficiency (8), withdrew consent (4), lost to follow-
up (3), protocol violation (3), other (2)
• Placebo (19): AE (7), lack efficiency (5), withdrew consent (2), lost to follow-up
(1), protocol violation (2), other(2)
Interventions Intervention
A. Apremilast (n = 173), orally, 10-20 mg, twice a day, 12 weeks
Control intervention
B. Placebo (n = 87)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA
• PASI 50/90
• BSA
• AEs
Notes Funding source quote (p 27): “This study was sponsored by Celgene Corporation”
Declarations of interest (p27): “Dr Papp is a consultant and investigator for Celgene
Corporation, Abbott, Amgen, Centocor, Janssen-Ortho, Merck, Novartis and Pfizer
and an investigator for Astellas, Leo Pharma and Galderma, receiving honoraria and
grants. Dr Kaufmann is an investigator for Abbott, Centocor, Leo, Novartis, Wyeth and
Celgene Corporation, but has not received financial compensation. The Department of
Dermatology received investigator fees for performing the clinical trials. He served as a
speaker for Basilea and Allmiral and received honoraria from each. Dr Thac i is on the
advisory board of and is a consultant, investigator and speaker for Abbott, Leo, Novartis,
Pfizer, Biogen-Idec, Janssen-Cilag and MSD, and received honoraria from each. He is
also an investigator for Celgene Corporation. The Department of Dermatology received
honoraria compensation for conducting studies; no direct compensation was received.
Ms Hu receives a salary as an employee of Celgene Corporation. Ms Sutherland receives
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a salary, stocks and stock options as an employee of Celgene Corporation. Dr Rohane
received a salary and stock options as a former employee of Celgene Corporation. ”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 377): “ investigators randomised
subjects 1 : 1 : 1 to double-blind treatments
for 12 weeks with placebo, apremilast 20
mg QD or apremilast 20 mg twice daily”
Comment: no description of themethod to
guarantee the random sequence generation
Allocation concealment (selection bias) Low risk Quote (p 377): “Using an interactive voice
response system, investigators randomised
subjects 1 : 1 : 1 to double-blind treat-
ments”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 377): “One capsule of placebo or
apremilast was taken orally in the morning
before meals, and one capsule of placebo or
apremilast was taken in the evening”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 377): “One capsule of placebo or
apremilast was taken orally in the morning
before meals, and one capsule of placebo or
apremilast was taken in the evening”
Comment: probably done, placebo con-
trolled
Incomplete outcome data (attrition bias)
All outcomes
High risk 260 included / 260 analysed
Management of missing data were not
stated and substantial number lost to fol-
low-up (18%)
Selective reporting (reporting bias) High risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00606450)
The pre-specified outcomes listed on Clin-
icalTrials.gov were not detailed, the choice
of the primary outcome was not clearly de-
fined. In the methods section, PASI 75 was
defined as the primary outcome, no QoL
outcomes were listed in the methods sec-
tion although they were in the protocol on
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clinicaltrilas.gov
Papp 2015a
Methods RCT, active/placebo-controlled, double blind
Date of study: November 2010-June 2012
Location: 64 centres in Europe, Asia & North America
Participants Randomised: 355 participants (mean age 45 years, 270 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10, PGA
moderate, marked or severe), age ≥ 18 years
Exclusion criteria
• Active infection, past history of malignant tumours, active infection, kidney or
liver insufficiency, uncontrolled cardiovascular disorder, uncontrolled diabetes,
uncontrolled hypertension
• Had received ≥ 2 TNF alpha antagonists with discontinuation owing to lack of
efficacy
• Had received anti IL12/23
Dropouts and withdrawals
• 15/355 (4.5%)
• AEs: tildrakizumab 5 (1), tildrakizumab 25 (2), tildrakizumab 100 (1),
tildrakizumab 200 (1), placebo (1)
• Withdrew consent: tildrakizumab 5 (0), tildrakizumab 25 (3), tildrakizumab 100
(0), tildrakizumab 200 (0), placebo (4)
• Protocol noncompliance: tildrakizumab 5 (0), tildrakizumab 25 (0),
tildrakizumab 100 (0), tildrakizumab 200 (1), placebo (0)
• Did not meet protocol eligibility: tildrakizumab 5 (1), tildrakizumab 25 (0),
tildrakizumab 100 (0), tildrakizumab 200 (0), placebo (1)
Interventions Intervention
A. Tildrakizumab (n = 42), SC, 5 mg weeks 0, 4, every 12 weeks
Control intervention
B. Tildrakizumab (n = 92), SC, 15 mg weeks 0, 4, every 12 weeks
C. Tildrakizumab (n = 89), SC, 50 mg weeks 0, 4, every 12 weeks
D. Tildrakizumab (n = 86), SC, 100 mg weeks 0, 4, every 12 weeks
E. Tildrakizumab (n = 46), SC, 200 mg weeks 0, 4, every 12 weeks
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 90
• PASI 75 at week 12
• PGA 0/1
• DLQI
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Notes Funding source:
Quote (p 930): “This study was funded by Merck & Co, nc., Kenilworth, NJ, USA”
Declarations of interest (Appendix 1): ”E.P.B., A.M., Q.L., Y.Z. and R.S. are current or
former employees of Merck & Co., Inc. K.P. has served as a consultant, advisory board
member and/or investigator for Abbott (AbbVie), Amgen, Biogen Idec, Boehringer In-
gelheim, Celgene, Centocor, Foreward Pharma, Galderma, Genentech, Incyte, Isotech-
nika, Janssen, Kyowa Kirin, LEO Pharma, Lilly, Medimmune, Merck Sharp Dome,
Merck Serono, Novartis, Regeneron, Stiefel, Takeda, Pfizer and USB. D.T. has served
as a consultant, advisory board member and/or investigator for Abbott (AbbVie), Almi-
ral, Amgen, Astellas, Biogen Idec, Boehringer Ingelheim, Celgene, Dignity, Forward
Pharma, Galderma, GlaxoSmithKline, Isotechnika, Janssen-Cilag, LEO Pharma, Lilly,
Maruho, Medac, Medimmune, Merck Sharp Dome, Merck Serono, Novartis, Regen-
eron, Sandoz, Sanofi-Aventis, Takeda and Pfizer. K.R. has served as a consultant and/
or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Amgen,
Biogen Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-
Cilag, LEO Pharma, Lilly, Medac, Merck, Novartis, Pfizer, Vertex and Takeda. E.R. has
received travel support and nonfinancial support for histology study report preparation
fromMerck & Co., Inc., and has received speaker’s fees and travel support, or served on
advisory boards for Abb- Vie, Novartis, Pfizer, Janssen and Amgen. R.G.L. has served
as a consultant and/or paid speaker for and/or participated in clinical trials sponsored
by companies that manufacture drugs used for the treatment of psoriasis, including Ab-
bVie, Celgene, Centocor, Janssen-Cilag, LEO Pharma, Merck, MSD (formerly Essex,
Schering-Plough), Novartis and Pfizer (formerly Wyeth). J.G.K. has received personal
fees (consulting and/or speaking fees) and grants paid to his institution from Novartis,
Pfizer, Janssen, Lilly, Merck, Kadmon, Dermira, Boehringer and BMS; Amgen, Inno-
vaderm, Paraxel and Kyowa have paid grants to J.G.K.’s institution; J.G.K. has also re-
ceived personal fees from Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Xeno-
port and Kineta. A.B.G. has current consulting/advisory board agreements with Amgen
Inc., Astellas, Akros, Centocor (Janssen) Inc., Celgene Corp., Bristol Myers Squibb Co.
, Beiersdorf Inc., Abbott Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, No-
vartis, Dermipsor Ltd, Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm,
CSL Behring Biotherapies for Life, GlaxoSmithKline, Xenoport, Catabasis Meiji Seika
Pharma Co., Ltd, Takeda, Mitsubishi Tanabe Pharma Development America, Inc, and
has received research/educational grants (paid to Tufts Medical Center) from Centocor
(Janssen), Amgen, Abbott (Abb- Vie), Novartis, Celgene, Pfizer, Lilly, Coronado, Levia,
Merck and Xenoport. H.N. has received consultancy/speaker honoraria and/or grants
from Novartis, Tanabe Mitsubishi, Maruho, Abbott/AbbVie, Eli Lilly, Merck Sharp &
Dohme, Janssen and LEO Pharma.“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 931): “Randomisation of treat-
ment and allocation was done centrally by
means of an interactive web response sys-
tem…
Comment: no description of the method
used to guarantee the random sequence
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generation
Allocation concealment (selection bias) Low risk Quote (p 931): “Randomisation of treat-
ment and allocation was done centrally by
means of an interactive web response sys-
tem…”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (p 931): “double-blind”
Comment: no description of the method
used to guarantee blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p 932): “double-blind“
Comment: no description of the method
used to guarantee blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 355, analysed 352
Management of missing data:
Quote (p 932): “The primary analysis was
performed on all randomised participants
who received at least one or more doses of
treatment. Participants who discontinued
treatment prior to week 16... were consid-
ered to not have achieved PASI 75 at week
16”
Comment: low number lost to follow-up
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01225731)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Papp AMAGINE-1, 2016
Methods RCT, placebo-controlled, double blind
Date of study: 29 August 2012-12 March 2014
Location: 73 centres worldwide (Europe, USA & Canada)
Participants Randomised: 661 participants (mean age 46 years, 484 male)
Inclusion criteria
• Aged 18-75
• Participants with moderate-severe psoriasis (PASI ≥ 12, PPGA ≥ 3 and BSA ≥
10), failed to respond to, had a contraindication to, or were intolerant to at least one
conventional systemic treatment
Exclusion criteria
• Not plaque-type psoriasis
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• Active infection (TB, hepatitis B, C or HIV), had Crohn’s disease and any
uncontrolled significant medical condition
• Had a myocardial infarction or unstable angina pectoris within 12 months before
the first dose
• Had active malignancy or a history of malignancy within 5 years
Dropouts and withdrawals
• 33/661(5%); brodalumab 210 (10), brodalumab 140 (11), placebo (12)
• Ineligibility determined: brodalumab 210 (0), brodalumab 140 (0), placebo (2)
• Not received study medication
• AEs: brodalumab 210 (2), brodalumab 140 (3), placebo (3)
• Death: brodalumab 210 (0), brodalumab 140 (0), placebo (0)
• Lost to follow-up: brodalumab 210 (1), brodalumab 140 (1), placebo (1)
• Withdrawal consent: brodalumab 210 (4), brodalumab 140 (3), placebo (3)
• Other reason: brodalumab 210 (3), brodalumab 140 (4), placebo (3)
Interventions Intervention
A. Brodalumab (n = 222), SC, 210 mg every 2 weeks
Control intervention
B. Brodalumab (n = 219), SC, 140 mg every 2 weeks
C. Placebo (n = 220)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
• PGA success
Secondary outcomes of the trial
• PASI 100 & PGA 0
• Participant-reported outcomes)
• AEs
Notes Funding source:
Quote (p 1): “This study was funded by Amgen Inc. & AstraZeneca/MedImmune.”
Declarations of interest (p 13-14): “K.A.P. has served as a consultant, investigator and/
or speaker for AbbVie, Amgen Inc., Astellas Pharma, Bayer AG, Boehringer Ingelheim,
Celgene, Eli Lilly and Company, Forward Pharma, Galderma, Janssen Biotech Inc., LEO
Pharma,Merck,Novartis, Pfizer, Roche andUCBPharma.K.R. has served as a consultant
and/or paid speaker for and/or participated in clinical trials sponsored by companies that
manufacture drugs used for the treatment of psoriasis, including AbbVie, Amgen Inc.,
Biogen-Idec, Celgene, Centocor, Covagen, Forward Pharma, GSK, Janssen-Cilag, LEO
Pharma, Lilly, Medac, MSD, Novartis, Pfizer, Takeda and Vertex. C.P. has served as a
consultant and investigator for Amgen Inc., AbbVie, Boehringer, Janssen-Cilag, LEO
Pharma, Lilly, Novartis and Pfizer. A.B. has served as a consultant and investigator for
AbbVie, Amgen Inc., Anacor, Boehringer Ingelheim, Celgene, Eli Lilly and Company,
Genentech, Janssen, Merck, Novartis, Pfizer, Regeneron and Sandoz.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (p 2 & 3): “Patients were random-
ized... IP supply was controlled by interac-
tive voice response system and box num-
bers were assigned at each visit”
Comment: no description of the method
used to guarantee the random sequence
generation
Allocation concealment (selection bias) Low risk Quote (p 2 & 3): “Patients were random-
ized...IP supply was controlled by interac-
tive voice response system and box num-
bers were assigned at each visit”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 3): “Randomizations remained
blinded to all patients and investigators..
. Throughout the study, patients received
placebo as needed to maintain the blind
until it was broken. ”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 3): “Randomizations remained
blinded to all patients and investigators..
. Throughout the study, patients received
placebo as needed to maintain the blind
until it was broken. ”
Comment: probably done, placebo-con-
trolled
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 661, 661 analysed
Management of missing data: quote (p 4 &
5): “The full analysis set included all ran-
domised patients... Mutiple imputations
for missing data”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment: the protocol for the study was
available on ClinicalTrials.gov
(NCT01708590; AMAGINE-1). The pre-
specified outcomes and thosementioned in
the methods section appeared to have been
reported
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Methods RCT, placebo-controlled, double blind
Date of study: September 2010-December 2012
Location: 72 centres in USA, Canada, Australia, Belgium, France, UK, Italy, Germany
Participants Randomised: 844 participants (apremilast (562) mean age 46 years, 379 male; placebo
(282) mean age 47 years, 194 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10%, PGA ≥ 3,
• Age ≥ 18 years
• Number of allowed previous treatment line: any (candidate for systemic/
phototherapy)
• Number of allowed previous biologic treatments: any
Exclusion criteria
• Pregnancy, immunodepression, clinically significant or major uncontrolled disease
• Had an active infection
• Clinically significant abnormality on 12-lead ECG at screening
• Malignancy or history of malignancy (except for treated (ie, cured) basal cell or
squamous cell in situ skin carcinomas and treated (ie, cured), CIN or carcinoma in situ
of the cervix with no evidence of recurrence within the previous 5 years)
Dropouts and withdrawals
• 92/844 (11%) at 16w;
• Apremilast (59): AE (23), lack efficiency (2), withdrew consent (12), lost to
follow-up (7), deviation (7), noncompliance (7), other (1)
• Placebo(33): AE (5), lack efficiency (7), withdrew consent (9), lost to follow-up
(9), death (1), deviation (1), other (1)
Interventions Intervention
A. Apremilast (n = 562), orally, 30 mg, twice a day, 16 weeks
Control intervention
B. Placebo (n = 282), orally, twice a day, 16 weeks
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• Static PGA 0 or 1
• Number of participants with AEs (AE) in the placebo-controlled phase
• Number of participants with a psoriasis flare or rebound during the placebo-
controlled phase
• Percent change from baseline in percent of affected BSA
• Percent change from baseline in the PASI score
• Percentage of participants who achieved a 50% improvement (response) in the
PASI Score (PASI 50)
• Change from baseline in pruritus VAS score
• Change from baseline in the DLQI total score
• Change from baseline in the Mental Component Summary score of the SF-36
Health Survey Version 2.0
• Percentage of participants who achieved both a 75% improvement (response) in
the PASI and static PGA score of clear (0) or almost clear (1) with at least 2 points’
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reduction from baseline
Notes Funding source quote (p 37): “This study was sponsored by Celgene Corporation”
Declarations of interest (p 48): “Dr Papp has served as an investigator for Abbott (Abb-
Vie), Amgen, Biogen Idec, Boehringer Ingelheim,Celgene, Centocor, Galderma,Genen-
tech, Incyte, Isotechnika, Janssen, LEO Pharma, Lilly, MedImmune, Merck Sharp &
Dohme, Merck-Serono, Novartis, Pfizer, Stiefel, and Wyeth; a consultant for Abbott,
Amgen, Astellas, Biogen Idec, Boehringer Ingelheim, BMS, Celgene, Centocor, Forward
Pharma, Galderma, Genentech, Incyte, Isotechnika, Janssen, Johnson &Johnson, Ky-
owa Kirin, LEO Pharma, Lilly, MedImmune, Merck Sharp & Dohme, Merck-Serono,
Novartis, Pfizer, Takeda Pharmaceuticals, UCB, and Wyeth; and a speaker for Abbott,
Amgen, Astellas, Celgene, Centocor, Isotechnika, Janssen, Novartis, and Pfizer. Dr Reich
has served as a consultant and/or paid speaker for and/or participated in clinical trials
sponsored by companies that manufacture drugs used for the treatment of psoriasis in-
cluding AbbVie, Amgen, Biogen Idec, Celgene, Centocor, Covagen, Forward Pharma,
GlaxoSmithKline, Janssen-Cilag, LEO Pharma, Lilly, Medac, Merck Sharp & Dohme,
Novartis, Pfizer, Takeda, and Vertex. Dr Leonardi has served on the advisory board
and as an investigator and/or speaker for Abbott, Amgen, Celgene,Centocor, Galderma,
Genentech, GlaxoSmithKline, Lilly, Novartis, Novo Nordisk, Pfizer, Sirtris, Stiefel, Vas-
cular Biogenics, and Wyeth.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 38): “ESTEEM 1 was.. multi-
center, randomised, double-blind, placebo
controlled study”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 38): “ESTEEM 1 was.. multi-
center, randomised, double-blind, placebo
controlled study”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 38): “ESTEEM 1 was.. multi-
center, randomised, double-blind, placebo
controlled study... Blinding was main-
tained until all patients discontinued or
completed the week 52 visit”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 38 & 39): “ESTEEM 1 was.
. multicenter, randomised, double-blind,
placebo controlled study... Blinding was
maintained until all patients discontinued
or completed the week 52 visit”
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Comment: probably done, placebo-con-
trolled
Incomplete outcome data (attrition bias)
All outcomes
Low risk 844included/844 analysed
Quote (p 39): “Efficacy data were as-
sessed for the full analysis set (all ran-
domised patients)...Missing data were han-
dled with the last-observation-carried-for-
ward methodology”
Comment: done
Selective reporting (reporting bias) Unclear risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01194219)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported except the
number of participants with a psoriasis
flare or rebound during placebo-controlled
phase
Papp OPT Pivotal-1, 2015
Methods RCT, active/placebo-controlled, double blind
Date of study: 12 January 2012-18 September 2014
Location:multicentre (74) inUSA,Canda,Colombia,Germany, Japan,Hungary, Serbia,
Taiwan, Ukraine
Participants Randomised: 901 participants (mean age 46 years, 643 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Past history of malignant tumour, active infection, uncontrolled significant
medical condition
• Had received efalizumab treatment
Dropouts and withdrawals
• 136/901 (15%); tofacitinib 5 group (50), tofacitinib 10 group (40), placebo
group (45)
• plus 1 participant not treated
• AEs: tofacitinib 5 group (11), tofacitinib 10 group (8), placebo group (11)
• Lack of efficacy: tofacitinib 5 group (20), tofacitinib 10 group (15), placebo
group (25)
• Withdrawal consent: tofacitinib 5 group (8), tofacitinib 10 group (5), placebo
group (4)
• Lost to follow-up: tofacitinib 5 group (3), tofacitinib 10 group (5), placebo group
(3)
• Participant died: tofacitinib 5 group (1), tofacitinib 10 group (0), placebo group
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(1)
• Other reason: tofacitinib 5 group (7), tofacitinib 10 group (7), placebo group (2)
Interventions Intervention
A. Tofacitinib (n = 363), orally, 5 mg twice daily
Control intervention
B. Tofacitinib (n = 360), orally, 10 mg twice daily
B. Placebo (n = 177), orally (same drug administration)
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
• PGA 0/1
Secondary outcomes of the trial
• PASI 75
• PGA 0/1
• PASI 90
• DLQI
• AEs
Notes Funding source:
Quote (p 949): “Pfitzer Inc”
Declarations of interest (appendix): “K.A.P. has participated in advisory boards or panels
for AbbVie, Amgen, Astellas, Baxter, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen,
LEO Pharma, Merck, Novartis, Pfizer Inc. and UCB. He has been an investigator for
AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Janssen,
LEO Pharma, Merck, Novartis, Pfizer, Takeda and UCB. He has acted as a consultant
for AbbVie, Amgen, Astellas, Baxter, Boehringer Ingelheim, Celgene, Eli Lilly, Forward
Pharma, Janssen, Merck, Novartis, Pfizer Inc., Takeda and UCB. He has been a speaker
for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech,
Janssen, LEO Pharma, Merck, Novartis, Pfizer and UCB. M.A.M. has participated in
advisory boards or panels for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Genen-
tech, Janssen Biotech, LEO Pharma and Pfizer Inc. He has served as a consultant for Ab-
bVie, Allergan, Amgen, Convoy Therapeutics, Eli Lilly, Janssen Biotech, LEO Pharma,
Novartis, Pfizer Inc., Syntrix,Wyeth and XenoPort. He has been an Investigator for Abb-
Vie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Technolo-
gies, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Merck, Novartis, Pfizer Inc.,
Symbio/Maruho, Syntrix andWyeth.He has been a speaker for AbbVie, Amgen, Janssen
Biotech, LEO Pharma and Wyeth. He has received grants from AbbVie, Allergan, Am-
gen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Technologies, Genentech,
Janssen Biotech, LEO Pharma, Merck, Pfizer Inc., Symbio/Maruho and Syntrix. He
has received honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Convoy
Technologies, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Novartis, Pfizer Inc.
, Syntrix, Wyeth and XenoPort.”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote (p 951): “Randomization using an
automated web/telephone randomization
system at the study site ensured patient, in-
vestigator and sponsor blinding ”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 951): “Randomization using an
automated web/telephone randomization
system at the study site ensured patient, in-
vestigator and sponsor blinding ”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 951): “Investigator and sponsor
blinding… with placebo tablets according
to the treatment group, appropriately la-
belled to avoid treatment-group conflict.
All patients took a total of two tablets for
each dose”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 951): “Investigator and sponsor
blinding… with placebo tablets according
to the treatment group, appropriately la-
belled to avoid treatment-group conflict.
All patients took a total of two tablets for
each dose”
Comment: probably done, placebo-con-
trolled
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 901, analysed 900
Management of missing data: Quote (p
951): “The full analysis set included all pa-
tients who were randomised and received
at least one dose of the study drug...Non-
responder imputation was used to manage
missing values.”
Comment: withdrawal for lack of efficacy:
tofacitinib 5 group 5% (20/363), tofaci-
tinib 10 group4%(15/360), placebo group
14% (25/177)
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01276639)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
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Methods RCT, active/placebo-controlled, double blind
Date of study: 4 March 2011-18 September 2014
Location: multicentre (94) in Mexico, Poland, Puerto Rico, Serbia, Taiwan, Ukraine
Participants Randomised: 960 participants (mean age 46 years, 648 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Past history of malignant tumour, active infection, uncontrolled significant
medical condition
• Had received efalizumab treatment
Dropouts and withdrawals
• 136/901 (15%); tofacitinib 5 group (51), tofacitinib 10 group (40), placebo
group (44)
• plus 1 participant not treated
• AEs: tofacitinib 5 group (11), tofacitinib 10 group (10), placebo group (5)
• Lack of efficacy: tofacitinib 5 group (15), tofacitinib 10 group (2), placebo group
(24)
• Withdrawal consent: tofacitinib 5 group (7), tofacitinib 10 group (6), placebo
group (7)
• Lost to follow-up: tofacitinib 5 group (7), tofacitinib 10 group (8), placebo group
(3)
• Participant died: tofacitinib 5 group (1), tofacitinib 10 group (0), placebo group
(1)
• Other reason: tofacitinib 5 group (10), tofacitinib 10 group (14), placebo group
(4)
Interventions Intervention
A. Tofacitinib (n = 382), orally, 5 mg twice daily
Control intervention
B. Tofacitinib (n = 381), orally, 10 mg twice daily
C. Placebo (n = 196), orally (same drug administration)
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
• PGA 0/1
Secondary outcomes of the trial
• PASI 75
• PGA 0/1
• PASI 90
• DLQI
• AEs
Notes Funding source:
Quote (p 949): “Pfitzer Inc”
Declarations of interest (appendix) : “K.A.P. has participated in advisory boards or panels
for AbbVie, Amgen, Astellas, Baxter, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen,
LEO Pharma, Merck, Novartis, Pfizer Inc. and UCB. He has been an investigator for
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AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, Janssen,
LEO Pharma, Merck, Novartis, Pfizer, Takeda and UCB. He has acted as a consultant
for AbbVie, Amgen, Astellas, Baxter, Boehringer Ingelheim, Celgene, Eli Lilly, Forward
Pharma, Janssen, Merck, Novartis, Pfizer Inc., Takeda and UCB. He has been a speaker
for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Genentech,
Janssen, LEO Pharma, Merck, Novartis, Pfizer and UCB. M.A.M. has participated in
advisory boards or panels for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Genen-
tech, Janssen Biotech, LEO Pharma and Pfizer Inc. He has served as a consultant for Ab-
bVie, Allergan, Amgen, Convoy Therapeutics, Eli Lilly, Janssen Biotech, LEO Pharma,
Novartis, Pfizer Inc., Syntrix,Wyeth and XenoPort. He has been an Investigator for Abb-
Vie, Allergan, Amgen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Technolo-
gies, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Merck, Novartis, Pfizer Inc.,
Symbio/Maruho, Syntrix andWyeth.He has been a speaker for AbbVie, Amgen, Janssen
Biotech, LEO Pharma and Wyeth. He has received grants from AbbVie, Allergan, Am-
gen, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Technologies, Genentech,
Janssen Biotech, LEO Pharma, Merck, Pfizer Inc., Symbio/Maruho and Syntrix. He
has received honoraria from AbbVie, Allergan, Amgen, Boehringer Ingelheim, Convoy
Technologies, Eli Lilly, Genentech, Janssen Biotech, LEO Pharma, Novartis, Pfizer Inc.
, Syntrix, Wyeth and XenoPort.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 951): “Randomization using an
automated web/telephone randomization
system at the study site ensured patient, in-
vestigator and sponsor blinding ”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 951): “Randomization using an
automated web/telephone randomization
system at the study site ensured patient, in-
vestigator and sponsor blinding ”
Comment: no description of the method
to guarantee the allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 951): “Investigator and sponsor
blinding… with placebo tablets according
to the treatment group, appropriately la-
belled to avoid treatment-group conflict.
All patients took a total of two tablets for
each dose”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 951): “Investigator and sponsor
blinding… with placebo tablets according
to the treatment group, appropriately la-
belled to avoid treatment-group conflict.
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All patients took a total of two tablets for
each dose”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 960, analysed 959
Management of missing data: Quote (p
951): “The full analysis set included all pa-
tients who were randomised and received
at least one dose of the study drug...Non-
responder imputation was used to manage
missing values.”
Comment: imbalance of withdrawal be-
tween groups: lack of efficacy: tofacitinib
5 group (15), tofacitinib 10 group (2),
placebo group (24)
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01276639)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Papp PHOENIX-2, 2008
Methods RCT, placebo-controlled, double-blind trial
Date of study: March 2006-September 2007
Location: 70 centres in Europe and North America
Participants Randomised: 1230 participants (mean age 45 years, 840 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
• Authors’ assessment ≥ 6 months, PASI ≥ 12, BSA > 10%
• Age ≥ 18 years
Exclusion criteria
• Had received IL12/23 drug
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 33/1230 (2.7%)
• Ustekinumab 45 (6): AE (2), other (4)
• Ustekinumab 90 (9): AE (5), death (1), other (3)
• Placebo (18): lack of efficacy (2), AE (8), other (8)
Interventions Intervention
A. Ustekinumab (n = 409), SC, 45 mg, weeks 0-4 and every 12 weeks, 52 weeks
Control intervention
B. Ustekinumab (n = 411), SC, 90 mg, weeks 0-4 and every 12 weeks, 52 weeks
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C. Placebo (n = 410), SC, weeks 0-4, 4 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA cleared or minimal at 12 weeks
• Change of QoL from baseline at week 12
• PASI 90 at 12 weeks
Notes Funding Centocor Inc (p1675)
Declaration of interest (p1684): “KP has served as a consultant and advisory board mem-
ber for Abbott, Alza, Amgen, Celgene, Centocor, Isotechnika, Janssen Ortho Biotech,
Johnson& Johnson,Medimmune,MerckSerono, andWyeth. RGL has received research
grants, served on scientific advisory boards, and has been a speaker for Amgen, Biogen-
Idec, Centocor, Genentech, Novartis, Schering-Plough, and Serono. ML has received
honoraria, served as a speaker and advisory board member for Abbott, Amgen, Centocor,
Genentech, and Stiefel, and has served as an advisory board member for Astellas and a
consultant for UCB. GK has received fees as a consultant or advisory board member for
Abbott, Almirall, Alza, Amgen, Anacor, Astellas, Barrier Therapeutics, Boehringer Ingle-
heim, Bristol Myers Squibb, Centocor, CombinatoRx, Exelixis, Genentech, Genzyme,
Isis, L’Oreal, Lupin Limited, Magen Biosciencs, MedaCorp, Medicis, Novartis, Nova
Nordisc, Schering-Plough, Somagenics, theDerm.org, Synvista, Warner Chilcot, UCB,
USANAHealth Sciences, and ZARS, owns equities and stock in ZARS, and has received
lecture fees from Abbott, Amgen, Astellas, Boehringer Ingleheim, Centocor, Connetics,
National Psoriasis Foundation, The Foundation for Better Health Care, and Warner
Chilcot, and has received partial stipend support for a clinical research fellowship from
Abbott, Amgen, and Centocor. KR has received honoraria as a consultant and advisory
board member and acted as a paid speaker for Abbot, Biogen-Idec, Centocor, Janssen-
Cilag, Schering-Plough, MerckSerono, UCB, and Wyeth. PS, NY, CG, M-CH, YW,
SL, and LTD are employees of Centocor. PS, NY, CG, YW, SL, and LTD own stock in
Johnson and Johnson.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 1676): “Patients were randomly
assigned... with biais coin assignment via
a centralised interactive voice response sys-
tem (ClinPhone, East Windsor, NJ, USA)
”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 1676): “Patients were randomly
assigned... with biais coin assignment via
a centralised interactive voice response sys-
tem (ClinPhone, East Windsor, NJ, USA)
”
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Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1676 & 1977): “Double-blind,
..., placebo-controlled...Site monitors in-
vestigators personels involved in the study
conduct,and patients remained blinded...
until W52”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1676 & 1977): “Double-blind,
..., placebo-controlled...Site monitors in-
vestigators personels involved in the study
conduct,and patients remained blinded...
until W52”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1230 included/ 1230 analysed
Quote (p 1679): “Efficacy data were anal-
ysed by the assigned treatment group...
Non-responder status was assigned for bi-
nary variables ... for those patients who dis-
continued study treatment ...”
Comment: ITT analyses
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00307437)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Paul ESTEEM-2, 2015
Methods RCT, active/placebo-controlled, double blind
Date of study: 29 October 2012-25 March 2016
Location: 40 centres in Europe & USA
Participants Randomised: 413 participants (mean age 45 years, 276 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12 or BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency, past
history of malignant tumours, active infection, uncontrolled cardiovascular disorder,
uncontrolled diabetes, uncontrolled hypertension
Dropouts and withdrawals
• 62/413 (15%); apremilast group (36), placebo group (26)
• Error of randomization, did not receive study medication; apremilast group (1),
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placebo group (1)
• AEs: apremilast group (12), placebo group (8)
• Lack of efficacy: apremilast group (3), placebo group (2)
• Withdrawal consent: apremilast group (9), placebo group (7)
• Lost to follow-up: apremilast group (6), placebo group (6)
• Protocol violation: apremilast group (2), placebo group (1)
• Non compliance: apremilast group (1), placebo group (0)
• Other reason:apremilast group (2), placebo group (1)
Interventions Intervention
A. Apremilast (n = 275), orally, 30 mg twice a day until week 32
Control intervention
B. Placebo (n = 138), orally (same drug administration)
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 50
• PASI 90
• PASI 100
• PGA 0/1
• DLQI
• Pruritus VAS
• AEs
Notes Funding source:
Quote (p 1387): ”This study was sponsored by Celgene Corporation“
Declarations of interest (Appendix): C.P. has served as an investigator and consultant
for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, LEO Pharma, Novartis and Pfizer. J.
Cather has been an investigator for Amgen, Celgene, Galderma, Merck, Novartis and
Pfizer, and has served on advisory boards for AbbVie, Janssen, OrthoBiotech and Medac.
M.G. has been an investigator for AbbVie, Allergan, Celgene, Dermira, Dr. Reddy’s
Laboratories, Eli Lilly, Galderma, Janssen Pharmaceutical, Kythera, Kyowa Hakko Kirin
Pharma, LEO Pharma, Merck, Novartis, Pfizer, Regeneron and Takeda, and has served
as a speaker for AbbVie, Actelion, Amgen, Astellas, Galderma, Janssen Pharmaceutical,
LEO Pharma, Novartis and Pfizer. Y.P. has been an investigator for AbbVie, Amgen,
Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor/Janssen, Eli
Lilly, Galderma, Isotechnika, LEO Pharma, Merck, Novartis, Pfizer, Pharmascience,
Regeneron, Schering and Stiefel/GSK, and has served as a speaker for AbbVie, Amgen,
Galderma, Janssen, LEO Pharma and Novartis. U.M. has been an advisor for and/
or received speaker honoraria from and/or received grants from and/or participated in
clinical trials for Abbott/AbbVie, Almirall-Hermal, Amgen, BASF, Biogen Idec, Celgene,
Centocor, Eli Lilly, Forward Pharma, Galderma, Janssen, LEO Pharma, Medac, MSD,
Miltenyi Biotech, Novartis, Pfizer, Teva, VBL and XenoPort. C.F. has served on the
advisory board for and/or received speaker honoraria fromCelgene,Novartis, Janssen and
AbbVie. J. Crowley has been an investigator for AbbVie, Amgen, AstraZeneca, Celgene,
Janssen, Maruho, Merck, Pfizer and Regeneron; has served on the advisory board for
AbbVie, Amgen, Celgene and Lilly; and has been a speaker for AbbVie and Amgen.”
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Paul ESTEEM-2, 2015 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 1388): “Patient were randomised
(2:1) via an interactive voice response sys-
tem...”
Comment: no description of the method
used to guarantee the random sequence
generation
Allocation concealment (selection bias) Low risk Quote (p 1388): “Patient were randomised
(2:1) via an interactive voice response sys-
tem...”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1388) “identically matching
placebo tablets twice daily during the
placebo controlled phase”
Comment: Probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1388): “double-blind”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 413, analysed 411
Management of missing data: Quote (p
1389-90): “Efficacy assessments were con-
ducted for the modified intention-to-treat
population... The last-observation-carried-
forward methodology was used....”
Comment: we judged this as a low risk of
bias
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00235820)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
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Paul JUNCTURE, 2015
Methods RCT, active/placebo-controlled, double blind
Date of study: 7 June 2012- 4 January 2013
Location: 38 centres worldwide
Participants Randomised: 182 participants (mean age 45 years, 125 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, IGA 3-4 or BSA ≥ 10),
age ≥ 18 years
Exclusion criteria
• Immunosuppression, active infection
• Had received anti IL17 drug
Dropouts and withdrawals
• 5/182 (2.7%)
• AEs: secukinumab 300 (0), secukinumab 150 (1), placebo (1)
• Lack of efficacy: secukinumab 300 (0), secukinumab 150 (0), placebo (1)
• Physician decision: secukinumab 300 (0), secukinumab 150 (1), placebo (0)
• Participant/guardian decision: secukinumab 300 (0), secukinumab 150 (1),
placebo (0)
Interventions Intervention
A. Secukinumab (n = 61), SC, 150 mg weeks 0, 1, 2, 3 then monthly
Control intervention
B. Secukinumab (n = 60), SC, 300 mg weeks 0, 1, 2, 3 then monthly
C. Placebo (n = 61), (same drug administration)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PGA0/1
• PASI 75
Secondary outcomes of the trial
• PASI 50/75/90
• DLQI
Notes Funding source:
Quote (supplemental file) “The study was sponsored by Novartis Pharma and designed
by the scientific steering committee andNovartis personnel. Novartis conducted the data
analysis, and all authors had access to the data”
Declarations of interest (p 29): “Dr Paul has served as a consultant for AbbVie Pharma-
ceuticals, Amgen, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuti-
cals, LEO Pharma, Novartis Pharmaceuticals Corporation, Pfizer Inc and Pierre Fabre.
Dr Lacour has participated in clinical trials sponsored by Novartis and has received hon-
oraria as a coordinator of clinical trials sponsored by Novartis. Dr Kreutzer has received
honoraria for giving speeches for, has received travel grants from, and conducts clinical
trials for AbbVie Pharmaceuticals, Biogen, Novartis and Janssen-Cilag. Dr Jazayeri has
served as investigator for and received grants from Novartis. Dr Adams has served as
investigator for and received grants from Amgen, Eli Lilly and Company and Novartis.
Ms Guindon and Dr Papavassilis are full-time employees of and own stock in Novartis.
Mr You is a full-time employee of Novartis. Dr Tedremets has no conflicts of interest to
declare.”
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Paul JUNCTURE, 2015 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 28 and supplemental file): “were
randomly allocated”, “Randomization was
conducted via Interactive Response Tech-
nology, which assigned a randomisation
number that linked the subject to a treat-
ment arm and specified unique medication
pack number“
Comment: no description of the method
used to guarantee the random sequence
generation
Allocation concealment (selection bias) Low risk Quote: “Randomizationwas conducted via
InteractiveResponseTechnology,which as-
signed a randomisation number that linked
the subject to a treatment arm and specified
unique medication pack number”
Comment: well described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1083): “During the induction pe-
riod, subjects…in the secu 150 mg group
were administrated one 150 mg injec-
tion and one placebo,….,in the placebo
group…2 placebo autoinjections”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1083): “During the induction pe-
riod, subjects … in the secu 150 mg group
were administrated one 150 mg injection
and one placebo, …., in the placebo group
… 2 placebo autoinjections”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 182, analysed 181
Management of missing data:
Quote (Supplemental file): “Missing values
with respect to response variables based on
PASI score or IGA mod 2011 score were
imputed as nonresponse regardless of the
reason for missing data”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01636687)
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Paul JUNCTURE, 2015 (Continued)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Piskin 2003
Methods RCT, active-controlled, open-label trial
Date of study: not stated
Location: Amsterdam and throughout the Netherlands, number not stated
Participants Randomised: 10 participants (ciclosporin (5), mean age 41 years, 4 male; Methotrexate
(5), mean age 45 years, 3 male)
Inclusion criteria
• Participants with moderate-severe psoriasis, PASI ≥ 8
• Age ≥ 18
• Non-response to topical treatment
Exclusion criteria
• Not stated
Dropouts and withdrawals
• Not stated
• All participants seemed to be evaluated at week 12
Interventions Intervention
A. Ciclosporin (n = 5), orally, 3 mg/kg/d, 16 weeks
Control intervention
B. Methotrexate (n = 5), orally, 15 mg/kg/week, 16 weeks
Outcomes Assessments at 12 weeks
Primary and secondary outcomes of the trial
• Not clearly defined
Outcomes of the trial
• PASI 75
• Number of cutaneous T-cell 1-2
• Creatine kinase balance
• Psoriatic skin
Notes Funding not declared
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 559): ”Patients were randomised.
..“
Comment: no description of the method
used to guarantee random sequence gener-
ation
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Allocation concealment (selection bias) Unclear risk Quote (p 559): ”Patients were randomised.
..“
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 559): “Laboratory results were
obtained in a blinded fashion before ran-
domisation and at week 12 of therapy. The
code was broken only after all definitive re-
sults were obtained from all participating
patients.”
Comment: open-label trial, no double
dummy used to guarantee blinding of par-
ticipants and personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: no description of the method
used to guarantee blinding of outcome as-
sessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10 included/10 analysed
Comment: no statistical analyses section;
however, the results were available for the
10 participants initially randomised.Meth-
ods for dealing with missing data: not ap-
plicable
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Reich 2012
Methods RCT, placebo-controlled, double blind
Date of study: October 2005-November 2006
Location: 15 centres in France and Germany
Participants Randomised: 176 participants, mean age 43 years, 213 male
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10, age ≥ 18
years)
• Non-response to conventional systemic treatment
• Non-response to biologics
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had an active infection
• Had uncontrolled cardiovascular disorder
• Had uncontrolled diabetes
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Reich 2012 (Continued)
• Had uncontrolled hypertension
• Had past history of malignant tumours
Dropouts and withdrawals
• 28/176 (16%)
• Placebo (19): lack efficacy (14), AE (3), lost to follow-up (2)
• Certolizumab 200 (5): lack efficacy (3), AE (2)
• Certolizumab 400 (4): lack efficacy (1), AE (2), pregnancy(1)
Interventions Intervention
A. Certolizumab (n = 59), SC, 200 mg,
Certolizumab pegol (CZP) 400 mg week 0 - certolizumab 200 mg weeks 1-10, 10 weeks
Control intervention
B. Certolizumab (n = 58), SC, 400 mg, certolizumab 400 mg week 0 - certolizumab
400 mg weeks 1-10, 10 weeks
C. Placebo (n = 59), SC, certolizumab 400 mg week 0 - placebo weeks 1-10, 10 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
• PGA
Secondary outcomes of the trial
• PASI 50
• PASI 90
• Time to PASI 75 response
• Time to relapse
• Change from baseline BSA
• DLQI Dermatology Life Quality Index)
• PGA week 12
Notes Funding source quote (p 180): “This study was funded by UCB Pharma, Brussels,
Belgium”
Declarations of interest (p 180): “K.R. has served as consultant and or paid speaker
for and or has participated in clinical trials sponsored by companies that manufac-
ture drugs used for the treatment of psoriasis, including Abbott, Biogen Idec, Celgene,
Centocor, Janssen-Cilag, Leo, Medac, Merck, MSD (formerly Essex, Schering-Plough)
, Novartis and Pfizer (formerly Wyeth). J.-P.O. is a consultant for Abbott, Centocor,
Galderma, Janssen- Cilag, Leo, Meda Pharma, Merck Serono and UCB Pharma. A.B.
G. has current consulting advisory board agreements with Amgen, Astellas, Centocor
(Janssen), Celgene, Bristol-Myers Squibb, Beiersdorf, Abbott, TEVA, Actelion, UCB
Pharma, Novo Nordisk, Novartis, Dermipsor, Incyte, Pfizer, Canfite, Merck and Lilly.
Research educational grants paid to Tufts Medical Center: Centocor (Janssen), Amgen,
Immune Control, Abbott, Novo Nordisk, UCB Pharma, Novartis, Celgene and Pfizer.
I.J.T. and G.C. are full-time employees of UCB Pharma. C.T. is a former employee of
UCB Pharma. P.M. has served as consultant and or paid speaker for and has received
grants, consulting and or speaker fees from Abott Amgen, Biogen Idec, Bristol-Myers
Squibb, Celgene, Janssen, Novartis, Merck, Pfizer and UCB Pharma.”
Risk of bias
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Reich 2012 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 181): “Eligible patients were
randomised to receive... Randomization
was centralized using a dynamic alloca-
tion procedure... Treatment was assigned
using an interactive voice-response sys-
tem”“Randomization was conducted via
InteractiveResponseTechnology,which as-
signed a randomisation number that linked
the subject treatment arm and specified
unique medication pack number
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 181): “Eligible patients were ran-
domised to receive... Randomization was
centralized using a dynamic allocation pro-
cedure... Treatment was assigned using an
interactive voice-response system”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 181): “CZP... or matching
placebo in liquid formulation for subcuta-
neous injection... Study doses of CZP or
placebo were prepared containing the same
volume and labelled in the samemanner by
designed unblinded pharmacists”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 181): “CZP... or matching
placebo in liquid formulation for subcuta-
neous injection... Study doses of CZP or
placebo were prepared containing the same
volume and labelled in the samemanner by
designed unblinded pharmacists”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 176 included/176 analysed
Quote (p 182): “Co-primary efficacy as-
sessments were performed on the inten-
tion-to-treat population... Nonresponder
imputations for missing values were used
for the primary analysis”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00245765)
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Reich 2012 (Continued)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported except for
pharmacokinetic profile of CDP870
Reich 2015
Methods RCT, active/placebo-controlled, double blind
Date of study: December 2008-July 2009
Location: 14 centres in the USA and Canada
Participants Randomised: 100 participants (mean age 44 years, 100 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, IGA ≥ 3 or BSA ≥ 10),
age 18-65 years
Exclusion criteria
• Not stated
Dropouts and withdrawals
• 11/100 (11%); secukinumab 3 mg group (2), secukinumab 10 mg group (0),
secukinumab 3 x 10 mg group (3), placebo group (6)
• AEs: secukinumab 3 mg group (0), secukinumab 10 mg group (0), secukinumab
3 x 10 mg group (1), placebo group (0)
Interventions Intervention
A. Secukinumab (n = 30), SC, 3 mg/kg, 1 infusion (day 1)
Control intervention
B. Secukinumab (n = 29), SC, 10 mg/kg, 1 infusion (day 1)
C. Secukinumab (n = 31), SC, 10 mg/kg, 3 infusions (says 1, 15, 29)
D. Placebo (n = 10)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• Change from baseline in PASI score at 12 weeks
• (Proportion of participants who did not relapse at any time through week 56)
Secondary outcomes of the trial
• PASI 50
• PASI 75
• PASI 90
• Change in DLQI score
• AEs
Notes Funding source:
Quote (p 534): “This trial and publication were found by Novartis Pharma AG, Basel,
Switzerland.”
Declarations of interest (p 534): “ KR has served as a consultant or paid speaker for, or
participated in clinical trials sponsored by, AbbVie, Amgen, Biogen-Idec, Celgene, Cen-
tocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, Lilly, Medac,
MSD, Novartis, Pfizer, Takeda and Vertex. KAP has received grants and has consulted
and served as an investigator for AbbVie, Amgen, Astellas, Biogen-Idec, Celgene, Cento-
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cor, Eli Lilly, Forward Pharma, Fujisawa, GlaxoSmithKline, Janssen, Kyowa-Kirin, Leo,
MSD, Novartis (outside the submitted work), Pfizer and Takeda. RTM has received
grants/clinical trial stipends from Novartis. JHT served as a clinical investigator for No-
vartis during conduct of this study. RB received grants from Novartis during the con-
duct of this study and has received grants, personal fees and non- financial support from
AbbVie, Amgen, Astellas, Celgene, Eli Lilly, Janssen, Pfizer and Tribute. MB has served
as a clinical trial sponsor for Amgen, Eli Lilly and Novartis. DG has served as a clinical
trial investigator for Novartis. RAK is a member of an advisory board for Novartis and
several other pharmaceutical companies. YP has received grants from AbbVie, Amgen,
Celgene, Eli Lilly, Janssen, Merck, Pfizer and Novartis (outside the submitted work).
LAR, WMB, TMF and NAB-S declare no conflict of interests. GS has received grants/
clinical trial payments from Janssen, MSD and Novartis (unrelated to secukinumab).
JMS, US, TP, EK, GAW, FK and CCB are full-time employees of Novartis. WH and
DML are full-time employees of and own stock in Novartis. MMS was a full-time em-
ployee of Novartis at the time the study was conducted and the manuscript”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (supplemental appendix): “The ran-
domisation scheme was generated by No-
vartis Drug Supply Management using
a validated system. The randomisation
scheme was reviewed and approved by
the Biostatistics Quality Assurance group
of Novartis and was locked after ap-
proval. Subjects were assigned randomisa-
tion numbers, according to the randomi-
sation schedule. Each site, upon evaluation
of a qualified subject for the trial, faxed
the enrolment sheet to the clinical trial
leader (CTL) at the fax number provided.
The CTL then assigned the randomisation
number in a sequential manner and faxed it
back to the unblinded pharmacist or quali-
fied site personnel at the site, who then pre-
pared and provided the study medication
for the clinic in a blinded fashion.”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (supplemental appendix): “Each
site, upon evaluation of a qualified subject
for the trial, faxed the enrolment sheet to
the clinical trial leader (CTL) at the fax
number provided. The CTL then assigned
the randomisation number in a sequential
manner and faxed it back to the unblinded
pharmacist or qualified site personnel at the
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site, who then prepared and provided the
study medication for the clinic in a blinded
fashion..
Treatment allocation and clinical assess-
ment of the subjects were blinded. For
preparation of the study medication from
bulk supplies, treatment allocation cards
were sent to the pharmacist or qualified site
personnel at the investigator’s site.”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (supporting information): “To
maintain the blind of the study, the ap-
pearance of placebo infusion bags, ready to
administer to the subject, was identical to
that of active drug infusion bags. Placebo
and active medication were prepared by an
unblinded pharmacist or qualified site per-
sonnel assigned at each site.”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (supporting information): “To
maintain data integrity, no subject-level
data were circulated; therefore, blinding
was maintained at the individual subject
level”
Comment probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 100 randomised participants, 94 analysed
for PASI 75 or 90, 87 analysed for primary
outcome (change in PASI)
Quote (p 530): “Efficacy and pharmaco-
dynamic parameters were evaluated in all
subjects who received ≥ 1 dose of study
medication and had a major protocol de-
viations... Subjects lost to follow-up were
considered relapsed on the day of th first
visit without available PASI data”
Comment: low rate of loss to follow-up and
reasons comparable between groups
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00805480)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
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Reich EXPRESS, 2005
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: 32 centres in Europe and Canada
Participants Randomised: 378 participants (mean age 43 years, 268 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Immunosuppression
• Had received biologics
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals (week 24)
• 41/378 (10.8%)
• Discontinued study: infliximab (18), placebo (7)
• No description of the reasons of withdrawals
Interventions Intervention
A. Infliximab (n = 301), IV, 5 mg/kg weeks 0, 2, 6 and every 8 weeks, 10 weeks
Control intervention
B. Placebo (n = 77), IV, equivalent, weeks 0, 2, 6 and every 8 weeks, 10 weeks
Outcomes Assessments at 10 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI90/50
• PGA
• NAPSI
Notes Funding source (p 386): This study was funded by Centocor, and Schering-Plough,
Kenilworth, NJ, USA“
Declarations of interest (p 386): ”Consultancies: Dr Reich (Abbott, Biogen Idec, Cento-
cor, Schring-Plough, Essex, Serano, Wyeth), Dr Nestle (Biogen Idec, Centocor, Schring-
Plough, Genentech, Galderma)...“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 1368): ”A adaptative treatment
allocation was used... The treatment as-
signment was stored electronically and the
stored data were used to allocate future pa-
tients in such a way that the imbalance be-
tween treatment groups was kept to a mini-
mum“ “Randomization was conducted via
InteractiveResponseTechnology,which as-
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Reich EXPRESS, 2005 (Continued)
signed a randomisation number that linked
the subject to a treatment arm and specified
unique medication pack number”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 1368): “A adaptative treatment
allocation was used... The treatment as-
signment was stored electronically and the
stored data were used to allocate future pa-
tients in such a way that the imbalance be-
tween treatment groups was kept to a min-
imum”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1368): “The investigators, study
site personnel, and patients remained
blinded until the database lock at week 50.
.. placebo group”
Comment: probably done, placebo con-
trolled trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1368): “The investigators, study
site personnel, and patients remained
blinded until the database lock at week 50.
.. placebo group”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 378 included / 378 analysed
Quote (p 1368): “The primary endpoint ..
. as well as.. were analysed on an intention-
to-treat basis... In patients who discontin-
ued the study agent ... the patients were re-
garded as not achieving the endpoints for
binary responses”
Comment: probably done
Selective reporting (reporting bias) Unclear risk Comment: no protocol available. The pre-
specified outcomesmentioned in themeth-
ods section appeared to have been reported
Reich LIBERATE, 2017
Methods RCT, active/placebo-controlled, double blind
Date of study: October 2012-April 2016
Location: 82 centres worldwide (USA, Europe, Australia)
Participants Randomised: 250 participants (mean age 45 years, 157 male)
Inclusion criteria
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• Participants with moderate-severe psoriasis (PASI ≥ 12, PGA 3-4 or BSA ≥ 10), a
• Age ≥ 18 years
• Failed to respond to, had a contraindication to, or were intolerant to at least one
conventional systemic treatment
Exclusion criteria
• Failure of > 3 systemic agents for psoriasis
• Active infection
• History of known demyelinating diseases
• Congestive heart failure
• Significant/major uncontrolled diseases
Dropouts and withdrawals
• 17/250 (6.8%); apremilast (6), etanercept (2), placebo group (9)
• AEs: apremilast (2), etanercept (1), placebo group (2)
• Lack of efficacy: apremilast (0), etanercept (0), placebo group (4)
• Withdrawal consent: apremilast (3), etanercept (0), placebo group (1)
• Other reason: apremilast (1), etanercept (1), placebo group (2)
Interventions Intervention
A. Apremilast (n = 83), orally, 30 mg twice daily
Control intervention
B. Etanercept (n = 83), SC, 50 mg weekly
D. Placebo (n = 84)
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 50
• PASI 90
• PGA rating of clear or almost clear
• DLQI score
• AEs
Notes Funding source:
Quote (p 2): ”This study was sponsored by Celgene Corporation.“
Declarations of interest (p1): ”K. Reich has received honoraria as a consultant and/or
advisory board member and/or acted as a paid speaker and/or participated in clinical
trials sponsored by AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene Corpora-
tion, Centocor, Covagen, Eli Lilly, Forward Pharma, GlaxoSmithKline, Janssen-Cilag,
LEO Pharma, Medac, Merck Sharp & Dohme Corp., Novartis, Ocean Pharma, Pfizer,
Regeneron, Takeda, UCB Pharma and XenoPort. M. Gooderham has received hono-
raria, grants and/or research funding as a speaker, investigator, advisory board member,
data safety monitoring board member and/or consultant for AbbVie, Actelion, Amgen,
Astellas Pharma US, Boehringer Ingelheim, Celgene Corporation, Dermira, Eli Lilly,
Galderma, Janssen, Kyowa Hakko Kirin Pharma, LEO Pharma, MedImmune, Merck
& Co., Inc., Novartis, Pfizer, Regeneron, Roche“
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 3): ”Eligible patients were ran-
domised (1 : 1 : 1) via an interactive
voice response system to placebo; apremi-
last oral tablet, 30mg twice daily; or etaner-
cept subcutaneous injection, 50 mg QW“.
“Randomization was conducted via In-
teractive Response Technology, which as-
signed a randomisation number that linked
the subject to a treatment arm and specified
unique medication pack number”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 3): “Eligible patients were ran-
domised (1 : 1 : 1) via an interactive
voice response system to placebo; apremi-
last oral tablet, 30mg twice daily; or etaner-
cept subcutaneous injection, 50 mg QW”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 3): “Per the double dummy de-
sign, patients received oral tablets (apremi-
last 30 mg or placebo) twice daily and two
subcutaneous injections (etanercept 25 mg
each dose or saline placebo) QW.”
Comment: clearly defined
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 3): “Per the double dummy de-
sign, patients received oral tablets (apremi-
last 30 mg or placebo) twice daily and two
subcutaneous injections (etanercept 25 mg
each dose or saline placebo) QW.”
Comment: clearly defined
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 250, 250 analysed
Management of missing data: quote (p 3)
: “Efficacy assessments were conducted for
the modified intent-to treat (mITT) pop-
ulation (all randomised patients who re-
ceived
≥1 dose of study medication and had
both baseline PASI and≥1 post-treatment
PASI evaluations)... Last-observation-car-
ried-forward (LOCF) methodology was
used to impute missing efficacy measure-
ments.”
Comment: done
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Selective reporting (reporting bias) High risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01241591)
The pre-specified outcomes and those
mentioned in themethods section have not
been reported as DLQI
Reich VOYAGE-2, 2017
Methods RCT, active/placebo-controlled, double blind
Date of study: November 2014-May 2016
Location: 115 centres worldwide
Participants Randomised: 992 participants (mean age 44 years, 692 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, IGA ≥ 3 or BSA ≥ 10),
age ≥ 18 years
Exclusion criteria
• Had a history or current signs of a severe, progressive, or uncontrolled medical
condition
• Had current or history of malignancy, except nonmelanoma skin cancer, within 5
years
• Patients with history or symptoms of active TB were excluded
• Patients could not participate if they received guselkumab or adalimumab
previously
Dropouts and withdrawals
• 44/992 (4.4%); guselkumab (18), adalimumab (11), placebo group (15)
• AEs: guselkumab (9), adalimumab (4), placebo group (2)
• Lack of efficacy: guselkumab (0), adalimumab (2), placebo group (4)
• Lost to follow-up: guselkumab (3), adalimumab (2), placebo group (1)
• Withdrawal consent: guselkumab (1), adalimumab (0), placebo group (7)
• Non compliance: guselkumab (1), adalimumab (2), placebo group (0)
• Protocol violation: guselkumab (3), adalimumab (1), placebo group (1)
• Others: guselkumab (1), adalimumab (0), placebo group (0)
Interventions Intervention
A. Guselkumab (n = 496), SC, 100 mg, weeks 0 and 4, then every 8 weeks
Control intervention
B. Adalimumab (n = 248), 80 mg week 0, then 40 mg week 1, and every 2 weeks
C. Placebo (n = 248)
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 90
• IGA clear or almost clear
Secondary outcomes of the trial
• PASI 50/75
• Mean DLQI score
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• NAPSI
• Scalp-specific IGA
• Fingernail PGA
• AEs
Notes Funding source:
Quote (p 1): “Supported by Janssen Research & Development, LLC.”
Declarations of interest (p 1): “Dr Reich has served as advisor and/or paid speaker for
and/or participated in clinical trials sponsored by AbbVie, Amgen, Biogen, Boehringer
Ingelheim Pharma, Celgene, Covagen, Eli Lilly, Forward Pharma, GlaxoSmithKline,
Janssen, Leo, Medac, Merck Sharp & Dohme, Novartis, Ocean Pharma, Pfizer, Regen-
eron, Takeda,UCBPharma, andXenoport. Dr Armstrong has served as investigator and/
or advisor/consultant for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis,
and Pfizer. Dr Foley has served as a consultant, investigator, speaker, and/or advisor for
and/or received travel grants from 3M/iNova/Valeant, Abbott/AbbVie, Amgen, Biogen
Idec, BMS, Boehringer Ingelheim, Celtaxsys, Celgene, Cutanea, Eli Lilly, Galderma,
GSK/Stiefel, Janssen, LEO/Peplin, Novartis, Regeneron, Schering-Plough/MSD, UCB,
andWyeth/Pfizer.Dr Gordon has received research support from AbbVie, Amgen, Boer-
ingher Ingelheim, Eli Lilly, and Janssen, and consultant/ honoraria from AbbVie, Am-
gen, Boeringher Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, and Pfizer. Drs Song,
Wasfi, Randazzo, Li, and Shen are all employees of Janssen Research & Development,
LLC (subsidiary of Johnson & Johnson) and own stock in Johnson & Johnson.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 3): “Patients were randomized
2:1:1 using a permuted block method at
baseline to guselkumab 100 mg at weeks
0, 4, 12, and 20; placebo at weeks 0, 4,
and 12, then guselkumab at weeks 16 and
20; or adalimumab 80 mg at week 0, 40
mg at week 1, and every 2 weeks there-
after through week 23 (Fig 1). Central ran-
domization occurred using an interactive
web based response system (Perceptive In-
formatics, East Windsor, NJ).”
Comment: clearly defined
Allocation concealment (selection bias) Low risk Quote (p 3): “Patients were randomized
using a permuted block method at base-
line in a 2:1:2 ratio to guselkumab 100
mg at weeks 0, 4, 12, and every 8 weeks
through week 44; placebo at weeks 0, 4,
and 12 followed by guselkumab 100 mg
at weeks 16 and 20, and every 8 weeks
through week 44; or adalimumab 80 mg at
week 0, 40 mg at week 1, and 40 mg ev-
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ery 2 weeks through week 47. Central ran-
domization was implemented using an in-
teractiveWorldWideWeb response system
(Perceptive Informatics, East Windsor, NJ)
.”
Comment: clearly defined
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 3): “double-blind, placebo- and
adalimumab comparator controlled study”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 3): “double-blind, placebo- and
adalimumab comparator controlled study”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 992, 992 analyzed
Management of missing data: quote (p 3):
“All randomized patients were included in
the primary analysis and some secondary
efficacy analyses according to their assigned
treatment group.... Patients who discontin-
ued treatment due to lack of efficacy or an
adverse event [AE] of worsening of psori-
asis, or started a protocol-prohibited med-
ication/therapy to improve psoriasis were
considered
treatment failures.”
Comment: done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT02207244)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Rich 2013
Methods RCT, placebo-controlled, double-blind trial
Date of study: July 2009-December 2010
Location: 60 centres in Portland, USA
Participants Randomised: 404 participants
Secukinimab A (66) (mean age 43 years, 53 male)
Secukinimab B (138) (mean age 44 years, 104 male)
Secukinimab C (133) (mean age 45 years, 105 male)
Placebo (67) (mean age 44 years, 44 male)
Inclusion criteria
• Participants with moderate-severe psoriasis
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• PASI ≥ 12, IGA ≥ 3 or BSA ≥ 10
• Age ≥ 18 years
• Non-response to topical treatment
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Pregnancy
• Immunosuppresion
• Had an active infection
• Dropouts and withdrawals
• 24/404 (6%)
• Secukinimab A (5): lack efficacy (2), withdrew consent (1), AE (1), other (1)
• Secukinimab B (4): lack efficacy (1), withdrew consent (2), other (1)
• Secukinimab C (6): withdrew consent (2), AE (3), other (1)
• Placebo (9): lack efficacy (5), withdrew consent (2), AE (2)
Interventions Intervention
A. Secukinumab (n = 66), SC, 150 mg, week 0, 12 weeks
Control intervention
B. Secukinumab (n = 138), SC, 150 mg, weeks 0, 4, 8, 12 weeks
C. Secukinumab (n = 133), SC, 150 mg, weeks 0, 1, 2, 4, 12 weeks
D. Placebo (n = 67), SC, weeks 0, 1, 2, 4, 8, 12 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 75 20/28 weeks
• IGA 12 weeks
• PASI 90 12 weeks
Notes Funding support quote (p 402): “Novartis Pharma AG, Basel, Switzerland”
Declarations of interest (appendix): “P.R. has received honoraria for lecturing in indus-
try-sponsored meetings and has received research grants from pharmaceutical companies
as an investigator. B.S. has consulted for Novartis and several other pharmaceutical com-
panies; he has served on an advisory board for Novartis and several other pharmaceutical
companies. D.T. has served as a speaker and served on advisory boards for Abbott, Bio-
gen-Idec, Janssen-Cilag, Leo, MSD, Novartis and Pfizer. C. Paul has received honoraria
from and has been a paid consultant to Abbott, Amgen, Celgene, Janssen-Cilag, Novartis
and Pierre Fabre. K.R., E.H., A.G., M.M. and C. Papavassilis are full-time employees
of, and own stock in Novartis. J.-P.O., A.M. and R.E.S. declare no conflicts of interest.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 404): “Randomization numbers
were generated by the interactive response
technology provider using a validated sys-
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tem that automated the random assign-
ment of patients numbers to randomisa-
tion numbers”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 404): “Randomization numbers
were generated by the interactive response
technology provider using a validated sys-
tem that automated the random assign-
ment of patients numbers to randomisa-
tion numbers”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 404): “Patients, investigator staff,
persons performing the assessments and
data analysts were blinded to the identity of
treatment from the time of randomisation
until primary outcome analysis”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 404): “Patients, investigator staff,
persons performing the assessment and
data analysts were blinded to the identity of
treatment from the time of randomisation
until primary outcome analysis”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 404 included/404 analysed
Quote (p 405): “Following th intent-to-
treat principle, data were analysed... Miss-
ing values were replaced using the last-ob-
servation-carried-forward approach”
Comment: ITT analyses
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00941031)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Ruzicka 1990
Methods RCT, placebo-controlled, double blind
Date of study: December 1986-March 1988
Location: 7 centres in Germany
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Participants Randomised: 82 participants (mean age 44 years, 55 male)
Inclusion criteria
• Aged 18-75
• Generalized chronic plaque or exanthematic
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had uncontrolled cardiovascular disorder
• Had uncontrolled diabetes
• Had uncontrolled hypertension
Dropouts and withdrawals
• 4/82 (5%)
• Acitretin (2) overweight & dyslipidaemia
• Placebo (2) erythrodermia
Interventions Intervention
A. Acitretin, orally, 35 mg, daily, 8 weeks (n=42)
Control intervention
B. Placebo, orally, daily, 8 weeks (n=40)
Outcomes Assessments at 8 weeks
Primary outcomes of the trial
• PASI
Secondary outcomes of the trial
• Side effects
Notes Funding sources: not stated
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 483): “The study was designed as
a randomized, double-blind, placebo-con-
trolled parallel group trial”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 483): “The study was designed as
a randomized, double-blind, placebo-con-
trolled parallel group trial”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 483): “The study was designed as
a randomized, double-blind, placebo-con-
trolled parallel group trial”
Comment: no description of the method
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used to guarantee blinding as visible side
effects are related to acitretin
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 483): “The study was designed as
a randomized, double-blind, placebo-con-
trolled parallel group trial... the investiga-
tors blinded to treatment assignment”
Comment: no description of the method
used to guarantee blinding of outcome as-
sessment as visible side effects are related to
acitretin
Incomplete outcome data (attrition bias)
All outcomes
Low risk 82 included/78 analysed
Quote (p 483): “... according to the inten-
tion-to-treat principle.. Dropout data were
evaluated on the date of dropout”
Comment: probably done
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available.
The pre-specified outcomes mentioned in
the methods section appeared to have been
reported
Sandhu 2003
Methods RCT, active-controlled, open label
Date of study: not stated
Location: multicentric (number not stated) in North India
Participants Randomised: 30 participants (methotrexate: mean age 39 years, 12 male; ciclosporin:
mean age 46 years, 13 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA > 40%), age ≥ 18 years
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had uncontrolled hypertension
• Had past history of malignant tumours
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Methotrexate (n = 15), orally, 0.5 mg/kg dose tapered after PASI 75 obtained
Control intervention
B. Ciclosporin (n = 15), orally, 3 mg/kg increased to 4 if no change or rise of dose tapered
after PASI 75 obtained
Outcomes Assessments at 12 weeks
Primary or secondary outcomes of the trial
• Not clearly defined
282Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sandhu 2003 (Continued)
Outcomes of the trial
• PASI
Notes Funding source: not stated
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 459): “Patients were randomly
assigned to either...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 459): “Patients were randomly
assigned to either...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not blind
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: not blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 30 included/30 analysed
Methods for dealing with missing data: not
stated
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported.No primary outcome declared
Saurat 1988
Methods RCT, active/placebo-controlled, double blind
Date of study: not stated
Location: 6 centres in France and Switzerland
Participants Randomised: 42 participants (placebo (22) mean age 43 years, 16 male; acitretin (20),
mean age 46 years, 16 male)
Inclusion criteria
• BSA > 20%
Exclusion criteria
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• Kidney insufficiency, liver insufficiency, had uncontrolled cardiovascular disorder
Dropouts and withdrawals
• 7/65 (11%)
Interventions Intervention
A. Acitretin (n = 20), orally, 2 x 25/d 2 weeks and 25/d + UVA 3/weeks, daily, 10 weeks
Control intervention
C. Placebo, orally (n = 22), daily, 10 weeks
Co-intervention: UVA 3/week, 10 weeks
Outcomes Assessments not clearly stated (reported at 8 weeks)
Primary outcomes of the trial
• Not clearly stated
Outcomes of the trial
• Change in PASI
• Time to clear
• AEs
Notes Funding: not stated
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 219): “This multicenter study
was performed in a double-blind, parallel
fashion... The patients were randomly allo-
cated to ...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 219): “This multicenter study
was performed in a double-blind, parallel
fashion... The patients were randomly allo-
cated to ...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p 219): “This multicenter study
was performed in a double-blind, paral-
lel fashion...All patients initially received
2 capsules of test medication (placebo, ac-
itretin 2x25 mg, ....”
Comment: no description of the method
used to guarantee blinding of outcome as-
sessment with visible AE in both acitretin
and etretinate groups
284Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Saurat 1988 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: no description of the method
used to guarantee blinding of outcome as-
sessment with visible AE in both acitretin
and etretinate groups
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote (p 220): “Patients who left the study
... were not included in the evaluation of
efficacy”
Comment: not ITT analyses (number lost
to follow-up unknown)
Selective reporting (reporting bias) Low risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Saurat CHAMPION, 2008
Methods RCT, active/placebo-controlled, double blind
Date of study: unreported
Location: multicentre (n = 28) in Europe & Canada
Participants Randomised: 271 participants (mean age 42, 178 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 10 or BSA ≥ 10), age > 18
years
Exclusion criteria
• Pregnancy, immunosuppression, kidney insufficiency, liver insufficiency, past
history of malignant tumours
• Had received conventional systemic treatments for “Methotrexate” arm
• Had received biologics
Dropouts and withdrawals
• 15/271 (5.5%): adalimumab group (4), methotrexate group (6), placebo group (5)
• AEs: adalimumab group (1), methotrexate group (6), placebo group (1)
• Lack of efficacy: adalimumab group (0), methotrexate group (0), placebo group
(4)
• Withdrawal consent: adalimumab group (2), methotrexate group (0), placebo
group (0)
• Other reason:adalimumab group (1), methotrexate group (0), placebo group (0)
Interventions Intervention
A. Adalimumab (n = 108), SC, 80 mg at week 0, 40 mg at week 1 and 40 mg eow
Control intervention
B. Methotrexate (n = 110), orally, 7.5-25 mg weekly
C. Placebo (n = 53), SC and orally (same drug administration)
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Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 50
• PASI 90
• PASI 100
• PGA
• DLQI
• AEs
Notes Funding source:
Quote (p 561): “Abbott Laboratories funded this study and participated in the study de-
sign, data collection, data management, data analysis and preparation of the manuscript”
Declarations of interest (p 558): “J.-H.S., G.S., L.D., K.P. and J.-P.O. have served as
consultants for Abbott Laboratories. In addition, they have participated in continuing
medical education events supported by unrestricted educational grants from Abbott. R.
G.L. reports receiving fees as a consultant or advisory board member for Abbott, Amgen,
Astellas, Boehringer- Ingelheim, Barrier Therapeutics and Genentech;
he has received lecture fees from Abbott, Amgen/ Wyeth and Biogen-Idec, and has been
the principal investigator and received grants from Abbott, Amgen, Astellas, Centocor,
Galderma and Genentech. K.U., M.K. and A.C. are employees of Abbott. ”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 559):“Randomisation was com-
pleted through a central computer-gener-
ated scheme stratified by centre, with block
sizes of four”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 559): “Patient numbers were cen-
trally assigned by an interactive voice-re-
sponse system in consecutive order”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 559): “Adalimumab (Humira;
Abbott Laboratories) or matching placebo
for SC injection was provided as sterile
preservative-free solution in prefilled sy-
ringes. Oral methotrexate tablets were sup-
plied by Wyeth Pharma (Münster, Ger-
many), and placebo tablets were sup-
plied by Abbott GmbH & Co. KG (Lud-
wigshafen,Germany). Both themethotrex-
ate and placebo tablets were administered
286Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Saurat CHAMPION, 2008 (Continued)
as capsules (encapsulated tablets) as a sin-
gle weekly dose. The capsules for both
methotrexate and
placebo were supplied by Fisher Clinical
Services (Basel, Switzerland).”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 559): “Adalimumab (Humira;
Abbott Laboratories) or matching placebo
for SC injection was provided as sterile
preservative-free solution in prefilled sy-
ringes. Oral methotrexate tablets were sup-
plied by Wyeth Pharma (Münster, Ger-
many), and placebo tablets were sup-
plied by Abbott GmbH & Co. KG (Lud-
wigshafen,Germany). Both themethotrex-
ate and placebo tablets were administered
as capsules (encapsulated tablets) as a sin-
gle weekly dose. The capsules for both
methotrexate and
placebo were supplied by Fisher Clinical
Services (Basel, Switzerland).”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 271, analysed 271
Management of missing data: quote (p
562): “Data for 16 patients with miss-
ing week 16 assessments for PASI, includ-
ing the 15 patients who discontinued and
one additional patient in the methotrexate
group, were imputed as nonresponse.”
Comment: probably done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00235820)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported except for
DLQI that was published in a second study
Shehzad 2004
Methods RCT, active-controlled, open label
Date of study: March 2001-November 2001
Location: 1 centre in Karachi, Pakistan
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Participants Randomised: 40 participants (age from 18-50 years, 60 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI > 10)
Exclusion criteria
• Immunosuppresion, kidney insufficiency, liver insufficiency
• Had an active infection
• Had uncontrolled cardiovascular disorder
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. PUVA therapy (+ psoralen) (n = 20), 4 times/week
Control intervention
B. Methothrexate (n = 20), orally, 10 mg/week, 5 mg Saturday + Sunday
Outcomes Time of assessments: not stated
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• Time to clearance
• AEs
Notes Funding source: Immunex Corporation
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (in the method section): “The se-
lected patients ... randomly allocated to...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (in the method section): “The se-
lected patients ... randomly allocated to...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: not blinded
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: no description of the methods
used to manage missing data, no descrip-
tion of the methods used to assess the pri-
mary outcome (ITT, PP...)
Selective reporting (reporting bias) High risk Comment: no protocol was available. The
outcomes mentioned in the results section
were not specified in the methods section
Sommerburg 1993
Methods RCT, placebo-controlled, double blind
Date of study: 1986-1988
Location: 7 centres in Germany
Participants Randomised: 88 participants (mean age 45 years, 68 male)
Inclusion criteria
• Generalized chronic plaque psoriasis or exanthematic
• Aged 19-75 years
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had uncontrolled cardiovascular disorder
• Had uncontrolled diabetes
• Had uncontrolled hypertension
Dropouts and withdrawals
• 5/88 (6%)
• Acitretin (4), placebo (1)
• Missing outcome (3) erythroderma (1)
Interventions Intervention
A. Acitretin (n = 44), orally, 50 mg (15 days) then 25 mg, daily, 8 weeks
Control intervention
B. Placebo (n = 44), orally, daily, 8 weeks
Co-intervention
PUVA (8-methoxypsoralen), orally 0.6 mg/kg, 3-5/week, 8 weeks
Outcomes Assessments at 8 weeks
Primary outcomes of the trial
• PSI
Secondary outcomes of the trial
• PSI 75
Notes Funding source: not stated
Declarations of interest: not stated
Risk of bias
289Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sommerburg 1993 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 310): “The study was designed
as a randomised, double-blind, parallel
groups trial... Both investigators and bio-
statisticians were blinded”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 310): “The study was designed
as a randomised, double-blind, parallel
groups trial... Both investigators and bio-
statisticians were blinded”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote (p 310 & 311): “The study was
designed as a randomised, double-blind,
parallel group trial... Both investigators
and biostatisticians were blinded… how-
ever due to well know side effect pattern of
acitretin, ..., the possibility of an investiga-
tor bias cannot be excluded”
Comment: visible AE in acitretin groups
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p 310 & 311): “ The study was
designed as a randomised, double-blind,
parallel group trial... Both investigators
and biostatisticians were blinded… how-
ever due to well know side effect pattern of
acitretin, ..., the possibility of an investiga-
tor bias cannot be excluded”
Comment: visible AE in acitretin groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk 88 included/83 analysed
Quote (p 311): “Patients who discontinued
the trial prematurely were evaluated on the
date of discontinuation of therapy”
Comment: not ITT, low number of drop-
outs
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
290Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sterry PRESTA, 2010
Methods RCT, active-controlled, double blind
Date of study: December 2005-May 2008
Location: centres (n = 98) worldwide
Participants Randomised: 754 participants (mean age 46 years, 473 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PGA moderate-severe, BSA > 10)
• Age ≥ 18
Exclusion criteria
• Pregnancy
• Had received biologics
• Had an active infection
Dropouts and withdrawals
• 59/754 (8%)
• No drug administered (2)
• Etanercept twice a week (29): AE (14), lost to follow-up (2), deviation (4),
decision (5), lack efficacy (4)
• Etanercept once a week (28): AE (10), lost to follow-up (2)
Interventions Intervention
A. Etanercept, SC, 50 mg, twice a week, 12 weeks
Control intervention
B. Etanercept, SC, 50 mg, once a week, 12 weeks
Outcomes Assessments at 12 weeks
Primary and secondary outcomes of the trial
• Clear or almost clear PGA (0/1)
Outcomes of the trial
• PGA 24 weeks
• PASI 75
• PASI 90
• Mean PASI
• ACR (American College of Rheumatology) 20, 50 and 70 (weeks 12 and 24)
• Participant-reported outcomes
Notes Funding, quote (p 8): “Wyeth Research, which was acquired by Pfizer in October 2009,
sponsored this clinical trial and was responsible for the collection and analysis of data...”
Declarations of interest (p 8): “WS has received fees for speaking/consulting fromAbbott,
Schering-Plough, Wyeth, and Janssen-Cilag. J-PO has received fees for speaking/con-
ferences/consulting from Schering-Plough, Abbott, Merck-Serono, Centocor, Wyeth,
Janssen-Cilag, MedPharma, Laboratorios Pierre-Fabre, Galderma Laboratories, and Leo
Pharma. BK has served on advisory boards for Schering-Plough and Roche; has received
funds for research/travel/conferences from Wyeth, Centocor, Abbott, Schering-Plough,
Roche, and Bristol-Myers Squibb; and has served on a speaker panel for Bristol-Myers
Squibb. OB has received fees from Wyeth, Schering-Plough, Abbott, Roche, Chugai,
and Bristol-Myers Squibb. DR, RDP, JE, CM, and BF are all employees of Pfizer.”
Risk of bias
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Sterry PRESTA, 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 3): “We randomly assigned par-
ticipants to ...”
Comment: no description of the method
used to generate random sequences
Allocation concealment (selection bias) Unclear risk Quote (p 3): “We randomly assigned par-
ticipants to ...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 3): “In the double blind period..
.”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 3): “In the double blind period..
.”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 754 included/752 analysed
Quote (p 4): “The modified intention-to-
treat (ITT) population included all ran-
domised participants who took at least one
dose of the test drug and at least one post
baseline efficacy evaluation... Efficacy anal-
yses used the last observation carried for-
ward method for imputation of missing
data”
Comment: mITT and only 2 of 754 par-
ticipants not included in the analysis of the
primary outcome
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00245960)
The pre-specified outcomes mentioned in
the methods section appeared to have been
reported except for the results of partici-
pant-reported endpoints summarized in a
separate publication
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Strober 2011
Methods RCT, placebo-controlled, double blind
Date of study: July 2008-April 2009
Location: 41 centres in the USA
Participants Randomised: 211 participants (mean age 45 years, 131 male)
Inclusion criteria
• -Participants with moderate-severe psoriasis (PGA ≥ 3, PASI ≥ 12, BSA ≥ 10),
age ≥ 18 years
Exclusion criteria
• Previous exposure to either etanercept or ABT-874
Dropouts and withdrawals
• 18/211 (8.5%): etanercept 12, placebo 6
• Time and reasons:
◦ Etanercept: AE (3), lost to follow-up (1), withdrew consent (3), protocol
violation (4), other (1)
◦ Placebo: AE (2), lost to follow-up (1), protocol violation (2), other (1)
Interventions Intervention
A. Etanercept (n = 139), SC auto-administered, 50 mg twice a week, 11 weeks
Control intervention
B. Placebo (n = 72), SC auto-administered, twice a week
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
• PGA 0/1
Secondary outcomes of the trial
At 4, 8, 12 weeks
• PASI 50
• PASI 75
• PASI 90
• DLQI
• PGA
• Safety
• Patient global assessment of psoriasis
Notes Funding source, quote (Appendix 1): “Abbott Laboratories funded this study and partic-
ipated in the study design, data collection, data management, data analysis and prepara-
tion of the manuscript. All of the authors had full access to the data and were involved in
the analysis of data, development and revision of the manuscript, and decision to submit
the manuscript for publication. The corresponding author takes responsibility for the
integrity of the data and the accuracy of the data analysis.”
Declarations of interest (appendix 1): “B.E.S. has been an investigator, consultant,
speaker, and served on an advisory board for Amgen, Abbott and Centocor; and has also
been a speaker for Astellas. J.J.C. has received research support from Abbott, Amgen,
Centocor, Celgene and Eli Lilly; has been a consultant for Abbott, Amgen and Centocor;
and has been a speaker for Abbott. P.S.Y. has served as a consultant, principle investigator,
speaker or advisory board member for Abbott, Amgen, Astellas and Centocor. M.O. and
D.A.W. are employees of Abbott.”
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Strober 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 662): “Patients were randomised.
..”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 662): “Patients were randomised”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 662): “Patients enrolled in the
placebo arm received SC injections match-
ing active treatment to maintain the blind.
To maintain the blind, all patients received
two SC injections at weeks 0 and 4 and
one SC injection at week 8, consisting of
either briakinumab or matching placebo,
depending on the treatment arm. In ad-
dition, each patient also received two SC
injections biweekly, 3 days apart, week 0
through week 11, consisting of either etan-
ercept or matching placebo, depending on
the treatment arm.”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 662): “Patients enrolled in the
placebo arm received SC injections match-
ing active treatment to maintain the blind.
To maintain the blind, all patients received
two SC injections at weeks 0 and 4 and
one SC injection at week 8, consisting of
either briakinumab or matching placebo,
depending on the treatment arm. In ad-
dition, each patient also received two SC
injections biweekly, 3 days apart, week 0
through week 11, consisting of either etan-
ercept or matching placebo, depending on
the treatment arm.”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 211, analysed 211
Management of missing data:
Quote (p 663): “The primary efficacy anal-
ysis consisted of four comparisons per-
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Strober 2011 (Continued)
formed in the intent-to-treat population (i.
e. all randomised patients),…,Nonrespon-
der imputation was used to handle missing
data.”
Comment: done
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00710580)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Strohal PRISTINE, 2013
Methods RCT, active-controlled, double blind
Date of study: April 2008-March 2012
Location: 32 centres in Europe, Latin America and Asia
Participants Randomised: 273 participants (mean age 44 years, 190 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 10, BSA ≥ 10), age ≥ 18
years
• Non-response to topical treatment
• Non-response to phototherapy
• Non-response to conventional systemic treatment
Exclusion criteria
• Had received biologics
• Had an active infection
Dropouts and withdrawals
• 25/273 (9%)
• Time and reasons:
◦ No efficacy evaluations (3)
◦ Etanercept once a week (10): AE (3), lack of efficacy (1), decision (5), other
(1)
◦ Etanercept twice a week (12): AE (6), lack of efficacy (1), decision (2),
deviation (1), other (2)
Interventions Intervention
A. Etanercept (n = 137), SC, 50 mg, once a week, 24 weeks
Control intervention
B. Etanercept (n = 136), SC, 50 mg, twice a week, 24 weeks
Outcomes Assessments at 24 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 50, 75, 90
• Mean PASI
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Strohal PRISTINE, 2013 (Continued)
• PGA (Physician Global Assessment) 0/1
• DLQI
• AE
Notes Funding source, quote (p 177): “The PRISTINE trial was sponsored by Pfizer Inc...”
Declarations of interest (p 177-178): “Robert Strohal has been a paid consultant of and
has received research grants from Pfizer Inc, which provided funding for the PRISTINE
study. He is also a member of the Pfizer European Expert Board and of the Pfizer
Speakers Bureau. Luis Puig has been a paid consultant of and has received research grants
from Pfizer; he has served on Pfizer advisory boards and the Speakers Bureau. Edgardo
Chouela is a paid consultant and speaker for Pfizer Inc and Galderma and has conducted
clinical studies for Novartis, Jannssen, Pfizer and Roche. Tsen-Fang Tsai has been a paid
consultant of Pfizer Inc; he has served as an investigator and received honoraria for serving
as an advisor and speaker for Pfizer. Jeffrey Melin, Bruce Freundlich and Charles Molta
were previous employees of Wyeth and Pfizer Inc. Joanne Fuiman, Ronald Pedersen and
Deborah Robertson are current employees of Pfizer Inc.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 170): “Subjects were randomly
assigned to one of the 2 etanercept treat-
ment groups... in 1:1 treatment allocation”
Comment: not specified
Allocation concealment (selection bias) Unclear risk Quote (p 170): “Subjects were randomly
assigned to one of the 2 etanercept treat-
ment groups... in 1:1 treatment allocation”
Comment: not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 170): “The study consisted of a
12-week double-blind treatment period”
Comment: probably done, placebo-con-
trolled
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 170): “The study consisted of a
12-week double-blind treatment period”
Comment: probably done, placebo-con-
trolled
Incomplete outcome data (attrition bias)
All outcomes
Low risk 273 enrolled and randomised and270 anal-
ysed
Quote (p 171): “All efficacy analyses were
performed using the modified intent-to-
treat population which included all ran-
domised subjects who received at least one
dose of etanercept and had both baseline
and on therapy PASI evaluations. The last
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Strohal PRISTINE, 2013 (Continued)
observation-carried-forward method was
used for the imputation of missing data...”
Comment: mITT and only 3 of 273 par-
ticipants not included in the analyses of the
primary outcome
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00663052)
The pre-specified outcomes mentioned in
the methods section appeared to have been
reported
Tanew 1991
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: 2 centres in Austria (Vienna, Innsbruck)
Participants Randomised: 60 participants (mean age 40 years (acitretin), 49 years (placebo); 42male)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 20), age ≥ 18 years
Exclusion criteria
• Not stated
Dropouts and withdrawals
• 12/60 (20%)
• Time and reasons:
◦ acitretin group (7): severe muscle pain (1), serum triglycerides exceeding 400
mg/dL (2), irregular drug intake (4)
◦ placebo group (5): unrelated to therapy
Interventions Intervention
A. Acitretin (n = 30), orally, 1 mg/kg, daily, 12 weeks or until complete clearing
Control intervention
B. Placebo (n = 30), orally, daily, 12 weeks
Co-intervention
PUVA, phototherapy, 4 times/week, 12 weeks
Outcomes Assessments at 12 weeks
Primary and secondary outcomes of the trial
• Not defined
Outcomes of the trial
• Complete remission
• Side effects
Notes Funding: supported by a grant from Hoffma La Roche & Co Ltd
Declarations of interest: not stated
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 682): “Only patients ... were in-
cluded and assigned randomly...”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 682): “Only patients ... were in-
cluded and assigned randomly...”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (p682): “Acitretin ... or placebo...”
Comment: no description of the method
used to guarantee blinding of participants
and personnel as acitretin leads to visible
adverse effects (cheilitis)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (p682): “Acitretin ... or placebo...”
Comment: no description of the method
used to guarantee blinding of participants
and personnel as acitretin leads to visible
adverse effects (cheilitis)
Incomplete outcome data (attrition bias)
All outcomes
High risk Randomly assigned 60, analysed 48
Quote (p 683): “Of the 60 patients, 48
completed the study and were included in
the statistical analysis”
Comment: not ITT
Selective reporting (reporting bias) Unclear risk Noprotocol available, no outcomes defined
in the method section
Thaci CLEAR, 2015
Methods RCT, active-controlled, double blind
Date of study: 27 February 2014-11 May 2015
Location: 137 centres in Europe, Australia and Asia
Participants Randomised: 676 participants (mean age 46 years, 481 male)
Inclusion criteria
• -Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10), age ≥ 18
years
Exclusion criteria
• Immunosuppression, active infection
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Thaci CLEAR, 2015 (Continued)
• Had received anti IL17 drug or ustekinumab
Dropouts and withdrawals
• 32/676 (4.7%)
• Did not receive the treatment (4)
• Information consent obtained the day after study-related procedure (1, excluded
from the efficacy analysis)
• AE (7)
• Lost to follow-up (3)
• Protocol deviation (5)
• Participant/guardian decision (7)
• Physician decision (1)
• Non compliance with study treatment (1)
• Technical problem (1)
Interventions Intervention
A. Secukinumab (n = 334), SC, 300 mg weeks 0, 1, 2, 3 then monthly
Control intervention
B. Ustekinumab (n = 335), SC, 45/90 mg weeks 0, 4 then every 12 weeks
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 90
Secondary outcomes of the trial
• PASI 75
• PASI 90 at week 54
• DLQI
• AEs
Notes Funding source:
Quote (p 400): “Novartis Pharma supported this study”
Declarations of interest (p 400): “Dr Thac i has served as a consultant, served as an
advisory board member, and/or received honoraria for lecturing for AbbVie, Amgen,
Biogen-Idec, Celgene, Eli Lilly, Janssen-Cilag, Leo Pharma, MSD, Novartis, Pfizer, Re-
generon, and Sanofi. Dr Blauvelt has served as a scientific consultant and clinical study
investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen Or-
tho Biotech, Merck, Novartis, Pfizer, and Sandoz. Dr Reich has served as a consultant
and/or paid speaker for and/or participated in clinical trials sponsored by companies
that manufacture drugs used for the treatment of psoriasis including AbbVie, Amgen,
Biogen-Idec, Celgene, Centocor, Covagen, Eli Lilly, Forward Pharma, GSK, Janssen-
Cilag, Leo Pharma, Medac, MSD, Novartis, Pfizer, Vertex, Takeda, and Xenoport...”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 402): “were randomised via an in-
teractive response technology system“Ran-
domization was conducted via Interactive
Response Technology, which assigned a
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Thaci CLEAR, 2015 (Continued)
randomisation number that linked the sub-
ject to a treatment armand specifiedunique
medication pack number
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p402): “were randomised via an in-
teractive response technology system “
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p402) : “To maintain blinding,
placebo injections matching the secuk-
inumab regimen were given in the ustek-
inumab group”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p402) : “To maintain blinding,
placebo injections matching the secuk-
inumab regimen were given in the ustek-
inumab group”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 676, analysed 669
Management of missing data:
Quote (p 403): “Missing values with re-
spect to response variables based on PASI
and IGAmod 2011 scores were imputed as
nonresponse (nonresponder imputation).”
Comment: however it was not an ITT anal-
ysis as 7 participants were not taken into
account but low rate of dropout
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT02074982)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Torii 2010
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Location: 28 centres in Japan
Participants Randomised: 54 participants (mean age 46 years, 36 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10)
Exclusion criteria
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Torii 2010 (Continued)
• Active infection
• Past history of malignant tumours
Dropouts and withdrawals
• 7/54 (13%) at W14;
• Infliximab (3): therapeutic effect (2), adverse event (1)
• Placebo (4): AE (1), withdrawal of consent (3)
Interventions Intervention
A. Infliximab (n = 35), IV, 5 mg/kg, weeks 0, 2, 6; 10 weeks
Control intervention
B. Placebo (n = 19), IV, weeks 0, 2, 6; 10 weeks
Outcomes Assessments at 10 weeks
Primary outcomes of the trial
• PASI75
Secondary outcomes of the trial
• PASI50
• DLQI
• PGA
• AE
Notes Funding: not stated
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 41): “Eligible patients were ran-
domised in a 2:1 ratio to either... using the
dynamic allocation method”
Comment: no description of the methods
used to guarantee the random sequence
generation
Allocation concealment (selection bias) Unclear risk Quote (p41): “Eligible patients were ran-
domised in a 2:1 ratio to either... using the
dynamic allocation method”
Comment: no description of the methods
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p41): “The induction phase of th
treatment was .. double-blind placebo con-
trolled trial... Infliximab or placebo was ad-
ministered by IV drip infusion over a pe-
riod of at least 2h ..
Comment: probably done
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p41): ”The induction phase of th
treatment was .. double-blind placebo con-
trolled trial... Infliximab or placebo was
administered by intravenous drip infusion
over a period of at least 2h ..
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 54, analysed 54
Quote (p42): “This primary endpoint anal-
ysis was performed on an ”intent-to-treat“
basis...Patients who discontinued the study
treatment ... were handled as ”not im-
proved“ in the assessment”
Comment: probably done
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available.
The pre-specified outcomes mentioned in
the methods section appeared to have been
reported
Tsai PEARL, 2011
Methods RCT, placebo-controlled, double blind
Date of study: December 2008-March 2010
Location: 13 centres in Taiwan and Korea
Participants Randomised: 121 participants (mean age 41 years, 103 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI≥ 12, BSA≥ 10), age > 20 years
Exclusion criteria
• Had an active infection
• Past history of malignant tumours
Dropouts and withdrawals
• 9/121 (7.4%): ustekinumab group (4), placebo group (5)
• AEs: placebo group (3)
• Unsatisfactory therapeutic effects: ustekinumab group (1), placebo group (2)
• Invalid study entry criteria: ustekinumab group (2)
• Withdrawal of consent: ustekinumab group (1)
Interventions Intervention
A. Ustekinumab, SC, 45 mg, weeks 0, 4, 16 + placebo week 12, 16 weeks
Control intervention
B. Placebo, SC, weeks 0-4 + ustekinumab 45 mg weeks 12-16
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
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• PGA cleared or minimal at 12 weeks
• Change from baseline in the DLQI at 12 weeks
• AEs
Notes Funding source quote (p 162): ”This study was supported by Centocore, Inc“
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 155): “Patients were enrolled in
this multicenter..., double-blind, placebo-
controlled study... Randomization was per-
formed via an interactive voice response
system based on minimization with bias-
coin assignment...”“Randomization was
conducted via Interactive Response Tech-
nology, which assigned a randomisation
number that linked the subject to a treat-
ment arm and specified unique medication
pack number”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p155): “Patients were enrolled in
this multicenter..., double-blind, placebo-
controlled study... Randomization was per-
formed via an interactive voice response
system based on minimization with bias-
coin assignment...”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p155): “Patients were enrolled in
this multicenter..., double-blind, placebo-
controlled study..
Comment: placebo trial, probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p155): “Patients were enrolled in
this multicenter..., double-blind, placebo-
controlled study..
Comment: placebo trial, probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 121, analysed 121
Quote (p 156): “For all efficacy analyses,
patients were analysed by assigned treat-
ment groups...Data were analysed by in-
tent-to-treat for the primary endpoint... Pa-
tients who discontinued study treatment..
. were judged as non-responders for binary
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endpoints”
Comment: ITT analyses
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available.
The pre-specified outcomes mentioned in
the methods section appeared to have been
reported
Tyring 2006
Methods RCT, placebo-controlled, double blind
Date of study: June 2003-January 2004
Location: 39 centres in Houston, USA and Canada
Participants Randomised: 620 participants (mean age 46 years, 419 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI≥ 10, BSA≥ 10), age > 18 years
Exclusion criteria
• Kidney insufficiency, liver insufficiency, past history of malignant tumours
• Had received conventional systemic treatments
• Had received biologics (etanercept or anti-TNF)
Dropouts and withdrawals
• 23/620 (3.7%); etanercept group (6), placebo group (15)
• AEs: etanercept group (4), placebo group (3)
• Disease progression: etanercept group (1), placebo group (4)
• Withdrawal of consent: etanercept group (1), placebo group (5)
• Lost to follow-up: placebo group (4)
• Non-compliance: placebo group (1)
Interventions Intervention
A. Etanercept (n = 311), 50 mg, SC, twice weekly, 12 weeks
Control intervention
B. Placebo (n = 309), SC, twice weekly, 12 weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• DLQI at 12w
• PASI 50
• PASI 90
• the 17-item Hamilton rating scale for depression
• Beck depression inventory
Notes Funding, quote (p 361): “The study was designed by Immunex, S Tyring, and other
members of the Etanercept Psoriasis study group (The complete data set was held at the
central data-processing facility at Amgen)
Declarations of interest (p 367-368): ”S Tyring has received research support from Am-
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gen. A Gottlieb is a consultant for several companies (Amgen, BiogenIdec, CellGate,
Centocor, Genentech, Novartis AG,Wyeth Pharmaceuticals, Schering-Plough Corpora-
tion, Eisai, Celgene, Bristol Myers Squibb, Beiersdorf,Warner Chilcott, Abbott Labs, Al-
lergan, Kemia, Roche, Sankyo, Medarex, Celera, TEVA, Actelion, and Advanced Immu-
niT) and is on the speaker’s bureau for Amgen, BiogenIdec, andWyeth Pharmaceuticals.
She has also received research funding from Amgen, BiogenIdec, Centocor, Genentech,
Abbott Labs, Ligand Pharmaceuticals, Beiersdorf, Fujisawa Healthcare, Celgene Corp,
Synta, Bristol Myers Squibb,Warner-Chilcott, and Paradigm. K Papp is a consultant, has
received research funding, and has served as a speaker for Amgen, BiogenIdec, Centocor,
Genentech, Novartis, Wyeth, Schering-Plough, Abbott, Allergan,Medimmune, Serono,
Xoma, Isotechnica, and GlaxoSmithKline. He has also served as a medical or scientific
officer for Amgen, Centocor, Genentech, and Serono. K Gordon has received research
support and honoraria from Abbott, Amgen, Biogen-IDEC, Centocor, Genentech, and
Synta. C Leonardi is: a consultant, investigator, and speaker for Amgen and Genentech
and has received educational grants from these companies; a consultant, investigator,
and speaker for Centocor; a consultant and investigator for Serono; and a consultant,
investigator, and speaker for Abbott...“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 30): “Randomisation code lists
were generated in the Biostatistics Depart-
ment at Amgen by a designed person with
no other association with the study”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p 30): “Randomisation code lists
were generated in the Biostatistics Depart-
ment at Amgen by a designed person with
no other association with the study”
Comment: no precision
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 30): ”All patients received 2 injec-
tions per dose of investigational product”,
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 30): “To prevent study assessors
from being influenced by the presence of
an injection site reaction, patients applied
dressings to the last three injection sites and
to any erythematous injection sites before
each psoriasis evaluation”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 620, analysed 617 for
the primary outcome
Management of missing data: quote (p 31)
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: “The primary analyses for all efficacy
endpoints included all randomised patients
who received at least one dose of investi-
gational product. Missing values were im-
puted using last observation carried for-
ward”
Comment: only 2 participants did not re-
ceive at least one dose, 618 participants
should be involved in the mITT, however
617 participants were analysed for the pri-
mary outcome
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT00111449)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Vaclavkova 2014
Methods RCT, active/placebo-controlled, double blind
Date of study: 22 September 2010-24 October 2012
Location: 58 centres in Europe and Russia
Participants Randomised: 326 participants (mean age 40 years, 245 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 10, BSA ≥ 10), age 18-60
years
Exclusion criteria
• Immunosuppressive treatment for other diseases than psoriasiss
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 48/326 (14.7%); ponesimod 20 group (17), ponesimod 40 group (20), placebo
group (11)
• Patient decision: ponesimod 20 group (4), ponesimod 40 group (3), placebo
group (7)
• AE and patient decision: ponesimod 20 group (1), ponesimod 40 group (1),
placebo group (1)
• AEs: ponesimod 20 group (6), ponesimod 40 group (12), placebo group (0)
• Withdrew consent: ponesimod 20 group (3), ponesimod 40 group (3), placebo
group (0)
• Lack of efficacy: ponesimod 20 group (1), ponesimod 40 group (0), placebo
group (1)
• Lack of efficacy and patient decision: ponesimod 20 group (0), ponesimod 40
group (0), placebo group (1)
• Administrative : ponesimod 20 group (2), ponesimod 40 group (1), placebo
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group (1)
Interventions Intervention
A. Ponesimod (n = 126), orally, 10 mg for 7 days then 20 mg, 16 weeks
B. Ponesimod (n = 133), orally, 10 mg for 7 days then 20 mg days 8 -15 then 40 mg,
16 weeks
Control intervention
C. Placebo (n = 67), orally, 16 weeks
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA 0 or 1
• PASI 90
• Change from baseline pain psoriatic arthritis
Notes Funding (p 2044): “This study was sponsored by Actelions Pharmaceuticals”
Declarations of interest (p 2044): “AV,MB, and DD’A were employees and stockholders
of Actelion Pharmaceuticals when the study was done. SC has been lecturer, consultant,
or both, for AbbVie, Janssen-Cilag, Leo-Pharma, Merck, Novartis, and Pfizer. MS has
received personal fees for statistical consultancy from Actelion Pharmaceuticals and SDE
Research. PA, PH, and P-GS declare that they have no competing interests.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 2037): “A unique seven-digit ran-
domisation number was assigned to each
patient by an independent service provider
(ICONClinical Research,Dublin, Ireland)
via an interactive voice or internet-based re-
sponse system”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (p 2037): “A unique seven-digit ran-
domisation number was assigned to each
patient by an independent service provider
(ICONClinical Research,Dublin, Ireland)
via an interactive voice or internet-based re-
sponse system”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 2037): “The investigational drug
and matching placebo were identical in
appearance and packaging...The primary
investigator, care providers, patients, and
sponsor were unaware of study treatment
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assignment and lymphocyte count. An in-
dependent physician monitored patients
after the first dose was administered or in-
creased until the end of the study.”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 2037): “The investigational drug
and matching placebo were identical in
appearance and packaging...The primary
investigator, care providers, patients, and
sponsor were unaware of study treatment
assignment and lymphocyte count. An in-
dependent physician monitored patients
after the first dose was administered or in-
creased until the end of the study.”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 326, analysed 326
Quote (p 2037): “All randomised patients
were assessed by intention-to-treat for the
primary, secondary, and all efficacy end-
points in the induction period... Missing
or invalid values were handled with nonre-
sponder imputation”
Comment: ITT analyses
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01208090)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Van Bezooijen 2016
Methods RCT, placebo-controlled, double blind
Date of study: 2013 and June 2015
Location: single centre in the Netherlands
Participants Randomised: 33 participants
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI≥ 10, BSA≥ 10), age > 18 years
Exclusion criteria
• Any other subtype of psoriasis
• Previous treatment failure on etanercept or fumarates
• Had a clinically significant adverse event with prior use of both drugs.
• Pregnant or lactating women
Dropouts and withdrawals
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• None at week 12
Interventions Intervention
A. Fumaric acid (n = 18), from 215 mg once daily up to a maximum of 215 mg 4 times
a day, 24 weeks
Control intervention
B. Placebo
Co-intervention
Etanercept (n = 14) (50mg SC twice weekly for 12 weeks followed by 50 mg once weekly
for an additional 12 weeks)
Outcomes Assessments at 24 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA0/1
• DLQI
• AEs
Notes Funding, quote (supplemental appendix): ”This investigator-initiated study was sup-
ported by a grant of Pfizer Pharmaceuticals. Pfizer was not involved in any study proce-
dure, but Pfizer was granted the right to read, but not to edit, the manuscript prior to
submission for publication.“
Declarations of interest (p 413): ”Investigator-initiated project grant fromPfizer. E. Prens
has acted as a consultant for AbbVie, Amgen, Astra-Zeneca, Baxter, Eli Lilly, Galderma,
Janssen-Cilag, Novartis and Pfizer and has received investigator-initiated research grants
(paid to Erasmus MC) from Pfizer, Janssen-Cilag and AbbVie. M.B.A. van Doorn has
acted as a consultant for Abbott, Janssen, LEO Pharma, MSD and Pfizer, and has been
an investigator for Eli Lilly, Idera Pharmaceu-ticals, Cutanea and Novartis. T. van Gelder
has been on the speakers’ bureau or worked as consultant for Sandoz, Novartis, Teva,
Chiesi, Astellas and Roche“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (supplemental appendix): “Using
a computer-generated randomisation list,
patients were randomised at baseline to a
1:1 ratio to receive either etanercept com-
bined with oral fumarates (combination
group) or etanercept only (monotherapy
group). ”
Comment: probably done
Allocation concealment (selection bias) Low risk Quote (supplemental appendix): “Using
a computer-generated randomisation list,
patients were randomised at baseline to a
1:1 ratio to receive either etanercept com-
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Van Bezooijen 2016 (Continued)
bined with oral fumarates (combination
group) or etanercept only (monotherapy
group).”
Comment: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (supplemental appendix): ”Patients
and the study physicians were not blinded
for the allocated treatment group.”
Comment: not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (supplemental appendix): “The
independent PASI assessor (E.P.P.) was
blinded to treatment throughout the course
of the study.”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 33, analysed 33 for the
primary outcome
Management of missing data: quote (sup-
plemental appendix): “Patients lost to fol-
low-up were not included in the PASI 75
response and PGA score analyses. ”
Comment: not ITT analyses however all
randomised participants reached the pri-
mary outcome assessment
Selective reporting (reporting bias) Unclear risk Comment: the protocol for the study
was available on European Clinical Trials
Database (EudraCT) (EudraCTNo. 2011-
005685-38) (not found)
The pre-specified results mentioned in the
methods section appeared to have been re-
ported
Van de Kerkhof 2008
Methods RCT, placebo-controlled, double blind
Date of study: Jun 2006-May 2007
Location: multicentre (numbers of centres not stated) in Belgium, France, Germany,
Hungary, Italy, Netherlands, Poland, Romania, Spain
Participants Randomised: 143 participants (mean age 45 years, 84 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI≥ 10, BSA≥ 10), age > 18 years
Exclusion criteria
• Had received biologics (etanercept, anti TNF)
• Had an active infection
Dropouts and withdrawals
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• 16/143 (11%): etanercept group (6), placebo group (10)
• AEs: etanercept group (3), placebo group (3)
• Lack of efficacy: etanercept group (2), placebo group (4)
• Other reason:etanercept group (1), placebo group (3)
Interventions Intervention
A. Etanercept, 50 mg, self-administered SC, once a week, 12 weeks (n=96)
Control intervention
B. Placebo, self-administered SC, once a week, 12 weeks (n=46)
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• Proportion of patients PASI 75 or greater
Secondary outcomes of the trial
• PASI 75 at other time points
• PASI 50 at 12 ,24
• PASI 90 at 12 ,24
• PASI 100 at 24
• PASI improvement from baseline
• PGA
• DLQI
Notes Funding source (p 1184): “This study was supported financially by Wyeth Pharmaceu-
ticals, Collegeville, PA, USA)”
Comments: 3 authors were employed by Wyeth pharmaceuticals which supported this
study financially
Declarations of interest (p 1177): “C.Z., M.P.B., L.P. and J.W. are employed by Wyeth
Pharmaceuticals, which supported this study financially. ”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote (p 1178): “Patients were randomly
assigned (using the Clinical Operations
Randomization Environment system) ...
according to a 2:1 treatment allocation”
Comment: probably done
Allocation concealment (selection bias) Unclear risk Quote (p1178): “Patients were randomly
assigned (using the Clinical Operations
Randomization Environment system) ...
according to a 2:1 treatment allocation”
Comment: not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 1178): “In both the double blind
controlled study..., etanercept was supplied
as a sterile lyophilised powder. All study
drugs were self-administrated QW by the
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patient by subcutaneous injections”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 1178): “In both the double blind
controlled study..., etanercept was supplied
as a sterile lyophilised powder. All study
drugs were self-administrated QW by the
patient by subcutaneous injections”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 142, analysed 142
Management of missing data, quote (p
1179): “The primary population for effi-
cacy and safety analyses ... was the modi-
fied intent-to-treat population.The last ob-
servations were carried forward in cases of
missing efficacy data”
Comment: done
Selective reporting (reporting bias) Unclear risk Comment: the specified outcomes men-
tioned in the methods section appeared to
have been reported however no protocol
was available,
Warren METOP, 2017
Methods RCT, placebo-controlled
Date of study: 22 February 2013-13 May 2015
Location: 13 centres in Europe
Participants Randomised: 120 participants
Inclusion criteria
• Definition moderate-severe psoriasis
• Methotrexate treatment-naive
• Aged ≥ 18 years
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 21/212 (17.5%), methotrexate n = 14, placebo, n = 7
• AEs: methotrexate (10), placebo (4)
• Lost to follow-up: methotrexate (2)
• Participants’ choice: placebo (2)
• Poor efficacy: methotrexate (1), placebo (1)
• Other: methotrexate (1)
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Interventions Intervention
A. Methotrexate (n = 91), SC, IM, 17.5-22.5 mg/week, 12 weeks
Control intervention
B. Placebo (n = 29)
Outcomes 16 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PASI 90
• PGA
• NAPSI
• DLQI
• AEs
Notes Funding source:
Quote (p 528) “Funding source: Medac. The funder of the study had no role in study
design, data collection, data analysis, data interpretation or writing of the report. The
corresponding author had full access to all the data in the study and all authors had final
responsibility for the decision to submit for publication”
Declarations of interest (p 536): “RBW has received personal fees from AbbVie, Almi-
rall, Amgen, Boehringer Ingelheim Pharma, Celgene, Janssen-Cilag, Leo, Lilly, Novartis,
Pfizer, and Xenoport outside the submitted work. UM has been an advisor to, received
speakers honoraria or grants from, or participated in clinical for Abbott/AbbVie, Almi-
rall Hermal, Amgen, BASF, Biogen Idec, Boehringer Ingelheim, Celgene, Centocor, Eli
Lilly, Foamix, Forward Pharma, Galderma, Janssen, Leo Pharma, Medac, MSD, Mil-
tenyi Biotech, Novartis, Pfizer, Teva, VBL, and Xenoport. RvK has been an investigator,
consultant, advisor, or speaker for Abbvie, Almirall, Amgen, Biogen Idec, Boehringer
Ingelheim, Celgene, Eli Lilly, GSK, Leo, Janssen-Cilag, MSD, Novartis, Pfizer, UCB,
and VBL Pharma. JN has received grants from Amgen, Novartis, Janssen-Cilag, LEO,
Lilly, Medac, Regeneron, and Dermapharm, outside the submitted work. DW-T has
been an advisor to, received speakers honoraria or grants from, or participated in clinical
for Abbvie, Almirall, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Forward
Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme,
Novartis, Pfizer, UCB Pharma, and VBL. KG has been an advisor to, received speak-
ers honoraria or grants from, or participated in clinical for Abbott/AbbVie, Almirall,
Biogen, Boehringer Ingelheim, Celgene, Delenex, Eli Lilly, Galderma, Janssen, Medac,
MSD, Novartis, and Pfizer. KR has received personal fees from AbbVie, Amgen, Biogen,
Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithK-
line, Janssen-Cilag, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Regen-
eron, Takeda, UCB Pharma, and Xenoport, outside the submitted work. IZ, TMF, and
NB-S declare no competing interests.”
Risk of bias
Bias Authors’ judgement Support for judgement
313Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Warren METOP, 2017 (Continued)
Random sequence generation (selection
bias)
Low risk Quote (p 3): “Eligible patients were ran-
domly assigned (3:1), via computer-gen-
erated random numbers (RandList 1.2)
in an ascending order, to receive either
methotrexate or placebo injections for the
first 16 weeks of the study (phase 1).”
Comments: probably done
Allocation concealment (selection bias) Low risk Quote (p 3): “Eligible patients were ran-
domly assigned (3:1), via computer-gen-
erated random numbers (RandList 1.2)
in an ascending order, to receive either
methotrexate or placebo injections for the
first 16 weeks of the study (phase 1).”
Comments: probably done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 3): “Study phase 1 was done in
a double-blind manner, with group alloca-
tion concealed from participants and in-
vestigators from the time of randomisation
until an interim database lock at week 16.
..The syringes for placebo and active drug
were not distinguishable and were fully
coated to prevent identification of colour
differences between injections”
Comments: clearly defined
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 3): “Study phase 1 was done in
a double-blind manner, with group alloca-
tion concealed from participants and in-
vestigators from the time of randomisation
until an interim database lock at week 16.
..The syringes for placebo and active drug
were not distinguishable and were fully
coated to prevent identification of colour
differences between injections”
Comments: clearly defined
Incomplete outcome data (attrition bias)
All outcomes
Low risk Number of randomised participants, n =
120, 120 analysed
Quote (p 4): “All outcomes were analysed
in the modified intention to-treat popula-
tion of patients who had received at least
one injection of study drug, with missing
data treated as indicating no response (non-
responder imputation).”
Comment: probably done
314Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Warren METOP, 2017 (Continued)
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT02902861)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
Yan 2011
Methods RCT, active-controlled,
Date of study: April 2007-January 2009
Setting: 7 centres in China
Participants Randomised: 212 participants
Inclusion criteria
• Definition moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10)
• Age 18-65 years
Exclusion criteria
• Pregnancy, kidney insufficiency, liver insufficiency
• Had an active infection
• Had past history of malignant tumours
Dropouts and withdrawals
• 20/212 (9%)
• Alefacept (7): AE (1), lost to follow-up (6)
• Methotrexate (13): AE (3), lost to follow-up (8), deviation (2)
Interventions Intervention
A. Alefacept + placebo oral methotrexate (n = 107), IM, 15 mg/week, 12 weeks
Control intervention
B. Methotrexate + placebo (n = 105), IM, alefacept, orally, 7.5 mg/week, 12 weeks
Outcomes Time to evaluate assessment: not stated
Primary outcomes of the trial
• Not clearly defined
Secondary outcomes of the trial
• PASI
• PGA
• DLQI
• VAS
Notes Funding source (p 742): none reported
Declarations of interest (p 742): none reported
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Quote (p 738): “Each patient was assigned
a randomnumber in a chronological order”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 738): “ The present study,...,
double-blind, double dummy... Patients in
the experimental group were intramuscu-
larly injected with... and orally adminis-
tered with the bank dummy methotrexate.
.. and the patients in the control group...”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p 738): “The present study,..., dou-
ble-blind, double dummy... Patients in the
experimental group were intramuscularly
injected with... and orally administered
with the bank dummy methotrexate... and
the patients in the control group...”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote (p 739): “Full set analysis was as-
sessed”
Comment: no description of the methods
used for dealing with missing data
Selective reporting (reporting bias) High risk Comment: no protocol available. No pri-
mary outcome clearly identified
Yang 2012
Methods RCT, placebo-controlled, double blind
Date of study: February 2009-February 2010
Location: 9 centres in China
Participants Randomised: 129 participants (mean age 39 years (infliximab) and 40 years (placebo),
95 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI ≥ 12, BSA ≥ 10), age 18-65
years
• Had a diagnosis of plaque psoriasis for at least 6 months
• Had failed to respond to conventional systemic treatment of psoriasis including:
ciclosporin, methotrexate, or acitretin as previous treatment
Exclusion criteria
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• Non-plaque forms of psoriasis
• A history of a chronic infectious disease or opportunistic infection
• A serious infection within 2 months of enrolment
• Active or latent TB
• Pregnancy or planned pregnancy within 12 months of enrolment
• A history of lymphoproliferative disease
• An active malignancy or history of malignancy within 5 years
Dropouts and withdrawals
• 2/129 (1.55%): infliximab group (1), placebo group (1)
• Withdrawal of informed consent: infliximab group (0), placebo group (1)
• Adverse event: infliximab group (1), placebo group (0)
Interventions Intervention
A. Infliximab (n = 84), IV, 5 mg/kg, weeks 0, 2, 6, 14, 22; 22 weeks
Control intervention
B. Placebo (n = 45), IV, weeks 0, 2, 6 then infliximab 5 mg/kg weeks 10, 12, 16
Outcomes Assessments at 10 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• PGA
• DLQI
Notes Funding source: not stated
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p1846): “This randomised, dou-
ble-blind, placebo controlled trial... Eligi-
ble patients were randomly assigned in a 1:
2 ratio to the placebo and infliximab”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p1846): “This randomised, dou-
ble-blind, placebo controlled trial... Eligi-
ble patients were randomly assigned in a 1:
2 ratio to the placebo and infliximab”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p1846): “This randomised, dou-
ble-blind, placebo controlled trial... Eligi-
ble patients were randomly assigned in a 1:
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2 ratio to the placebo and infliximab... In-
fliximab 5 mg/kg or placebo was adminis-
tered by intravenous drip infusion over a
period of at least 2 hours on the starting
day of treatment (week 0) and at weeks 2
and 6 (induction)”
Comment: probably done
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote (p1846): “This randomised, dou-
ble-blind, placebo controlled trial... Eligi-
ble patients were randomly assigned in a 1:
2 ratio to the placebo and infliximab... In-
fliximab 5 mg/kg or placebo was adminis-
tered by intravenous drip infusion over a
period of at least 2 hours on the starting
day of treatment (week 0) and at weeks 2
and 6 (induction)”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 129, 129 Analysed
Quote: “In the primary efficacy analysis,
data from all randomised subjects were
analysed according to their assigned treat-
ment group...”
Comment: no description of the method
used to manage the missing data
Selective reporting (reporting bias) Unclear risk Comment: no protocol was available. The
pre-specified outcomes mentioned in the
methods section appeared to have been re-
ported
Yilmaz 2002
Methods RCT, placebo-controlled, open-label trial
Date of study: unreported
Location: Turkey
Participants Randomised: 50 participants (no description of the study population)
Inclusion/exclusion criteria
• Not stated
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Acitretin (n = 50), orally, 0.5-0.7 mg/kg, daily
Control intervention
B. Placebo (n = 50)
Co-intervention
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PUVA, twice weekly, 8-MOP at a dosage of 0.4-0.6 g/kg, 2h before UVA exposure
Outcomes Time of assessments not stated
Primary or secondary outcomes of the trial
• Not clearly defined
Outcomes of the trial
• Complete remission
Notes Funding source: not stated
Declarations of interest: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (abstract): “The patients were
equally allocated to treatment groups in the
study”
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (abstract): “The patients were
equally allocated to treatment groups in the
study”
Comment: no description of the method
used to guarantee allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote (abstract): “We performed an open,
controlled study...”
Comment: not blinded, subjective out-
come
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote (abstract): “We performed an open,
controlled study...”
Comment: not blinded, subjective out-
come
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Randomly assigned 50
Comment: no description of the number
of participants analysed, no description of
the method used to manage missing data
Selective reporting (reporting bias) Unclear risk Comment: only an abstract available
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Zhu LOTUS, 2013
Methods RCT, placebo-controlled, double blind (LOTUS)
Date of study: 23 October 2009-07 July 2011
Location: 14 centres in China
Participants Randomised: 322 participants (mean age 40 years, 248 male)
Inclusion criteria
• Participants with moderate-severe psoriasis (PASI≥12 and BSA ≥ 10), age >18
years
Exclusion criteria
• Severe uncontrolled or progressive medical conditions
• Known to be infected with HIV (HIV), hepatitis B virus (HBV), hepatitis C virus
(HCV), or syphilis
Dropouts and withdrawals
• 6/322 (1.86%): ustekinumab group (3), placebo group (3)
• AEs: ustekinumab group (2), placebo group (1)
• Other reasons: ustekinumab group (1), placebo group (2)
Interventions Intervention
A. Ustekinumab (n = 160), SC, 45 mg, week 0, week 4, 4weeks
Control intervention
B. Placebo (n = 162), SC, week 0, week 4, 4weeks
Outcomes Assessments at 12 weeks
Primary outcomes of the trial
• PASI 75
Secondary outcomes of the trial
• - PGA 0 /1
• - DLQI
Notes Funding source quote (p 173): ”This study was supported by Janssen Research & De-
velopment“
Declarations of interest (p 173): ”Drs Zhu, Zang and Wand served as investigators for
this Janssen RD-sponsored study...“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote (p 167): ”The LOTUS study is a
phase 3, multicenter, randomized, double
blind, placebo-controlled..
Comment: no description of the method
used to guarantee random sequence gener-
ation
Allocation concealment (selection bias) Unclear risk Quote (p 167):
Comment: no description of the method
used to guarantee allocation concealment
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Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote (p 167): “The LOTUS study is a
phase 3, multicenter, randomized, double
blind, placebo-controlled..
Comment: placebo-controlled study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote (p 167): ”The LOTUS study is a
phase 3, multicenter, randomized, double
blind, placebo-controlled..
Comment: no description of the method
used to guarantee blinding of outcome as-
sessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Randomly assigned 322, analyzed 322
Quote (p 167): “For efficacy analyses, all
randomized patients were included... Pa-
tients who discontinued study treatment...
were considered treatment failures”
Comment: ITT analyses
Selective reporting (reporting bias) Low risk Comment:
the protocol for the study was available on
ClinicalTrials.gov (NCT01008995)
The pre-specified outcomes and those
mentioned in the methods section ap-
peared to have been reported
AEs: adverse events; ACR: American College of Rheumatology; ALT: alanine aminotransferase; AST: aspartate aminotransferase;
BSA: Body Surface Area; eow: every other week; CIN: cervical intraepithelial neoplasia; DLQI: Dermatology Life Quality Index;
ECG: electrocardiogram; HD: high dose; IGA: Investigator’s Global Assessment; IM: intramuscular; ITT: intention-to-treat; IV:
intravenous; LD: low dose;m-ITT: modified ITT;MD: medium dose;NAPSI: Nail psoriasis severity index;NBUVB: narrow-band
UVB; PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment; PP: per protocol; PSI: Psoriasis Severity Index;
PSSI: Psoriasis Scalp Severity Index; PUVA: psoralen plus ultraviolet A;QoL: quality of life; RCT: randomised controlled trial; SC:
subcutaneous; SF36: 36-item Short Form Health Survey; SIAQ: Self- Injection Assessment Questionnaire; TB: tuberculosis; TBR:
target background ratio; UVB: ultraviolet B; VAS: visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abufarag 2010 Other treatment
Akhyani 2010 Other treatment
Altmeyer 1994 Not plaque-type psoriasis
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Angsten 2007 Not a trial
Anonymous 2005 Not a trial
Anonymous 2008 Not a trial
Arifov 1998 Not a randomized trial
Armati 1972 Other treatment
Avgerinou 2011 Not randomized trial
Bagot 1994 Other treatment
Bartlett 2008 Not a trial
Barzegari 2004 Other treatment
Batchelor 2009 Not a trial
Bayerl 1992 Other treatment
Beissert 2009 Other treatment
Berbis 1989 Assessment < 8 weeks
Bhuiyan 2010 Other treatment
Bigby 2004 Not a trial
Bissonnette 2006 Other treatment
Bissonnette 2010 Other treatment
Bjerke 1989 Other treatment
Callis Duffin 2017 Comparison of the same drug with the same dosages
Cassano 2006 Identical dosing regimens
Cassano 2010 Not a trial
Cather 2006 Dose ranging after remission
Chládek 2002 Basic science (aim of study: to understand the physiopathology of the disease)
Chodorowska 1999a Not a trial
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Chodorowska 1999b Not a trial
de Jong 2003 Other treatment
Dubiel 1972 Not a trial
Duffin 2016 Comparison of 2 different ways of drug injection for the same drug and the same dosage
Ecker-Schlipf 2009 Other treatment
Elewski 2007 Pooled trials
Ellis 1986 Assessement < 8 weeks
Ellis 2002 Medico-economic study
Ellis 2012 Other treatment
Engst 1989 Assessment < 8 weeks
Erkko 1997 Basic science (aim of study: to understand the physiopathology of the disease)
Ezquerra 2007 Other treatment
Fernandes 2013 Not a trial
Finzi 1993 Other treatment
Fleischer 2005 Other treatment
Fredriksson 1971 Other treatment
Fredriksson 1978 Other treatment
Friedrich 2001 Other treatment
Gambichler 2011 Other treatment
Ganguly 2004 Pooled trials
Gil 2003 Not a randomized trial
Goerz 1978 Not a trial
Gollnick 1988 Other treatment
Gollnick 1993 Other treatment
Gollnick 2002 Other treatment
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Gottlieb 2002c Other treatment
Gottlieb 2003a Other Treatment
Gottlieb 2004b Pooled trials
Gottlieb 2005a Other treatment
Gottlieb 2010 Cross-over trial
Goupille 1995 Not a randomized trial
Griffiths 1998 Other treatment
Griffiths 2002a Pooled trials
Griffiths 2002b Pooled trials
Griffiths 2005 Pooled trials
Grim 2000 Basic science (aim of study: to understand the physiopathology of the disease)
Grossman 1994 Other treatment
Gulliver 1996 Not a trial
Gupta 2005 Other treatment
Gupta 2007 Other treatment
Gupta 2008 Other treatment
Han 2013 Other treatment
Hashizume 2007 Comparison of 2 methods of administration
Heule 1988 Assessment < 8 weeks
Ho 2010 Other treatment
Hunter 1972 Other treatment
Iest 1989 Not randomized trial
Kavanaugh 2009 Not a randomized trial
Kimball 2008 Drug withdrawn for safety reasons
Kimball 2011 Drug withdrawn for safety reasons
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Koo 1998 Other treatment
Kopp 2015 Phase 1 trial
Kragballe 1989 Other treatment
Krishnan 2005 Pooled trials
Krueger 1980 Other treatment
Krueger 2002b Not a trial
Krueger 2003 Not a trial
Krueger 2012 Phase 1 trial
Krueger 2015 Phase 1 trial
Kuijpers 1998 Other treatment
Lajevardi 2015 Other treatment
Langewouters 2005 Other treatment
Langley 2006 Other treatment
Langley 2010 Other treatment
Langner 2004 Not plaque-type psoriasis
Lauharanta 1989 Other treatment
Lawrence 1983 Other treatment
Leavell 1970 Other treatment
Lebwohl 2003a Pooled trials
Lebwohl 2009 Pooled trials
Lebwohl 2012 Other treatment
Lebwohl 2013 Other treatment
Ledo 1988 Other treatment
Legat 2005 Other treatment
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Leonardi 2010a Pooled trials
Leonardi 2010b Not a randomized trial
Leonardi 2010c Pooled trials
Leonardi 2011a Not plaque-type psoriasis
Levell 1995 Other treatment
Liang 1995 Assessment < 8 weeks
Lui 2011 Other treatment
Lui 2012 Other treatment
Lynde 2012 Other treatment
Macdonald 1972 Not a randomized trial
Mahrle 1995 Other treatment
Malik 2010 Other treatment
Marecki 2004 Other treatment
Marks 1986 Not a randomized trial
McInnes 2013 Pooled trials
Mease 2011 Drug withdrawn for safety reason
Meffert 1989 Other treatment
Menon 2012 Basic science (aim of study: to understand the physiopathology of the disease)
Menter 2007a Pooled trials
Menter 2014 Drug withdrawn for safety reasons
Meyer 2011 Other treatment
Mittal 2009 Other treatment
Moller 2009 Other treatment
Monk 1986 Not a randomized trial
Montgomery 1993 Other treatment
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Mrowietz 1991 The two study arms compared the same molecule with the same dosage
Mrowietz 2012 Pooled trials
Narang 2012 Other treatment
Nieboer 1990 Other treatment
Nijsten 2008 Not a trial
Noda 2011 Not a randomized trial
Novotny 1973 Not a trial
Nyfors 1978 Not a trial
Orfanos 1978 Other treatment
Orfanos 1979 Other treatment
Ortonne 2008 Comparison of 2 schemes of administration
Ortonne 2011 Other treatment
Osamu 2014 Phase 1 trial
Papp 2001 Other treatment
Papp 2006 Other treatment
Papp 2008a Other treatment
Papp 2009 Pooled data
Papp 2011a Pooled trials
Papp 2011b Drug withdrawn for safety reasons
Papp 2011c Drug withdrawn for safety reasons
Papp 2012c Phase 1 trial
Papp 2012d Pooled trials
Park 2013 Other treatment
Paul 2012 Other treatment
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Paul 2014 Other treatment
Pettit 1979 Assessment < 8 weeks
Petzelbauer 1990 Not a randomized trial
Piascik 2003 Not a trial
Ports 2013 Other treatment
Punwani 2012 Other treatment
Rabasseda 2012 Not a trial
Radmanesh 2011 Comparison of 2 schemes of administration
Raman 1998 Other treatment
Reich 2011 Pooled trials
Reich 2014 Other treatment
Reitamo 1999 Other treatment
Reitamo 2001 Other treatment
Rim 2003 Other treatment
Rinsho Iyaku 1991 Other treatment
Ritchlin 2006a Not a randomized trial
Ritchlin 2006b Not a randomized trial
Ritchlin 2006c Not a randomized trial
Salim 2006 Other treatment
Scholl 1981 Other treatment
Schopf 1998 Other treatment
Schulze 1991 Other treatment
Shintani 2011 Comparison of 2 schemes of administration
Shiohara 1992 Not a trial
Shupack 1997 Not a trial
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Simonova 2005 Other treatment
Sofen 2011 Basic science (aim of study: to understand the physiopathology of the disease)
Sofen 2014 Phase 1 trial
Spadaro 2008 Not a trial
Spuls 2012 Not a trial
Sticherling 1994 Not a trial
Strober 2004 Not a trial
Strober 2012 Not a randomized trial
Sweetser 2006 Cross over trial
Talwar 1992 Not a randomized trial
Tejasvi 2012 Other treatment
Thaçi 2002 The two study arms compared the same molecule with the same dosage
Thaçi 2010 Other treatment
Tong 2008 Other treatment
Van Joost 1988 Assessment shorter than 8 weeks
Vena 2005 Comparison of 2 schemes of administration
Vena 2012 Other treatment
Viglioglia 1978 Not a trial
Witkamp 1995 Other treatment
Wolf 2012 Other treatment
Wright 1966 Not a randomized trial
Wu 2015 Other treatment
Yesudian 2013 Other treatment
Yoon 2007 Dose-escalation study
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Zachariae 2008 Other treatment
Zhang 2007 Other treatment
Zhang 2009a Other treatment
Zhang 2009b Other treatment
Zhang 2012 Other treatment
Zhu 2009 Pooled trials
Zhuang 2016 Phase 1 trial
Zobel 1987 Not a trial
Characteristics of studies awaiting assessment [ordered by study ID]
Chow 2015
Methods RCT, active/placebo-controlled, double blind
Date of study: not stated
Location: Canada, Germany and Poland
Participants Randomised: 455 participants (mean age 43, 313 male)
Inclusion criteria
• Aged ≥ 18 years at time of screening
• Diagnosed with plaque psoriasis ≥ 6 months prior to screening
• Diagnosis of stable, plaque psoriasis; i.e. psoriasis must not be spontaneously improving or worsening in the 4
weeks prior to the screening visit
• Psoriasis failing ≥ 1 systemic treatment regimen or where other systemic therapies are contraindicated or
where tolerability is an issue.
• Plaque psoriasis involving ≥ 10% of the body surface area and a SPGA score ≥ 3 at screening and prior to
randomisation at the day 0 visit
• Not pregnant or nursing
• Sexually active women of childbearing potential or < 1 year post-menopausal and sexually active men who are
not surgically sterile must use a reliable form of birth control during study treatment and for ≥ 3 months after the
last dose of study drug. Surgically sterile women are not considered to be of childbearing potential. Reliable forms
of birth control include oral or depot contraceptives, and double-barrier methods
• Written informed consent prior to washout and screening procedures
• Able to keep study appointments and co-operate with all study requirements, in the opinion of the Investigator
Exclusion criteria
• Has generalised erythrodermic, guttate, or pustular psoriasis
• Have other dermatoses that would interfere with the evaluation of psoriasis, at the discretion of the Investigator
• A current malignancy or history of malignancy within 5 years or a history of lymphoma at any time. Subjects
can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with
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curettage and electrodesiccation
• Has a current, uncontrolled bacterial, viral, or fungal infection that requires IV antibiotics or antifungals or
has had such infections within 60 days prior to screening
• A known history of TB
• Serologic evidence or known latent HIV, hepatitis B or C virus
• Uncontrolled hypertension of systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg
• Modification of Diet in Renal Disease < 60 mL/min
• Liver enzyme serum levels≥ 2 x upper limit of normal (ULN)
• White blood cell count ≤ 2.8 x 10 to the ninth power/L
• Requires the following prohibited medications or treatments during the washout or treatment period: drugs
potentiating the nephrotoxicity of voclosporin, drugs interfering with its pharmacokinetics, drugs considered to
contribute to psoriasis flare; or, systemic and topical psoriasis medication that may interfere with assessment of
study drug efficacy
• Has used any investigational drug or device within 30 days or 10 half lives (whichever is longer) prior to the
screening visit
• Current participation in another clinical trial of any drug or biological agent
• Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3 months of randomisation.
Biological agents include any virus, live vaccine, therapeutic serum, toxin, antitoxin, monoclonal antibodies or
analogous product applicable to the prevention, treatment, or cure of diseases or injuries of man
• Previous exposure to voclosporin
• A history of clinically defined allergy to ciclosporin, constituents of Neoral or any of the constituents of the
ISA247 formulation
• A history of alcoholism or drug addiction
• Weighs < 45 kg (99 lbs)
• A history of disease, including mental/emotional disorder that would interfere with the participant’s
participation in the study, in the evaluation of his/her response or that might cause the administration of
voclosporin to pose a significant risk to the participant, in the opinion of the Investigator
• White blood cell count ≤ 2.8 x 10 to the ninth power/L.
• Requires the following prohibited medications or treatments during the washout or treatment period: drugs
potentiating the nephrotoxicity of voclosporin, drugs interfering with its pharmacokinetics, drugs considered to
contribute to psoriasis flare; or, systemic and topical psoriasis medication that may interfere with assessment of
study drug efficacy
• Has used any investigational drug or device within 30 days or 10 half lives (whichever is longer) prior to the
screening visit
• Current participation in another clinical trial of any drug or biological agent
• Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3 months of randomisation.
Biological agents include any virus, live vaccine, therapeutic serum, toxin, antitoxin, monoclonal antibodies or
analogous product applicable to the prevention, treatment, or cure of diseases or injuries of man
• Previous exposure to voclosporin
• A history of clinically defined allergy to ciclosporin, constituents of Neoral or any of the constituents of the
ISA247 formulation
• A history of alcoholism or drug addiction
• Weighs < 45 kg (99 lbs)
• A history of disease, including mental/emotional disorder that would interfere with the participant’s
participation in the study, in the evaluation of his/her response or that might cause the administration of
voclosporin to pose a significant risk to the participant, in the opinion of the Investigator
Interventions Interventions
(n = 355)
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Drug: voclosporin 0.8 mg/kg/day
Drug: ciclosporin 3.0 mg/kg/day
Control intervention
(n = 89)
Drug: placebo
Outcomes At week 24,
Primary outcome measures
• Superiority in the proportion of participants achieving a score of clear or almost clear in the SPGA score
Secondary outcome measures
• To show non-inferiority of voclosporin compared to ciclosporin in the proportion of participants achieving a
score of clear or almost clear in the SPGA score
• Superiority in de novo hypertriglyceridemia, defined as proportion of participants developing fasting
triglycerides ≥ 1.7 mmol/L
• Superiority in de novo hypertension, defined as proportion of participants developing blood pressure ≥ 140
mmHg (systolic) or ≥ 90 mmHg (diastolic)
• Superiority of renal function, defined as the proportion of participants experiencing a confirmed ≥ 30% rise
in serum creatinine
• Superiority in proportion of participants achieving a 75% reduction in the PASI score (PASI 75)
Notes Randomised, placebo and ciclosporin controlled study of ISA247 in plaque psoriasis patients (ESSENCE),
NCT00408187
Participants in the voclosporin and ciclosporin arms (n = 355) were treated for 24 weeks; these participants were
combined into a ‘24-week treatment group’. In the placebo group, 89 participants were included
As the authors presented their results grouping ciclosporin and voclosporin together, we asked them to provide the
results for the subgroup of participants with ciclosporin treatment arm
Two emails were sent without response (8 November 2016, 16 December 2016)
CTRI/2015/05/005830
Methods Randomised, parallel group, multiple arm trial
Date of study: 10/12/2013 (starting date)
Location: India
Participants Total sample size: 120
Inclusion criteria:
• Be diagnosed to be suffering exclusively from Palmo-plantar psoriasis either by clinical examination or
histopathology if required will be included in palmoplantar psoriasis group
• Be diagnosed to be suffering from psoriasis vulgaris having more than 20% BSA will be included in psoriasis
vulgaris group
• Have completed 18 years of age
Exclusion criteria:
• Hypersensitivity to drug or intolerance to the study medication
• Pregnant and lactating
• Clinically significant cardiovascular, haematological, pancreatic, metabolic neurological or any other laboratory
anomaly, which in the judgement of investigator, would interfere in participation in study or proper evaluation
• On any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation
of results
• History of TB or chest X-ray showing evidence of any infective pathology
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Interventions Intervention 1: acitretin: orally, 25-50 mg/day, daily single dose
Total duration: 90 days
Intervention 2: ciclosporin: orally 2.5-5 mg/kg/day, daily in 2 divided doses
Total duration: 90 days
Intervention 3: methotrexate: orally 7.5-15 mg/week in 3 divided doses
Total duration: 90 days
Control Intervention 1: palmoplantar psoriasis: variant of psoriasis in which only palms and soles are affected
Control Intervention 2: psoriasis vulgaris: variant of psoriasis in which lesions appear on body skin
Outcomes At 90 days
• 75% reduction in PASI or modified PASI
• 75% reduction in BSA
• 75% reduction in psoriasis severity index. Timepoint: 90 days
• DLQI
Notes Starting date: 10-12-2013. Recruitment status: open to recruitment
We sent an email to Prof. Shah (5 and 12 January 2017) without response
DRKS00000716
Methods Randomised, active-controlled, parallel-group, simple blind
Date of study: 03/06/2008 (starting date)
Location: Germany
Participants Total sample size: 50
Inclusion criteria
• Aged 18-65 years
• Clinical diagnosis of psoriasis for > 6 months
• Plaque-type psoriasis (PASI > 10)
• BSA > 10%
Exclusion criteria
• Contraindications for treatment with TNF-alpha inhibitors and FAEs
• Women who are pregnant or who are breast-feeding. Women of childbearing potential must follow a
medically recognised form of contraception
• Currently receiving or have received within 4 weeks prior to first administration of study administration:
systemic therapy for psoriasis; monoclonal antibody therapy for psoriasis; phototherapy
• TB anamnesis, infections (Hepatitis B, C, HIV)
• History of lymphoproliferative disorders, malignancies, demyelinating disease, severe heart failure
• History of substance abuse (drugs or alcohol) or any factor (e.g. serious psychiatric condition) which limits the
patient’s ability to co-operate with the study procedures
• Unco-operative, known to miss appointments (according to patient’s records) and are unlikely to follow
medical instructions or are not willing to attend regular visits
Interventions Intervention 1: adalimumab (Humira), SC, 80 mg initially and 40 mg eow for 24 weeks
Intervention 2: etanercept (Enbrel), SC, 50 mg twice a week for 12 weeks and 25 mg twice a week subsequently for
another 12 weeks
Intervention 3: FAEs (Fumaderm), orally, up to 6 doses/day for 24 weeks
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Outcomes Week 8:
• PASI: clinical score of skin lesions
• DLQI
• skin biopsy: immunohistology
• T cells in peripheral blood
Week 24:
• PASI: clinical score of skin lesions
• DLQI
• skin biopsy: immunohistology
• T cells in peripheral blood
Notes Starting date: 03/06/2008, Prof. Arnd Jacobi, Klinik fürDermatologie undAllergologie Philipps-UniversitätMarburg
Recruitment status on ICTRP search portal: complete: follow-up complete
We emailed Prof. Jacobi (5 January 2017) without response
Elewski 2016
Methods Randomised, placebo-controlled, double-blind trial
date: January 2014 to April 2016
Location: worldwide
Participants Total sample size: 217
Inclusion criteria
• Adults with clinical diagnosis of chronic plaque psoriasis (with a disease duration of ≥ 6 months) and ≥ 1
fingernail with nail psoriasis
• BSA ≥ 10% and a target fingernail mNAPSI ≥ 8 at Week 0, OR BSA ≥ 5%, a target fingernail Nail Psoriasis
Severity index (NAPSI) ≥ 8 and a total mNAPSI score of ≥ 20 at Week 0
• Nail Psoriasis Physical Functioning Severity score of > 3, OR a Nail Psoriasis Pain score of > 3
• PGA of fingernail psoriasis and a PGA of skin psoriasis of ≥ moderate
• Must have discontinued use of all systemic therapies for the treatment of psoriasis, or systemic therapies
known to improve psoriasis for ≥ 4 weeks prior to Week 0, ustekinumab must have been discontinued ≥ 12 weeks
prior to Week 0
• Target fingernail must have mNAPSI score of ≥ 8
Exclusion Criteria
• Prior adalimumab therapy
• Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere with
evaluation of skin or fingernail psoriasis
• Recent infection requiring treatment
• Significant medical events or conditions that may put patients at risk for participation, including recent
history of drug or alcohol abuse
• Women who are pregnant or breast-feeding or considering becoming pregnant during the study
• History of cancer, except successfully treated skin cancer
Interventions Intervention
Adalimumab, SC, 40 mg, eow for 25 weeks starting 1 week after initial loading dose of 80 mg
Control intervention
Placebo
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Outcomes At week 12
mNAPSI 75, PGA of fingernails of clear or minimal
PASI 75/90/100 for participants with baseline PASI at 5
Notes NCT02016482
• Enrollment: 217
• Study start date: January 2014
• Study completion date: April 2016
Abstract
• Journal of the European Academy of Dermatology and Venereology 2016, 30:65
No original paper published.
We emailed the study authors (3 and 12 January 2017) for the protocol and results
Abbvie response: “As this data has not been published in a manuscript at this time I am providing the link below for
you to submit a request for this data. Please let me know if you have any further questions”
Will be included when published
Han 2007
Methods Randomised, double-blind, active-controlled trial
Date: not stated
Location: China
Participants No statement except a total number of participants (n = 144)
Interventions Intervention
Recombinant human tumour necrosis factor receptor (50 mg/week)
Control intervention
Methotrexate (7.5 mg/week)
Outcomes At 12 weeks
Proportion of PASI 50, PASI 75, PASI 90
Notes Abstract in Journal of Clinical Dermatology 2007 (730-2)
HAN Ling, FANGXu, HUANGQiong, YANGQin-ping, FUWen-wen, ZHENG Zhi-zhong, GU Jun, SUN Jiao-
fang, XU Ai-e (Department of Dermatology,Huashan Hospital, Fudan University, Shanghai 200040, China)
Objective: To evaluate the effect of recombinant human tumour necrosis factor receptor (rhTNFR:Fc) in the treat-
ment of moderate to severe plaque psoriasis on psoriasis area and severity index (PASI).Methods: Using randomised,
double-blind and double-simulated, parallel-controlled with positive drug, multicenter, clinical trial was employed
to investigate 144 cases of patients with moderate to severe plaque psoriasis, of which there were 72 cases in both
trial group and the control group respectively, to evaluate the effect on PASI. Results: 124 cases of patients had
accomplished the 12-week clinical trial. After 12 weeks the rate of PASI50, PASI75, PASI90 were significantly higher
than those of the control group (P < 0.01). The therapeutic effects on trunk and limbs of the trial group were also
much better. Conclusion: The effect of rhTNFR:Fc is more quick and significant, especially assessed by PASI sore
Abstract not available at the BIUM and United States NLM libraries
No email address for the authors available
When we searched Google, we found another abstract of the same study
“Chinese Journal ofDermatology 2007, 40(11) 655-658” http://manu41.magtech.com.cn/Jwk cmazp/EN/abstract/
abstract11844.shtml#), which had no supplemental information to enable contacting the authors:
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Abstract
“Objective To investigate the efficacy and tolerability of a recombinant human tumour necrosis factor:Fc fusion
protein (rhTNFR:Fc,with a trade name of Yisaipu) in the treatment of moderate to severe psoriasis vulgaris.Methods
A multicentre,randomised,double blind,and parallel-controlled trial was performed. One hundred and forty-four
patients with moderate to severe psoriasis vulgaris from four centres were randomly assigned and treated with either
once-weekly subcutaneous injection of rhTNFR:Fc (50 mg) or oral methotrexate (methotrexate)(7.5 mg) for 12
weeks.Patients were followed up at 2,4,8,12 weeks after the treatment.ResultsOne hundred and twenty-four patients
finished the 12-week course of treatment. At 12 weeks after the treatment,a 50%, 75%, 90% improvement in psoriasis
area and severity index (PASI) was achieved by 86.11%, 76.39%, 52.78% respectively of rhTNFR:Fc-treated patients,
and by 63.89%, 44.44%, 22.22% respectively in methotrexate-treated patients,and all the three improvement rates
were of significant difference between the two groups of patients (all P<0.01).Physician global assessment (PGA),
dermatology life quality index (DLQI) and 10-cm visual analogue scale (VAS) all reduced more significantly, and
more patients were cured or approximately cured in rhTNFR:Fc-treated patients than in MTX-treated patients
(all P<0.05).Adverse reactions,mainly including decrease of leucocytes or neutrophils,infection, dysfunction of liver,
edema and pruritus at the injection site,etc,occurred in 26.39% of rhTNFR:Fc-treated patients and 29.17% ofMTX-
treated patients (P>0.05). Conclusion Compared with MTX,rhTNFR:Fc acts more quickly with a higher cure rate
and less toxic reactions in the treatment of psoriasis vulgaris.”
No contact with the authors as Authors’ emails were not found
Khatri 2016
Methods Randomised, double-blind, active-controlled trial
Date: April 2015-August 2016
Location: USA
Participants Total sample size: 12
Inclusion criteria
• Present with chronic moderate-severe plaque psoriasis based on a confirmed (by a dermatologist) diagnosis of
chronic plaque psoriasis for ≥ 6 months prior to baseline
• Active psoriatic skin lesions of plaque psoriasis (Ps)
• Are a candidate for phototherapy and/or systemic therapy
• Men must agree to use a reliable method of birth control or remain abstinent during the study and for ≥ 12
weeks after stopping treatment
• Women must agree to use reliable birth control or remain abstinent during the study and for ≥ 12 weeks after
stopping treatment
Exclusion criteria
• Are unable to commit to the photography schedule for the duration of the study
• Have participated in any study with interleukin 17 (IL-17) or (IL-23) antagonists, including ixekizumab
• Serious disorder or illness other than psoriasis
• Serious infection within the last 3 months
• Breastfeeding or nursing (lactating) women
Interventions Intervention:
Ixekizumab once every 2 weeks, SC, 160 mg 2 injections at week 0 followed by 80 mg ixekizumab given as a single
SC injection once every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4
weeks through week 44
Control intervention:
Ixekizumab once every 4 weeks, SC, 160 mg, 2 injections at week 0 followed by 80 mg ixekizumab given as a single
SC injection once every 4 weeks through week 44
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Outcomes At week 12,
Primary outcome
• Patient’s Global Assessment of Disease Severity
Secondary outcomes
• Itch Numeric Rating Scale
• DLQI
• PASI
• BSA
• AEs
Notes NCT02387801
Study start date: April 2015
Study completion date: August 2016
Published abstract entitled “Early onset of clinical improvement with ixekizumab in patients with moderate-severe
plaque psoriasis” published in 2016 in Journal of the European Academy of Dermatology and Venereology, Vol 30
No original paper published.
We emailed the study authors (3 and 12 January 2017) for the protocol and results but have not had a response
Lee 2016
Methods RCT, placebo-controlled, open-label trial
Date of study: July 2009-April 2011
Setting: Korea
Participants Total sample size: 60
Inclusion criteria
• Active, moderate-severe psoriasis defined by the following criteria: clinically stable, plaque psoriasis involving
more than 10% BSA or PASI 10
• In the opinion of the investigator, failure, intolerance, contraindication or not a candidate for the following:
methotrexate, ciclosporin, and psoralen plus ultraviolet A radiation (PUVA) therapy
• Negative urine pregnancy test before the first dose of study drug in all female participants
Exclusion criteria
• Evidence of skin conditions (e.g. eczema) other than psoriasis that would interfere with evaluations of the
effect of study medication on psoriasis
• Any rheumatologic disease such as rheumatoid arthritis, psoriatic arthritis, gout, systemic lupus erythematous,
systemic vasculitis, scleroderma and polymyositis, or associated syndromes
• Prior exposure to TNF inhibitors including etanercept. Prior exposure to efalizumab (Raptiva®) and alefacept
(Amevive®) is also prohibited.
Interventions Intervention
Etanercept + acitretin (combination of etanercept, 25 mg twice a week and acitretin 10 mg twice a day for 24 weeks)
Control intervention
Etanercept, 50 mg twice a week for 12 weeks followed by 25 mg twice a week for 12 weeks
Acitretin, 10 mg twice a day for 24 weeks
Outcomes At week 24
Primary outcome
• PASI 75
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Secondary outcomes
• PASI 50
• PGA0/1
• PSSQ (Psoriasis Subject Satisfaction Questionnaire)
Notes NCT00936065 (Study evaluating the efficacy and safety of etanercept and acitretin in Korean patient with moderate
to severe psoriasis)
Study start date: July 2009
Study completion date: April 2011
Abstracts:
• BMC Dermatology 2016, 16:11
• BMC dermatology 2016, 16 (no pagination)
We emailed the study authors (3 and 12 January 2017) for the protocol and results as additional information request
for risk of bias assessment but have not had a response
Mrowietz 2005
Methods RCT, placebo-controlled, double-blind trial
Date of study: not stated
Setting: not stated
Participants Randomised: 175 participants (characteristics not stated)
Inclusion criteria
• Not stated
Exclusion criteria
• Not stated
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Dimethyl fumarate (n = 105), orally, 240 mg, 3 times/day; 16 weeks
Control Intervention
B. Placebo (n = 70), orally, 2 capsules , 3 times/day; 16 weeks
Outcomes Assessments at 16 weeks
Primary outcomes of the trial
• PASI
Secondary outcomes of the trial
• PASI 50
• PASI 75
• SKINDEX-29
• Side effects
Notes Funding, quote (abstract) by Biogen Idec, Inc and Fumapharm
Abstracts:
“Results of a phase III study of a novel oral formulation of dimethyl fumarate in the treatment of moderate to severe
plaque psoriasis: efficacy, safety, and quality of life effects” published in 2005 in the JEADV, Suppl. 2 (Poster P/06.
97)
We asked the study authors to provide the protocol and results by email. Additional data to the publication not
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Mrowietz 2005 (Continued)
provided
Finally, as the ’Risk of bias’ tool assessment was not possible and there were missing data for the results, Mrowietz
2005 was included in “awaiting classification”
NCT01961609
Methods RCT, active-controlled, double-blind trial (SIGNATURE)
Date of study: October 2013-July 2016
Location: UK
Participants Randomised: 230 participants
Inclusion criteria
• Chronic plaque-type psoriasis diagnosed for ≥ 6 months prior to screening, aged ≥ 18 years at screening
• Moderate-severe disease severity: PASI ≥ 10 and DLQI > 10
• Failed to respond to systemic therapies including ciclosporin and/or methotrexate and/or PUVA (or is
intolerant and/or has a contraindication to these)
• Previously treated with ≥ 1 anti-TNFα for moderate or severe psoriasis but is a primary or secondary non-
responder
Exclusion criteria
• Forms of psoriasis other than chronic plaque-type (e.g. pustular, erythrodermic and guttate psoriasis)
• Drug-induced psoriasis (i.e. new onset or current exacerbation from beta-blockers, calcium channel inhibitors
or lithium)
• Ongoing use of prohibited psoriasis treatments (e.g. topical or systemic corticosteroids (CS), UV therapy).
Washout periods detailed in the protocol must be adhered to.
• Ongoing use of other non-psoriasis prohibited treatments. Washout periods detailed in the protocol have to be
adhered to. All other prior non-psoriasis concomitant treatments must be on a stable dose for ≥ 4 weeks before
initiation of study drug.
• Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or the IL-17 receptor
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception
and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL)
• Women of childbearing potential, defined as all women physiologically capable of becoming pregnant unless
they use 2 effective forms of contraception during the study and for 16 weeks after stopping treatment
• Men with a female partner of childbearing potential defined as all women physiologically capable of becoming
pregnant unless they use 1 effective form of contraception during the study and for 16 weeks after stopping
treatment
• Active systemic infections during the last 2 weeks (exception: common cold) prior to initiation of study drug
and any infections that recur on a regular basis; investigator discretion should be used regarding patients who have
travelled or recently resided in areas of endemic mycoses, such as histoplasmosis, coccidioidomycosis or
blastomycosis and for patients with underlying conditions that may predispose them to infection, such as advanced
or poorly controlled diabetes
• History of an ongoing, chronic or recurrent infectious disease, or evidence of TB infection as defined by a
positive QuantiFERON TB-Gold test (QFT) at screening. Patients with a positive QFT test may participate in the
study if further work up establishes conclusively that the patient has no evidence of active TB. If presence of latent
TB is established, then treatment must have been initiated and maintained according to UK guidelines
• Known infection with HIV, hepatitis B or hepatitis C at screening or at initiation of study drug
Interventions Intervention
Biological: secukinumab 150 mg at day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4
Control Intervention
339Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01961609 (Continued)
Biological: secukinumab 300 mg at day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4
Outcomes At 16 weeks
Primary outcome
• PASI 75
Secondary outcomes
• PASI 90 and PASI 75 after 2, 4, 8, 12, 24, 48 and 72 weeks
• Quality of life at 16 weeks
Notes On www.clinicaltrials.gov
Study completion date: July 2016
Ongoing study
NCT01988103
Methods RCT, placebo-controlled, double-blind trial, phase 2
Date of study: July 2013-December 2015
Location: Japan
Participants Randomised: 254 participants
Inclusion criteria
• Male or female Japanese people ≥ 20 years of age
• Diagnosis of chronic, stable plaque psoriasis for ≥ 6 months prior to screening as defined by: PASI score ≥ 12
and BSA ≥ 10%
• Psoriasis considered inappropriate for topical therapy (based on severity of disease and extent of affected area)
or has not been adequately controlled or treated by topical therapy in spite of ≥ 4 weeks of prior therapy with ≥ 1
topical medication for psoriasis or per label.
• In otherwise good health based on medical history, physical examination, 12-lead ECG, serum chemistry,
haematology, immunology, and urinalysis.
Exclusion criteria
• Other than psoriasis, history of any clinically significant and uncontrolled systemic diseases; any condition,
including the presence of laboratory abnormalities, which would place the subject at unacceptable risk or confound
the ability to interpret the data in the study
• Prior medical history of suicide attempt or major psychiatric illness requiring hospitalization within the last 3
years
• Pregnant or breastfeeding
• History of or ongoing chronic or recurrent infectious disease
• Active TB or a history of incompletely treated TB
• Clinically significant abnormality on 12-lead ECG or on chest radiograph at screening.
• History of HIV infection or have congenital or acquired immunodeficiencies (e.g. Common Variable
Immunodeficiency).
• Hepatitis B surface antigen or hepatitis B core antibody positive at screening; positive for antibodies to
hepatitis C at screening
• Malignancy or history of malignancy, except for treated (i.e. cured) basal cell or squamous cell in situ skin
carcinomas or treated (i.e. cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix with no
evidence of recurrence within previous 5 years
• Psoriasis flare within 4 weeks of screening
• Topical therapy within 2 weeks prior to randomisation or systemic therapy for psoriasis or psoriatic arthritis
340Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01988103 (Continued)
within 4 weeks prior to randomisation
• Use of etretinate within 2 years prior to randomisation for women of childbearing potential or within 6
months for men, and within 4 weeks prior to randomisation for women not of childbearing potential
• Use of phototherapy (i.e. UVB, PUVA) within 4 weeks prior to randomisation or prolonged sun exposure or
use of tanning booths or other ultraviolet light sources.
• Use of adalimumab, etanercept, certolizumab pegol, abatacept, tocilizumab, golimumab or infliximab within
12 weeks prior to randomisation; use of ustekinumab, alefacept or briakinumab within 24 weeks prior to
randomisation
• Any investigational drug within 4 weeks prior to randomisation
Interventions Intervention:
A. Apremilast (30 mg tablet twice a day for 68 weeks)
Control intervention:
B. Apremilast (20 mg tablet twice a day for 68 weeks)
C. Placebo
Outcomes At week 16
Primary outcome:
• PASI 75
Secondary outcomes:
• PGA 0/1
• PASI 90
• VAS
• DLQI total score
• Mental Component Summary (MCS) score of SF-36
• AEs
Notes Study completed, but not yet published
Enrollment: 254
Study start date: July 2013
Study completion date: December 2015
Sent e-mail to Dr Nogarales, MD Celgene Corporation (12 January 2017)
Will be included when published as the article has just been submitted
NCT02054481
Methods RCT, placebo-controlled, double-blind trial, phase 2
Date of study: February 2014-July 2015
Location: world-wide
Participants Randomised: 166 participants
Inclusion criteria
• BMI ≥ 18.5 and < 40 kg/m²
• Stable moderate-severe chronic plaque-type psoriasis with or without psoriatic arthritis involving ≥ 10% body
surface area, with disease severity PASI ≥ 12 and sPGA score of moderate and above (score of ≥ 3) at screening visit
and visit 2 (randomisation), as assessed by the investigator
• Psoriasis disease duration of ≥ 6 months prior to screening, as assessed by the investigator
• Patients must be candidates for systemic psoriasis treatment or phototherapy, as assessed by the investigator
• Patients must be suitable candidates for ustekinumab (Stelara®) therapy as given in the local labelling
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• Patient must give informed consent and sign an approved consent form prior to any study procedures in
accordance with GCP and local legislation
Exclusion criteria
• Patients with guttate, erythrodermic, or pustular psoriasis and patients with drug-induced psoriasis, as
diagnosed by the investigator
• Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding
of the medical examination (including vital signs and ECG), that in the opinion of the investigator, would
compromise the safety of the patient or the quality of the data. This criterion provides an opportunity for the
investigator to exclude patients based on clinical judgment, even if other eligibility criteria are satisfied. (Psoriatic
arthritis is not considered an exclusion criterion)
• Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders,
diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders, or history
of orthostatic hypotension, fainting spells or blackouts, that in the investigator’s judgement, could jeopardize the
safe conduct of the study.
• Clinically important acute or chronic infections including hepatitis and HIV.
With regards to TB the following applies:
• Have signs or symptoms suggestive of current active or latent TB upon medical history, physical examination
and/or a chest radiograph (both posterior-anterior and lateral views, taken within 3 months prior to the first
administration of study drug and read by a qualified radiologist)
• Have history of latent or active TB prior to screening, except for patients who have documentation of having
completed an adequate treatment regimen ≥ 6 months prior to the first administration of study agent
• Have positive IGRA testing (QuantiFERON-TB Gold) within 2 months prior to or during screening, in
which active TB has not been ruled out, except for patients with history of latent TB and documentation of having
completed an adequate treatment regimen ≥ 6 months prior to the first administration of study agent
• Have had a live vaccination ≤ 12 weeks prior to randomisation (visit 2). Patients must agree not to receive a
live vaccination during the study. No BCG vaccines should be given for one year prior to randomisation (visit 2),
during the study and for one year after last administration of study drug (according to the Stelara® SPC).
• History of clinically significant hypersensitivity to a systemically administered biologic agent or its excipient
• History of malignancy in the past 5 years or suspicion of active malignant disease except treated cutaneous
squamous cell or basal cell carcinoma
• Has received any therapeutic agent directly targeted to IL-12, IL-23 (including ustekinumab (Stelara®))
• Use of biologic agents within 12 weeks (infliximab, etanercept, adalimumab, other biologics) prior to
treatment, systemic anti-psoriatic medications or phototherapy within 4 weeks prior to treatment, or topical anti-
psoriasis medications within 2 weeks prior to treatment
Interventions Intervention
A. Drug: BI 655066 (low dose) (18 mg BI 655066 administered by SC injection plus 2 placebo-matching BI 655066
injections at week 0, followed by 2 placebo-matching BI 655066 injections each at weeks 4 and 16.)
Control intervention
B. Drug: BI 655066 (median dose) (90 mg BI 655066 administered by SC injection plus 2 placebo-matching BI
655066 injections at week 0, followed 90 mg BI 655066 plus 1 placebo-matching BI 655066 injection at weeks 4
and 16.)
C. Drug: BI 655066 (high dose) (180 mg BI 655066 administered by SC injection as 2 injections plus a placebo-
matching BI 655066 injection at week 0, followed 180 mg BI 655066 administered as 2 injections at 2eeks 4 and
16.)
D. Drug: ustekinumab (Stelara administered by SC injection plus 2 saline injections at week 0, Stelara injection
plus 1 saline injection at weeks 4 and 16. Stelara dose was 45 mg for participants with body weight ≤ 100 kg at
randomisation or 90 mg for participants with body weight > 100 kg at randomisation.)
342Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02054481 (Continued)
Outcomes At week 12
Primary outcome
• PASI 90
Secondary outcomes
• PASI 50, 75, 100 (weeks 12 & 24)
• PGA
Notes Study completed July 2015 and the results are available on ClinicalTrials.gov
BI 655066 is a new anti-IL23, not included in the initial search. It will be in the Cochrane Review update, so the
trial will be included too
NCT02248792
Methods RCT, active-controlled, double-blind trial, phase 3
Date of study: November 2013-January 2015
Location: India
Participants Randomised: 50 participants
Inclusion criteria
• Age range 18-65 years
• Both sexes
• Severe plaque-type psoriasis (BSA > 10% or PASI > 12)
Exclusion criteria
• Pregnancy
• Lactation
• Malignancy or immunosuppression including HIV
• Liver disease
• Renal disease
• Non compliant
• Psychiatric illness
• Hypersensitivity to methotrexate in the past
Interventions Intervention
Methotrexate 10 mg/week
Control intervention
Methotrexate 25 mg/week
Outcomes At week 12
Primary outcome
• Improvement in health related quality of life
Secondary outcomes
• Comparison of improvement in health related quality of life between Group A and Group B
Notes On ClinicalTrials.gov,
Estimated Enrollment: 50
Study start date: November 2013
Estimated primary completion date: January 2015 (final data collection date for primary outcome measure)
Emails sent to Prof. Krishna (5 and 12 January 2017)
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Reich 2004
Methods RCT, placebo-controlled, double blind
Date of study: not stated
Setting: multicenter (locations not stated)
Participants Randomised: 195 participants (no description of the study population)
Inclusion criteria
• Participants with moderate-severe psoriasis (BSA ≥ 10)
• Age ≥ 16 years
• Non-response to phototherapy
• Non-response to conventional systemic treatment
• Number of allowed previous treatments: 3
Exclusion criteria
• Previous treatments > 3
Dropouts and withdrawals
• Not stated
Interventions Intervention
A. Alefacept (n = 130), IM, 15 mg, once a week, 12 weeks
Control Intervention
B. Placebo (n = 65), IM, once a week, 12 weeks
Outcomes Assessments at 14 weeks
Primary or secondary outcomes of the trial
• PASI50
Outcomes of the trial
• AEs
Notes Funding: not stated
Abstracts:
“Alefacept in the treatment of psoriasis for whom conventional therapies are ineffective or inappropriate” published
in 2004 in the Journal of the European Academy of Dermatology and Venereology, Poster P105
We asked the study authors to provide the protocol and results by email. The had no acces to the data (“I do not
have access to the data you require”)
Finally, as the ’Risk of bias’ tool assessment was not possible and there were missing data for the results, Reich 2004
was included in “awaiting classification”
Reich 2016
Methods RCT, active-controlled, double-blind trial, phase 3
Date of study: November 2013-January 2015
Location: India
Participants Randomised: 198 participants
Inclusion criteria
• Chronic moderate-severe plaque type psoriasis for ≥ 6 months prior to randomisation, including significant
nail involvement, defined as NAPSI score ≥ 16 and number of fingernails involved ≥ 4 and PASI score ≥ 12 and
BSA score ≥ 10%
• Candidates for systemic therapy, i.e. psoriasis inadequately controlled by topical treatment (including super
potent topical corticosteroids) and/or phototherapy and/or previous systemic therapy
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Exclusion criteria
• Forms of psoriasis other than chronic plaque type psoriasis (e.g. pustular psoriasis, palmoplantar pustulosis,
acrodermatitis of Hallopeau, erythrodermic and guttate psoriasis)
• Drug-induced psoriasis (e.g. new onset or current exacerbation from β-blockers, calcium channel inhibitors or
lithium)
• Ongoing inflammatory skin diseases other than psoriasis or any other disease affecting the fingernails that may
potentially confound the evaluation of study treatment effects
• Ongoing use of prohibited treatments (e.g. topical or systemic corticosteroids (CS), UV therapy). Washout
periods do apply
• Prior exposure to secukinumab (AIN457) or any other biological drug directly targeting IL-17 or the IL-17
receptor
• Exposure to any investigational drugs within 4 weeks prior to study treatment initiation or within a period of
5 half-lives of the investigational treatment, whichever is longer
• History of hypersensitivity to constituents of the study treatment
• Other protocol-defined inclusion/exclusion criteria do apply
Interventions Intervention
Biological: secukinumab 150 mg weekly for 5 weeks, then once every 4 weeks up to and including Week 128
Control Intervention
Biological: secukinumab 300 mg weekly for 5 weeks, then once every 4 weeks up to and including Week 128
Biological: Placebo
Outcomes At week 16
Primary outcome
• NAPSI
Secondary outcomes
• NAPSI at 132 weeks
• PASI 75 at weeks 16 and 132
• IGA 0/1 at weeks 16 and 132
• AEs
Notes NCT01807520
Enrollment: 198
Study start date: June 2013
Estimated study completion date: January 2017
Abstracts
• Annals of the Rheumatic Diseases 2016, 75:603-4
• Australasian Journal of Dermatology 2016, 57:77
We asked the study authors to provide the protocol and results by email (3 January 2017)
As there is no original publication available, the authors and the firm could not send us such details
Will be included when published.
AEs: adverse effects;BMI: body mass index; BSA: body surface area;DLQI: Dermatology Life Quality Index; ECG: electrocardiogram;
eow: every other week;FAEs: fumaric acid esters; IGA: Investigator’sGlobal Assessment; IM: intramuscular; IV: intravenous;NAPSI:
Nail Psoriasis Severity Index; PASI: Psoriasis Area and Severity Index; PGA: Physician’s Global Assessment; PUVA: psoralen plus
ultraviolet A; RCT: randomised controlled trial; SC: subcutaneous; SF36: short-form 36; SPGA: static physician global assessment;
TB: tuberculosis; UVB: ultraviolet B; VAS: visual analogue scale
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Characteristics of ongoing studies [ordered by study ID]
ChiCTR-INR-16009710
Trial name or title Acitretin plus methotrexate in the treatment of moderate to severe psoriasis vulgaris
Methods Phase 4
RCT, active/placebo-controlled, double-blind trial
Date of study: January 2016-December 2016
Location: China
Participants Randomised: 350 participants
Inclusion criteria
• Men and women aged 18-75 years
• Mild psoriasis vulgaris defined by the following criteria: BSA > 10% at screening and baseline and
PASI > 7 at screening and baseline
• Provide written informed consent and willing and able to comply with all aspects of the protocol
Main exclusion criteria
• Other types of psoriasis than mild psoriasis vulgaris e.g. guttate, pustular, erythrodermic, etc
• Active infectious disease, which was hard to control
• History of hepatitis B or hepatitis C, and advanced HIV infection
• Laboratory data such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and blood
lipid profile was 1.5 times higher than the normal limits
• History of severe systemic disease or cancer
• Pregnant or lactating women or planning to get pregnant in 2 years
• Allergic to methotrexate and acitretin - any ingredient
Interventions Intervention group
A. Acitretin plus methotrexate group (n = 100)
Control intervention group
B. Acitretin Capsules (n = 100), 1 pill, twice a day
C. Methotrexate (n = 100), 7.5 mg/week, and then 25 mg/week
D. Blank group (n = 50), none
Outcomes Time point outcome measured: not stated
Primary outcome
• PASI
Secondary outcome
• DLQI
Starting date January 2016
Contact information Prof. Xia Yumin; xiayumin1202@163.com
Notes Ongoing study
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CTRI/2016/10/007345
Trial name or title A randomised, double-blind, placebo-controlled, comparative, prospective, multicentre trial to assess efficacy
and safety of apremilast tablets in subjects with moderate to severe plaque psoriasis who are candidates for
phototherapy or systemic therapy
Methods Phase 3
RCT, placebo-controlled, double-blind trial
Date of study: October 2016 -
Location: India
Participants Randomised: 231 participants
Inclusion criteria
• Men and women, aged 18-65 years
• Moderate-severe plaque psoriasis for ≥ 6 months who are candidates for phototherapy or systemic
therapy
Exclusion criteria
• Pregnant or lactating women
• Known hypersensitivity to the study drug or any of the excipient
• History of current erythrodermic, guttate or pustular psoriasis
• Psoriasis flare or rebound within 4 weeks prior to screening
• Used topical therapy within 2 weeks of randomisation or systemic therapy or phototherapy (i.e. UVB,
PUVA) for psoriasis within 28 days of randomisation
• Used biological therapy for psoriasis within 6 months of randomisation
• History of malignancy (except for treated (i.e. cured) basal cell or squamous cell in situ skin carcinomas
and treated (i.e. cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix with no
evidence of recurrence) within 5 years of screening
• Evidence of skin conditions that would interfere with clinical assessments in the opinion of the
investigator
• Active substance abuse or a history of substance abuse within 6 months prior to Screening
• Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal
infections
• Used any investigational drug or device within 30 days of randomisation preceding informed consent
or scheduled to participate in another clinical study involving an investigational product or investigational
drug during the course of this study
Interventions Intervention
Apremilast 30 mg tablets: administered 1 tablet twice daily for 16 weeks
Control intervention
Placebo tablets: administered 1 tablet twice daily for 16 weeks
Outcomes At week 16
Primary outcome
• Proportion of participants achieving PASI 75 responses
Secondary outcomes
• Proportion of participants achieving PGA score of clear (0) or almost clear (1) at 16 weeks
• Proportion of participants achieving PASI 50 at 16 weeks
• Proportion of participants achieving PASI 90 at 16 weeks
• Proportion of participants who have taken rescue medication during the treatment period at 16 weeks
Starting date 20 October 016
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Contact information Dr Piyush Agarwal, DrPiyush.Agarwal@glenmarkpharma.com
Notes Ongoing study
EUCTR2013-004918-18-NL
Trial name or title Optimising adalimumab treatment in psoriasis with concomitant methotrexate - OPTIMAP
Methods Phase 4
RCT, placebo-controlled, open-label trial
Date of study: February 2014 -
Location: the Netherlands
Participants Randomised: number of participants not stated
Inclusion criteria
• Diagnosis of moderate-severe plaque psoriasis (PASI = 8 at time of screening)
• Candidate for the treatment with biologic drugs according to the pertaining guidelines
• Willing and able to use an adequate contraceptive during the study (all men and pre-menopausal
women)
• Adalimumab therapy will be started for the treatment of psoriasis
• Signed informed consent
Exclusion criteria
• History of significant methotrexate or adalimumab toxicity, intolerability or contraindication
• Prior treatment with adalimumab
• Age < 18 years
• Pregnant and nursing women
• Other immunosuppressive medication (prednisone, mycophenolate mofetil (e.g. Cellcept), ciclosporin
(e.g. Neoral), sirolimus (Rapamune), systemic tacrolimus (e.g. Prograft)
Interventions Intervention
Adalimumab with methotrexate
Control intervention
Adalimumab monotherapy
Dosage and frequency of adalimumab and methotrexate: not stated
Outcomes Primary end point(s)
• Drug survival at 1 year
• Drug survival by efficacy
• Drug survival by adverse events
Timepoint(s) of evaluation of this end point: week 49
Secondary end point(s)
• Efficacy expressed as the proportion of participants achieving PASI 75 and 90 at weeks 13, 25, 37 and
49 and reduction of absolute PASI at these time points
• Change in patient global assessment and IGA
• Average adalimumab serum trough concentrations and titers
• Change in impact on QoL (Skindex 29 and DLQI)
• Treatment satisfaction (measured by Treatment Satisfaction Questionnaire for Medication)
• Occurrence of (serious) AEs;
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• Patient characteristics (age, gender, ethnicity, BMI, psoriatic arthritis, smoking, alcohol use, disease
duration, disease severity by PASI, concomitant medication, naïve for biologics versus non-naïve (perhaps
specified per biologic), trial medication and potential other co-variates (e.g. genetic polymorphisms)
Timepoint(s) of evaluation of this end point: week 13, 25, 37 and 49
Starting date 12 December 2013
Contact information Pr Phyllis Spuls
Department of Dermatology Academic Medical Center
Meibergdreef 9 1105AZ Amsterdam Netherlands
Notes Recruitment status (ICTRP search portal): authorised-recruitment may be ongoing or finished
Target sample: not specified
We emailed Prof. Phyllis Spuls (5 January 2017)
Email response “The study is currently ongoing and has not yet been analysed. Therefore, we are not able
to provide data on efficacy or safety. We can provide you with the study protocol. Will this be helpful? Kind
regards, Phyllis Spuls and Celine Busard ”
Will be included when published
EUCTR2015-002423-26-FI
Trial name or title A randomised, multicenter Study to evaluate the Effect of secukinumab 300 mg s.c. administered during 52
weeks to patients suffering from new-onset moderate to severe plaque Psoriasis as early Intervention compared
to standard treatment with narrow band UVB (STEPin study) - STEPin
Methods RCT, placebo-controlled, open-label trial
Date of study: November 2016 -
Location: Europe
Phase 4
Participants Randomised: 196 participants
Inclusion criteria:
• Aged 18-40 years inclusive
• Moderate-severe plaque psoriasis with either new onset or lasting for ≥ 5 years
Exclusion criteria:
• Forms of psoriasis other than plaque-type (e.g. pustular, erythrodermic, guttate, light sensitive, drug
induced)
• Ongoing use of prohibited treatments
• Pregnant or nursing (lactating) women
• Women of childbearing potential not willing to use contraception
• Active ongoing inflammatory diseases other than psoriasis or psoriatic arthritis that might confound
the evaluation of the benefit of secukinumab therapy
Interventions Secukinumab 300 mg SC. versus narrowband-UVB
Dosage and frequency not stated
Outcomes At 52 weeks,
Primary outcome
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• PASI 90
Secondary outcomes
• PASI 90 at week 104
• IGA 0/1 at weeks 52 and 104
Starting date 8 November 2016
Contact information Novartis medical information service, novartis.laakeinformaatio@novartis.com
Notes Ongoing study
EUCTR2015-003623-65-DE
Trial name or title BI 655066 (risankizumab) versus adalimumab in a randomised, double blind, parallel group trial in moderate
to severe plaque psoriasis to assess safety and efficacy after 16 weeks of treatment and after inadequate
adalimumab treatment response (IMMvent) - BI 655066 (risankizumab) versus adalimumab
Methods RCT, active/placebo-controlled, double-blind trial
Date of study: February 2016 -
Location: worldwide
Phase 3
Participants Randomised: 600 participants planned
Inclusion criteria
• Men and women. Women of childbearing potential must be ready and able to use highly effective
methods of birth control per ICH M3(R2) that result in a low failure rate of less than 1% per year when
used consistently and correctly. A list of contraception methods meeting these criteria is provided in the
patient information.
• Age≥ 18 years at screening
• Diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for ≥ 6 months before the
first administration of study drug. Duration of diagnosis may be reported by the participant
• Stable moderate-severe chronic plaque psoriasis with or without psoriatic arthritis at both screening
and baseline (randomization)
• BSA ≥ 10%
• PASI score ≥ 12
• sPGA score of ≥ 3
• Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the
investigator
• Must be candidates for treatment with adalimumab (Humira®) according to local label as confirmed
by the investigator
Exclusion criteria
Patients with
• Non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)
• Current drug-induced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium
channel blockers, or lithium)
• Active ongoing inflammatory diseases other than psoriasis that might confound trial evaluations
according to investigator’s judgment
• Previous exposure to BI 655066
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• Previous exposure to adalimumab (Humira®).
• Major surgery performed within 12 weeks prior to randomisation or planned within 12 months after
screening (e.g. hip replacement, removal aneurysm, stomach ligation).
• Known chronic or relevant acute infections, such as active TB, HIV or viral hepatitis; confirmation of
these diseases testing is required at screening. QuantiFERON® TB test or PPD skin test will be performed
according to local labelling for Humira®. If the result is positive, patients may participate in the study if
further work up (according to local practice/guidelines) establishes conclusively that the patient has no
evidence of active TB. If presence of latent TB is established, then treatment should have been initiated and
maintained according to local country guidelines.
• Any documented active or suspected malignancy or history of malignancy within 5 years prior to
screening, except appropriately treated basal cell or squamous cell carcinoma of the skin or in situ carcinoma
of uterine cervix.
• Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse)
other than psoriasis, surgical procedure (i.e. organ transplant), medical examination finding (including vital
signs and ECG), or laboratory value at the Screening Visit outside the reference range that in the opinion of
the investigator is clinically significant and would make the study participant unreliable to adhere to the
protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data
Interventions Intervention
Product Name: BI 655066
Product Code: BI 655066 90 mg/mL
Pharmaceutical Form: solution for injection in pre-filled syringe
INN or proposed INN: risankizumab
Control intervention
Humira® (adalimumab) solution for Injection 40 mg/0.8 mL in a single-use, pre-filled syringe
Outcomes At week 16
Primary outcome
• PASI 90
Secondary outcomes
• PGA 0/1
• PASI 75 PASI 100
Starting date 17 May 17 2016
Contact information Boehringer Ingelheim Pharma GmbH & Co. KG
Notes Ongoing study
BI 655066 (a new anti-IL23) will be included
NCT01553058
Trial name or title Vascular inflammation in psoriasis trial (The VIP Trial) (VIP)
Methods RCT, active/placebo-controlled, double blind trial
Date of study: February 2012 -
Location: USA
Phase 4
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Participants Randomised: 96 participants
Inclusion criteria
• Men and women ≥ 18 years
• Clinical diagnosis of psoriasis for ≥ 6 months as determined by subject interview of his/her medical
history and confirmation of diagnosis through physical examination by Investigator
• Stable plaque psoriasis for ≥ 2 months before screening and at baseline (week 0) as determined by
subject interview of his/her medical history
• Moderate-severe psoriasis defined by ≥ 10 percent BSA involvement at the baseline (week 0) visit
• PASI score of ≥ 12 at the baseline (week 0) visit
• Subject is a candidate for systemic therapy or phototherapy and has active psoriasis despite prior
treatment with topical agents
• Women are eligible to participate in the study if they meet one of the following criteria: women of
childbearing potential who are willing to undergo regular pregnancy testing and agree to use one method of
contraception throughout the study are eligible to participate; women who are postmenopausal (for ≥ 1
year), sterile, or hysterectomised are eligible to participate; women who have undergone tubal ligation are
eligible to participate; women who agree to be sexually abstinent, defined as total abstinence from sexual
intercourse, as a form of contraception are eligible to participate in the study.
• Judged to be in good general health as determined by the Principal Investigator based upon the results
of medical history, laboratory profile, physical examination, and 12-lead ECG performed at screening
• Able and willing to give written informed consent and to comply with requirements of this study
protocol
Exclusion criteria
• Previous AE following exposure to a TNF-alpha antagonist and/or UV phototherapy that led to
discontinuation of either of these therapies and contraindicates future treatment
• Previous lack of response to a TNF-alpha antagonist and/or UV phototherapy that led to
discontinuation of either of these therapies
• Diagnosis of erythrodermic psoriasis, generalised or localised pustular psoriasis, medication-induced or
medication-exacerbated psoriasis, or new onset guttate psoriasis
• Diagnosis of other active skin diseases or skin infections (bacterial, fungal, or viral) that may interfere
with evaluation of psoriasis
• Cannot avoid UVB phototherapy for ≥ 14 days prior to the baseline (week 0) visit
• Cannot avoid psoralen-UVA phototherapy for ≥ 30 days prior to the baseline (week 0) visit and
during the study
• Cannot discontinue systemic therapies for the treatment of psoriasis, or systemic therapies known to
improve psoriasis, during the study: systemic (investigational or marketed) therapies must be discontinued
≥ 30 days prior to the baseline (week 0) visit except for biologics. All biologics, except ustekinumab, must be
discontinued for ≥ 90 days prior to baseline (week 0). The IL-12/IL-23 antagonist ustekinumab (half-life of
45.6 ± 80.2 days) must be discontinued for ≥ 180 days prior to baseline (week 0). Investigational agents
must be discontinued ≥ 30 days or 5 half-lives (whichever is longer) prior to the baseline (week 0) visit
• Taking or requires oral or injectable corticosteroids during the study. Inhaled corticosteroids for stable
medical conditions are allowed
• Poorly controlled medical condition, such as unstable ischaemic heart disease, congestive heart failure,
recent cerebrovascular accidents, psychiatric disease requiring frequent hospitalisation, and any other
condition, which, in the opinion of the Investigator, would put the participant at risk by participation in the
study
• History of diabetes mellitus, type 1 or type 2
• Uncontrolled hypertension, with measured systolic blood pressure > 180 mmHg or diastolic blood
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pressure > 90 mmHg
• History of demyelinating diseases or lupus
• Infection or risk factors for severe infections, for example: positive serology or known history of HIV,
hepatitis B or C, or other severe, recurrent, or persistent infections; excessive immunosuppression or other
factors associated with it, including HIV infection; active TB disease; evidence of latent TB infection
demonstrated by Purified Protein Derivative (PPD) ≥ 5 mm of induration or positive Quantiferon-GOLD
results; except if prophylactic treatment for TB, as recommended by local guidelines, is initiated prior to
administration of study drug or if there is documentation that the subject has received prophylactic
treatment for TB previously. Any other significant infection requiring hospitalisation or IV antibiotics in the
month prior to baseline; infection requiring treatment with oral or parenteral antibiotics within 14 days
prior to baseline; received vaccination with Bacille Calmette-Guerin (BCG) within 365 days prior to
screening; received vaccination with a live viral agent 30 days prior to screening or will require a live
vaccination during study participation including up to 30 days after the last dose of study drug
• History of haematological or solid malignancy other than successfully treated basal cell carcinoma,
non-metastatic cutaneous squamous cell carcinoma or cervical carcinoma in situ
• Pregnant or breast-feeding or considering becoming pregnant during the study
• Screening clinical laboratory analyses showing any of the following abnormal results: haemoglobin
(Hgb) < 10 g/dL in women or < 12 g/dL in men; white blood cell (WBC) count < 2.5 x 109/L or can be
included if WBC count is < 2.5 x 109/L and absolute neutrophil count (ANC) is > 1000 cells/mm3. WBC
count > 15 x 109/L; platelet count < 100 x 109/L; serum aspartate transaminase (AST) or alanine
transaminase (ALT) > 2.5 upper limits of normal (ULN); serum total bilirubin ≥ 2 mg/dL (≥ 26 µmol/L);
or serum creatinine > 1.6 mg/dL (> 141 µmol/L)
• Recent history of substance abuse or psychiatric illness that could preclude compliance with the
protocol
• History of any substance abuse within 365 days of screening visit
• Alcohol use > 14 drinks per week at the screening visit or within 30 days of the screening period
• If on cholesterol-lowering medication (e.g. statin), dose and form of medication must be stable for 90
days prior to week 0 and remain stable throughout the duration of the study
• History of photosensitivity of medical condition that may be exacerbated by UV exposures such as
lupus or dermatomyositis
Interventions Intervention
A. Adalimumab (Humira). Humira will be given at an initial dose of 80 mg followed by 40 mg the 2nd week,
subsequent doses will be given at 40 mg and follow FDA dosing schedule
Control intervention
B. NB-UVB phototherapy. Phototherapy will be given 3 times per week according to the Fitzpatrick scale for
skin types
C. Placebo injection will be given according to the same dose and schedule as the active comparator
Outcomes At weeks 4 and 12
Primary outcome measures
• Vascular inflammation and biomarkers
• Change in total vascular inflammation of 5 aortic segments as assessed on FDG-PET/CT between
baseline and week 12
• Change in metabolic, lipid, and inflammatory biomarker levels between baseline, week 4 and 12
Secondary outcome measures:
• Change in psoriasis activity (PASI 50, PASI 75, PASI 90, and PGA < 1)
• Number of participants with AEs
• Change in participant-reported outcomes (e.g. EuroQoL-5D, DLQI, and International Physical
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Activity Questionnaire (IPAQ))
Starting date 14 February 2012
Contact information Joel Gelfand, MD MSCE (Principal investigator)
Notes On ClinicalTrials.gov,
Estimated Primary Completion Date: July 2017
Ongoing study
NCT01558310
Trial name or title A study to evaluate the effectiveness of Stelara™ (ustekinumab) in the treatment of scalp psoriasis
Methods RCT, placebo-controlled, double-blind trial
Date of study: March 2012 -
Location: USA
Phase 4
Participants Randomised: 30 participants
Inclusion criteria
• Capable of giving informed consent and the consent must be obtained prior to any study related
procedures
• ≥ 18 years at the time of consent; may be male or female
• Diagnosis of plaque psoriasis ≥ 6 months prior to administration of study agent
• Presence of moderate or severe psoriasis on the body other than the scalp
• ≥ 30% of scalp affected with erythema, induration and desquamation and s-PGA score ≥ 4
• Candidates for phototherapy or systemic treatment of psoriasis
• Women of childbearing potential and all men must be using adequate birth control measures (e.g.
abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization)
and must agree to continue use of such measures and not become pregnant or plan a pregnancy until 12
months after receiving the last injection of study agent
• Be able to adhere to protocol requirements and study visit schedule
• Must agree not to receive a live virus or live bacterial vaccination during the trial and 12 months after
last study injection
• Must agree not to receive a BCG vaccination during the trial and up to 12 months after the last
injection
• Must avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources
during the study
• Considered eligible according to the following TB screening criteria.
◦ Have no history of latent or active TB prior to screening. An exception is made for participants
currently receiving treatment for latent TB with no evidence of active TB, or who have a history of latent
TB and documentation of having completed appropriate treatment for latent TB within 3 years prior to the
first administration of study agent. It is the responsibility of the investigator to verify the adequacy of
previous antituberculous treatment and provide appropriate documentation.
◦ Have no signs or symptoms suggestive of active TB upon medical history or physical
examination, or both.
◦ Within 6 weeks prior to the first administration of study agent, have a negative QuantiFERON-
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TB Gold test result.
◦ Have a chest radiograph (both posterior-anterior and lateral views), taken within 3 months prior
to the first administration of study agent and read by a qualified radiologist, with no evidence of current,
active TB or old, inactive TB.
• Have screening laboratory test results within the following parameters:
◦ Heamoglobin > 10g/dL
◦ White Blood Cells > 3.5 x 109/L
◦ Neutrophils > 1.5 x 109/L
◦ Platelets > 100 X109/L
◦ Serum Creatinine < 1.5 mg/dL (or 133 micromol/L)
◦ AST, ALT, and alkaline phosphatase levels must be within 1.5 times the upper limit of normal
range for the laboratory conducting the test
Exclusion criteria
• Currently have non-plaque forms of psoriasis (erythrodermic, guttate, or pustular)
• Have current drug-induced psoriasis
• Presence of any skin conditions ( including scalp) other than psoriasis that would interfere with
evaluations of the effect of study agents
• Are pregnant, nursing, or planning pregnancy (both men and women) while enrolled in the study
• Have used any therapeutic agent targeted at reducing IL-12 and/or IL-23, including but not limited to
ustekinumab and ABT -874
• Have used any investigational drug within the previous 4 weeks or 5 times the half-life of the
investigational agent, whichever is longer
• Have used any investigational drug within the previous 3 months or 5 times the half-life of the
biological, whichever is longer
• Have ever received natalizumab or other agents that target alpha-4-integrin
• Have received phototherapy or any systemic medications/treatments that could affect psoriasis or s-
PGA/PASI evaluations (including but not limited to, oral or injectable corticosteroids, retinoids, 1, 25
dihydroxy vitamin D3 and analogues, psoralens, sulfasalazine, hydroxyurea, or fumaric acid derivatives)
within 4 weeks of administration of study agent
• Have used topical mediations/treatments that could affect psoriasis or s-PGA/PASI evaluation ( e.g.
corticosteroids , anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, methoxsalen,
trimethyl psoralens) within 2 weeks of the first administration of study agent
• Have used any systemic immunosuppressants (e.g. methotrexate, azathioprine, ciclosporin, 6-
thioguanine, mercaptopurine, mycophenolate, mofetil, hydroxyurea, and tacrolimus) within 4 weeks of the
first administration of study agent
• Are currently receiving lithium, anti-malarials, or intramuscular gold, or have received lithium, anti-
malarials, or intramuscular gold, or have received lithium, anti-malarials, or intramuscular gold within 4
weeks of the first administration of study agent
• Have received within 3 months prior to the first injection a live virus or bacterial vaccination.
Participants must agree not to receive a live virus or bacterial vaccination during the trial or up to 12 months
after the last study agent injection
• Have had a BCG vaccination within 12 months of screening. Participants must agree not to receive a
BCG vaccination during the trial or up to 12 months after the last study agent injection
• Have a history of chronic or recurrent infectious disease, including but not limited to chronic renal
infection, chronic chest infections (e.g. bronchiectasis), recurrent urinary tract infections (recurrent
pyelonephritis or chronic non-remitting cystitis), or open, draining, or infected skin wounds or ulcers
• Have or have had a serious infection (e.g. sepsis, pneumonia,or pyelonephritis) or have been
hospitalised or received IV antibiotics for an infection during the 2 months prior to screening
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• Have a history of latent or active granulomatous infection, including histoplasmosis or
coccidioidomycosis, prior to screening
• Have persistently indeterminate (indeterminate on repeat sampling) QuantiFERON-TB Gold test
results
• Have had a Bacille Calmette-Guérin (BCG) vaccination within 12 months of screening
• Have a chest radiograph within 3 months prior to the first administration of study agent that shows an
abnormality suggestive of a malignancy or current active infection, including TB
• Have had a non-tuberculous mycobacterial infection or opportunistic infection (e.g. cytomegalovirus,
pneumocystosis, aspergillosis) within 6 months prior to screening
• Known to be infected with HIV, hepatitis B, or hepatitis C
• Have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, haematological,
gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease
• Have a transplanted organ
• Have a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms
suggestive of possible lymphoproliferative disease, such as lymphadenopathy and /or splenomegaly
• Have a known malignancy or have a history of malignancy (with the exception of basal cell carcinoma,
squamous cell carcinoma in situ of the skin or cervix that has been treated with no evidence of recurrence, or
squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years
prior to the first administration of study agent)
• Have been hospitalised in the past 3 years for asthma, ever required intubation for treatment of
asthma, currently require oral corticosteroids for the treatment of asthma, or required more than one short-
term (< 2 weeks) course of oral corticosteroids for asthma within the previous year
• Have undergone allergy immunotherapy previously for prevention of anaphylactic reactions
• Have shown a previous immediate hypersensitivity response, including anaphylaxis, to an
immunoglobulin product (e.g. plasma-derived or recombinant monoclonal antibody).
• Be known to have had a substance abuse (drug or alcohol) problem within the previous 12 months
• Be participating in another trial using an investigational agent or procedure during participation in the
trial
• Use of tar shampoos within 14 days of first dose of study drug
• Use of over-the-counter shampoos for scalp psoriasis will not be allowed during study
• Use of topical corticosteroids or other topical agents for the treatment of psoriasis on the scalp will not
be allowed during the study
Interventions Intervention
Ustekinumab (at weeks 0, 4, 16, 28, and week 40 and placebo at weeks 12 and 52. The participants when
assigned to ustekinumab, depending on body weight, will receive either 45 mg or 9 mg ustekinumab doses)
Control intervention
Placebo
Outcomes At week 12,
Primary outcome
• Scalp specific PGA
Secondary outcomes
• Not stated
Starting date August 2012
Contact information Paul Steven Yamauchi, MD, PhD
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Notes On ClinicalTrials.gov
Estimated enrolment: 30
Study start date: August 2012
Estimated study completion date: December 2013
We emailed Dr Yamauchi (5 and 12 January 2017)
Email response:DearDr Sbidian, Thank you for your kind email, forwarded tome byDr Paul Yamauchi,MD,
PhD. Our ” Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of
Scalp Psoriasis (NCT 01558310)” completed enrolment in December 2016 and the last subject will complete
in December 2017, as such we do not have the final data analysis. What is you absolute cut- off for publication
data ? Would an interim analysis report be acceptable ? Best regards, Rickie Patnaik Director, Clinical Science
Institute
Will be included when published
NCT01722331
Trial name or title A study to evaluate the efficacy and safety of subcutaneous MK-3222, followed by an optional long-term
safety extension study, in participants with moderate-severe chronic plaque psoriasis (MK-3222-010)
Methods RCT, placebo-controlled, double-blind trial
Date of study: December 2012 -
Location: not stated
Phase 3
Participants Randomised: 772 participants
Inclusion criteria
• Clinical diagnosis of moderate-severe plaque psoriasis for ≥ 6 months prior to study enrolment
• A candidate for phototherapy or systemic therapy
• For the extension study: must have completed Part 3 of the base study
• For the extension study: must have achieved ≥ PASI 50 response by the end of Part 3 of the base study
• For the extension study: must have received active MK-3222 treatment within 12 weeks prior to the
end of Part 3 of the base study
• Premenopausal female participants must agree to abstain from heterosexual activity or use a medically
accepted method of contraception or use appropriate effective contraception as per local regulations or
guidelines
• If enrolled at a Japanese site, participants with psoriatic arthritis using non-steroidal anti-inflammatory
drugs (NSAIDs) must be on a stable dose for ≥ 4 weeks prior to the first dose of study drug and must not
be expected to require an increase in dose over the course of the study
Exclusion criteria
• Has erythrodermic psoriasis, predominantly pustular psoriasis, medication-induced or medication-
exacerbated psoriasis, or new onset guttate psoriasis
• Current or history of severe psoriatic arthritis and is well-controlled on current treatment
• Women of childbearing potential that are pregnant, intend to become pregnant within 6 months of
completing the trial, or that are breastfeeding
• Expected to require topical treatment, phototherapy, or systemic treatment during the trial
• Presence of any infection
• History of recurrent infection requiring treatment with systemic antibiotics within 2 weeks of screening
• Previous use of MK-3222 or other IL-23/Th-17 pathway inhibitors including P40, p19, and IL-17
antagonists
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• Evidence of active or untreated latent TB (TB)
• Positive test for HIV (HIV), hepatitis B surface antigen (HBs Ag) or hepatitis C virus (HCV)
• At Japanese sites, positive test for HBs antibody and hepatitis B virus (HBV) deoxyribonucleic acid
(DNA)
• At Japanese sites, positive test for the Hepatitis B core (HBc) antibody and HBV DNA
• For the extension study: women of child-bearing potential that are pregnant, intend to become
pregnant within 6 months of completing the trial, or that are breastfeeding
• For the extension study: active or uncontrolled significant organ dysfunction or clinically significant
laboratory abnormalities
• For the extension study: expected to require topical treatment, phototherapy, or systemic treatment
during the extension study
• At Japanese sites, abnormal for Beta D Glucan and/or KL-6 test result(s) at the screening visit.
Interventions Intervention
Drug: MK-3222 200 mg (SC, 200 mg at week 0 and week 4, and then every 12 weeks until study end or
participant discontinuation.)
Control intervention
Drug: MK-3222 100 mg (SC at a dose of 100 mg at week 0 and week 4, and then every 12 weeks until study
end or participant discontinuation.)
Drug: matching placebo (SC at week 0 and week 4)
Outcomes At week 12
Primary outcome (composite outcome)
• PASI 75
• PGA 0/1
Secondary outcomes
• PASI 90
• PASI 100
• DLQI
• AEs
Starting date December 2012
Contact information Medical Director: Merck Sharp & Dohme Corp.
Notes On ClinicalTrials.gov
Estimated study completion date: October 2019
Still ongoing
NCT01729754
Trial name or title A study to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (SCH 900222/MK-
3222) in participants with moderate-to-severe chronic plaque psoriasis followed by a long-term extension
study (MK-3222-011)
Methods RCT, active/placebo-controlled, double-blind trial
Date of study: February 2013 -
Location: not stated
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Phase 3
Participants Randomised: 1090 participants
Inclusion criteria
• Clinical diagnosis of moderate-severe plaque psoriasis for ≥ 6 months prior to enrolment
• Candidate for phototherapy or systemic therapy
• Premenopausal female participants must agree to abstain from heterosexual activity or use a medically
approved method of contraception or use appropriate effective contraception as per local regulations or
guidelines
• For the extension study: must have completed Part 3 of the base study
• For the extension study: must have achieved ≥ PASI 50 response by the end of Part 3 of the base study
Exclusion criteria
• Non-plaque forms of psoriasis
• Presence or history of severe psoriatic arthritis and is well-controlled on current treatment regimen
• Women of childbearing potential who are pregnant, intend to become pregnant, or are lactating
• Participant is expected to require topical therapy, phototherapy, or systemic therapy during the trial
• Presence of any infection or history of recurrent infection requiring treatment with systemic antibiotics
• Previous use of etanercept, tildrakizumab (MK-3222), or other interleukin-23 (IL-23)/T- helper cell
17 (Th-17) pathway inhibitors including p40, p19, and IL-17 antagonists
• Latex allergy or sensitivity
• Active or untreated latent TB
Interventions Intervention
Tildrakizumab 200 mg (SC on weeks 0, 4, 16, 28, 40 and 52)
Control interventions
Tildrakizumab 100 mg (SC on weeks 0, 4, 16, 28, 40 and 52)
Etanercept 50 mg (twice weekly until week 12 and once weekly from week 12 to week 28)
Placebo
Outcomes At week 12
Primary outcome (composite outcome)
• PASI 75
• PGA 0/1
Secondary outcomes
• PASI 75 and PGA 0/1 (at weeks 28, 40, and 52)
• PASI 90 (at weeks 12, 28, 40, and 52)
• PASI 100 (at weeks 12, 28, 40, and 52)
• DLQI (at weeks 12, 28, 40, and 52)
• AEs
Starting date February 2013
Contact information Medical director: Merck Sharp & Dohme Corp
Notes On ClinicalTrials.gov
Estimated Study Completion Date: June 2019
Ongoing study
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Trial name or title A study of guselkumab in participants with moderate to severe plaque-type psoriasis and an inadequate
response to ustekinumab (NAVIGATE)
Methods RCT, active/placebo-controlled, double-blind trial
Date of study: October 2014 -
Location: world-wide
Phase 3
Participants Randomised: 872 participants
Inclusion criteria
• Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis for ≥ 6 months before the
first administration of study drug
• PASI ≥ 12 at screening and at baseline
• IGA ≥ 3 at screening and at baseline
• BSA ≥ 10% at screening and at baseline
• Be a candidate for phototherapy or systemic treatment for psoriasis (either naïve or history of previous
treatment)
Exclusion criteria
• History or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac,
vascular, pulmonary, gastrointestinal, endocrine, neurologic, haematologic, rheumatologic, psychiatric, or
metabolic disturbances
• Unstable cardiovascular disease, defined as a recent clinical deterioration (e.g. unstable angina, rapid
atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
• Currently has a malignancy or has a history of malignancy within 5 years before screening (with the
exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for
≥ 3 months before the first study drug administration, or cervical carcinoma in situ that has been treated
with no evidence of recurrence for ≥ 3 months before the first study drug administration)
• Has previously received guselkumab or ustekinumab
Interventions Intervention
Ustekinumab (45 mg or 90 mg given by SC injection at weeks 0 and 4 for all participants, Participants with
an IGA score of 0 or 1 at week 16 will also receive ustekinumab every 12 weeks from week 16 to week 40)
Control intervention
Guselkumab (100 mg given by SC injection at weeks 16 and 20 and every 8 weeks)
Placebo
Outcomes At week 12
Primary outcome (composite outcome)
• PASI 75
• PGA 0/1
Secondary outcomes
• PASI 75 and PGA 0/1 (at weeks 28, 40, and 52)
• PASI 90 (at weeks 12, 28, 40, and 52)
• PASI 100 (at weeks 12, 28, 40, and 52)
• DLQI (at week 12, 28, 40, and 52)
• AEs
Starting date October 2014
Final completion date: May 2016
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Contact information Janssen Research & Development, LLC Clinical Trial
Notes Ongoing study
NCT02258282
Trial name or title Safety and efficacy of etanercept in patients with psoriasis
Methods RCT, placebo-controlled, double-blind trial
Date of study: October 2014 -
Location: China
Phase 4
Participants Randomised: 80 participants
Inclusion criteria
• Has plaque psoriasis and has shown an unsatisfactory response to traditional disease-modifying
antirheumatic drugs (DMARDs)
• 18-75 years old
• PGA ≥ 3 at Day 0
• BSA ≥ 3% at Day 0
• Has psoriasis severe enough to be eligible for systemic therapy
• Willing to use an effective method of contraception for ≥ 30 days before day 0 and until ≥ 1 month
after the last drug administration
• Capable of giving informed consent
• Normal or non clinically significant chest X-ray within 6 months prior to day 0
• Negative Purified Protein Derivative (PPD) or Quantiferon TB Gold test within 90 days prior to day 0
• Women of childbearing potential have a negative serum pregnancy test
• Able to start etanercept per the approved product monograph
Exclusion criteria
• Used topical steroids, topical tar preparations, or other anti-psoriatic preparations within the two
weeks prior to Day 0 or during the study period
• Presence of erythrodermic, pustular or guttate psoriasis
• Significant infections within the 30 days prior to day 0
• Received investigational drugs within the 4 weeks prior to screening or during the study period
• Treated with systemic anti-psoriatic drugs such as steroids, retinoids, ciclosporin, PUVA therapy or
methotrexate within the 4 weeks prior to day 0 or during the study period
• Received systemic antibiotics within the 4 weeks prior to day 0
• Treated with UV light therapy (UVB, nbUVB) within the 2 weeks prior to day 0 or during the study
period
• Used infliximab within 14 days of day 0 or during the study period
• Used other biologic agents for the treatment of psoriasis besides etanercept 8 weeks prior to day 0 or
during the study period
• Had an allergic reaction to infliximab
• Unstable or serious medical condition as defined by the investigator or presence of any significant
medical condition that might cause this study to be detrimental to the participant
• Uncontrolled or severe comorbidities such as poorly controlled diabetes mellitus, NYHA (New York
Heart Association) class III or IV heart failure, history of myocardial infarction or cerebrovascular accident
361Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02258282 (Continued)
or transient ischaemic attack within three months of screening visit; unstable angina pectoris
• Uncontrolled hypertension, oxygen-dependent severe pulmonary disease
• Known sero-positivity for HIV virus or history of any other immunosuppressive disease
• Active or chronic Hepatitis B or C
• Any mycobacterial disease, patient with a chest X-ray suggestive of TB or taking anti-TB medication
• Known hypersensitivity to etanercept or one of its components
• Received a live attenuated vaccine within the 12 weeks prior to day 0 or plans to receive one during the
study
• Current pregnancy or lactation
Interventions Intervention
Etanercept (participants under the treatment of 50 mg Etanercept)
Control intervention
Placebo
Outcomes At week 24
Primary outcome
• PGA
Secondary outcomes
• PASI
• BSA
Starting date May 2014
Contact information Yang Min, Ph.D, Chengdu PLA General Hospital
Notes On ClinicalTrials.gov
Estimated Primary Completion Date: December 2016
Ongoing study
NCT02313922
Trial name or title Optimizing psoriasis treatment of etanercept combined methotrexate
Methods RCT, placebo-controlled, double-blind trial
Date of study: December 2014 -
Location: China
Phase 4
Participants Randomised: 488 participants
Inclusion criteria
• Adults of both sexes, ≥ 18 years of age
• Stable plaque psoriasis for ≥ 6 months, psoriasis involving ≥ 10% BSA, minimal PASI of 10 at
screening
• Previously received phototherapy or systemic psoriasis therapy at least once or candidates for such
therapy in the opinion of the investigator
Exclusion criteria
• Patients with guttate, erythrodermic, or pustular psoriasis at the time of screening
• Recent infection or opportunistic infections, active TB, hepatitis B and so on
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• Liver and kidney dysfunction
• Other serious, progressive, uncontrolled disorders of vital organs and systems (including cardiovascular,
liver, lung and kidney), other autoimmune diseases, cancer, HIV infection, which are not suitable for
participation in the study of the disease
• History of significant methotrexate toxicity or total cumulative methotrexate exposure > 1000 mg
(unless grade IIIb liver injury has not occurred)
• Use of UVB therapy, topical ciclosporin or calcineurin inhibitors, class III through VII topical
corticosteroids (permitted on the scalp, axillae, and/or groin), or topical vitamin A or D analogues within 14
days of screening
• Psoralen or UVA therapy, systemic psoriasis therapy (including methotrexate), oral retinoids, class I or
II topical corticosteroids, dithranol, cyclophosphamide, sulfasalazine, or intravenous or oral calcineurin
inhibitors within 28 days of screening
• Patients were excluded if they had received a tumour necrosis factor (TNF) blocking agent or other
biologics within 3 months or interleukin (IL)-12 or IL-23 inhibitors within 6 months of study initiation
Interventions Intervention
Methotrexate (dosage not stated)
Control intervention
Co-intervention: etanercept (dosage not stated)
Outcomes At week 24
Primary outcome
• PASI 75
Secondary outcomes
• PASI 90
• DLQI
• AEs
Starting date November 2014
Contact information Min Zheng, director of dermatology, Zhejiang University
Notes On ClinicalTrials.gov,
Estimated Primary CompletionDate: October 2016 (Final data collection date for primary outcomemeasure)
Still ongoing
NCT02325219
Trial name or title An efficacy and safety of CNTO 1959 (guselkumab) in participants with moderate to severe plaque-type
psoriasis
Methods RCT, active/placebo-controlled, double-blind trial
Date of study: December 2014 -
Location: Japan
Phase 3
Participants Randomised: 226 participants
Inclusion criteria
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• Have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis for ≥ 6 months before
screening
• Have a PASI ≥ 12 at screening and at baseline
• Have an IGA ≥ 3 at screening and at baseline
• BSA ≥ 10% at screening and at baseline
• Be a candidate for phototherapy or systemic treatment for psoriasis (either naive or history of previous
treatment)
Exclusion criteria
• History of or current signs or symptoms of severe, progressive, or uncontrolled cardiac, vascular,
pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances
• Unstable cardiovascular disease, defined as a recent clinical deterioration (example, unstable angina,
atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months before screening
• Currently has a malignancy or has a history of malignancy within 5 years before screening (with the
exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for
≥ 3 months before the first study drug administration or cervical carcinoma in situ that has been treated
with no evidence of recurrence for ≥ 3 months before screening
• History of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of
undetermined significance (MGUS); or signs and symptoms suggestive of possible lymphoproliferative
disease, such as lymphadenopathy and/or splenomegaly
• History of chronic or recurrent infectious disease, including but not limited to chronic renal infection,
chronic chest infection (e.g. bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or
chronic nonremitting cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or infected
skin wounds or ulcers
Interventions Intervention
CNTO 1959 50 mg (50 mg at weeks 0, 4 and then every 8 weeks thereafter)
Control interventions
CTNO 1959 100 mg (100 mg at weeks 0, 4 and then every 8 weeks thereafter)
Placebo
Outcomes At week 16
Primary composite outcome
• IGA 0/1
• PASI 90
Secondary outcomes
• PASI 75
• DLQI
• AEs
Starting date Study start date: December 2014
Final completion date: September 2018
Contact information Janssen Pharmaceutical K.K.
Notes Ongoing study
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Trial name or title A study to evaluate the efficacy and safety of two dose levels of certolizumab pegol (CZP) in subjects with
plaque psoriasis (PSO) (CIMPASI-2)
Methods RCT, active/placebo-controlled, double-blind trial
Date of study: December 2014 -
Location: World-wide
Phase 3
Participants Randomised: 227 participants
Inclusion criteria
• Provided informed consent
• Adult men or women ≥ 18 years
• Chronic plaque psoriasis for ≥ 6 months
• Baseline PASE ≥ 12 and BSA ≥ 10% and PGA score ≥ 3
• Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy
• Other protocol-defined inclusion criteria may apply
Exclusion criteria
• Erythrodermic, guttate, generalised pustular form of psoriasis
• History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in
the protocol
• Congestive heart failure
• History of a lymphoproliferative disorder including lymphoma or current signs and symptoms
suggestive of lymphoproliferative disease
• History of other malignancy concurrent malignancy as described in the protocol
• History of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or
optic neuritis)
• Breastfeeding, pregnant, or plan to become pregnant during the study or within 3 months following
last dose of study drug. Men who are planning a partner pregnancy during the study or within 10 weeks
following the last dose
• Any other condition which, in the Investigator’s judgment, would make the person unsuitable for
participation in the study
• Other protocol-defined exclusion criteria may apply
Interventions Intervention
Certolizumab pegol (400 mg at weeks 0, 2, 4, followed by certolizumab pegol 200 mg every 2 weeks from
week 6 to week 14)
Control intervention
Certolizumab pegol (certolizumab pegol 400 mg every 2 weeks through week 14)
Placebo
Outcomes At week 16
Primary composite outcome
• PASI 75
• PGA 0/1
Secondary outcomes
• PASI 90
• DLQI
Starting date Starting study date: 22 December 2014
Study completion date: September 2018
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Contact information UCB Biopharma S.P.R.L.
Notes Ongoing study
NCT02346240
Trial name or title Efficacy and safety study of certolizumab pegol (CZP) versus active comparator and placebo in subjects with
plaque psoriasis (PSO) (CIMPACT)
Methods RCT, active/placebo-controlled, double-blind trial
Date of study: January 2015 -
Location: worldwide
Phase 3
Participants Randomised: 559 participants
Inclusion criteria
• Provided informed consent
• Adult men or women ≥ 18 years
• Chronic plaque psoriasis for ≥ 6 months
• Baseline PASI ≥ 12 and BSA ≥ 10% and PGA score ≥ 3
• Candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy
• Other protocol-defined inclusion criteria may apply
Exclusion criteria
• Erythrodermic, guttate, generalised pustular form of psoriasis
• History of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in
the protocol
• Congestive heart failure
• History of a lymphoproliferative disorder including lymphoma or current signs and symptoms
suggestive of lymphoproliferative disease
• History of other malignancy, concurrent malignancy as described in the protocol
• History of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or
optic neuritis)
• Breastfeeding, pregnant, or plan to become pregnant during the study or within 3 months following
last dose of study drug. Men who are planning a partner pregnancy during the study or within 10 weeks
following the last dose
• Any other condition which, in the Investigator’s judgment, would make the subject unsuitable for
participation in the study
• Other protocol-defined exclusion criteria may apply
• Prior etanercept use
Interventions Intervention
Certolizumab pegol (SC injection 400 mg at weeks 0, 2, 4, followed by certolizumab pegol 200 mg every 2
weeks from week 6 to week 14)
Control intervention
Certolizumab pegol (SC injection 400 mg every 2 weeks through week 14)
Etanercept (SC injection 50 mg twice weekly through week 12)
Placebo
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Outcomes At week 12
Primary outcome
• PASI (Psoriasis Activity and Severity Index) 75
Secondary outcomes
• PGA 0/1 (at weeks 12 and 16)
• PASI 75 (at week 16)
• PASI 90 (at weeks 12 and 16)
Starting date Start study date: 20 January 2015
Study completion date: January 2019
Contact information UCB Biopharma S.P.R.L.
Notes Ongoing study
NCT02425826
Trial name or title A phase 4 study of efficacy and safety of apremilast in subjects with moderate plaque psoriasis (UNVEIL)
Methods RCT, placebo-controlled, double-blind trial
Date of study: April 2015 -
Location: USA
Phase 4
Participants Randomised: 221 participants
Inclusion criteria
• Men or women, ≥ 18 years at the time of signing the informed consent document
• Understand and voluntarily sign an informed consent document prior to any study-related
assessments/procedures being conducted
• Able to adhere to the study visit schedule and other protocol requirements
• Diagnosis of chronic plaque psoriasis for ≥ 6 months prior to signing the informed consent
• Have moderate plaque psoriasis at screening and baseline as defined by BSA 5%-10% and sPGA 3
(moderate) based on a 0-5-point scale
• Must be in general good health (except for psoriasis) as judged by the investigator, based on medical
history, physical examination, and clinical laboratories.
• No prior exposure to systemic treatments or biologics for the treatment of psoriatic arthritis, psoriasis,
or any other indication that could impact the assessment of psoriasis.
• Women of childbearing potential must have a negative pregnancy test at screening and baseline. While
on investigational product and for ≥ 28 days after taking the last dose of investigational product, women
who engage in activity in which conception is possible must use one of the approved contraceptive options
described below:
◦ Option 1: any one of the following highly effective methods: hormonal contraception (oral,
injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner’s
vasectomy; or
◦ Option 2: male or female condom (latex condom or nonlatex condom not made out of natural
(animal) membrane (for example, polyurethane)) plus one additional barrier method: (a) diaphragm with
spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
• Men (including those who have had a vasectomy) who engage in activity in which conception is
367Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02425826 (Continued)
possible must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural
(animal) membrane (for example, polyurethane)) while on investigational product and for ≥ 28 days after
the last dose of investigational product
Exclusion criteria
• Other than psoriasis, any clinically significant (as determined by the Investigator) cardiac,
endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic,immunologic disease, or
other major disease that is currently uncontrolled
• Any condition, including the presence of laboratory abnormalities, which would place the subject at
unacceptable risk if he/she were to participate in the study
• Any condition, including other inflammatory diseases or dermatologic conditions, which confounds
the ability to interpret data from the study, including other types of psoriasis (i.e. erythrodermic, guttate,
inverse, or pustular psoriasis), other than plaque psoriasis.
• Prior history of suicide attempt at any time in the subject’s life time prior to signing the informed
consent and randomisation, or major psychiatric illness requiring hospitalization within the last 3 years
prior to signing the informed consent
• Pregnant or breast feeding
• Active substance abuse or a history of substance abuse within 6 months prior to signing the informed
consent
• Malignancy or history of malignancy, except for:treated (i.e. cured) basal cell or squamous cell in situ
skin carcinomas;treated (i.e. cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix
with no evidence of recurrence within 5 years of signing the informed consent
• Topical therapy within 2 weeks of randomisation (including, but not limited to, topical
corticosteroids, retinoids or vitamin D analogue preparations, tacrolimus, pimecrolimus, or anthralin/
dithranol). Use of phototherapy within 4 weeks prior to randomisation
• Use of any investigational drug within 4 weeks prior to randomisation, or 5 pharmacokinetic/
pharmacodynamic half-lives, if known (whichever is longer)
• Prolonged sun exposure or use of tanning booths, which may confound the ability to interpret data
from the study
• Prior treatment with apremilast
Interventions Intervention
Apremilast (30 mg tablets orally twice daily weeks 0-52)
Control intervention
Drug: placebo
Outcomes At week 16,
Primary composite outcome
• Change from baseline in the product of BSA (%) and PGA 0/1
Secondary outcomes
• PGA 0/1 at week 52
• PASI 75
• PASI 90
• DLQI
Starting date Study starting date: 3 April 2015
Study completion date: November 2016
Contact information Joana Goncalves, MD Celgene Corporation
368Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02425826 (Continued)
Notes Ongoing study
NCT02474082
Trial name or title Study of secukinumab compared to Fumaderm® in adults with moderate to severe psoriasis (PRIME)
Methods RCT, active-controlled, open-label study
Date of study: June 2015 -
Location: USA
Phase 3
Participants Randomised: 202 participants
Inclusion criteria
• Men or women must be ≥ 18 years of age at the time of screening
• Chronic plaque-type psoriasis diagnosed for ≥ 6 months before randomisation.
• Patients with moderate-severe plaque psoriasis who are candidates for systemic therapy as defined at
randomisation by:
◦ PASI score of > 10
◦ BSA) > 10%
◦ DLQI > 10
• Inadequate response, intolerance or contraindication to topical psoriasis treatment as documented in
the patient’s medical history or reported by the patient or determined by the investigator at screening
Exclusion criteria
• Previous systemic treatment of plaque psoriasis or known contraindication for systemic therapy at
baseline
• Ongoing use of other prohibited psoriasis and non-psoriasis treatment
• Clinically important active infections or infestations, chronic, recurrent or latent infections or
infestations
• Severe liver diseases
• Severe gastrointestinal diseases including but not limited to ventricular and duodenal ulcers
• Severe kidney diseases or serum creatinine above 1 x ULN
• Known hematological disease or lab abnormalities
• Pregnancy, breast feeding, or unwillingness/inability to use appropriate measures of contraception (if
necessary)
Interventions Intervention
Secukinumab (300 mg at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20)
Control intervention
Fumaderm® (week 0: 1 tablet of Fumaderm® INITIAL in the evening
Week 1: 1 tablet Fumaderm® INITIAL, in the morning and evening
Week 2: 1 tablet Fumaderm® INITIAL in the morning, at noon and in the evening until the last tablet of a
40-tablet-blister is consumed
Week 2-3: At the day after the last tablet of the Fumaderm® INITIAL 40-tablet-blister is consumed and
through week 3, 1 tablet of Fumaderm® in the evening
Week 4: 1 tablet Fumaderm® in the morning and evening
Week 5: 1 tablet Fumaderm® in the morning, at noon and in the evening
Week 6: 1 tablet of Fumaderm® in the morning and at noon, 2 tablets of Fumaderm® in the evening
Week 7: 2 tablets of Fumaderm® in the morning, 1 tablet of Fumaderm® at noon, 2 tablets of Fumaderm®
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in the evening
Weeks 8-24: 2 tablets of Fumaderm® in the morning, at noon and in the evening)
Outcomes At week 24
Primary outcome
• PASI 75
Secondary outcomes
• PASI 90
• IGA 0/1
• DLQI
Starting date Study starting date: April 2015
Study completion date: June 2016
Contact information Novartis Pharmaceuticals
Notes Ongoing study
NCT02513550
Trial name or title A study comparing different dosing regimens of ixekizumab (LY2439821) in participants with moderate to
severe plaque psoriasis (IXORA-P)
Methods RCT, active/placebo-controlled, double-blind trial
Date of study: July 2015 -
Location: worldwide
Phase 3
Participants Randomised: 1227 participants
Inclusion criteria
• Present with chronic plaque psoriasis for ≥ 6 months prior to enrolment
• ≥ 10% BSA of psoriasis at screening and at enrolment
• sPGA score of ≥ 3 and PASI score of ≥ 12 at screening and at enrolment
• Candidates for phototherapy and/or systemic therapy
• Participant must agree to use reliable method of birth control during the study; women must continue
using birth control for ≥ 12 weeks after stopping treatment
Exclusion criteria
• Predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis
• History of drug-induced psoriasis
• Cannot avoid excessive sun exposure or use of tanning booths for ≥ 4 weeks prior to enrolment and
during the study
• Received systemic non-biologic psoriasis therapy or phototherapy within the previous 4 weeks; or had
topical psoriasis treatment within the previous 2 weeks prior to enrolment
• Concurrent or recent use of any biologic agent
• Have participated in any study with ixekizumab
• Received a live vaccination within 12 weeks prior to enrolment
• Serious disorder or illness other than psoriasis
• Ongoing or serious infection within the last 12 weeks or evidence of TB
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• Major surgery within 8 weeks of baseline, or will require surgery during the study
• Breastfeeding or nursing (lactating) women
Interventions Intervention
Ixekizumab (160 mg ixekizumab given as 2 SC injections at baseline and then 80 mg ixekizumab given as 1
SC injection every 2 weeks to week 52)
Control interventions
Ixekizumab (160 mg ixekizumab given as 2 SC injections at baseline and then 80 mg ixekizumab given as 1
SC injection every 4 weeks to week 52)
Placebo
Outcomes At week 52
Primary composite outcome
• PGA 0/1
• Achieving 75% improvement in PASI 75
Secondary outcomes
• PASI 90
• PASI 75
• NAPSI
• Psoriasis Scalp Severity Index
• Palmoplantar PASI
• Itch Numeric Rating Scale
• DLQI
Starting date Study starting date: August 2015
Study completion date: October 2017
Contact information Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/
GMT - 5 hours, EST)
Notes Ongoing study
NCT02555826
Trial name or title Study of the efficacy and safety Of apremilast (CC-10004), in subjects with moderate plaque psoriasis
Methods RCT, placebo-controlled, double-blind study
Date of study: April 2015 -
Location: USA
Phase 4
Participants Randomised: 221 participants
Inclusion criteria
• Men or women, ≥ 18 years of age
• Able to adhere to the study visit schedule and other protocol requirements
• Diagnosis of chronic plaque psoriasis for ≥ 6 months prior to signing the informed consent
• Have moderate plaque psoriasis at screening and baseline as defined by:
◦ BSA (Body Surface Area) 5% to 10%, and
◦ sPGA (Physician’s Global Assessment) 3 (moderate) based on a 0 to 5 point scale
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• Must be in general good health (except for psoriasis) as judged by the investigator
• No prior systemic treatments or biologics for the treatment of psoriatic arthritis, psoriasis
• Women must have a negative pregnancy test at screening and baseline. Participants must agree to use
contraception during the course of the study
Exclusion criteria
• Other than psoriasis, any clinically significant (as determined by the Investigator) major disease that is
currently uncontrolled
• Any condition, including the presence of laboratory abnormalities, which would place the subject at
unacceptable risk if he/she were to participate in the study
• Pregnant or breastfeeding
• Active substance abuse or a history of substance abuse within 6 months prior to signing the informed
consent
• Malignancy or history of malignancy
• Topical therapy within 2 weeks of starting trial
• Use of phototherapy within 4 weeks prior to starting trial
• Use of any investigational drug within 4 weeks prior to starting trial
• Prolonged sun exposure or use of tanning booths, which may confound the ability to interpret data
from the study
• Prior treatment with apremilast
Interventions Intervention
Apremilast (30 mg tablets orally twice daily weeks 0-52)
Control intervention
Placebo
Outcomes At week 16,
Primary composite outcome
• Change from baseline in the product of BSA (%) and the sPGA which is considered as the Total
Psoriasis Severity Index
Secondary outcomes
• Mean change from baseline in the DLQI
• PGA 0/1
• Treatment Satisfaction Questionnaire for Medication
• PASI 75
Starting date Study starting date: 18 September 2015
Study completion date: November 2016
Contact information Joana Goncalves, MD Celgene Corporation
Notes Ongoing study
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Trial name or title Evaluation of cardiovascular risk markers in psoriasis patients treated with secukinumab (CARIMA)
Methods RCT, placebo-controlled, double-blind study
Date of study: September 2015 -
Location: Germany
Phase 4
Participants Randomised: 151 participants
Key inclusion criteria
• Chronic moderate-severe plaque type psoriasis for ≥ 6 months prior to randomisation with a PASI
score ≥ 10 at randomisation
• Inadequate response, intolerance or contraindication to ciclosporin, methotrexate and psoralen plus
ultraviolet A light treatment (PUVA) as documented in the patient’s medical history or reported by the
patient or determined by the investigator at screening. Relative contraindications such as interference of
patient’s lifestyle with the treatment are accepted
Key exclusion criteria
• Forms of psoriasis other than chronic plaque-type (e.g. pustular, erythrodermic and guttata psoriasis)
at screening or randomisation
• Ongoing use of prohibited psoriasis and non-psoriasis treatments. Washout periods have to be adhered
to
Interventions Intervention
Secukinumab 300 (300 mg every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until
week 48)
Control interventions
Secukinumab 150 (150 mg every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until
week 48)
Placebo
Outcomes At week 12,
Primary outcome
• Flow Mediated Dilation (FMD)
Secondary outcomes
• Aortic Augmentation Index at heart rate of 75
• Pulse wave velocity
• Biomarkers
• PASI
• IGA
Starting date April 2014
Contact information Novartis Pharmaceuticals
Notes On ClinicalTrials.gov,
Primary completion date: April 2016 (final data collection date for primary outcome measure)
Still ongoing
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Trial name or title A study of ixekizumab (LY2439821) in participants with moderate-to-severe plaque psoriasis (IXORA-S)
Methods RCT, active-controlled, open-label study
Date of study: September 2015 -
Location: USA
Phase 3
Participants Randomised: 300 participants
Inclusion criteria:
• Chronic plaque psoriasis for ≥ 6 months before baseline
• Failure, contraindication, or intolerability to ≥ 1 systemic therapy (including ciclosporin,
methotrexate, or phototherapy)
• PASI score ≥ 10 at screening and at baseline
• Participant must agree to use reliable method of birth control during the study; women must continue
using birth control for ≥ 15 weeks after stopping treatment
Exclusion criteria
• Predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis
• History of drug-induced psoriasis
• Cannot avoid excessive sun exposure or use of tanning booths for ≥ 4 weeks before baseline and
during the study
• Have received systemic nonbiologic psoriasis therapy or phototherapy within 4 weeks of baseline, or
have had topical psoriasis treatment within 2 weeks of baseline
• Concurrent or recent use of any biologic agent within the following washout periods: etanercept < 28
days; infliximab, adalimumab, or alefacept < 60 days; golimumab < 90 days; rituximab < 12 months; or any
other biologic agent < 5 half-lives prior to baseline
• Have prior use of ustekinumab, or have any condition or contraindication to ustekinumab that would
preclude the participant from participating in this protocol
• Have previously completed or withdrawn from this study, participated in any other study with
ixekizumab, have participated in any study investigating other interleukin (IL)-17 or IL-12/23 antagonists,
or have received treatment with other IL-17 or IL-12/23 antagonists
• Have had a live vaccination within 12 weeks of baseline, or intend to have a live vaccination during the
course of the study or within 15 weeks of completing treatment in this study
• Have had a vaccination with Bacillus Calmette-Guérin (BCG) within 12 months of baseline or intend
to have vaccination with BCG during the course of the study or within 12 months of completing treatment
in this study
• Have a known allergy or hypersensitivity to latex
• Have had any major surgery within 8 weeks of baseline or will require such during the study
• Have active or history of malignant disease within 5 years prior to baseline
• Significant uncontrolled disorder
• Ongoing infection or serious infection within 12 weeks of baseline; serious bone or joint infection
within 24 weeks of baseline
• Are women who are lactating or breastfeeding
Interventions Intervention
Ixekizumab (160 mg ixekizumab given as 2 SC injections at baseline followed by 80 mg ixekizumab given
as a single SC injection once every 2 weeks from week 2 through week 12. After week 12 participants will
receive 80 mg ixekizumab every 4 weeks through week 52)
Control intervention
Ustekinumab (45 mg ustekinumab given as SC injection for participants ≤ 100 kg and 90 mg SC injection
for participants > 100 kg at weeks 0, 4, 16, 28, and 40)
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Outcomes At week 12,
Primary outcome
• PASI 90
Secondary outcomes
• PASI 75
• PGA
• DLQI
Starting date Start study date: October 2015
Completion study date: May 2017
Contact information Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/
GMT - 5 hours, EST)
Notes Ongoing study
NCT02634801
Trial name or title A study of ixekizumab (LY2439821) in participants withmoderate-to-severe plaque psoriasis naive to systemic
treatment
Methods RCT, active-controlled, single-blind study
Date of study: December 2015 -
Location: Germany
Phase 3
Participants Randomised: 162 participants
Inclusion criteria
• Present with moderate-to-severe chronic plaque psoriasis based on a diagnosis of chronic psoriasis for
≥ 6 months before baseline
• Participants who are candidates for systemic therapy and who are naive to systemic treatment for
psoriasis
• Have PASI score > 10 or BSA > 10 and DLQI > 10 at screening and at baseline
Exclusion criteria
• Have predominant pattern of pustular, erythrodermic, and/or guttate forms of psoriasis
• Have received systemic nonbiologic psoriasis therapy
• Have prior, concurrent, or recent use of ixekizumab or any other biological psoriasis therapy
• Have any condition or contraindication as addressed in the local labelling for methotrexate or FAE
• Presence of significant uncontrolled cerebro-cardiovascular, respiratory, hepatic, renal, gastrointestinal,
endocrine, hematologic, neurologic, or neuropsychiatric disorders or abnormal laboratory values at screening
• Have severe gastrointestinal disease, oral ulcer, or known, active gastrointestinal ulcer
• Have had a serious infection or are immunocompromised
• At screening, participants with significant, present, or early liver disease, e.g. explained by alcohol
consumption or hepatic insufficiency
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Interventions Intervention
Ixekizumab (60 mg ixekizumab given as 2 SC injections followed by 80 mg ixekizumab given SC every 2
weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24)
Control interventions
FAEs (105 mg FAE given orally followed by 215 mg FAE given orally 1-3 times/day until week 24)
Methotrexate (7.5 mg starting dose up to 30 mg methotrexate given orally once a week until week 24)
Outcomes At week 24
Primary outcome
• PASI 75
Secondary outcome
• PGA 0/1
• PASI 90
• DLQI
Starting date Study start date: January 2016
Study completion date: November 2017
Contact information Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/
GMT - 5 hours, EST)
Notes Ongoing study
NCT02655705
Trial name or title Comparison study of psoriasis severity assessment tools
Methods RCT, placebo-controlled, open-label study
Date of study: September 2015 -
Location: Korea
Phase 4
Participants Randomised: 34 participants
Inclusion criteria
• Present with chronic plaque psoriasis based on a clinical diagnosis
• Have > 5% BSA involvement at screening
• Are a candidate for systemic therapy
• Are male or female patients ≥18 years
• Have given written informed consent approved by the Institutional Review Board
Exclusion criteria
• Have predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis
• Have had any of the systemic non-biologic psoriasis therapy (including neotigason, ciclosporin, and
methotrexate) within 4 weeks prior to baseline
• Have had etanercept within 4 weeks prior to baseline
• Have had adalimumab and infliximab within 8 weeks prior to baseline
• Have had ustekinumab within 16 weeks prior to baseline
• Presence of significant hepatic or renal disorders
• Have uncontrolled arterial hypertension
376Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02655705 (Continued)
• Are women who are lactating, breastfeeding or planning pregnancy
• Have any other condition that precludes from following and completing the protocol
Interventions Intervention
Ciclosporin A (men 200 mg/day, women 150 mg/day for 16 weeks)
Control intervention
Methotrexate (initial dose 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week)
Outcomes At week 16
Primary outcome
• Change in PASI
Secondary outcome
• PASI 75, PASI 90
• AEs
Starting date Study start date: August 2014
Study completion date: March 2016
Contact information Sang Woong Youn, Associate Professor, Seoul National University Hospital
Notes Ongoing study
NCT02672852
Trial name or title BI 655066/ABBV-066 (risankizumab) in moderate to severe plaque psoriasis with randomized withdrawal
and re-treatment
Methods RCT, placebo-controlled, double-blind study
Date of study: February 2016 -
Location: worldwide
Phase 3
Participants Randomised: 500 participants
Inclusion criteria
• Men or women
• Women of childbearing potential must be ready and willing to use highly effective methods of birth
control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently
and correctly
• Age ≥ 18 years at screening
• Diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) ≥ 6 months before the first
administration of study drug. Duration of diagnosis may be reported by the patient.
• Stable moderate-severe chronic plaque psoriasis with or without psoriatic arthritis at both screening
and baseline (randomization);
• Have an involved BSA ≥ 10%, PASI ≥ 12 a sPGA score of ≥ 3
• Must be a candidate for systemic therapy or phototherapy for psoriasis treatment, as assessed by the
investigator
• Signed and dated written informed consent prior to admission to the study and performance of any
study procedures in accordance with GCP and local legislation
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Exclusion criteria:
• Non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular); current drug-induced
psoriasis (including a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium
channel blockers, or lithium); active ongoing inflammatory diseases other than psoriasis and psoriatic
arthritis that might confound trial evaluations according to the investigators judgment
• Previous exposure to ABBV-066
• Currently enrolled in another investigational study or < 30 days (from screening) since completing
another investigational study
• Use of any restricted medication as noted or any drug considered likely to interfere with the safe
conduct of the study
• Major surgery performed within 12 weeks prior to randomisation or planned within 12 months after
screening (e.g. hip replacement, removal aneurysm, stomach ligation)
• Known chronic or relevant acute infections such as active TB, HIV, or viral hepatitis
• Any documented active or suspected malignancy or history of malignancy within 5 years prior to
screening, except appropriately treated basal cell carcinoma or squamous cell carcinoma of the skin or in situ
carcinoma of uterine cervix
• Evidence of a current or previous disease (including chronic alcohol or drug abuse), medical condition
other than psoriasis, surgical procedure (i.e. organ transplant), medical examination finding (including vital
signs and ECG), or laboratory value at the screening visit outside the reference range that in the opinion of
the -Investigator, is clinically significant and would make the study participant unable to adhere to the
protocol or to complete the trial, compromise the safety of the patient, or compromise the quality of the data
• History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients
• Women who are pregnant, nursing, or who plan to become pregnant while in the trialPrevious
enrolment in this trial
Interventions Intervention
ABBV-066 (SC injection, dosage not stated)
Control intervention
Placebo
Outcomes At week 16
Primary composite outcome
• PASI 90
• PGA 0/1
Secondary outcomes
• PASI 75 at weeks 16 and 52
• PASI 90 at weeks 52
• PGA 0/1 at weeks 52
Starting date February 2016
Contact information Boehringer Ingelheim
Notes Ongoing study
BI 655066 will be included
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Trial name or title BI 655066 compared to placebo & active comparator (ustekinumab) in patients with moderate to severe
chronic plaque psoriasis
Methods RCT, placebo/active-controlled, double-blind study
Date of study: September 2017 -
Location: worldwide
Phase 3
Participants Randomised: 500 participants
Inclusion criteria
• Male or female patients. Women of childbearing potential* must be ready and able to use highly
effective methods of birth control per ICH M3(R2) that result in a low failure rate of less than 1% per year
when used consistently and correctly. A list of contraception methods meeting these criteria is provided in
the patient information. *Women of childbearing potential are defined as: having experienced menarche
and are not postmenopausal (12 months with no menses without an alternative medical cause) and are not
permanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral
salpingectomy)
• Age ≥ 18 years at screening
• Diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for ≥ 6 months before the
first administration of study drug. Duration of diagnosis may be reported by the patient
• Stable moderate-severe chronic plaque psoriasis with or without psoriatic arthritis at both screening
and baseline (randomization)
• Have an involved BSA ≥ 10%, PASI score ≥ 12 and sPGA score of ≥ 3
• Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the
investigator
• Must be a candidate for treatment with Stelara® (ustekinumab) according to local label
• Signed and dated written informed consent prior to admission to the study in accordance with GCP
and local legislation
Exclusion criteria
• Non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular), current drug-induced
psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium),
active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial
evaluations according to investigator’s judgment
• Previous exposure to BI 655066
• Currently enrolled in another investigational study or < 30 days (from screening) since completing
another investigational study (participation in observational studies is permitted)
• Previous exposure to ustekinumab (Stelara®)
• Use of any restricted medication, or any drug considered likely to interfere with the safe conduct of the
study
• Major surgery performed within 12 weeks prior to randomisation or planned within 12 months after
screening (e.g. hip replacement, aneurysm removal, stomach ligation),
• Known chronic or relevant acute infections including active TB, HIV or viral hepatitis;
QuantiFERON® TB test or PPD skin test will be performed according to local labelling for comparator
products. If the result is positive, patients may participate in the study if further work up (according to local
practice/guidelines) establishes conclusively that they have no evidence of active TB. If presence of latent TB
is established, then treatment should have been initiated and maintained according to local country
guidelines
• Any documented active or suspected malignancy or history of malignancy within 5 years prior to
screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of
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uterine cervix
• Evidence of a current or previous disease, medical condition (including chronic alcohol or drug abuse)
other than psoriasis, surgical procedure (i.e. organ transplant), medical examination finding (including vital
signs and ECG), or laboratory value at the screening visit outside the reference range that is in the opinion
of the investigator, is clinically significant and would make the study participant unreliable to adhere to the
protocol or to complete the trial, compromise the safety of the participant, or compromise the quality of the
data
• History of allergy/hypersensitivity to a systemically administered biologic agent or its excipients
• Women who are pregnant, nursing, or who plan to become pregnant while in the trial
• Previous enrolment in this trial
Interventions Intervention
ABBV-066 (SC, dosage not stated)
Control interventions
Ustekinumab (dosage not stated))
Placebo
Outcomes At week 16
Primary composite outcome
• PASI 90
• PGA 0/1
Secondary outcomes
• PASI 75 at weeks 16 and 52
• PASI 90 at week 52
• PGA 0/1 at week 52
Starting date February 2016
Contact information Boehringer Ingelheim
Notes Ongoing study
BI 655066 will be included
NCT02684370
Trial name or title BI 655066/ABBV-066 (risankizumab) versus ustekinumab and placebo comparators in a randomized double
blind trIal for maintenance use in moderate to severe plaque type psoriasis (UltIMMa-1)
Methods RCT, active/placebo-controlled, double-blind study
Date of study: February 2016 -
Location: worldwide
Phase 3
Participants Randomised: 500 participants
Inclusion criteria
• Men or women aged ≥ 18 years at screening
• Diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for ≥ 6 months before the
first administration of study drug
• Stable moderate-severe chronic plaque psoriasis with or without psoriatic arthritis at both screening
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and baseline (randomisation)
• Involved BSA ≥ 10%
• PASI score ≥ 12
• sPGA score of ≥3
• Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the
investigator
• Must be a candidate for treatment with Stelara® (ustekinumab) according to local label
Exclusion criteria
• Non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular) current drug-induced
psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial
evaluations according to investigator’s judgment
• Previous exposure to BI 655066
• Previous exposure to ustekinumab (Stelara®)
Interventions Intervention
ABBV-066 (SC, dosage not stated)
Control interventions
Ustekinumab (dosage not stated))
Placebo
Outcomes At week 16
Primary composite outcome
• PASI 90
• PGA 0/1
Secondary outcomes
• PASI 75 at weeks 16 and 52
• PASI 90 at week 52
• PGA 0/1 at week 52
Starting date February 2016
Contact information Boehringer Ingelheim
Notes Ongoing study
BI 655066 will be included
NCT02690701
Trial name or title Study to evaluate the effect of secukinumab compared to placebo on aortic vascular inflammation in subjects
with moderate to severe plaque psoriasis (VIP-S)
Methods RCT, placebo-controlled, double-blind study
Date of study: February 2016 -
Location: USA
Phase 4
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Participants Randomised: 84 participants
Inclusion criteria
• Men and women ≥ 18 years with moderate-severe plaque psoriasis
Exclusion criteria
• Forms of psoriasis other than chronic plaque psoriasis
• Previous exposure to IL-17A or IL-17 receptor targeting agents
• Other active or ongoing disease that may interfere with evaluation of psoriasis or places the participant
at unacceptable risk
Interventions Intervention
Secukinumab 300 (300 mg once weekly at baseline, weeks 1, 2, 3 and 4 followed by monthly dosing starting
at week 8 through week 48 inclusive)
Control intervention
Placebo
Outcomes At week 12
Primary outcome
• Aortic vascular inflammation as measured by FDG-PET/CT
Secondary outcomes
• PASI 75
• PASI 90
• PASI 100
• IGA 0/1
• DLQI
Starting date Study start date: February 2016
Study completion date: March 2018
Contact information Novartis Pharmaceuticals, 1-888-669-6682
Notes Ongoing study
NCT02748863
Trial name or title Study of secukinumab with 2 mL pre-filled syringes (ALLURE)
Methods RCT, placebo-controlled, double-blind study
Date of study: April 2016 -
Location: worldwide
Phase 4
Participants Randomised: 210 participants
Inclusion criteria
Subjects eligible for inclusion in this study must fulfil all of the following criteria:
• Must be able to understand and communicate with the investigator and comply with the requirements
of the study and must give a written, signed and dated informed consent before any study-related activity is
performed. Where relevant, a legal representative will also sign the informed study consent according to
local laws and regulations.
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• Men or women of ≥ 18 years of age at the time of screening
• Chronic plaque-type psoriasis present for ≥ 6 months and diagnosed before randomization
• Moderate-severe psoriasis as defined at randomization by: PASI score of ≥ 12, IGA mod 2011 score of
≥ 3 (based on a scale of 0-4), and BSA affected by plaque-type psoriasis of ≥ 10%
• Candidate for systemic therapy. This is defined as having moderate-severe chronic plaque-type psoriasis
that is inadequately controlled by topical treatment and/or phototherapy and/or previous systemic therapy
Exclusion criteria
• Forms of psoriasis other than chronic plaque-type (e.g. pustular, erythrodermic and guttate psoriasis) at
screening or randomization
• Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to.
Participants not willing to limit UV light exposure (e.g. sunbathing and/or the use of tanning devices)
during the course of the study will be considered not eligible for this study since UV light exposure is
prohibited. Note: administration of live vaccines 6 weeks prior to randomization or during the study period
is also prohibited.
• Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the
IL-17 receptor
• Use of other investigational drugs at the time of enrolment, or within 5 half-lives of enrolment, or
within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or
longer if required by local regulations.
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a woman after
conception and until the termination of gestation, confirmed by a positive hCG laboratory test
• History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ
system treated or untreated within the past 5 years, regardless of whether there is evidence of local
recurrence or metastases (except for Bowen’s disease, or basal cell carcinoma or actinic keratoses that have
been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-
invasive malignant colon polyps that have been removed)
• History of hypersensitivity to any of study drug constituent
Interventions Intervention
Secukinumab 2 mL form (secukinumab 300 mg/2 mL + 2 x 1 mL placebo SC. at randomization, weeks 1 ,
3, 4, thereafter 4-weekly until week 48)
Control interventions
Secukinumab 1 mL form (secukinumab 150 mg/1 mL x 2 + 2 mL placebo SC. at randomization, weeks 1 ,
3, 4, thereafter 4-weekly until Week 48)
Placebo (2 mL + 2 x 1 mL placebo SC at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week
48)
Outcomes At week 12
Primary composite outcome
• PASI 75 and IGA mod 2011 0 or 1 response
Secondary outcome
• PASI 90, 100 at weeks 12 and 52
• PASI 75 at week 52
• DLQI at weeks 12 and 52
Starting date Study start date: 8 March 2016
Study completion date: September 2018
Contact information Novartis Pharmaceuticals, 1-888-669-6682, +41613241111
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Notes Ongoing study
NCT02826603
Trial name or title Study of secukinumab compared to ustekinumab in subjects with plaque psoriasis (CLARITY)
Methods RCT, active-controlled, double-blind study
Date of study: July 2016 -
Location: worldwide
Phase 3
Participants Randomised: 1100 participants
Inclusion criteria
• Must give a written, signed and dated informed consent
• Chronic plaque-type psoriasis present for ≥ 6 months before randomisation
• Moderate-severe plaque psoriasis as defined at randomisation by: PASI score of ≥ 12 and Body Surface
Area (BSA) affected by plaque-type psoriasis ≥10% and IGA mod 2011 ≥3 (based on a scale of 0-4)
• Candidate for systemic therapy, defined as having psoriasis inadequately controlled by: topical
treatment (including topical corticosteroids) or phototherapy, or previous systemic therapy, or both
Exclusion criteria
• Forms of psoriasis other than plaque psoriasis
• Drug-induced psoriasis
• Ongoing use of prohibited treatments
• Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA, or
ustekinumab, or any therapies targeting IL-12 or IL-23
• Use of any other investigational drugs within 5 half-lives of the investigational treatment before study
drug initiation
• Pregnant or nursing (lactating) women
Interventions Intervention
Secukinumab 300 (300 mg, SC at randomization, weeks 1, 2 and 3 and thereafter 4-weekly till week 48)
Control intervention
Ustekinumab 45/90 (45 mg or 90 mg SC based on participant’s weight (at randomization visit) to be
administered at randomization, week 4, 16, 28 and 40)
Outcomes At week 12
Primary composite outcome
• IGA 0/1
• PASI 90
Secondary outcomes
• PASI 75 at week 12 and 52
• PASI 90 at week 52
• AEs
Starting date Study start date: June 2016
Study completion date: August 2018
Contact information Novartis Pharmaceuticals, 1-888-669-6682, +41613241111
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Notes Ongoing study
NCT02905331
Trial name or title Efficacy and safety study of guselkumab in the treatment of participants with moderate to severe plaque-type
psoriasis
Methods RCT, placebo-controlled, double-blind study
Date of study: September 2016 -
Location: worldwide
Phase 3
Participants Randomised: 78 participants
Inclusion criteria
• Women of childbearing potential must have a negative urine pregnancy test (beta-human chorionic
gonadotropin) at screening and at week 0
• Before randomisation, women must be either:
◦ not of childbearing potential: premenarchal; postmenopausal (> 45 years of age with amenorrhea
for ≥ 12 months or any age with amenorrhea for ≥ 6 months and a serum follicle-stimulating hormone
level (FSH) > 40 IU/L; permanently sterile (example, tubal occlusion, hysterectomy, bilateral
salpingectomy); or otherwise be incapable of pregnancy
◦ of childbearing potential and practicing a highly effective method of birth control, consistent with
local regulations regarding the use of birth control methods for subjects participating in clinical studies:
example, established use of oral, injected or implanted hormonal methods of contraception; placement of an
intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom or occlusive cap
(diaphragm or cervical/vault caps) plus spermicidal foam/gel/film/cream/suppository (if available in their
locale); male partner sterilization (the vasectomised partner should be the sole partner for that participant);
true abstinence (when this is in line with the preferred and usual lifestyle of the participant)
• Agree not to receive a Bacillus Calmette Guerin (BCG) vaccination during the study, or within 12
months after the last administration of study drug
• PASI ≥ 12 at screening and at baseline
• Involved BSA ≥ 10% at screening and at baseline
Exclusion criteria
• Unstable cardiovascular disease, defined as a recent clinical deterioration (e.g. unstable angina, rapid
atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months
• History of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of
undetermined significance (MGUS); or signs and symptoms suggestive of possible lymphoproliferative
disease, such as lymphadenopathy or splenomegaly
• Transplanted organ (with exception of a corneal transplant > 3 months before the first administration
of study drug)
• Non-plaque form of psoriasis (e.g. erythrodermic, guttate, or pustular)
• Received any anti-tumour necrosis factor alpha (TNF-alpha) biologic therapy within 3 months before
the first administration of study drug
Interventions Intervention
Guselkumab (100 mg guselkumab administered as a 100 mg/mL solution in a single-use prefilled syringe
(PFS) assembled in a self-dose device at weeks 0, 4, 12, 20, and 28)
Control intervention
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Placebo
Outcomes At week 16
Primary outcome
• IGA 0/1
• PASI 90
Secondary outcomes
• PASI 75
• PASI 100
Starting date Study start date: 14 September 2016
Study completion date: July 2018
Contact information Janssen Research & Development, LLC Clinical Trial
Notes Ongoing study
NCT02951533
Trial name or title A study to compare the efficacy of guselkumab to FAEs for the treatment of participants with moderate to
severe plaque psoriasis (POLARIS)
Methods RCT, active-controlled, open-label study
Date of study: November 2016 -
Location: Germany
Phase 3
Participants Randomised: 119 participants
Inclusion criteria
• Diagnosis of plaque-type psoriasis for ≥ 6 months before the first administration of study drug
• PASI) ≥ 10 or BSA >10 at screening and at baseline
• DLQI >10 at screening and at baseline
• Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after
the last administration of study drug; for information on Bacille Calmette-Guérin (BCG) vaccination, agree
not to receive a BCG vaccination during the study, or within 12 months after the last administration of
study drug
• No dipstick detection of proteins or glucose in urine. If there are signs of proteins and/or glucose on
urine test strip, the urine sample must be analysed centrally. Here, protein and glucose levels must not
exceed trace levels, example, ≥ (+); one re-test (central urine analysis) is allowed
Exclusion criteria
• History or current signs or symptoms of severe, progressive, or uncontrolled liver or renal insufficiency,
significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, haematologic,
rheumatologic, psychiatric, or metabolic disturbances
• Participants with non-plaque forms of psoriasis (for example, erythrodermic, guttate, or pustular) or
with current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis
from beta blockers, calcium channel blockers, or lithium)
• Known allergies, hypersensitivity, or intolerance to guselkumab or its excipients
• Pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study or within 12
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weeks after the last dose of study drug
• Any condition for which, in the opinion of the investigator, participation would not be in the best
interest of the participant (for example, compromise the well-being) or that could prevent, limit, or
confound the protocol-specified assessments
Interventions Intervention
Guselkumab (100 mg administered as 100 mg/mL solution SC by single-use prefilled syringe (PFS) at weeks
0, 4, 12 and 20)
Control intervention
FAEs (to this aim, FAE doses will be slowly increased beginning with increasing doses of Fumaderm initial
(containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to
Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may
be increased to a maximum of 3x2 tablets per day)
Outcomes At week 24
Primary outcome
• PASI 90
Secondary outcomes
• PASI 75
• DLQI
Starting date Study start date: December 2016
Study completion date: December 2017
Contact information Janssen-Cilag G.m.b.H, Germany Clinical Trial
Notes Ongoing study
NCT02982005
Trial name or title A Study of KHK4827 (brodalumab) in subjects with moderate to severe psoriasis in Korea
Methods RCT, placebo-controlled, double-blind study
Date of study: December 2016 -
Location: Korea
Phase 3
Participants Randomised: 60 participants
Inclusion criteria
• Stable moderate-severe plaque psoriasis for ≥ 6 months
• Involved BSA ≥ 10%, PASI ≥ 12, and sPGA ≥ 3 at screening and at baseline
Exclusion criteria
• Diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, or a medication-induced
psoriasis, or other skin conditions (e.g. eczema) at screening that would interfere with study evaluations
• Scheduled to undergo a surgical intervention during the study period
• Any active infection or history of infections as defined in the study protocol
• Known history of Crohn’s disease
• Any other significant concurrent medical condition or laboratory abnormalities, as defined in the study
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protocol
• Has not stopped using certain psoriasis therapies as defined in the study protocol
• Previously used any anti-IL-17 biologic therapy
• Pregnant or breastfeeding, or planning to become pregnant while enrolled in the study
• Women of childbearing potential or fertile men who do not agree to use effective contraception from
the day of providing consent through 12 weeks after the last dose of investigational product
• Known history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behaviour based on
an assessment with the Columbia-Suicide Severity Rating Scale (C-SSRS) at screening or at baseline
• Severe depression based on a total score of ≥ 15 on the Patient Health Questionnaire-8 (PHQ-8) at
screening or at baseline
• Known history or evidence of a psychiatric disorder that, in the opinion of the investigator, would pose
a risk to subject safety or interfere with the study evaluation, procedures or completion
• Known history of alcohol and/or substance abuse within the last 12 months
Interventions Intervention
KHK4827 (SC, dosage not stated)
Control intervention
Placebo
Outcomes At week 12
Primary composite outcome
• PPGA 0/1
• PASI 75
Secondary outcomes
• PASI 90 at weeks 12 and 64
• PASI 75 at week 64
• NAPSI score at week 64
• Psoriasis scalp severity index (PSSI) score at week 64
• DLQI at week 64
• AEs
Starting date Study start date: 1 December 2016
Study completion date: December 2018
Contact information Kyowa Hakko Kirin Korea Co., Ltd
Notes Ongoing study
RPCEC00000201
Trial name or title Randomized controlled double blind trial to study safety and efficaccy of itolizumab (antiCD6) in moderate-
to-severe psoriasis
Methods RCT, placebo-controlled, double-blind trial
Date of study: February 2016 -
Location: worldwide
Phase 3
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Participants Randomised: 144 participants
Inclusion criteria
• Able and willing to give written informed consent
• Diagnosis of plaque psoriasis or vulgar
• Time course of the disease in ≥ 1 year
• Be tributary of systemic therapy
• Willingness to complete a washout period prior to receiving the first dose of treatment (for participants
in treatment only): interrupting or systemic therapy ≥ 4 weeks; interrupting or topical steroid treatment ≥
2 weeks
• Moderate-severe psoriasis activity, defined by: PASI ≥ 10; BSA ≥ 10%
• Normal laboratory values, considering laboratory range of each institution: CBC: haemoglobin men ≥
12.0 g/dL, women ≥ 11.0 g/dL, leukocytes ≥ 5 x109 L, platelets≥ 150 x 109/L, neutrophils ≥ 1.8 x 109/
L, lymphocytes > 1.2 x 109 cells/mL; renal function: creatinine normal value; liver function: ALT, AST,
GGT, up to 2.5 times the upper limit of normal
• Aged 18-70 years (both included)
Exclusion criteria
• Diagnosis of other types of psoriasis, psoriatic arthritis
• Critical State of psoriasis (erythroderma)
• Suffering from decompensated chronic diseases (heart disease, diabetes mellitus, hypertension, chronic
kidney disease, bronchial asthma, etc) to the doctor involves an unreasonable risk to the participant’s life
• Malignancy
• Immunocompromised patient
• Received systemic retinoids or immunosuppressive therapy including steroids, within < 30 days prior
to enrolment, except participants with psoriatic arthritis who are receiving stable treatment for ≥ 30 days
prior to inclusion of oral steroids ≤ 10 mg/day
• Significant acute or chronic systemic infection that to the doctor involves an unreasonable risk to the
participant
• Being treated with a monoclonal antibody, including itolizumab
• Allergy to any component of the formulation
• Pregnancy, postpartum and/or breastfeeding
• Be reproductive age and refuse to use contraception (pills, IUDs, barrier methods, etc) during
treatment and ≥ 8 weeks after the last dose of itolizumab
• Suffering intellectual or sensory psychological dysfunction that may impede understanding and
compliance with the requirements of the study at the discretion of the clinical investigator
Interventions Intervention
Itolizumab: itolizumab 1.6 mg/kg body weight bi-weekly administered IV by 12 weeks (weeks 0-8), and every
4 weeks by 24 weeks (Week 12-36)
Control intervention
Placebo 1.6 mg/kg body weight bi-weekly administered intravenously by 12 weeks (weeks 0-8), then 1.6 mg/
kg body weight biweekly administered intravenously by 12 weeks (weeks 12-20), and every 4 weeks by 12
weeks (weeks 24-36)
Outcomes At week 12
Primary outcome
• PASI 75
Secondary outcomes
• PASI 50, 75, 90, 100 at weeks 12, 24, 36, 48 and 60
• IGA 0/1 at weeks 12, 24, 36, 48 and 60
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• DLQI at weeks 12, 24, 36, 48 and 60
• AEs
Starting date Start study date: 15/10/2015
Study completion date: not specified
Contact information Dr Gray Lovio, ogray@infomed.sld.cu
Notes Ongoing study
TCTR20161028001
Trial name or title A randomised, double-blind, placebo controlled, multicenter study of subcutaneous secukinumab, to demon-
strate efficacy after twelve weeks of treatment and to assess safety, tolerability and long-term efficacy up to
one year in subjects with moderate to severe chronic plaque-type psoriasis with or without psoriatic arthritis
comorbidity
Methods RCT, active/placebo-controlled, double-blind trial
Date of study: February 2017 -
Location: Thailand
Participants Randomised: 40 participants
Inclusion criteria
• Must be able to understand and communicate with the investigator and comply with the requirements
of the study and must give a written, signed and dated informed consent before any study-related activity is
performed. Where relevant, a legal representative will also sign the informed study consent according to
local laws and regulations
• Men and women ≥ 18 years of age at the time of screening
• Chronic plaque-type psoriasis present for ≥ 6 months and diagnosed before baseline
• Moderate-severe psoriasis
Exclusion criteria
• Forms of psoriasis other than chronic plaque-type (e.g. pustular, erythrodermic and guttate psoriasis) at
screening or baseline
• Drug-induced psoriasis (i.e. new onset or current exacerbation from beta-blockers, calcium channel
inhibitors or lithium) at baseline
• Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to
(Table 5-1). Paricipants not willing to limit UV light exposure (e.g. sunbathing and/or the use of tanning
devices) during the course of the study will be considered not eligible for this study since UV light exposure
is prohibited. Note: administration of live vaccines 6 weeks prior to Randomization or during the study
period is also prohibited
• Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the
IL-17 receptor
• Use of other investigational drugs at the time of enrolment, or within 5 half-lives of enrolment, or
within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or
longer if required by local regulations
Interventions Intervention
A. Secukinumab 300 mg SC (administration not specified)
Control intervention
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B. Secukinumab 150 mg SC (administration not specified)
C. Placebo
Outcomes At week 12
Primary outcome (composite)
• IGA 0/1
• PASI 75
Secondary outcomes
• ACR 20/50/70 (timeframe 12 weeks and 52 weeks)
• PASI 50/75/90/100 (timeframe 12 weeks and 52 weeks PASI score)
• Safety and tolerability
Starting date 28 February 2017
Contact information Kerstin
Letzelter, kerstin.letzelter@novartis.com
Notes Ongoing study
BMI: body mass index; BSA: Body Surface Area; ECG: electrocardiogram; FAEs: fumaric acid esters; IV: intravenous; NAPSI: Nail
Psoriasis Severity Index; PASI: Psoriasis Area and Severity Index; PGA: Physician’s Global Assessment; QoL: quality of life; RCT:
randomised controlled trial: SC: subcutaneous; sPGA: static physician global assessment; TB: tuberculosis; UVA/B: ultraviolet A/B
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D A T A A N D A N A L Y S E S
Comparison 1. Primary outcome - PASI 90
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Conventional systemic agents
versus placebo
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Methotrexate 2 282 Risk Ratio (M-H, Random, 95% CI) 2.60 [0.26, 25.90]
1.2 Fumaric acid esters 1 704 Risk Ratio (M-H, Random, 95% CI) 4.47 [2.01, 9.95]
2 Conventional systemic 1 versus
conventional systemic 2
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Ciclosporin versus
methotrexate
2 172 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.47, 2.98]
2.2 Methotrexate versus
fumaric acid esters
1 60 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.19, 20.90]
3 Anti-TNF alpha versus placebo 21 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Etanercept versus placebo 12 4954 Risk Ratio (M-H, Random, 95% CI) 11.17 [7.66, 16.28]
3.2 Adalimumab versus
placebo
8 3199 Risk Ratio (M-H, Random, 95% CI) 14.86 [8.93, 24.73]
3.3 Certolizumab versus
placebo
1 176 Risk Ratio (M-H, Random, 95% CI) 24.58 [3.48, 173.49]
4 Ustekinumab versus placebo 7 3832 Risk Ratio (M-H, Random, 95% CI) 22.59 [14.74, 34.64]
5 Anti-IL17 versus placebo 16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Secukinumab versus
placebo
7 2707 Risk Ratio (M-H, Random, 95% CI) 26.52 [14.91, 47.17]
5.2 Ixekizumab versus placebo 4 3268 Risk Ratio (M-H, Random, 95% CI) 53.85 [15.34, 189.
07]
5.3 Brodalumab versus
placebo
5 4109 Risk Ratio (M-H, Random, 95% CI) 26.33 [16.77, 41.33]
6 Anti-IL23 versus placebo 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Guselkumab versus
placebo
3 1502 Risk Ratio (M-H, Random, 95% CI) 24.87 [14.20, 43.55]
6.2 Tildrakizumab versus
placebo
1 355 Risk Ratio (M-H, Random, 95% CI) 15.63 [2.24, 109.29]
7 Other biologics 1 225 Risk Ratio (M-H, Random, 95% CI) 12.26 [0.76, 197.54]
7.1 Itolizumab versus placebo 1 225 Risk Ratio (M-H, Random, 95% CI) 12.26 [0.76, 197.54]
8 Biologic versus conventional
systemic treatments
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Etanercept versus acitretin 1 60 Risk Ratio (M-H, Random, 95% CI) 11.00 [0.64, 190.53]
8.2 Infliximab versus
methotrexate
1 868 Risk Ratio (M-H, Random, 95% CI) 2.86 [2.15, 3.80]
8.3 Adalimumab versus
methotrexate
1 218 Risk Ratio (M-H, Random, 95% CI) 3.73 [2.25, 6.19]
8.4 Alefacept versus
methotrexate
1 212 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.42, 2.98]
9 Biologic 1 versus biologic 2 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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9.1 Ustekinumab versus
Etanercept
1 903 Risk Ratio (M-H, Random, 95% CI) 1.80 [1.45, 2.24]
9.2 Secukinumab versus
etanercept
1 980 Risk Ratio (M-H, Random, 95% CI) 2.32 [1.85, 2.92]
9.3 Ixekizumab versus
etanercept
2 2209 Risk Ratio (M-H, Random, 95% CI) 2.98 [2.24, 3.98]
9.4 Secukinumab versus
ustekinumab
1 676 Risk Ratio (M-H, Random, 95% CI) 1.38 [1.23, 1.53]
9.5 Brodalumab versus
ustekinumab
2 3088 Risk Ratio (M-H, Random, 95% CI) 1.27 [1.16, 1.39]
9.6 Guselkumab versus
adalimumab
3 1658 Risk Ratio (M-H, Random, 95% CI) 1.41 [1.25, 1.60]
10 Small molecules versus placebo 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Apremilast versus
placebo
4 1775 Risk Ratio (M-H, Random, 95% CI) 6.78 [3.03, 15.17]
10.2 Tofacitinib versus
placebo
4 2826 Risk Ratio (M-H, Random, 95% CI) 6.80 [3.86, 11.99]
10.3 Ponesimod versus
placebo
1 326 Risk Ratio (M-H, Random, 95% CI) 6.60 [1.65, 26.41]
11 Biologic versus small molecules 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Etanercept versus
Tofacitinib
1 998 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.93, 1.38]
11.2 Etanercept versus
apremilast
1 166 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.72, 2.78]
Comparison 2. Primary outcome - serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Conventional systemic agents
versus placebo
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Methotrexate 2 283 Risk Ratio (M-H, Random, 95% CI) 0.16 [0.03, 0.88]
1.2 Fumaric acid esters 1 704 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.31, 2.21]
2 Anti-TNF alpha versus placebo 20 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Etanercept versus placebo 11 3783 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.61, 1.83]
2.2 Adalimumab versus
placebo
8 3199 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.60, 1.73]
2.3 Certolizumab versus
placebo
1 176 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.10, 2.36]
3 Ustekinumab versus placebo 8 4154 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.50, 1.58]
4 Anti-IL17 versus placebo 16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Secukinumab versus
placebo
7 2707 Risk Ratio (M-H, Random, 95% CI) 1.67 [0.79, 3.53]
4.2 Ixekizumab versus placebo 4 3268 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.65, 2.32]
4.3 Brodalumab versus
placebo
5 4109 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.52, 1.61]
5 Anti-IL23 versus placebo 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
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5.1 Guselkumab versus
placebo
3 1502 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.51, 2.85]
5.2 Tildrakizumab versus
placebo
1 355 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.07, 24.94]
6 Other biologics 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Alefacept versus placebo 2 736 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.34, 1.62]
7 Biologic versus conventional
systemic treatments
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Etanercept versus acitretin 1 60 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 Infliximab versus
methotrexate
1 868 Risk Ratio (M-H, Random, 95% CI) 2.41 [1.04, 5.59]
7.3 Adalimumab versus
methotrexate
1 218 Risk Ratio (M-H, Random, 95% CI) 2.04 [0.19, 22.14]
8 Biologic 1 versus biologic 2 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Ustekinumab versus
etanercept
1 903 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.38, 4.11]
8.2 Secukinumab versus
etanercept
1 980 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.41, 2.82]
8.3 Ixekizumab versus
etanercept
2 2209 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.55, 2.06]
8.4 Secukinumab versus
ustekinumab
1 676 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.42, 2.39]
8.5 Brodalumab versus
ustekinumab
2 3088 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.64, 3.56]
8.6 Guselkumab versus
adalimumab
3 1658 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.44, 1.82]
9 Small molecules versus placebo 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Apremilast versus placebo 5 2036 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.41, 1.49]
9.2 Tofacitinib versus placebo 5 2838 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.53, 2.06]
9.3 Ponesimod versus placebo 1 326 Risk Ratio (M-H, Random, 95% CI) 2.59 [0.34, 19.85]
10 Biologic versus small molecules 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Etanercept versus
tofacitinib
1 998 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.46, 2.89]
10.2 Etanercept versus
apremilast
1 166 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.04, 3.14]
Comparison 3. Secondary outcome - PASI 75
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Conventional systemic agents
versus placebo
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Methotrexate 2 283 Risk Ratio (M-H, Random, 95% CI) 2.36 [1.19, 4.68]
1.2 Fumaric acid esters 1 704 Risk Ratio (M-H, Random, 95% CI) 2.56 [1.68, 3.89]
2 Conventional systemic 1 versus
conventional systemic 2
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Ciclosporin versus
methotrexate
2 172 Risk Ratio (M-H, Random, 95% CI) 1.37 [0.84, 2.23]
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2.2 Methotrexate versus
fumaric acid esters
1 60 Risk Ratio (M-H, Random, 95% CI) 1.2 [0.41, 3.51]
3 Anti-TNF alpha versus placebo 22 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Etanercept versus placebo 13 5066 Risk Ratio (M-H, Random, 95% CI) 8.55 [6.94, 10.52]
3.2 Adalimumab versus
placebo
8 3199 Risk Ratio (M-H, Random, 95% CI) 9.08 [6.52, 12.65]
3.3 Certolizumab versus
placebo
1 176 Risk Ratio (M-H, Random, 95% CI) 11.31 [4.37, 29.24]
4 Ustekinumab versus placebo 8 4154 Risk Ratio (M-H, Random, 95% CI) 12.41 [8.69, 17.71]
5 Anti-IL17 versus placebo 16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Secukinumab versus
placebo
7 2707 Risk Ratio (M-H, Random, 95% CI) 15.70 [11.27, 21.87]
5.2 Ixekizumab versus placebo 4 3268 Risk Ratio (M-H, Random, 95% CI) 17.44 [10.45, 29.10]
5.3 Brodalumab versus
placebo
5 4109 Risk Ratio (M-H, Random, 95% CI) 12.80 [8.46, 19.36]
6 Anti-IL23 versus placebo 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Guselkumab versus
Placebo
3 1502 Risk Ratio (M-H, Random, 95% CI) 12.28 [8.79, 17.17]
6.2 Tildrakizumab versus
placebo
1 355 Risk Ratio (M-H, Random, 95% CI) 14.51 [3.73, 56.45]
7 Other biologics 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Alefacept versus placebo 2 736 Risk Ratio (M-H, Random, 95% CI) 2.95 [1.76, 4.94]
7.2 Itolizumab versus placebo 1 225 Risk Ratio (M-H, Random, 95% CI) 13.23 [1.88, 92.93]
8 Biologic versus conventional
systemic treatments
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Etanercept versus acitretin 1 60 Risk Ratio (M-H, Random, 95% CI) 2.13 [1.09, 4.16]
8.2 Alefacept versus
methotrexate
1 212 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.46, 1.21]
8.3 Infliximab versus
methotrexate
1 868 Risk Ratio (M-H, Random, 95% CI) 1.86 [1.58, 2.19]
8.4 Adalimumab versus
methotrexate
1 218 Risk Ratio (M-H, Random, 95% CI) 2.25 [1.72, 2.94]
9 Biologic 1 versus biologic 2 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Ustekinumab versus
etanercept
1 903 Risk Ratio (M-H, Random, 95% CI) 1.26 [1.13, 1.40]
9.2 Secukinumab versus
etanercept
1 980 Risk Ratio (M-H, Random, 95% CI) 1.64 [1.44, 1.88]
9.3 Ixekizumab versus
etanercept
2 2209 Risk Ratio (M-H, Random, 95% CI) 1.79 [1.43, 2.24]
9.4 Secukinumab versus
ustekinumab
1 676 Risk Ratio (M-H, Random, 95% CI) 1.13 [1.06, 1.20]
9.5 Brodalumab versus
ustekinumab
2 3088 Risk Ratio (M-H, Random, 95% CI) 1.10 [1.04, 1.17]
9.6 Guselkumab versus
adalimumab
3 1658 Risk Ratio (M-H, Random, 95% CI) 1.21 [1.13, 1.30]
10 Small molecules versus placebo 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Apremilast versus
placebo
5 2036 Risk Ratio (M-H, Random, 95% CI) 3.88 [2.42, 6.22]
10.2 Tofacitinib versus
placebo
5 2838 Risk Ratio (M-H, Random, 95% CI) 6.41 [3.84, 10.71]
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10.3 Ponesimod versus
placebo
1 326 Risk Ratio (M-H, Random, 95% CI) 3.51 [1.88, 6.53]
11 Biologic versus small molecules 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Etanercept versus
Tofacitinib
1 998 Risk Ratio (M-H, Random, 95% CI) 1.14 [1.02, 1.28]
11.2 Etanercept versus
apremilast
1 166 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.86, 1.71]
Comparison 4. Secondary outcome - PGA 0/1
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Conventional systemic agents
versus placebo
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Methotrexate 2 283 Risk Ratio (M-H, Random, 95% CI) 2.94 [1.47, 5.89]
1.2 Fumaric acid esters 1 704 Risk Ratio (M-H, Random, 95% CI) 2.73 [1.72, 4.32]
2 Conventional systemic 1 versus
conventional systemic 2
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Ciclosporin versus
methotrexate
1 88 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.47, 1.46]
3 Anti-TNF alpha versus placebo 19 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Etanercept versus placebo 11 4334 Risk Ratio (M-H, Random, 95% CI) 7.77 [5.98, 10.10]
3.2 Adalimumab versus
placebo
7 3051 Risk Ratio (M-H, Random, 95% CI) 8.38 [6.28, 11.18]
3.3 Certolizumab versus
placebo
1 176 Risk Ratio (M-H, Random, 95% CI) 35.88 [5.11, 251.73]
4 Ustekinumab versus placebo 8 4154 Risk Ratio (M-H, Random, 95% CI) 11.33 [7.38, 17.39]
5 Anti-IL17 versus placebo 15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Secukinumab versus
placebo
6 2607 Risk Ratio (M-H, Random, 95% CI) 17.16 [7.48, 39.36]
5.2 Ixekizumab versus placebo 4 3268 Risk Ratio (M-H, Random, 95% CI) 17.46 [9.87, 30.90]
5.3 Brodalumab versus
placebo
5 4109 Risk Ratio (M-H, Random, 95% CI) 18.78 [13.29, 26.55]
6 Anti-IL23 versus placebo 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Guselkumab versus
placebo
3 1502 Risk Ratio (M-H, Random, 95% CI) 10.59 [7.73, 14.51]
6.2 Tildrakizumab versus
placebo
1 355 Risk Ratio (M-H, Random, 95% CI) 27.54 [3.95, 191.78]
7 Other biologics 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Alefacept versus placebo 1 507 Risk Ratio (M-H, Random, 95% CI) 2.54 [1.22, 5.29]
7.2 Itolizumab versus placebo 1 225 Risk Ratio (M-H, Random, 95% CI) 3.78 [0.94, 15.17]
8 Biologic versus conventional
systemic treatments
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Alefacept versus
methotrexate
1 212 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.37, 1.29]
8.2 Infliximab versus
methotrexate
1 868 Risk Ratio (M-H, Random, 95% CI) 1.99 [1.67, 2.37]
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8.3 Adalimumab versus
methotrexate
1 218 Risk Ratio (M-H, Random, 95% CI) 2.44 [1.79, 3.32]
9 Biologic 1 versus biologic 2 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Ustekinumab versus
etanercept
1 903 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.24, 1.58]
9.2 Secukinumab versus
etanercept
1 980 Risk Ratio (M-H, Random, 95% CI) 2.09 [1.73, 2.53]
9.3 Ixekizumab versus
etanercept
2 2209 Risk Ratio (M-H, Random, 95% CI) 2.01 [1.74, 2.31]
9.4 Secukinumab versus
ustekinumab
1 676 Risk Ratio (M-H, Random, 95% CI) 1.23 [1.13, 1.35]
9.5 Brodalumab versus
ustekinumab
2 3088 Risk Ratio (M-H, Random, 95% CI) 1.17 [1.07, 1.27]
9.6 Guselkumab versus
adalimumab
3 1658 Risk Ratio (M-H, Random, 95% CI) 1.24 [1.17, 1.32]
10 Small molecules versus placebo 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Apremilast versus
placebo
4 1776 Risk Ratio (M-H, Random, 95% CI) 3.88 [2.04, 7.38]
10.2 Tofacitinib versus
placebo
5 2838 Risk Ratio (M-H, Random, 95% CI) 4.48 [3.51, 5.71]
10.3 Ponesimod versus
placebo
1 326 Risk Ratio (M-H, Random, 95% CI) 6.73 [2.19, 20.64]
11 Biologic versus small molecules 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Etanercept versus
tofacitinib
1 998 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.04, 1.27]
11.2 Etanercept versus
apremilast
1 166 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.78, 2.27]
Comparison 5. Secondary outcome - quality of life
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Conventional systemic agents
versus placebo
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Methotrexate 2 283 Std. Mean Difference (IV, Random, 95% CI) -0.67 [-1.40, 0.06]
2 Anti-TNF alpha versus placebo 14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Etanercept versus placebo 7 2779 Std. Mean Difference (IV, Random, 95% CI) -1.10 [-1.37, -0.83]
2.2 Adalimumab versus
placebo
7 2774 Std. Mean Difference (IV, Random, 95% CI) -1.02 [-1.16, -0.88]
3 Ustekinumab versus placebo 6 2917 Std. Mean Difference (IV, Random, 95% CI) -1.21 [-1.39, -1.03]
4 Anti-IL17 versus placebo 5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Ixekizumab versus placebo 3 3126 Std. Mean Difference (IV, Random, 95% CI) -1.76 [-2.09, -1.43]
4.2 Brodalumab versus
placebo
2 349 Std. Mean Difference (IV, Random, 95% CI) -0.96 [-1.44, -0.47]
5 Anti-IL23 versus placebo 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Guselkumab versus
placebo
2 1252 Std. Mean Difference (IV, Random, 95% CI) -1.39 [-1.63, -1.14]
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5.2 Tildrakizumab versus
placebo
1 355 Std. Mean Difference (IV, Random, 95% CI) -1.23 [-1.55, -0.91]
6 Other biologics 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Alefacept versus placebo 1 229 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.62, -0.02]
6.2 Itolizumab versus placebo 1 225 Std. Mean Difference (IV, Random, 95% CI) -0.34 [-0.68, -0.01]
7 Biologic versus conventional
systemic treatments
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Alefacept versus
methotrexate
1 212 Mean Difference (IV, Fixed, 95% CI) 1.31 [-0.28, 2.90]
7.2 Adalimumab versus
methotrexate
1 218 Mean Difference (IV, Fixed, 95% CI) -3.40 [-5.75, -1.05]
8 Biologic 1 versus biologic 2 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Ixekizumab versus
etanercept
2 2209 Mean Difference (IV, Fixed, 95% CI) -1.99 [-2.39, -1.59]
8.2 Guselkumab versus
adalimumab
2 1407 Mean Difference (IV, Fixed, 95% CI) -1.73 [-2.50, -0.97]
9 Small molecules versus placebo 7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Apremilast versus placebo 3 1609 Std. Mean Difference (IV, Random, 95% CI) -0.62 [-0.77, -0.47]
9.2 Tofacitinib versus placebo 3 2629 Std. Mean Difference (IV, Random, 95% CI) -1.09 [-1.28, -0.89]
9.3 Ponesimod versus placebo 1 326 Std. Mean Difference (IV, Random, 95% CI) -0.58 [-0.86, -0.31]
10 Biologic versus small molecules 1 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Etanercept versus
Tofacitinib
1 998 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.19, 0.07]
Comparison 6. Secondary outcome - adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Conventional systemic agents
versus placebo
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Methotrexate 2 283 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.81, 1.10]
1.2 Fumaric acid esters 1 704 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.22, 1.62]
2 Conventional systemic 1 versus
conventional systemic 2
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Ciclosporin versus
methotrexate
2 172 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.90, 1.34]
2.2 Methotrexate versus
fumaric acid esters
1 60 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.91, 1.39]
3 Anti-TNF alpha versus placebo 17 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Etanercept versus placebo 9 3529 Risk Ratio (M-H, Random, 95% CI) 1.12 [1.05, 1.20]
3.2 Adalimumab versus
placebo
7 3051 Risk Ratio (M-H, Random, 95% CI) 1.06 [1.00, 1.13]
3.3 Certolizumab versus
placebo
1 176 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.81, 1.22]
4 Ustekinumab versus placebo 8 4154 Risk Ratio (M-H, Random, 95% CI) 1.06 [1.00, 1.13]
5 Anti-IL17 versus placebo 16 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Secukinumab versus
placebo
7 2707 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.02, 1.29]
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5.2 Ixekizumab versus placebo 4 3268 Risk Ratio (M-H, Random, 95% CI) 1.24 [1.07, 1.45]
5.3 Brodalumab versus
placebo
5 4109 Risk Ratio (M-H, Random, 95% CI) 1.15 [1.00, 1.32]
6 Anti-IL23 versus placebo 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Guselkumab versus
placebo
3 1502 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.92, 1.16]
6.2 Tildrakizumab versus
placebo
1 355 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.76, 1.18]
7 Biologic versus conventional
systemic treatments
2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Infliximab versus
methotrexate
1 868 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.97, 1.20]
7.2 Adalimumab versus
methotrexate
1 218 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.78, 1.05]
8 Biologic 1 versus biologic 2 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Ustekinumab versus
etanercept
1 903 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.89, 1.06]
8.2 Secukinumab versus
etanercept
1 980 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.89, 1.12]
8.3 Ixekizumab versus
etanercept
2 2209 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.97, 1.15]
8.4 Secukinumab versus
ustekinumab
1 676 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.98, 1.25]
8.5 Brodalumab versus
ustekinumab
2 3088 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.93, 1.09]
8.6 Guselkumab versus
adalimumab
3 1658 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.88, 1.07]
9 Small molecules versus placebo 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Apremilast versus placebo 5 2036 Risk Ratio (M-H, Random, 95% CI) 1.22 [1.07, 1.38]
9.2 Tofacitinib versus placebo 4 2641 Risk Ratio (M-H, Random, 95% CI) 1.14 [1.03, 1.25]
9.3 Ponesimod versus placebo 1 326 Risk Ratio (M-H, Random, 95% CI) 1.31 [1.02, 1.68]
10 Biologic versus small molecules 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Etanercept versus
tofacitinib
1 998 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.89, 1.12]
10.2 Etanercept versus
apremilast
1 166 Risk Ratio (M-H, Random, 95% CI) 1.32 [1.03, 1.69]
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Analysis 1.1. Comparison 1 Primary outcome - PASI 90, Outcome 1 Conventional systemic agents versus
placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 1 Conventional systemic agents versus placebo
Study or subgroup
Conventional
treatments Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Methotrexate
Saurat CHAMPION, 2008 15/110 6/53 65.0 % 1.20 [ 0.50, 2.93 ]
Warren METOP, 2017 16/90 0/29 35.0 % 10.88 [ 0.67, 175.90 ]
Subtotal (95% CI) 200 82 100.0 % 2.60 [ 0.26, 25.90 ]
Total events: 31 (Conventional treatments), 6 (Placebo)
Heterogeneity: Tau2 = 1.91; Chi2 = 2.72, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Fumaric acid esters
Mrowietz BRIDGE, 2016 110/566 6/138 100.0 % 4.47 [ 2.01, 9.95 ]
Subtotal (95% CI) 566 138 100.0 % 4.47 [ 2.01, 9.95 ]
Total events: 110 (Conventional treatments), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.67 (P = 0.00025)
Test for subgroup differences: Chi2 = 0.19, df = 1 (P = 0.66), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 1.2. Comparison 1 Primary outcome - PASI 90, Outcome 2 Conventional systemic 1 versus
conventional systemic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 2 Conventional systemic 1 versus conventional systemic 2
Study or subgroup Conventional 1 Conventional 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ciclosporin versus methotrexate
Flytstro¨m 2008 9/43 4/41 37.9 % 2.15 [ 0.72, 6.43 ]
Heydendael 2003 14/44 17/44 62.1 % 0.82 [ 0.47, 1.46 ]
Subtotal (95% CI) 87 85 100.0 % 1.18 [ 0.47, 2.98 ]
Total events: 23 (Conventional 1), 21 (Conventional 2)
Heterogeneity: Tau2 = 0.27; Chi2 = 2.37, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Methotrexate versus fumaric acid esters
Fallah Arani 2011 2/30 1/30 100.0 % 2.00 [ 0.19, 20.90 ]
Subtotal (95% CI) 30 30 100.0 % 2.00 [ 0.19, 20.90 ]
Total events: 2 (Conventional 1), 1 (Conventional 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 0.17, df = 1 (P = 0.68), I2 =0.0%
0.01 0.1 1 10 100
Favours Conventional 2 Favours Conventional 1
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Analysis 1.3. Comparison 1 Primary outcome - PASI 90, Outcome 3 Anti-TNF alpha versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 3 Anti-TNF alpha versus placebo
Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus placebo
Bachelez 2015 108/336 1/108 3.7 % 34.71 [ 4.90, 245.72 ]
Bagel 2012 15/62 1/62 3.6 % 15.00 [ 2.04, 110.11 ]
Gottlieb 2011 33/141 1/68 3.7 % 15.91 [ 2.22, 113.92 ]
Griffiths UNCOVER-2, 2015 67/358 1/168 3.7 % 31.44 [ 4.40, 224.56 ]
Griffiths UNCOVER-3, 2015 98/382 6/193 21.9 % 8.25 [ 3.69, 18.47 ]
Langley FIXTURE, 2014 67/326 5/327 17.7 % 13.44 [ 5.49, 32.91 ]
Leonardi 2003 60/504 1/168 3.7 % 20.00 [ 2.79, 143.20 ]
Papp 2005 59/407 1/204 3.7 % 29.57 [ 4.13, 211.91 ]
Reich LIBERATE, 2017 17/83 3/84 10.0 % 5.73 [ 1.75, 18.84 ]
Strober 2011 27/139 3/72 10.6 % 4.66 [ 1.46, 14.85 ]
Tyring 2006 65/311 4/309 14.3 % 16.15 [ 5.96, 43.77 ]
Van de Kerkhof 2008 13/96 1/46 3.5 % 6.23 [ 0.84, 46.18 ]
Subtotal (95% CI) 3145 1809 100.0 % 11.17 [ 7.66, 16.28 ]
Total events: 629 (Anti-TNF), 28 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.61, df = 11 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 12.55 (P < 0.00001)
2 Adalimumab versus placebo
Asahina 2010 57/123 0/46 3.1 % 43.59 [ 2.75, 691.12 ]
Blauvelt VOYAGE-1, 2016 166/329 5/174 16.9 % 17.56 [ 7.35, 41.93 ]
Cai 2016 188/338 3/87 12.8 % 16.13 [ 5.28, 49.24 ]
Gordon 2006 35/96 0/52 3.1 % 38.79 [ 2.43, 619.78 ]
Gordon X-PLORE, 2015 19/43 1/42 5.6 % 18.56 [ 2.60, 132.47 ]
Menter REVEAL, 2008 366/814 9/398 21.6 % 19.88 [ 10.38, 38.10 ]
Reich VOYAGE-2, 2017 116/248 6/248 18.2 % 19.33 [ 8.67, 43.09 ]
Saurat CHAMPION, 2008 55/108 6/53 18.8 % 4.50 [ 2.07, 9.77 ]
Subtotal (95% CI) 2099 1100 100.0 % 14.86 [ 8.93, 24.73 ]
0.001 0.01 0.1 1 10 100 1000
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(. . . Continued)
Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 1002 (Anti-TNF), 30 (Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 12.15, df = 7 (P = 0.10); I2 =42%
Test for overall effect: Z = 10.39 (P < 0.00001)
3 Certolizumab versus placebo
Reich 2012 50/118 1/58 100.0 % 24.58 [ 3.48, 173.49 ]
Subtotal (95% CI) 118 58 100.0 % 24.58 [ 3.48, 173.49 ]
Total events: 50 (Anti-TNF), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.21 (P = 0.0013)
Test for subgroup differences: Chi2 = 1.25, df = 2 (P = 0.54), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours Placebo Favours Anti-TNF
Analysis 1.4. Comparison 1 Primary outcome - PASI 90, Outcome 4 Ustekinumab versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 4 Ustekinumab versus placebo
Study or subgroup Ustekinumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Igarashi 2012 48/126 1/32 4.6 % 12.19 [ 1.75, 84.99 ]
Krueger 2007 95/256 1/64 4.6 % 23.75 [ 3.38, 167.12 ]
Lebwohl AMAGINE-2, 2015 141/300 10/309 33.8 % 14.52 [ 7.80, 27.04 ]
Lebwohl AMAGINE-3, 2015 149/313 5/315 19.8 % 29.99 [ 12.47, 72.11 ]
Leonardi PHOENIX-1, 2008 200/511 5/255 19.9 % 19.96 [ 8.32, 47.86 ]
Papp PHOENIX-2, 2008 382/820 3/410 12.8 % 63.67 [ 20.57, 197.05 ]
Tsai PEARL, 2011 30/61 1/60 4.6 % 29.51 [ 4.16, 209.54 ]
Total (95% CI) 2387 1445 100.0 % 22.59 [ 14.74, 34.64 ]
0.01 0.1 1 10 100
Favours Placebo Favours Ustekinumab
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(. . . Continued)
Study or subgroup Ustekinumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 1045 (Ustekinumab), 26 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 6.79, df = 6 (P = 0.34); I2 =12%
Test for overall effect: Z = 14.30 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Placebo Favours Ustekinumab
Analysis 1.5. Comparison 1 Primary outcome - PASI 90, Outcome 5 Anti-IL17 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 5 Anti-IL17 versus placebo
Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Secukinumab versus placebo
Blauvelt FEATURE, 2015 63/118 0/59 4.3 % 64.03 [ 4.03, 1017.14 ]
Langley ERASURE, 2014 240/490 3/248 26.0 % 40.49 [ 13.10, 125.14 ]
Langley FIXTURE, 2014 312/654 5/327 43.5 % 31.20 [ 13.03, 74.73 ]
Papp 2013a 20/103 1/22 8.7 % 4.27 [ 0.60, 30.17 ]
Paul JUNCTURE, 2015 57/121 0/61 4.3 % 58.44 [ 3.67, 929.87 ]
Reich 2015 42/90 0/10 4.5 % 10.27 [ 0.68, 155.50 ]
Rich 2013 73/337 1/67 8.7 % 14.51 [ 2.05, 102.61 ]
Subtotal (95% CI) 1913 794 100.0 % 26.52 [ 14.91, 47.17 ]
Total events: 807 (Anti IL17), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.77, df = 6 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 11.16 (P < 0.00001)
2 Ixekizumab versus placebo
Gordon UNCOVER-1, 2016 586/865 2/431 28.2 % 145.99 [ 36.60, 582.31 ]
0.01 0.1 1 10 100
Favours Placebo Favours Anti IL17
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Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Griffiths UNCOVER-2, 2015 455/698 1/168 21.0 % 109.51 [ 15.51, 773.49 ]
Griffiths UNCOVER-3, 2015 514/771 6/193 36.7 % 21.44 [ 9.74, 47.21 ]
Leonardi 2012 57/115 0/27 14.0 % 27.76 [ 1.77, 435.55 ]
Subtotal (95% CI) 2449 819 100.0 % 53.85 [ 15.34, 189.07 ]
Total events: 1612 (Anti IL17), 9 (Placebo)
Heterogeneity: Tau2 = 0.96; Chi2 = 7.99, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 6.22 (P < 0.00001)
3 Brodalumab versus placebo
Lebwohl AMAGINE-2, 2015 731/1222 10/309 54.4 % 18.48 [ 10.03, 34.07 ]
Lebwohl AMAGINE-3, 2015 756/1253 5/315 26.8 % 38.01 [ 15.91, 90.79 ]
Nakagawa 2016 64/113 1/38 5.4 % 21.52 [ 3.09, 149.88 ]
Papp 2012 89/160 0/38 2.7 % 43.36 [ 2.75, 683.33 ]
Papp AMAGINE-1, 2016 249/441 2/220 10.7 % 62.11 [ 15.59, 247.38 ]
Subtotal (95% CI) 3189 920 100.0 % 26.33 [ 16.77, 41.33 ]
Total events: 1889 (Anti IL17), 18 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.76, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 14.21 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.15, df = 2 (P = 0.56), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.6. Comparison 1 Primary outcome - PASI 90, Outcome 6 Anti-IL23 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 6 Anti-IL23 versus placebo
Study or subgroup Anti IL23 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Guselkumab versus placebo
Blauvelt VOYAGE-1, 2016 241/334 5/174 41.8 % 25.11 [ 10.56, 59.72 ]
Gordon X-PLORE, 2015 47/208 1/42 8.2 % 9.49 [ 1.35, 66.89 ]
Reich VOYAGE-2, 2017 347/496 6/248 50.0 % 28.92 [ 13.09, 63.88 ]
Subtotal (95% CI) 1038 464 100.0 % 24.87 [ 14.20, 43.55 ]
Total events: 635 (Anti IL23), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.08, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 11.24 (P < 0.00001)
2 Tildrakizumab versus placebo
Papp 2015a 105/309 1/46 100.0 % 15.63 [ 2.24, 109.29 ]
Subtotal (95% CI) 309 46 100.0 % 15.63 [ 2.24, 109.29 ]
Total events: 105 (Anti IL23), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.77 (P = 0.0056)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
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Analysis 1.7. Comparison 1 Primary outcome - PASI 90, Outcome 7 Other biologics.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 7 Other biologics
Study or subgroup Other Biologics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Itolizumab versus placebo
Krupashankar 2014 25/182 0/43 100.0 % 12.26 [ 0.76, 197.54 ]
Total (95% CI) 182 43 100.0 % 12.26 [ 0.76, 197.54 ]
Total events: 25 (Other Biologics), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.8. Comparison 1 Primary outcome - PASI 90, Outcome 8 Biologic versus conventional systemic
treatments.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 8 Biologic versus conventional systemic treatments
Study or subgroup Biologic
Conventional
systemic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus acitretin
Caproni 2009 5/30 0/30 100.0 % 11.00 [ 0.64, 190.53 ]
Subtotal (95% CI) 30 30 100.0 % 11.00 [ 0.64, 190.53 ]
Total events: 5 (Biologic), 0 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
2 Infliximab versus methotrexate
Barker RESTORE-1, 2011 356/653 41/215 100.0 % 2.86 [ 2.15, 3.80 ]
Subtotal (95% CI) 653 215 100.0 % 2.86 [ 2.15, 3.80 ]
Total events: 356 (Biologic), 41 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 7.25 (P < 0.00001)
3 Adalimumab versus methotrexate
Saurat CHAMPION, 2008 55/108 15/110 100.0 % 3.73 [ 2.25, 6.19 ]
Subtotal (95% CI) 108 110 100.0 % 3.73 [ 2.25, 6.19 ]
Total events: 55 (Biologic), 15 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 5.11 (P < 0.00001)
4 Alefacept versus methotrexate
Yan 2011 8/107 7/105 100.0 % 1.12 [ 0.42, 2.98 ]
Subtotal (95% CI) 107 105 100.0 % 1.12 [ 0.42, 2.98 ]
Total events: 8 (Biologic), 7 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 5.44, df = 3 (P = 0.14), I2 =45%
0.01 0.1 1 10 100
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Analysis 1.9. Comparison 1 Primary outcome - PASI 90, Outcome 9 Biologic 1 versus biologic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 9 Biologic 1 versus biologic 2
Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ustekinumab versus Etanercept
Griffiths ACCEPT, 2010 231/556 80/347 100.0 % 1.80 [ 1.45, 2.24 ]
Subtotal (95% CI) 556 347 100.0 % 1.80 [ 1.45, 2.24 ]
Total events: 231 (Biologic 1), 80 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 5.34 (P < 0.00001)
2 Secukinumab versus etanercept
Langley FIXTURE, 2014 312/654 67/326 100.0 % 2.32 [ 1.85, 2.92 ]
Subtotal (95% CI) 654 326 100.0 % 2.32 [ 1.85, 2.92 ]
Total events: 312 (Biologic 1), 67 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 7.24 (P < 0.00001)
3 Ixekizumab versus etanercept
Griffiths UNCOVER-2, 2015 455/698 67/358 47.3 % 3.48 [ 2.79, 4.35 ]
Griffiths UNCOVER-3, 2015 514/771 98/382 52.7 % 2.60 [ 2.18, 3.10 ]
Subtotal (95% CI) 1469 740 100.0 % 2.98 [ 2.24, 3.98 ]
Total events: 969 (Biologic 1), 165 (Biologic 2)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.10, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 7.44 (P < 0.00001)
4 Secukinumab versus ustekinumab
Thaci CLEAR, 2015 264/337 193/339 100.0 % 1.38 [ 1.23, 1.53 ]
Subtotal (95% CI) 337 339 100.0 % 1.38 [ 1.23, 1.53 ]
Total events: 264 (Biologic 1), 193 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 5.78 (P < 0.00001)
5 Brodalumab versus ustekinumab
Lebwohl AMAGINE-2, 2015 731/1222 141/300 48.4 % 1.27 [ 1.12, 1.45 ]
Lebwohl AMAGINE-3, 2015 758/1253 149/313 51.6 % 1.27 [ 1.12, 1.44 ]
Subtotal (95% CI) 2475 613 100.0 % 1.27 [ 1.16, 1.39 ]
Total events: 1489 (Biologic 1), 290 (Biologic 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 5.27 (P < 0.00001)
0.01 0.1 1 10 100
Favours Biologic 2 Favours Biologic 1
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Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Guselkumab versus adalimumab
Blauvelt VOYAGE-1, 2016 241/334 166/329 48.2 % 1.43 [ 1.26, 1.62 ]
Gordon X-PLORE, 2015 97/208 19/43 10.2 % 1.06 [ 0.73, 1.52 ]
Reich VOYAGE-2, 2017 347/496 116/248 41.6 % 1.50 [ 1.29, 1.73 ]
Subtotal (95% CI) 1038 620 100.0 % 1.41 [ 1.25, 1.60 ]
Total events: 685 (Biologic 1), 301 (Biologic 2)
Heterogeneity: Tau2 = 0.00; Chi2 = 3.02, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 5.49 (P < 0.00001)
Test for subgroup differences: Chi2 = 53.70, df = 5 (P = 0.00), I2 =91%
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Analysis 1.10. Comparison 1 Primary outcome - PASI 90, Outcome 10 Small molecules versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 10 Small molecules versus placebo
Study or subgroup Small molecules Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Apremilast versus placebo
Papp 2012b 22/264 1/88 15.7 % 7.33 [ 1.00, 53.62 ]
Papp ESTEEM-1, 2015 55/562 1/282 16.0 % 27.60 [ 3.84, 198.40 ]
Paul ESTEEM-2, 2015 24/275 2/137 29.5 % 5.98 [ 1.43, 24.93 ]
Reich LIBERATE, 2017 12/83 3/84 38.8 % 4.05 [ 1.19, 13.83 ]
Subtotal (95% CI) 1184 591 100.0 % 6.78 [ 3.03, 15.17 ]
Total events: 113 (Small molecules), 7 (Placebo)
Heterogeneity: Tau2 = 0.04; Chi2 = 3.19, df = 3 (P = 0.36); I2 =6%
Test for overall effect: Z = 4.66 (P < 0.00001)
0.01 0.1 1 10 100
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Study or subgroup Small molecules Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
2 Tofacitinib versus placebo
Bachelez 2015 188/662 1/108 7.7 % 30.67 [ 4.34, 216.57 ]
Papp 2012a 32/147 0/50 4.0 % 22.40 [ 1.40, 359.19 ]
Papp OPT Pivotal-1, 2015 214/723 10/177 44.2 % 5.24 [ 2.84, 9.67 ]
Papp OPT Pivotal-2, 2015 237/763 10/196 44.1 % 6.09 [ 3.30, 11.24 ]
Subtotal (95% CI) 2295 531 100.0 % 6.80 [ 3.86, 11.99 ]
Total events: 671 (Small molecules), 21 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 4.14, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 6.62 (P < 0.00001)
3 Ponesimod versus placebo
Vaclavkova 2014 51/259 2/67 100.0 % 6.60 [ 1.65, 26.41 ]
Subtotal (95% CI) 259 67 100.0 % 6.60 [ 1.65, 26.41 ]
Total events: 51 (Small molecules), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.67 (P = 0.0077)
Test for subgroup differences: Chi2 = 0.00, df = 2 (P = 1.00), I2 =0.0%
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Analysis 1.11. Comparison 1 Primary outcome - PASI 90, Outcome 11 Biologic versus small molecules.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 1 Primary outcome - PASI 90
Outcome: 11 Biologic versus small molecules
Study or subgroup Biologic Small molecules Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus Tofacitinib
Bachelez 2015 108/336 188/662 100.0 % 1.13 [ 0.93, 1.38 ]
Subtotal (95% CI) 336 662 100.0 % 1.13 [ 0.93, 1.38 ]
Total events: 108 (Biologic), 188 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 Etanercept versus apremilast
Reich LIBERATE, 2017 17/83 12/83 100.0 % 1.42 [ 0.72, 2.78 ]
Subtotal (95% CI) 83 83 100.0 % 1.42 [ 0.72, 2.78 ]
Total events: 17 (Biologic), 12 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.39, df = 1 (P = 0.53), I2 =0.0%
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Analysis 2.1. Comparison 2 Primary outcome - serious adverse events, Outcome 1 Conventional systemic
agents versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 1 Conventional systemic agents versus placebo
Study or subgroup
Conventional
treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Methotrexate
Saurat CHAMPION, 2008 1/110 1/53 38.2 % 0.48 [ 0.03, 7.55 ]
Warren METOP, 2017 1/91 4/29 61.8 % 0.08 [ 0.01, 0.68 ]
Subtotal (95% CI) 201 82 100.0 % 0.16 [ 0.03, 0.88 ]
Total events: 2 (Conventional treatment), 5 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 2.11 (P = 0.035)
2 Fumaric acid esters
Mrowietz BRIDGE, 2016 17/566 5/138 100.0 % 0.83 [ 0.31, 2.21 ]
Subtotal (95% CI) 566 138 100.0 % 0.83 [ 0.31, 2.21 ]
Total events: 17 (Conventional treatment), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Chi2 = 2.70, df = 1 (P = 0.10), I2 =63%
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Analysis 2.2. Comparison 2 Primary outcome - serious adverse events, Outcome 2 Anti-TNF alpha versus
placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 2 Anti-TNF alpha versus placebo
Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus placebo
Bachelez 2015 7/336 2/108 12.4 % 1.13 [ 0.24, 5.33 ]
Bagel 2012 0/62 0/62 Not estimable
Gottlieb 2003 2/57 2/55 8.1 % 0.96 [ 0.14, 6.61 ]
Gottlieb 2011 1/141 1/68 4.0 % 0.48 [ 0.03, 7.59 ]
Griffiths UNCOVER-2, 2015 8/358 2/168 12.7 % 1.88 [ 0.40, 8.74 ]
Griffiths UNCOVER-3, 2015 5/382 5/193 20.0 % 0.51 [ 0.15, 1.72 ]
Langley FIXTURE, 2014 6/326 2/327 11.9 % 3.01 [ 0.61, 14.80 ]
Reich LIBERATE, 2017 0/83 0/84 Not estimable
Strober 2011 2/139 1/72 5.3 % 1.04 [ 0.10, 11.23 ]
Tyring 2006 6/311 3/309 15.9 % 1.99 [ 0.50, 7.87 ]
Van de Kerkhof 2008 2/96 3/46 9.8 % 0.32 [ 0.06, 1.85 ]
Subtotal (95% CI) 2291 1492 100.0 % 1.06 [ 0.61, 1.83 ]
Total events: 39 (Anti-TNF), 21 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.54, df = 8 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
2 Adalimumab versus placebo
Asahina 2010 4/123 2/46 10.1 % 0.75 [ 0.14, 3.95 ]
Blauvelt VOYAGE-1, 2016 6/329 3/174 14.8 % 1.06 [ 0.27, 4.18 ]
Cai 2016 4/338 3/87 12.8 % 0.34 [ 0.08, 1.51 ]
Gordon 2006 5/96 0/52 3.4 % 6.01 [ 0.34, 106.60 ]
Gordon X-PLORE, 2015 1/43 1/42 3.7 % 0.98 [ 0.06, 15.11 ]
Menter REVEAL, 2008 15/814 7/398 35.4 % 1.05 [ 0.43, 2.55 ]
Reich VOYAGE-2, 2017 6/248 3/248 14.8 % 2.00 [ 0.51, 7.91 ]
Saurat CHAMPION, 2008 2/108 1/53 4.9 % 0.98 [ 0.09, 10.58 ]
Subtotal (95% CI) 2099 1100 100.0 % 1.02 [ 0.60, 1.73 ]
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(. . . Continued)
Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 43 (Anti-TNF), 20 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.71, df = 7 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
3 Certolizumab versus placebo
Reich 2012 3/118 3/58 100.0 % 0.49 [ 0.10, 2.36 ]
Subtotal (95% CI) 118 58 100.0 % 0.49 [ 0.10, 2.36 ]
Total events: 3 (Anti-TNF), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.38)
Test for subgroup differences: Chi2 = 0.83, df = 2 (P = 0.66), I2 =0.0%
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Analysis 2.3. Comparison 2 Primary outcome - serious adverse events, Outcome 3 Ustekinumab versus
placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 3 Ustekinumab versus placebo
Study or subgroup Ustekinumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Igarashi 2012 3/126 2/32 10.8 % 0.38 [ 0.07, 2.18 ]
Krueger 2007 9/256 1/64 7.9 % 2.25 [ 0.29, 17.44 ]
Lebwohl AMAGINE-2, 2015 2/300 3/309 10.4 % 0.69 [ 0.12, 4.08 ]
Lebwohl AMAGINE-3, 2015 4/313 8/315 23.3 % 0.50 [ 0.15, 1.65 ]
Leonardi PHOENIX-1, 2008 6/511 2/255 13.0 % 1.50 [ 0.30, 7.36 ]
Papp PHOENIX-2, 2008 13/820 4/410 26.6 % 1.63 [ 0.53, 4.95 ]
Tsai PEARL, 2011 0/61 2/60 3.6 % 0.20 [ 0.01, 4.01 ]
Zhu LOTUS, 2013 1/160 1/162 4.3 % 1.01 [ 0.06, 16.05 ]
Total (95% CI) 2547 1607 100.0 % 0.89 [ 0.50, 1.58 ]
Total events: 38 (Ustekinumab), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.17, df = 7 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Primary outcome - serious adverse events, Outcome 4 Anti-IL17 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 4 Anti-IL17 versus placebo
Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Secukinumab versus placebo
Blauvelt FEATURE, 2015 3/118 1/59 11.1 % 1.50 [ 0.16, 14.11 ]
Langley ERASURE, 2014 5/490 1/248 12.2 % 2.53 [ 0.30, 21.54 ]
Langley FIXTURE, 2014 13/654 2/327 25.4 % 3.25 [ 0.74, 14.32 ]
Papp 2013a 3/103 2/22 18.6 % 0.32 [ 0.06, 1.81 ]
Paul JUNCTURE, 2015 4/121 1/61 11.8 % 2.02 [ 0.23, 17.65 ]
Reich 2015 10/90 0/10 7.3 % 2.54 [ 0.16, 40.40 ]
Rich 2013 12/337 1/67 13.6 % 2.39 [ 0.32, 18.04 ]
Subtotal (95% CI) 1913 794 100.0 % 1.67 [ 0.79, 3.53 ]
Total events: 50 (Anti IL17), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.80, df = 6 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Ixekizumab versus placebo
Gordon UNCOVER-1, 2016 18/865 5/431 41.5 % 1.79 [ 0.67, 4.80 ]
Griffiths UNCOVER-2, 2015 13/698 2/168 18.4 % 1.56 [ 0.36, 6.87 ]
Griffiths UNCOVER-3, 2015 15/771 5/193 40.2 % 0.75 [ 0.28, 2.04 ]
Leonardi 2012 0/115 0/27 Not estimable
Subtotal (95% CI) 2449 819 100.0 % 1.23 [ 0.65, 2.32 ]
Total events: 46 (Anti IL17), 12 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.62, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
3 Brodalumab versus placebo
Lebwohl AMAGINE-2, 2015 19/1222 3/309 21.5 % 1.60 [ 0.48, 5.38 ]
Lebwohl AMAGINE-3, 2015 19/1253 8/315 47.3 % 0.60 [ 0.26, 1.35 ]
Nakagawa 2016 3/113 1/38 6.3 % 1.01 [ 0.11, 9.41 ]
Papp 2012 2/160 1/38 5.6 % 0.48 [ 0.04, 5.10 ]
Papp AMAGINE-1, 2016 10/441 3/220 19.3 % 1.66 [ 0.46, 5.98 ]
Subtotal (95% CI) 3189 920 100.0 % 0.92 [ 0.52, 1.61 ]
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(. . . Continued)
Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 53 (Anti IL17), 16 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.06, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 1.62, df = 2 (P = 0.44), I2 =0.0%
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Analysis 2.5. Comparison 2 Primary outcome - serious adverse events, Outcome 5 Anti-IL23 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 5 Anti-IL23 versus placebo
Study or subgroup Anti IL23 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Guselkumab versus placebo
Blauvelt VOYAGE-1, 2016 8/334 3/174 42.8 % 1.39 [ 0.37, 5.17 ]
Gordon X-PLORE, 2015 3/208 1/42 14.7 % 0.61 [ 0.06, 5.68 ]
Reich VOYAGE-2, 2017 8/496 3/248 42.5 % 1.33 [ 0.36, 4.98 ]
Subtotal (95% CI) 1038 464 100.0 % 1.21 [ 0.51, 2.85 ]
Total events: 19 (Anti IL23), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.67)
2 Tildrakizumab versus placebo
Papp 2015a 4/309 0/46 100.0 % 1.36 [ 0.07, 24.94 ]
Subtotal (95% CI) 309 46 100.0 % 1.36 [ 0.07, 24.94 ]
Total events: 4 (Anti IL23), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.94), I2 =0.0%
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Analysis 2.6. Comparison 2 Primary outcome - serious adverse events, Outcome 6 Other biologics.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 6 Other biologics
Study or subgroup Other Biologics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Alefacept versus placebo
Ellis 2001 0/170 0/59 Not estimable
Lebwohl 2003 15/339 10/168 100.0 % 0.74 [ 0.34, 1.62 ]
Subtotal (95% CI) 509 227 100.0 % 0.74 [ 0.34, 1.62 ]
Total events: 15 (Other Biologics), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Primary outcome - serious adverse events, Outcome 7 Biologic versus
conventional systemic treatments.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 7 Biologic versus conventional systemic treatments
Study or subgroup Biologic
Conventional
systemic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus acitretin
Caproni 2009 0/30 0/30 Not estimable
Subtotal (95% CI) 30 30 Not estimable
Total events: 0 (Biologic), 0 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Infliximab versus methotrexate
Barker RESTORE-1, 2011 44/653 6/215 100.0 % 2.41 [ 1.04, 5.59 ]
Subtotal (95% CI) 653 215 100.0 % 2.41 [ 1.04, 5.59 ]
Total events: 44 (Biologic), 6 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 2.06 (P = 0.039)
3 Adalimumab versus methotrexate
Saurat CHAMPION, 2008 2/108 1/110 100.0 % 2.04 [ 0.19, 22.14 ]
Subtotal (95% CI) 108 110 100.0 % 2.04 [ 0.19, 22.14 ]
Total events: 2 (Biologic), 1 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.90), I2 =0.0%
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Analysis 2.8. Comparison 2 Primary outcome - serious adverse events, Outcome 8 Biologic 1 versus
biologic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 8 Biologic 1 versus biologic 2
Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ustekinumab versus etanercept
Griffiths ACCEPT, 2010 8/556 4/347 100.0 % 1.25 [ 0.38, 4.11 ]
Subtotal (95% CI) 556 347 100.0 % 1.25 [ 0.38, 4.11 ]
Total events: 8 (Biologic 1), 4 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
2 Secukinumab versus etanercept
Langley FIXTURE, 2014 13/654 6/326 100.0 % 1.08 [ 0.41, 2.82 ]
Subtotal (95% CI) 654 326 100.0 % 1.08 [ 0.41, 2.82 ]
Total events: 13 (Biologic 1), 6 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
3 Ixekizumab versus etanercept
Griffiths UNCOVER-2, 2015 13/698 8/358 57.1 % 0.83 [ 0.35, 1.99 ]
Griffiths UNCOVER-3, 2015 15/771 5/382 42.9 % 1.49 [ 0.54, 4.06 ]
Subtotal (95% CI) 1469 740 100.0 % 1.07 [ 0.55, 2.06 ]
Total events: 28 (Biologic 1), 13 (Biologic 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
4 Secukinumab versus ustekinumab
Thaci CLEAR, 2015 10/337 10/339 100.0 % 1.01 [ 0.42, 2.39 ]
Subtotal (95% CI) 337 339 100.0 % 1.01 [ 0.42, 2.39 ]
Total events: 10 (Biologic 1), 10 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
5 Brodalumab versus ustekinumab
Lebwohl AMAGINE-2, 2015 19/1222 2/300 35.3 % 2.33 [ 0.55, 9.96 ]
Lebwohl AMAGINE-3, 2015 19/1253 4/313 64.7 % 1.19 [ 0.41, 3.46 ]
Subtotal (95% CI) 2475 613 100.0 % 1.51 [ 0.64, 3.56 ]
Total events: 38 (Biologic 1), 6 (Biologic 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
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(. . . Continued)
Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.93 (P = 0.35)
6 Guselkumab versus adalimumab
Blauvelt VOYAGE-1, 2016 8/334 6/329 45.1 % 1.31 [ 0.46, 3.74 ]
Gordon X-PLORE, 2015 3/208 1/43 9.9 % 0.62 [ 0.07, 5.82 ]
Reich VOYAGE-2, 2017 8/496 6/248 45.1 % 0.67 [ 0.23, 1.90 ]
Subtotal (95% CI) 1038 620 100.0 % 0.90 [ 0.44, 1.82 ]
Total events: 19 (Biologic 1), 13 (Biologic 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 0.92, df = 5 (P = 0.97), I2 =0.0%
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Analysis 2.9. Comparison 2 Primary outcome - serious adverse events, Outcome 9 Small molecules versus
placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 9 Small molecules versus placebo
Study or subgroup Small molecules Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Apremilast versus placebo
Papp 2012b 7/264 2/88 16.3 % 1.17 [ 0.25, 5.51 ]
Papp 2013b 2/173 4/87 14.0 % 0.25 [ 0.05, 1.35 ]
Papp ESTEEM-1, 2015 12/562 8/282 45.7 % 0.75 [ 0.31, 1.82 ]
Paul ESTEEM-2, 2015 5/275 3/138 19.4 % 0.84 [ 0.20, 3.45 ]
Reich LIBERATE, 2017 3/83 0/84 4.7 % 7.08 [ 0.37, 135.04 ]
Subtotal (95% CI) 1357 679 100.0 % 0.79 [ 0.41, 1.49 ]
Total events: 29 (Small molecules), 17 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 4.23, df = 4 (P = 0.38); I2 =5%
Test for overall effect: Z = 0.74 (P = 0.46)
2 Tofacitinib versus placebo
Bachelez 2015 12/662 2/108 20.7 % 0.98 [ 0.22, 4.31 ]
Krueger 2016 0/9 1/3 5.1 % 0.13 [ 0.01, 2.63 ]
Papp 2012a 4/147 0/50 5.4 % 3.10 [ 0.17, 56.61 ]
Papp OPT Pivotal-1, 2015 18/723 5/177 47.6 % 0.88 [ 0.33, 2.34 ]
Papp OPT Pivotal-2, 2015 16/763 2/196 21.3 % 2.06 [ 0.48, 8.86 ]
Subtotal (95% CI) 2304 534 100.0 % 1.05 [ 0.53, 2.06 ]
Total events: 50 (Small molecules), 10 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.35, df = 4 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
3 Ponesimod versus placebo
Vaclavkova 2014 10/259 1/67 100.0 % 2.59 [ 0.34, 19.85 ]
Subtotal (95% CI) 259 67 100.0 % 2.59 [ 0.34, 19.85 ]
Total events: 10 (Small molecules), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
Test for subgroup differences: Chi2 = 1.35, df = 2 (P = 0.51), I2 =0.0%
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Analysis 2.10. Comparison 2 Primary outcome - serious adverse events, Outcome 10 Biologic versus small
molecules.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 2 Primary outcome - serious adverse events
Outcome: 10 Biologic versus small molecules
Study or subgroup Biologic Small molecules Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus tofacitinib
Bachelez 2015 7/336 12/662 100.0 % 1.15 [ 0.46, 2.89 ]
Subtotal (95% CI) 336 662 100.0 % 1.15 [ 0.46, 2.89 ]
Total events: 7 (Biologic), 12 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.77)
2 Etanercept versus apremilast
Reich LIBERATE, 2017 1/83 3/83 100.0 % 0.33 [ 0.04, 3.14 ]
Subtotal (95% CI) 83 83 100.0 % 0.33 [ 0.04, 3.14 ]
Total events: 1 (Biologic), 3 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Chi2 = 1.00, df = 1 (P = 0.32), I2 =0%
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Analysis 3.1. Comparison 3 Secondary outcome - PASI 75, Outcome 1 Conventional systemic agents versus
placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 1 Conventional systemic agents versus placebo
Study or subgroup
Conventional
treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Methotrexate
Saurat CHAMPION, 2008 39/110 10/53 69.0 % 1.88 [ 1.02, 3.47 ]
Warren METOP, 2017 37/91 3/29 31.0 % 3.93 [ 1.31, 11.81 ]
Subtotal (95% CI) 201 82 100.0 % 2.36 [ 1.19, 4.68 ]
Total events: 76 (Conventional treatment), 13 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Fumaric acid esters
Mrowietz BRIDGE, 2016 210/566 20/138 100.0 % 2.56 [ 1.68, 3.89 ]
Subtotal (95% CI) 566 138 100.0 % 2.56 [ 1.68, 3.89 ]
Total events: 210 (Conventional treatment), 20 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.39 (P = 0.000011)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
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Analysis 3.2. Comparison 3 Secondary outcome - PASI 75, Outcome 2 Conventional systemic 1 versus
conventional systemic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 2 Conventional systemic 1 versus conventional systemic 2
Study or subgroup Conventional 1 Conventional 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ciclosporin versus methotrexate
Flytstro¨m 2008 18/43 9/41 33.6 % 1.91 [ 0.97, 3.75 ]
Heydendael 2003 30/44 26/44 66.4 % 1.15 [ 0.84, 1.59 ]
Subtotal (95% CI) 87 85 100.0 % 1.37 [ 0.84, 2.23 ]
Total events: 48 (Conventional 1), 35 (Conventional 2)
Heterogeneity: Tau2 = 0.07; Chi2 = 1.94, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 1.24 (P = 0.21)
2 Methotrexate versus fumaric acid esters
Fallah Arani 2011 6/30 5/30 100.0 % 1.20 [ 0.41, 3.51 ]
Subtotal (95% CI) 30 30 100.0 % 1.20 [ 0.41, 3.51 ]
Total events: 6 (Conventional 1), 5 (Conventional 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
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Analysis 3.3. Comparison 3 Secondary outcome - PASI 75, Outcome 3 Anti-TNF alpha versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 3 Anti-TNF alpha versus placebo
Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus placebo
Bachelez 2015 197/336 6/108 6.9 % 10.55 [ 4.82, 23.09 ]
Bagel 2012 36/62 3/62 3.4 % 12.00 [ 3.90, 36.92 ]
Gottlieb 2003 17/57 1/55 1.1 % 16.40 [ 2.26, 119.10 ]
Gottlieb 2011 79/141 5/68 5.8 % 7.62 [ 3.24, 17.94 ]
Griffiths UNCOVER-2, 2015 149/358 4/168 4.5 % 17.48 [ 6.59, 46.39 ]
Griffiths UNCOVER-3, 2015 204/382 14/193 15.4 % 7.36 [ 4.41, 12.30 ]
Langley FIXTURE, 2014 142/326 16/327 16.6 % 8.90 [ 5.43, 14.58 ]
Leonardi 2003 159/504 6/168 6.6 % 8.83 [ 3.98, 19.58 ]
Papp 2005 160/407 6/204 6.6 % 13.37 [ 6.02, 29.67 ]
Reich LIBERATE, 2017 40/83 10/84 10.7 % 4.05 [ 2.17, 7.55 ]
Strober 2011 55/139 5/72 5.6 % 5.70 [ 2.39, 13.60 ]
Tyring 2006 147/311 15/309 15.8 % 9.74 [ 5.86, 16.17 ]
Van de Kerkhof 2008 36/96 1/46 1.1 % 17.25 [ 2.44, 121.93 ]
Subtotal (95% CI) 3202 1864 100.0 % 8.55 [ 6.94, 10.52 ]
Total events: 1421 (Anti-TNF), 92 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 12.36, df = 12 (P = 0.42); I2 =3%
Test for overall effect: Z = 20.23 (P < 0.00001)
2 Adalimumab versus placebo
Asahina 2010 83/123 2/46 4.9 % 15.52 [ 3.98, 60.53 ]
Blauvelt VOYAGE-1, 2016 244/329 10/174 14.9 % 12.90 [ 7.05, 23.63 ]
Cai 2016 263/338 10/87 15.4 % 6.77 [ 3.77, 12.16 ]
Gordon 2006 64/96 2/52 4.9 % 17.33 [ 4.42, 67.96 ]
Gordon X-PLORE, 2015 30/43 1/42 2.6 % 29.30 [ 4.18, 205.23 ]
Menter REVEAL, 2008 578/814 26/398 21.5 % 10.87 [ 7.48, 15.80 ]
Reich VOYAGE-2, 2017 170/248 20/248 19.8 % 8.50 [ 5.54, 13.05 ]
Saurat CHAMPION, 2008 86/108 10/53 15.9 % 4.22 [ 2.40, 7.44 ]
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Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 2099 1100 100.0 % 9.08 [ 6.52, 12.65 ]
Total events: 1518 (Anti-TNF), 81 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 13.64, df = 7 (P = 0.06); I2 =49%
Test for overall effect: Z = 13.06 (P < 0.00001)
3 Certolizumab versus placebo
Reich 2012 92/118 4/58 100.0 % 11.31 [ 4.37, 29.24 ]
Subtotal (95% CI) 118 58 100.0 % 11.31 [ 4.37, 29.24 ]
Total events: 92 (Anti-TNF), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 5.00 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.38, df = 2 (P = 0.83), I2 =0.0%
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Analysis 3.4. Comparison 3 Secondary outcome - PASI 75, Outcome 4 Ustekinumab versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 4 Ustekinumab versus placebo
Study or subgroup Ustekinumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Igarashi 2012 80/126 2/32 5.4 % 10.16 [ 2.64, 39.12 ]
Krueger 2007 166/256 1/64 2.9 % 41.50 [ 5.92, 290.72 ]
Lebwohl AMAGINE-2, 2015 210/300 25/309 19.2 % 8.65 [ 5.90, 12.69 ]
Lebwohl AMAGINE-3, 2015 217/313 19/315 17.9 % 11.49 [ 7.39, 17.88 ]
Leonardi PHOENIX-1, 2008 341/511 8/255 12.9 % 21.27 [ 10.73, 42.19 ]
Papp PHOENIX-2, 2008 584/820 15/410 16.6 % 19.47 [ 11.82, 32.05 ]
Tsai PEARL, 2011 41/61 3/60 7.2 % 13.44 [ 4.40, 41.07 ]
Zhu LOTUS, 2013 132/160 18/162 17.9 % 7.43 [ 4.78, 11.54 ]
Total (95% CI) 2547 1607 100.0 % 12.41 [ 8.69, 17.71 ]
Total events: 1771 (Ustekinumab), 91 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 17.25, df = 7 (P = 0.02); I2 =59%
Test for overall effect: Z = 13.87 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 Secondary outcome - PASI 75, Outcome 5 Anti-IL17 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 5 Anti-IL17 versus placebo
Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Secukinumab versus placebo
Blauvelt FEATURE, 2015 86/118 0/59 1.4 % 87.23 [ 5.51, 1381.52 ]
Langley ERASURE, 2014 374/490 11/248 32.7 % 17.21 [ 9.64, 30.73 ]
Langley FIXTURE, 2014 468/654 16/327 47.7 % 14.63 [ 9.05, 23.64 ]
Papp 2013a 85/103 2/22 6.3 % 9.08 [ 2.41, 34.13 ]
Paul JUNCTURE, 2015 95/121 2/61 5.9 % 23.95 [ 6.11, 93.88 ]
Reich 2015 59/90 1/10 3.2 % 6.56 [ 1.02, 42.34 ]
Rich 2013 137/337 1/67 2.9 % 27.24 [ 3.88, 191.36 ]
Subtotal (95% CI) 1913 794 100.0 % 15.70 [ 11.27, 21.87 ]
Total events: 1304 (Anti IL17), 33 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.99, df = 6 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 16.28 (P < 0.00001)
2 Ixekizumab versus placebo
Gordon UNCOVER-1, 2016 743/865 17/431 36.1 % 21.78 [ 13.66, 34.73 ]
Griffiths UNCOVER-2, 2015 584/698 4/168 18.1 % 35.14 [ 13.34, 92.59 ]
Griffiths UNCOVER-3, 2015 661/771 14/193 34.4 % 11.82 [ 7.13, 19.59 ]
Leonardi 2012 78/115 2/27 11.4 % 9.16 [ 2.40, 34.95 ]
Subtotal (95% CI) 2449 819 100.0 % 17.44 [ 10.45, 29.10 ]
Total events: 2066 (Anti IL17), 37 (Placebo)
Heterogeneity: Tau2 = 0.13; Chi2 = 6.24, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 10.95 (P < 0.00001)
3 Brodalumab versus placebo
Lebwohl AMAGINE-2, 2015 934/1222 25/309 36.1 % 9.45 [ 6.48, 13.77 ]
Lebwohl AMAGINE-3, 2015 966/1253 19/315 32.7 % 12.78 [ 8.26, 19.78 ]
Nakagawa 2016 74/113 3/38 11.2 % 8.29 [ 2.78, 24.78 ]
Papp 2012 104/160 0/38 2.2 % 50.63 [ 3.22, 796.97 ]
Papp AMAGINE-1, 2016 317/441 6/220 17.9 % 26.36 [ 11.95, 58.15 ]
Subtotal (95% CI) 3189 920 100.0 % 12.80 [ 8.46, 19.36 ]
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(. . . Continued)
Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 2395 (Anti IL17), 53 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 7.13, df = 4 (P = 0.13); I2 =44%
Test for overall effect: Z = 12.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.97, df = 2 (P = 0.62), I2 =0.0%
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Analysis 3.6. Comparison 3 Secondary outcome - PASI 75, Outcome 6 Anti-IL23 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 6 Anti-IL23 versus placebo
Study or subgroup Anti IL23 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Guselkumab versus Placebo
Blauvelt VOYAGE-1, 2016 300/334 10/174 30.9 % 15.63 [ 8.55, 28.56 ]
Gordon X-PLORE, 2015 150/208 2/42 6.1 % 15.14 [ 3.91, 58.72 ]
Reich VOYAGE-2, 2017 428/496 20/248 63.0 % 10.70 [ 7.02, 16.31 ]
Subtotal (95% CI) 1038 464 100.0 % 12.28 [ 8.79, 17.17 ]
Total events: 878 (Anti IL23), 32 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.13, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 14.68 (P < 0.00001)
2 Tildrakizumab versus placebo
Papp 2015a 195/309 2/46 100.0 % 14.51 [ 3.73, 56.45 ]
Subtotal (95% CI) 309 46 100.0 % 14.51 [ 3.73, 56.45 ]
Total events: 195 (Anti IL23), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.86 (P = 0.00011)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 3.7. Comparison 3 Secondary outcome - PASI 75, Outcome 7 Other biologics.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 7 Other biologics
Study or subgroup Other Biologics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Alefacept versus placebo
Ellis 2001 48/170 6/59 42.2 % 2.78 [ 1.25, 6.15 ]
Lebwohl 2003 56/339 9/168 57.8 % 3.08 [ 1.56, 6.08 ]
Subtotal (95% CI) 509 227 100.0 % 2.95 [ 1.76, 4.94 ]
Total events: 104 (Other Biologics), 15 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 4.11 (P = 0.000040)
2 Itolizumab versus placebo
Krupashankar 2014 56/182 1/43 100.0 % 13.23 [ 1.88, 92.93 ]
Subtotal (95% CI) 182 43 100.0 % 13.23 [ 1.88, 92.93 ]
Total events: 56 (Other Biologics), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0094)
Test for subgroup differences: Chi2 = 2.13, df = 1 (P = 0.14), I2 =53%
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Analysis 3.8. Comparison 3 Secondary outcome - PASI 75, Outcome 8 Biologic versus conventional
systemic treatments.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 8 Biologic versus conventional systemic treatments
Study or subgroup Biologic
Conventional
systemic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus acitretin
Caproni 2009 17/30 8/30 100.0 % 2.13 [ 1.09, 4.16 ]
Subtotal (95% CI) 30 30 100.0 % 2.13 [ 1.09, 4.16 ]
Total events: 17 (Biologic), 8 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.028)
2 Alefacept versus methotrexate
Yan 2011 22/107 29/105 100.0 % 0.74 [ 0.46, 1.21 ]
Subtotal (95% CI) 107 105 100.0 % 0.74 [ 0.46, 1.21 ]
Total events: 22 (Biologic), 29 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
3 Infliximab versus methotrexate
Barker RESTORE-1, 2011 508/653 90/215 100.0 % 1.86 [ 1.58, 2.19 ]
Subtotal (95% CI) 653 215 100.0 % 1.86 [ 1.58, 2.19 ]
Total events: 508 (Biologic), 90 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 7.46 (P < 0.00001)
4 Adalimumab versus methotrexate
Saurat CHAMPION, 2008 86/108 39/110 100.0 % 2.25 [ 1.72, 2.94 ]
Subtotal (95% CI) 108 110 100.0 % 2.25 [ 1.72, 2.94 ]
Total events: 86 (Biologic), 39 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 5.88 (P < 0.00001)
Test for subgroup differences: Chi2 = 15.69, df = 3 (P = 0.00), I2 =81%
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Analysis 3.9. Comparison 3 Secondary outcome - PASI 75, Outcome 9 Biologic 1 versus biologic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 9 Biologic 1 versus biologic 2
Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ustekinumab versus etanercept
Griffiths ACCEPT, 2010 397/556 197/347 100.0 % 1.26 [ 1.13, 1.40 ]
Subtotal (95% CI) 556 347 100.0 % 1.26 [ 1.13, 1.40 ]
Total events: 397 (Biologic 1), 197 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 4.25 (P = 0.000022)
2 Secukinumab versus etanercept
Langley FIXTURE, 2014 468/654 142/326 100.0 % 1.64 [ 1.44, 1.88 ]
Subtotal (95% CI) 654 326 100.0 % 1.64 [ 1.44, 1.88 ]
Total events: 468 (Biologic 1), 142 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 7.33 (P < 0.00001)
3 Ixekizumab versus etanercept
Griffiths UNCOVER-2, 2015 584/698 149/358 48.4 % 2.01 [ 1.77, 2.28 ]
Griffiths UNCOVER-3, 2015 661/771 204/382 51.6 % 1.61 [ 1.46, 1.77 ]
Subtotal (95% CI) 1469 740 100.0 % 1.79 [ 1.43, 2.24 ]
Total events: 1245 (Biologic 1), 353 (Biologic 2)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.73, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 5.12 (P < 0.00001)
4 Secukinumab versus ustekinumab
Thaci CLEAR, 2015 311/337 277/339 100.0 % 1.13 [ 1.06, 1.20 ]
Subtotal (95% CI) 337 339 100.0 % 1.13 [ 1.06, 1.20 ]
Total events: 311 (Biologic 1), 277 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 4.04 (P = 0.000054)
5 Brodalumab versus ustekinumab
Lebwohl AMAGINE-2, 2015 934/1222 210/300 49.5 % 1.09 [ 1.01, 1.18 ]
Lebwohl AMAGINE-3, 2015 966/1253 217/313 50.5 % 1.11 [ 1.03, 1.20 ]
Subtotal (95% CI) 2475 613 100.0 % 1.10 [ 1.04, 1.17 ]
Total events: 1900 (Biologic 1), 427 (Biologic 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00076)
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Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Guselkumab versus adalimumab
Blauvelt VOYAGE-1, 2016 300/334 244/329 51.0 % 1.21 [ 1.13, 1.30 ]
Gordon X-PLORE, 2015 150/208 30/43 9.9 % 1.03 [ 0.83, 1.28 ]
Reich VOYAGE-2, 2017 428/496 170/248 39.1 % 1.26 [ 1.15, 1.38 ]
Subtotal (95% CI) 1038 620 100.0 % 1.21 [ 1.13, 1.30 ]
Total events: 878 (Biologic 1), 444 (Biologic 2)
Heterogeneity: Tau2 = 0.00; Chi2 = 2.77, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 5.31 (P < 0.00001)
Test for subgroup differences: Chi2 = 46.89, df = 5 (P = 0.00), I2 =89%
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Analysis 3.10. Comparison 3 Secondary outcome - PASI 75, Outcome 10 Small molecules versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 10 Small molecules versus placebo
Study or subgroup Small molecules Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Apremilast versus placebo
Papp 2012b 71/264 5/88 15.7 % 4.73 [ 1.97, 11.35 ]
Papp 2013b 30/173 9/87 19.5 % 1.68 [ 0.83, 3.37 ]
Papp ESTEEM-1, 2015 186/562 15/282 24.4 % 6.22 [ 3.75, 10.32 ]
Paul ESTEEM-2, 2015 79/275 8/138 19.5 % 4.96 [ 2.47, 9.96 ]
Reich LIBERATE, 2017 33/83 10/84 20.9 % 3.34 [ 1.76, 6.33 ]
Subtotal (95% CI) 1357 679 100.0 % 3.88 [ 2.42, 6.22 ]
Total events: 399 (Small molecules), 47 (Placebo)
Heterogeneity: Tau2 = 0.17; Chi2 = 10.02, df = 4 (P = 0.04); I2 =60%
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Study or subgroup Small molecules Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 5.61 (P < 0.00001)
2 Tofacitinib versus placebo
Bachelez 2015 340/662 6/108 22.1 % 9.24 [ 4.23, 20.19 ]
Krueger 2016 5/9 1/3 7.6 % 1.67 [ 0.30, 9.16 ]
Papp 2012a 65/147 1/50 6.0 % 22.11 [ 3.15, 155.20 ]
Papp OPT Pivotal-1, 2015 358/723 11/177 28.8 % 7.97 [ 4.47, 14.19 ]
Papp OPT Pivotal-2, 2015 396/763 22/196 35.5 % 4.62 [ 3.10, 6.90 ]
Subtotal (95% CI) 2304 534 100.0 % 6.41 [ 3.84, 10.71 ]
Total events: 1164 (Small molecules), 41 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 8.11, df = 4 (P = 0.09); I2 =51%
Test for overall effect: Z = 7.10 (P < 0.00001)
3 Ponesimod versus placebo
Vaclavkova 2014 122/259 9/67 100.0 % 3.51 [ 1.88, 6.53 ]
Subtotal (95% CI) 259 67 100.0 % 3.51 [ 1.88, 6.53 ]
Total events: 122 (Small molecules), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.96 (P = 0.000076)
Test for subgroup differences: Chi2 = 2.83, df = 2 (P = 0.24), I2 =29%
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Analysis 3.11. Comparison 3 Secondary outcome - PASI 75, Outcome 11 Biologic versus small molecules.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 3 Secondary outcome - PASI 75
Outcome: 11 Biologic versus small molecules
Study or subgroup Biologic Small molecules Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus Tofacitinib
Bachelez 2015 197/336 340/662 100.0 % 1.14 [ 1.02, 1.28 ]
Subtotal (95% CI) 336 662 100.0 % 1.14 [ 1.02, 1.28 ]
Total events: 197 (Biologic), 340 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
2 Etanercept versus apremilast
Reich LIBERATE, 2017 40/83 33/83 100.0 % 1.21 [ 0.86, 1.71 ]
Subtotal (95% CI) 83 83 100.0 % 1.21 [ 0.86, 1.71 ]
Total events: 40 (Biologic), 33 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 4.1. Comparison 4 Secondary outcome - PGA 0/1, Outcome 1 Conventional systemic agents
versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 1 Conventional systemic agents versus placebo
Study or subgroup
Conventional
treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Methotrexate
Saurat CHAMPION, 2008 33/110 6/53 74.5 % 2.65 [ 1.18, 5.93 ]
Warren METOP, 2017 25/91 2/29 25.5 % 3.98 [ 1.00, 15.81 ]
Subtotal (95% CI) 201 82 100.0 % 2.94 [ 1.47, 5.89 ]
Total events: 58 (Conventional treatment), 8 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.04 (P = 0.0024)
2 Fumaric acid esters
Mrowietz BRIDGE, 2016 190/566 17/138 100.0 % 2.73 [ 1.72, 4.32 ]
Subtotal (95% CI) 566 138 100.0 % 2.73 [ 1.72, 4.32 ]
Total events: 190 (Conventional treatment), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.27 (P = 0.000019)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.86), I2 =0.0%
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Analysis 4.2. Comparison 4 Secondary outcome - PGA 0/1, Outcome 2 Conventional systemic 1 versus
conventional systemic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 2 Conventional systemic 1 versus conventional systemic 2
Study or subgroup Conventional 1 Conventional 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ciclosporin versus methotrexate
Heydendael 2003 14/44 17/44 100.0 % 0.82 [ 0.47, 1.46 ]
Subtotal (95% CI) 44 44 100.0 % 0.82 [ 0.47, 1.46 ]
Total events: 14 (Conventional 1), 17 (Conventional 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Secondary outcome - PGA 0/1, Outcome 3 Anti-TNF alpha versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 3 Anti-TNF alpha versus placebo
Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus placebo
Bachelez 2015 222/336 16/108 21.0 % 4.46 [ 2.82, 7.06 ]
Bagel 2012 33/62 3/62 4.9 % 11.00 [ 3.56, 33.99 ]
Gottlieb 2011 56/141 2/68 3.4 % 13.50 [ 3.40, 53.70 ]
Griffiths UNCOVER-2, 2015 129/358 4/168 6.4 % 15.13 [ 5.69, 40.24 ]
Griffiths UNCOVER-3, 2015 159/382 13/193 16.9 % 6.18 [ 3.61, 10.59 ]
Langley FIXTURE, 2014 88/326 9/327 12.2 % 9.81 [ 5.03, 19.14 ]
Leonardi 2003 173/504 8/168 11.7 % 7.21 [ 3.63, 14.33 ]
Papp 2005 184/407 7/204 10.4 % 13.18 [ 6.31, 27.50 ]
Reich LIBERATE, 2017 24/83 3/84 4.7 % 8.10 [ 2.53, 25.86 ]
Strober 2011 41/139 3/72 4.9 % 7.08 [ 2.27, 22.07 ]
Van de Kerkhof 2008 37/96 2/46 3.4 % 8.86 [ 2.23, 35.19 ]
Subtotal (95% CI) 2834 1500 100.0 % 7.77 [ 5.98, 10.10 ]
Total events: 1146 (Anti-TNF), 70 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 11.88, df = 10 (P = 0.29); I2 =16%
Test for overall effect: Z = 15.32 (P < 0.00001)
2 Adalimumab versus placebo
Asahina 2010 76/123 4/46 7.6 % 7.11 [ 2.76, 18.31 ]
Blauvelt VOYAGE-1, 2016 220/329 12/174 16.4 % 9.70 [ 5.59, 16.83 ]
Cai 2016 272/338 13/87 18.2 % 5.39 [ 3.25, 8.92 ]
Gordon X-PLORE, 2015 25/43 3/42 5.7 % 8.14 [ 2.66, 24.93 ]
Menter REVEAL, 2008 506/814 17/398 19.7 % 14.55 [ 9.11, 23.24 ]
Reich VOYAGE-2, 2017 168/248 21/248 22.0 % 8.00 [ 5.27, 12.15 ]
Saurat CHAMPION, 2008 79/108 6/53 10.6 % 6.46 [ 3.02, 13.85 ]
Subtotal (95% CI) 2003 1048 100.0 % 8.38 [ 6.28, 11.18 ]
Total events: 1346 (Anti-TNF), 76 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 9.49, df = 6 (P = 0.15); I2 =37%
Test for overall effect: Z = 14.45 (P < 0.00001)
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Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 Certolizumab versus placebo
Reich 2012 73/118 1/58 100.0 % 35.88 [ 5.11, 251.73 ]
Subtotal (95% CI) 118 58 100.0 % 35.88 [ 5.11, 251.73 ]
Total events: 73 (Anti-TNF), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.60 (P = 0.00032)
Test for subgroup differences: Chi2 = 2.39, df = 2 (P = 0.30), I2 =16%
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Analysis 4.4. Comparison 4 Secondary outcome - PGA 0/1, Outcome 4 Ustekinumab versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 4 Ustekinumab versus placebo
Study or subgroup Ustekinumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Igarashi 2012 80/126 3/32 8.7 % 6.77 [ 2.29, 20.05 ]
Krueger 2007 165/256 0/64 2.1 % 83.72 [ 5.28, 1326.17 ]
Lebwohl AMAGINE-2, 2015 183/300 12/309 14.8 % 15.71 [ 8.95, 27.55 ]
Lebwohl AMAGINE-3, 2015 179/313 13/315 15.1 % 13.86 [ 8.07, 23.80 ]
Leonardi PHOENIX-1, 2008 312/511 10/255 14.2 % 15.57 [ 8.45, 28.70 ]
Papp PHOENIX-2, 2008 580/820 20/410 16.6 % 14.50 [ 9.44, 22.28 ]
Tsai PEARL, 2011 43/61 5/60 11.1 % 8.46 [ 3.60, 19.89 ]
Zhu LOTUS, 2013 126/160 24/162 17.3 % 5.32 [ 3.64, 7.76 ]
Total (95% CI) 2547 1607 100.0 % 11.33 [ 7.38, 17.39 ]
Total events: 1668 (Ustekinumab), 87 (Placebo)
Heterogeneity: Tau2 = 0.24; Chi2 = 24.91, df = 7 (P = 0.00079); I2 =72%
Test for overall effect: Z = 11.11 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 Secondary outcome - PGA 0/1, Outcome 5 Anti-IL17 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 5 Anti-IL17 versus placebo
Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Secukinumab versus placebo
Blauvelt FEATURE, 2015 72/118 0/59 7.2 % 73.11 [ 4.61, 1159.72 ]
Langley ERASURE, 2014 285/490 6/248 26.7 % 24.04 [ 10.87, 53.18 ]
Langley FIXTURE, 2014 369/654 9/327 29.0 % 20.50 [ 10.73, 39.18 ]
Papp 2013a 23/103 2/22 18.0 % 2.46 [ 0.62, 9.66 ]
Paul JUNCTURE, 2015 76/121 0/61 7.2 % 77.75 [ 4.90, 1233.42 ]
Rich 2013 83/337 1/67 11.9 % 16.50 [ 2.34, 116.48 ]
Subtotal (95% CI) 1823 784 100.0 % 17.16 [ 7.48, 39.36 ]
Total events: 908 (Anti IL17), 18 (Placebo)
Heterogeneity: Tau2 = 0.51; Chi2 = 11.49, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 6.71 (P < 0.00001)
2 Ixekizumab versus placebo
Gordon UNCOVER-1, 2016 684/865 14/431 33.7 % 24.34 [ 14.53, 40.80 ]
Griffiths UNCOVER-2, 2015 545/698 4/168 19.9 % 32.79 [ 12.44, 86.43 ]
Griffiths UNCOVER-3, 2015 601/771 13/193 33.4 % 11.57 [ 6.84, 19.59 ]
Leonardi 2012 69/115 2/27 13.0 % 8.10 [ 2.12, 30.99 ]
Subtotal (95% CI) 2449 819 100.0 % 17.46 [ 9.87, 30.90 ]
Total events: 1899 (Anti IL17), 33 (Placebo)
Heterogeneity: Tau2 = 0.18; Chi2 = 7.06, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 9.82 (P < 0.00001)
3 Brodalumab versus placebo
Lebwohl AMAGINE-2, 2015 835/1222 12/309 38.8 % 17.60 [ 10.09, 30.68 ]
Lebwohl AMAGINE-3, 2015 874/1253 13/315 42.1 % 16.90 [ 9.91, 28.82 ]
Nakagawa 2016 74/113 2/38 6.5 % 12.44 [ 3.21, 48.26 ]
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Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Papp 2012 104/160 1/38 3.2 % 24.70 [ 3.56, 171.42 ]
Papp AMAGINE-1, 2016 286/441 3/220 9.4 % 47.56 [ 15.43, 146.63 ]
Subtotal (95% CI) 3189 920 100.0 % 18.78 [ 13.29, 26.55 ]
Total events: 2173 (Anti IL17), 31 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.32, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 16.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.07, df = 2 (P = 0.97), I2 =0.0%
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Analysis 4.6. Comparison 4 Secondary outcome - PGA 0/1, Outcome 6 Anti-IL23 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 6 Anti-IL23 versus placebo
Study or subgroup Anti IL23 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Guselkumab versus placebo
Blauvelt VOYAGE-1, 2016 280/334 12/174 33.0 % 12.16 [ 7.03, 21.03 ]
Gordon X-PLORE, 2015 143/208 3/42 8.3 % 9.63 [ 3.22, 28.75 ]
Reich VOYAGE-2, 2017 417/496 21/248 58.7 % 9.93 [ 6.58, 14.98 ]
Subtotal (95% CI) 1038 464 100.0 % 10.59 [ 7.73, 14.51 ]
Total events: 840 (Anti IL23), 36 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 14.69 (P < 0.00001)
2 Tildrakizumab versus placebo
Papp 2015a 185/309 1/46 100.0 % 27.54 [ 3.95, 191.78 ]
Subtotal (95% CI) 309 46 100.0 % 27.54 [ 3.95, 191.78 ]
Total events: 185 (Anti IL23), 1 (Placebo)
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Study or subgroup Anti IL23 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00081)
Test for subgroup differences: Chi2 = 0.91, df = 1 (P = 0.34), I2 =0.0%
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Analysis 4.7. Comparison 4 Secondary outcome - PGA 0/1, Outcome 7 Other biologics.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 7 Other biologics
Study or subgroup Other Biologics Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Alefacept versus placebo
Lebwohl 2003 41/339 8/168 100.0 % 2.54 [ 1.22, 5.29 ]
Subtotal (95% CI) 339 168 100.0 % 2.54 [ 1.22, 5.29 ]
Total events: 41 (Other Biologics), 8 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
2 Itolizumab versus placebo
Krupashankar 2014 32/182 2/43 100.0 % 3.78 [ 0.94, 15.17 ]
Subtotal (95% CI) 182 43 100.0 % 3.78 [ 0.94, 15.17 ]
Total events: 32 (Other Biologics), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.061)
Test for subgroup differences: Chi2 = 0.25, df = 1 (P = 0.62), I2 =0.0%
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Analysis 4.8. Comparison 4 Secondary outcome - PGA 0/1, Outcome 8 Biologic versus conventional
systemic treatments.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 8 Biologic versus conventional systemic treatments
Study or subgroup Biologic
Conventional
systemic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Alefacept versus methotrexate
Yan 2011 14/107 20/105 100.0 % 0.69 [ 0.37, 1.29 ]
Subtotal (95% CI) 107 105 100.0 % 0.69 [ 0.37, 1.29 ]
Total events: 14 (Biologic), 20 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 Infliximab versus methotrexate
Barker RESTORE-1, 2011 496/653 82/215 100.0 % 1.99 [ 1.67, 2.37 ]
Subtotal (95% CI) 653 215 100.0 % 1.99 [ 1.67, 2.37 ]
Total events: 496 (Biologic), 82 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 7.69 (P < 0.00001)
3 Adalimumab versus methotrexate
Saurat CHAMPION, 2008 79/108 33/110 100.0 % 2.44 [ 1.79, 3.32 ]
Subtotal (95% CI) 108 110 100.0 % 2.44 [ 1.79, 3.32 ]
Total events: 79 (Biologic), 33 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 5.68 (P < 0.00001)
Test for subgroup differences: Chi2 = 12.69, df = 2 (P = 0.00), I2 =84%
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Analysis 4.9. Comparison 4 Secondary outcome - PGA 0/1, Outcome 9 Biologic 1 versus biologic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 9 Biologic 1 versus biologic 2
Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ustekinumab versus etanercept
Griffiths ACCEPT, 2010 381/556 170/347 100.0 % 1.40 [ 1.24, 1.58 ]
Subtotal (95% CI) 556 347 100.0 % 1.40 [ 1.24, 1.58 ]
Total events: 381 (Biologic 1), 170 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 5.42 (P < 0.00001)
2 Secukinumab versus etanercept
Langley FIXTURE, 2014 369/654 88/326 100.0 % 2.09 [ 1.73, 2.53 ]
Subtotal (95% CI) 654 326 100.0 % 2.09 [ 1.73, 2.53 ]
Total events: 369 (Biologic 1), 88 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 7.57 (P < 0.00001)
3 Ixekizumab versus etanercept
Griffiths UNCOVER-2, 2015 545/698 129/358 46.9 % 2.17 [ 1.88, 2.50 ]
Griffiths UNCOVER-3, 2015 601/771 159/382 53.1 % 1.87 [ 1.65, 2.12 ]
Subtotal (95% CI) 1469 740 100.0 % 2.01 [ 1.74, 2.31 ]
Total events: 1146 (Biologic 1), 288 (Biologic 2)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.27, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 9.54 (P < 0.00001)
4 Secukinumab versus ustekinumab
Thaci CLEAR, 2015 277/337 226/339 100.0 % 1.23 [ 1.13, 1.35 ]
Subtotal (95% CI) 337 339 100.0 % 1.23 [ 1.13, 1.35 ]
Total events: 277 (Biologic 1), 226 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 4.55 (P < 0.00001)
5 Brodalumab versus ustekinumab
Lebwohl AMAGINE-2, 2015 835/1222 183/300 51.6 % 1.12 [ 1.02, 1.24 ]
Lebwohl AMAGINE-3, 2015 874/1253 179/313 48.4 % 1.22 [ 1.10, 1.35 ]
Subtotal (95% CI) 2475 613 100.0 % 1.17 [ 1.07, 1.27 ]
Total events: 1709 (Biologic 1), 362 (Biologic 2)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 3.63 (P = 0.00028)
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Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
6 Guselkumab versus adalimumab
Blauvelt VOYAGE-1, 2016 280/334 220/329 49.6 % 1.25 [ 1.15, 1.37 ]
Gordon X-PLORE, 2015 143/208 25/43 5.5 % 1.18 [ 0.90, 1.55 ]
Reich VOYAGE-2, 2017 417/496 168/248 44.9 % 1.24 [ 1.13, 1.36 ]
Subtotal (95% CI) 1038 620 100.0 % 1.24 [ 1.17, 1.32 ]
Total events: 840 (Biologic 1), 413 (Biologic 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 6.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 69.86, df = 5 (P = 0.00), I2 =93%
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Analysis 4.10. Comparison 4 Secondary outcome - PGA 0/1, Outcome 10 Small molecules versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 10 Small molecules versus placebo
Study or subgroup Small molecules Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Apremilast versus placebo
Papp 2012b 59/264 11/88 29.5 % 1.79 [ 0.98, 3.25 ]
Papp ESTEEM-1, 2015 122/562 11/282 29.4 % 5.57 [ 3.05, 10.14 ]
Paul ESTEEM-2, 2015 56/275 6/138 24.2 % 4.68 [ 2.07, 10.60 ]
Reich LIBERATE, 2017 18/83 3/84 16.9 % 6.07 [ 1.86, 19.84 ]
Subtotal (95% CI) 1184 592 100.0 % 3.88 [ 2.04, 7.38 ]
Total events: 255 (Small molecules), 31 (Placebo)
Heterogeneity: Tau2 = 0.27; Chi2 = 8.71, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 4.12 (P = 0.000037)
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Study or subgroup Small molecules Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
2 Tofacitinib versus placebo
Bachelez 2015 380/662 16/108 28.4 % 3.87 [ 2.45, 6.12 ]
Krueger 2016 4/9 1/3 1.9 % 1.33 [ 0.23, 7.74 ]
Papp 2012a 51/147 5/50 8.0 % 3.47 [ 1.47, 8.20 ]
Papp OPT Pivotal-1, 2015 365/723 16/177 26.5 % 5.58 [ 3.48, 8.96 ]
Papp OPT Pivotal-2, 2015 394/763 21/196 35.2 % 4.82 [ 3.20, 7.26 ]
Subtotal (95% CI) 2304 534 100.0 % 4.48 [ 3.51, 5.71 ]
Total events: 1194 (Small molecules), 59 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.55, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 12.07 (P < 0.00001)
3 Ponesimod versus placebo
Vaclavkova 2014 78/259 3/67 100.0 % 6.73 [ 2.19, 20.64 ]
Subtotal (95% CI) 259 67 100.0 % 6.73 [ 2.19, 20.64 ]
Total events: 78 (Small molecules), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.33 (P = 0.00086)
Test for subgroup differences: Chi2 = 0.70, df = 2 (P = 0.71), I2 =0.0%
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Analysis 4.11. Comparison 4 Secondary outcome - PGA 0/1, Outcome 11 Biologic versus small molecules.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 4 Secondary outcome - PGA 0/1
Outcome: 11 Biologic versus small molecules
Study or subgroup Biologic Small molecules Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus tofacitinib
Bachelez 2015 222/336 380/662 100.0 % 1.15 [ 1.04, 1.27 ]
Subtotal (95% CI) 336 662 100.0 % 1.15 [ 1.04, 1.27 ]
Total events: 222 (Biologic), 380 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 2.73 (P = 0.0063)
2 Etanercept versus apremilast
Reich LIBERATE, 2017 24/83 18/83 100.0 % 1.33 [ 0.78, 2.27 ]
Subtotal (95% CI) 83 83 100.0 % 1.33 [ 0.78, 2.27 ]
Total events: 24 (Biologic), 18 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Chi2 = 0.29, df = 1 (P = 0.59), I2 =0.0%
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Analysis 5.1. Comparison 5 Secondary outcome - quality of life, Outcome 1 Conventional systemic agents
versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 1 Conventional systemic agents versus placebo
Study or subgroup
Conventional
systemic Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Methotrexate
Saurat CHAMPION, 2008 110 -5.7 (6.1) 53 -3.4 (9.63) 52.0 % -0.31 [ -0.64, 0.02 ]
Warren METOP, 2017 91 -9.4 (6.58) 29 -2.6 (5.83) 48.0 % -1.05 [ -1.49, -0.61 ]
Subtotal (95% CI) 201 82 100.0 % -0.67 [ -1.40, 0.06 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 7.08, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Secondary outcome - quality of life, Outcome 2 Anti-TNF alpha versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 2 Anti-TNF alpha versus placebo
Study or subgroup anti TNF Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Etanercept versus placebo
Bachelez 2015 336 -8.97 (7.33) 108 -1.85 (6.86) 14.8 % -0.98 [ -1.21, -0.76 ]
Gottlieb 2011 141 -8.01 (6.18) 68 -3.3 (6) 13.7 % -0.77 [ -1.07, -0.47 ]
Griffiths UNCOVER-2, 2015 358 -7.7 (5.68) 168 -2 (5.18) 15.2 % -1.03 [ -1.22, -0.84 ]
Griffiths UNCOVER-3, 2015 382 -8 (3.91) 193 -1.7 (4.17) 15.2 % -1.57 [ -1.77, -1.38 ]
Leonardi 2003 504 -6.37 (6.02) 168 -1.4 (7.96) 15.4 % -0.76 [ -0.94, -0.58 ]
Strober 2011 139 -9.09 (7.43) 72 -2.89 (5.69) 13.7 % -0.90 [ -1.19, -0.60 ]
Van de Kerkhof 2008 96 -7.4 (5.34) 46 1.2 (3.53) 12.0 % -1.77 [ -2.18, -1.36 ]
Subtotal (95% CI) 1956 823 100.0 % -1.10 [ -1.37, -0.83 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 54.36, df = 6 (P<0.00001); I2 =89%
Test for overall effect: Z = 7.95 (P < 0.00001)
2 Adalimumab versus placebo
Asahina 2010 123 -5.3 (5.9) 46 1 (6.9) 10.2 % -1.01 [ -1.37, -0.66 ]
Blauvelt VOYAGE-1, 2016 329 -9.3 (7.8) 174 -0.6 (6.36) 18.6 % -1.18 [ -1.38, -0.99 ]
Gordon 2006 96 -11.2 (7.7) 52 -1.3 (7.36) 9.7 % -1.30 [ -1.67, -0.93 ]
Gordon X-PLORE, 2015 43 -10.1 (8.9) 42 -2.3 (6.8) 7.3 % -0.97 [ -1.43, -0.52 ]
Menter REVEAL, 2008 814 -8.4 (6.55) 398 -1.9 (6.62) 23.9 % -0.99 [ -1.11, -0.86 ]
Reich VOYAGE-2, 2017 248 -9.7 (6.8) 248 -2.6 (6.9) 19.4 % -1.03 [ -1.22, -0.85 ]
Saurat CHAMPION, 2008 108 -9.1 (10.92) 53 -3.4 (9.63) 11.0 % -0.54 [ -0.87, -0.21 ]
Subtotal (95% CI) 1761 1013 100.0 % -1.02 [ -1.16, -0.88 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 13.09, df = 6 (P = 0.04); I2 =54%
Test for overall effect: Z = 14.22 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.60), I2 =0.0%
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Analysis 5.3. Comparison 5 Secondary outcome - quality of life, Outcome 3 Ustekinumab versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 3 Ustekinumab versus placebo
Study or subgroup Ustekinumab Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Igarashi 2012 126 -7.7 (6.5) 32 -0.3 (5.3) 11.1 % -1.17 [ -1.58, -0.76 ]
Krueger 2007 256 -8.95 (8.4) 64 -2.2 (4.2) 15.8 % -0.87 [ -1.15, -0.59 ]
Leonardi PHOENIX-1, 2008 511 -8.4 (6.7) 255 -0.6 (5.97) 21.3 % -1.21 [ -1.37, -1.04 ]
Papp PHOENIX-2, 2008 820 -9.7 (6.9) 410 -0.5 (5.66) 22.6 % -1.41 [ -1.54, -1.28 ]
Tsai PEARL, 2011 61 -11.2 (7.1) 60 -0.5 (6.5) 11.1 % -1.56 [ -1.97, -1.15 ]
Zhu LOTUS, 2013 160 -9.3 (7.18) 162 -1.9 (6.63) 18.0 % -1.07 [ -1.30, -0.83 ]
Total (95% CI) 1934 983 100.0 % -1.21 [ -1.39, -1.03 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 17.81, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 13.10 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Secondary outcome - quality of life, Outcome 4 Anti-IL17 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 4 Anti-IL17 versus placebo
Study or subgroup Anti IL17 Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Ixekizumab versus placebo
Gordon UNCOVER-1, 2016 865 -10.9 (5.5) 431 -1 (5.6) 34.4 % -1.79 [ -1.92, -1.65 ]
Griffiths UNCOVER-2, 2015 698 -9.9 (5.6) 168 -2 (5.18) 32.8 % -1.43 [ -1.61, -1.25 ]
Griffiths UNCOVER-3, 2015 771 -9.9 (3.9) 193 -1.7 (4.17) 32.8 % -2.07 [ -2.25, -1.89 ]
Subtotal (95% CI) 2334 792 100.0 % -1.76 [ -2.09, -1.43 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 24.02, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 10.45 (P < 0.00001)
2 Brodalumab versus placebo
Nakagawa 2016 113 -7.1 (7.3) 38 -2 (6.7) 49.9 % -0.71 [ -1.09, -0.33 ]
Papp 2012 160 3.6 (4.95) 38 10.3 (7.6) 50.1 % -1.20 [ -1.58, -0.83 ]
Subtotal (95% CI) 273 76 100.0 % -0.96 [ -1.44, -0.47 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 3.33, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 3.87 (P = 0.00011)
Test for subgroup differences: Chi2 = 7.27, df = 1 (P = 0.01), I2 =86%
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Analysis 5.5. Comparison 5 Secondary outcome - quality of life, Outcome 5 Anti-IL23 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 5 Anti-IL23 versus placebo
Study or subgroup Anti IL23 Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Guselkumab versus placebo
Blauvelt VOYAGE-1, 2016 334 -11.2 (7.24) 174 -0.6 (6.36) 46.9 % -1.52 [ -1.73, -1.32 ]
Reich VOYAGE-2, 2017 496 -11.3 (6.8) 248 -2.6 (6.9) 53.1 % -1.27 [ -1.44, -1.11 ]
Subtotal (95% CI) 830 422 100.0 % -1.39 [ -1.63, -1.14 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.46, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 11.11 (P < 0.00001)
2 Tildrakizumab versus placebo
Papp 2015a 309 -8.3 (7.6) 46 1 (7.1) 100.0 % -1.23 [ -1.55, -0.91 ]
Subtotal (95% CI) 309 46 100.0 % -1.23 [ -1.55, -0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.59, df = 1 (P = 0.44), I2 =0.0%
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Analysis 5.6. Comparison 5 Secondary outcome - quality of life, Outcome 6 Other biologics.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 6 Other biologics
Study or subgroup Other biologics Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Alefacept versus placebo
Ellis 2001 170 -3.9 (6.9) 59 -1.7 (6.9) 100.0 % -0.32 [ -0.62, -0.02 ]
Subtotal (95% CI) 170 59 100.0 % -0.32 [ -0.62, -0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.036)
2 Itolizumab versus placebo
Krupashankar 2014 182 -5.5 (6.4) 43 -3.2 (7.8) 100.0 % -0.34 [ -0.68, -0.01 ]
Subtotal (95% CI) 182 43 100.0 % -0.34 [ -0.68, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
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Analysis 5.7. Comparison 5 Secondary outcome - quality of life, Outcome 7 Biologic versus conventional
systemic treatments.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 7 Biologic versus conventional systemic treatments
Study or subgroup Biologics
Conventional
systemic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Alefacept versus methotrexate
Yan 2011 107 -2.49 (5.91) 105 -3.8 (5.87) 100.0 % 1.31 [ -0.28, 2.90 ]
Subtotal (95% CI) 107 105 100.0 % 1.31 [ -0.28, 2.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
2 Adalimumab versus methotrexate
Saurat CHAMPION, 2008 108 -9.1 (10.92) 110 -5.7 (6.1) 100.0 % -3.40 [ -5.75, -1.05 ]
Subtotal (95% CI) 108 110 100.0 % -3.40 [ -5.75, -1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Chi2 = 10.58, df = 1 (P = 0.00), I2 =91%
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Analysis 5.8. Comparison 5 Secondary outcome - quality of life, Outcome 8 Biologic 1 versus biologic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 8 Biologic 1 versus biologic 2
Study or subgroup Biologic 1 Biologic 2
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Ixekizumab versus etanercept
Griffiths UNCOVER-2, 2015 698 -9.9 (5.6) 358 -7.7 (5.68) 30.7 % -2.20 [ -2.92, -1.48 ]
Griffiths UNCOVER-3, 2015 771 -9.9 (3.9) 382 -8 (3.91) 69.3 % -1.90 [ -2.38, -1.42 ]
Subtotal (95% CI) 1469 740 100.0 % -1.99 [ -2.39, -1.59 ]
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 9.79 (P < 0.00001)
2 Guselkumab versus adalimumab
Blauvelt VOYAGE-1, 2016 334 -11.2 (7.24) 329 -9.3 (7.8) 45.0 % -1.90 [ -3.05, -0.75 ]
Reich VOYAGE-2, 2017 496 -11.3 (6.8) 248 -9.7 (6.8) 55.0 % -1.60 [ -2.64, -0.56 ]
Subtotal (95% CI) 830 577 100.0 % -1.73 [ -2.50, -0.97 ]
Heterogeneity: Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 4.42 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
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Analysis 5.9. Comparison 5 Secondary outcome - quality of life, Outcome 9 Small molecules versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 9 Small molecules versus placebo
Study or subgroup Small molecules Placebo
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Apremilast versus placebo
Papp 2012b 264 -4.5 (6.02) 88 -1.9 (5.91) 25.5 % -0.43 [ -0.68, -0.19 ]
Papp ESTEEM-1, 2015 562 -6.6 (6.66) 282 -2.1 (5.69) 43.8 % -0.71 [ -0.85, -0.56 ]
Paul ESTEEM-2, 2015 275 -6.7 (6.14) 138 -2.7 (6.23) 30.8 % -0.65 [ -0.86, -0.44 ]
Subtotal (95% CI) 1101 508 100.0 % -0.62 [ -0.77, -0.47 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.60, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 8.00 (P < 0.00001)
2 Tofacitinib versus placebo
Bachelez 2015 662 -8.5 (7.6) 108 -1.85 (6.86) 30.6 % -0.89 [ -1.09, -0.68 ]
Papp OPT Pivotal-1, 2015 723 -7.9 (4.9) 177 -1.9 (4.4) 34.2 % -1.25 [ -1.42, -1.07 ]
Papp OPT Pivotal-2, 2015 763 -8.1 (4.9) 196 -2.8 (4.44) 35.2 % -1.10 [ -1.27, -0.94 ]
Subtotal (95% CI) 2148 481 100.0 % -1.09 [ -1.28, -0.89 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.82, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 10.99 (P < 0.00001)
3 Ponesimod versus placebo
Vaclavkova 2014 259 -6.1 (6.2) 67 -2.5 (5.9) 100.0 % -0.58 [ -0.86, -0.31 ]
Subtotal (95% CI) 259 67 100.0 % -0.58 [ -0.86, -0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.21 (P = 0.000026)
Test for subgroup differences: Chi2 = 15.76, df = 2 (P = 0.00), I2 =87%
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Analysis 5.10. Comparison 5 Secondary outcome - quality of life, Outcome 10 Biologic versus small
molecules.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 5 Secondary outcome - quality of life
Outcome: 10 Biologic versus small molecules
Study or subgroup Biologic Samll molecules
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Etanercept versus Tofacitinib
Bachelez 2015 336 -8.97 (7.33) 662 -8.5 (7.6) 100.0 % -0.06 [ -0.19, 0.07 ]
Subtotal (95% CI) 336 662 100.0 % -0.06 [ -0.19, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Secondary outcome - adverse events, Outcome 1 Conventional systemic agents
versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 1 Conventional systemic agents versus placebo
Study or subgroup
Conventional
treatment Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Methotrexate
Saurat CHAMPION, 2008 89/110 42/53 45.3 % 1.02 [ 0.87, 1.20 ]
Warren METOP, 2017 75/91 27/29 54.7 % 0.89 [ 0.77, 1.02 ]
Subtotal (95% CI) 201 82 100.0 % 0.94 [ 0.81, 1.10 ]
Total events: 164 (Conventional treatment), 69 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Fumaric acid esters
Mrowietz BRIDGE, 2016 472/566 82/138 100.0 % 1.40 [ 1.22, 1.62 ]
Subtotal (95% CI) 566 138 100.0 % 1.40 [ 1.22, 1.62 ]
Total events: 472 (Conventional treatment), 82 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 14.15, df = 1 (P = 0.00), I2 =93%
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Analysis 6.2. Comparison 6 Secondary outcome - adverse events, Outcome 2 Conventional systemic 1
versus conventional systemic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 2 Conventional systemic 1 versus conventional systemic 2
Study or subgroup Conventional 1 Conventional 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ciclosporin versus methotrexate
Flytstro¨m 2008 30/43 29/41 46.8 % 0.99 [ 0.75, 1.30 ]
Heydendael 2003 35/44 29/44 53.2 % 1.21 [ 0.93, 1.57 ]
Subtotal (95% CI) 87 85 100.0 % 1.10 [ 0.90, 1.34 ]
Total events: 65 (Conventional 1), 58 (Conventional 2)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.08, df = 1 (P = 0.30); I2 =7%
Test for overall effect: Z = 0.93 (P = 0.35)
2 Methotrexate versus fumaric acid esters
Fallah Arani 2011 27/30 24/30 100.0 % 1.13 [ 0.91, 1.39 ]
Subtotal (95% CI) 30 30 100.0 % 1.13 [ 0.91, 1.39 ]
Total events: 27 (Conventional 1), 24 (Conventional 2)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Test for subgroup differences: Chi2 = 0.03, df = 1 (P = 0.87), I2 =0.0%
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Analysis 6.3. Comparison 6 Secondary outcome - adverse events, Outcome 3 Anti-TNF alpha versus
placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 3 Anti-TNF alpha versus placebo
Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus placebo
Bachelez 2015 192/336 55/108 11.1 % 1.12 [ 0.91, 1.38 ]
Bagel 2012 32/62 34/62 4.4 % 0.94 [ 0.68, 1.31 ]
Gottlieb 2011 76/141 31/68 5.3 % 1.18 [ 0.87, 1.60 ]
Griffiths UNCOVER-2, 2015 211/358 89/168 17.2 % 1.11 [ 0.94, 1.31 ]
Griffiths UNCOVER-3, 2015 187/382 70/193 10.5 % 1.35 [ 1.09, 1.67 ]
Langley FIXTURE, 2014 186/326 163/327 23.1 % 1.14 [ 0.99, 1.32 ]
Reich LIBERATE, 2017 44/83 50/84 6.6 % 0.89 [ 0.68, 1.16 ]
Strober 2011 69/139 32/72 5.0 % 1.12 [ 0.82, 1.52 ]
Tyring 2006 153/311 137/309 16.8 % 1.11 [ 0.94, 1.31 ]
Subtotal (95% CI) 2138 1391 100.0 % 1.12 [ 1.05, 1.20 ]
Total events: 1150 (Anti-TNF), 661 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.08, df = 8 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.27 (P = 0.0011)
2 Adalimumab versus placebo
Asahina 2010 115/123 41/46 28.4 % 1.05 [ 0.94, 1.17 ]
Blauvelt VOYAGE-1, 2016 170/329 86/174 10.5 % 1.05 [ 0.87, 1.26 ]
Cai 2016 158/338 37/87 4.8 % 1.10 [ 0.84, 1.44 ]
Gordon X-PLORE, 2015 24/43 22/42 2.3 % 1.07 [ 0.72, 1.58 ]
Menter REVEAL, 2008 506/814 221/398 33.1 % 1.12 [ 1.01, 1.24 ]
Reich VOYAGE-2, 2017 120/248 111/248 9.9 % 1.08 [ 0.90, 1.31 ]
Saurat CHAMPION, 2008 79/108 42/53 11.0 % 0.92 [ 0.77, 1.10 ]
Subtotal (95% CI) 2003 1048 100.0 % 1.06 [ 1.00, 1.13 ]
Total events: 1172 (Anti-TNF), 560 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.75, df = 6 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.045)
3 Certolizumab versus placebo
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(. . . Continued)
Study or subgroup Anti-TNF Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Reich 2012 83/118 41/58 100.0 % 1.00 [ 0.81, 1.22 ]
Subtotal (95% CI) 118 58 100.0 % 1.00 [ 0.81, 1.22 ]
Total events: 83 (Anti-TNF), 41 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 2.09, df = 2 (P = 0.35), I2 =4%
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Analysis 6.4. Comparison 6 Secondary outcome - adverse events, Outcome 4 Ustekinumab versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 4 Ustekinumab versus placebo
Study or subgroup Ustekinumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Igarashi 2012 79/126 21/32 4.4 % 0.96 [ 0.72, 1.27 ]
Krueger 2007 200/256 48/64 14.7 % 1.04 [ 0.89, 1.22 ]
Lebwohl AMAGINE-2, 2015 177/300 165/309 18.0 % 1.10 [ 0.96, 1.27 ]
Lebwohl AMAGINE-3, 2015 168/313 152/315 15.0 % 1.11 [ 0.95, 1.30 ]
Leonardi PHOENIX-1, 2008 277/511 122/255 15.6 % 1.13 [ 0.97, 1.32 ]
Papp PHOENIX-2, 2008 412/820 202/410 24.9 % 1.02 [ 0.90, 1.15 ]
Tsai PEARL, 2011 40/61 42/60 5.9 % 0.94 [ 0.73, 1.20 ]
Zhu LOTUS, 2013 29/160 22/162 1.4 % 1.33 [ 0.80, 2.22 ]
Total (95% CI) 2547 1607 100.0 % 1.06 [ 1.00, 1.13 ]
Total events: 1382 (Ustekinumab), 774 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.23, df = 7 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Secondary outcome - adverse events, Outcome 5 Anti-IL17 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 5 Anti-IL17 versus placebo
Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Secukinumab versus placebo
Blauvelt FEATURE, 2015 64/118 28/59 10.1 % 1.14 [ 0.83, 1.57 ]
Langley ERASURE, 2014 283/490 116/248 23.7 % 1.23 [ 1.06, 1.44 ]
Langley FIXTURE, 2014 372/654 163/327 27.1 % 1.14 [ 1.00, 1.30 ]
Papp 2013a 51/103 8/22 3.6 % 1.36 [ 0.76, 2.45 ]
Paul JUNCTURE, 2015 81/121 33/61 13.1 % 1.24 [ 0.95, 1.61 ]
Reich 2015 71/90 3/10 1.4 % 2.63 [ 1.01, 6.82 ]
Rich 2013 221/337 47/67 21.1 % 0.93 [ 0.79, 1.11 ]
Subtotal (95% CI) 1913 794 100.0 % 1.15 [ 1.02, 1.29 ]
Total events: 1143 (Anti IL17), 398 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.09, df = 6 (P = 0.12); I2 =41%
Test for overall effect: Z = 2.33 (P = 0.020)
2 Ixekizumab versus placebo
Gordon UNCOVER-1, 2016 320/865 122/431 28.4 % 1.31 [ 1.10, 1.55 ]
Griffiths UNCOVER-2, 2015 420/698 89/168 30.7 % 1.14 [ 0.97, 1.33 ]
Griffiths UNCOVER-3, 2015 420/771 70/193 25.7 % 1.50 [ 1.23, 1.83 ]
Leonardi 2012 72/115 17/27 15.2 % 0.99 [ 0.72, 1.37 ]
Subtotal (95% CI) 2449 819 100.0 % 1.24 [ 1.07, 1.45 ]
Total events: 1232 (Anti IL17), 298 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.24, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 2.76 (P = 0.0058)
3 Brodalumab versus placebo
Lebwohl AMAGINE-2, 2015 719/1222 165/309 29.9 % 1.10 [ 0.98, 1.24 ]
Lebwohl AMAGINE-3, 2015 682/1253 152/315 28.7 % 1.13 [ 1.00, 1.28 ]
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(. . . Continued)
Study or subgroup Anti IL17 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nakagawa 2016 69/113 1/38 0.5 % 23.20 [ 3.34, 161.40 ]
Papp 2012 116/160 23/38 15.0 % 1.20 [ 0.91, 1.58 ]
Papp AMAGINE-1, 2016 257/441 112/220 25.8 % 1.14 [ 0.98, 1.33 ]
Subtotal (95% CI) 3189 920 100.0 % 1.15 [ 1.00, 1.32 ]
Total events: 1843 (Anti IL17), 453 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.75, df = 4 (P = 0.03); I2 =63%
Test for overall effect: Z = 2.02 (P = 0.043)
Test for subgroup differences: Chi2 = 0.77, df = 2 (P = 0.68), I2 =0.0%
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Analysis 6.6. Comparison 6 Secondary outcome - adverse events, Outcome 6 Anti-IL23 versus placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 6 Anti-IL23 versus placebo
Study or subgroup Anti IL23 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Guselkumab versus placebo
Blauvelt VOYAGE-1, 2016 170/334 86/174 39.3 % 1.03 [ 0.86, 1.24 ]
Gordon X-PLORE, 2015 103/208 22/42 13.0 % 0.95 [ 0.69, 1.30 ]
Reich VOYAGE-2, 2017 235/496 111/248 47.7 % 1.06 [ 0.90, 1.25 ]
Subtotal (95% CI) 1038 464 100.0 % 1.03 [ 0.92, 1.16 ]
Total events: 508 (Anti IL23), 219 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
2 Tildrakizumab versus placebo
Papp 2015a 198/309 31/46 100.0 % 0.95 [ 0.76, 1.18 ]
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(. . . Continued)
Study or subgroup Anti IL23 Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 309 46 100.0 % 0.95 [ 0.76, 1.18 ]
Total events: 198 (Anti IL23), 31 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.51), I2 =0.0%
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Analysis 6.7. Comparison 6 Secondary outcome - adverse events, Outcome 7 Biologic versus conventional
systemic treatments.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 7 Biologic versus conventional systemic treatments
Study or subgroup Biologic
Conventional
systemic Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Infliximab versus methotrexate
Barker RESTORE-1, 2011 466/653 142/215 100.0 % 1.08 [ 0.97, 1.20 ]
Subtotal (95% CI) 653 215 100.0 % 1.08 [ 0.97, 1.20 ]
Total events: 466 (Biologic), 142 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 Adalimumab versus methotrexate
Saurat CHAMPION, 2008 79/108 89/110 100.0 % 0.90 [ 0.78, 1.05 ]
Subtotal (95% CI) 108 110 100.0 % 0.90 [ 0.78, 1.05 ]
Total events: 79 (Biologic), 89 (Conventional systemic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Chi2 = 3.72, df = 1 (P = 0.05), I2 =73%
0.01 0.1 1 10 100
Favours Biologics Favours Conventional
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Analysis 6.8. Comparison 6 Secondary outcome - adverse events, Outcome 8 Biologic 1 versus biologic 2.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 8 Biologic 1 versus biologic 2
Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Ustekinumab versus etanercept
Griffiths ACCEPT, 2010 378/556 243/347 100.0 % 0.97 [ 0.89, 1.06 ]
Subtotal (95% CI) 556 347 100.0 % 0.97 [ 0.89, 1.06 ]
Total events: 378 (Biologic 1), 243 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
2 Secukinumab versus etanercept
Langley FIXTURE, 2014 372/654 186/326 100.0 % 1.00 [ 0.89, 1.12 ]
Subtotal (95% CI) 654 326 100.0 % 1.00 [ 0.89, 1.12 ]
Total events: 372 (Biologic 1), 186 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
3 Ixekizumab versus etanercept
Griffiths UNCOVER-2, 2015 420/698 211/358 56.1 % 1.02 [ 0.92, 1.13 ]
Griffiths UNCOVER-3, 2015 420/771 187/382 43.9 % 1.11 [ 0.99, 1.26 ]
Subtotal (95% CI) 1469 740 100.0 % 1.06 [ 0.97, 1.15 ]
Total events: 840 (Biologic 1), 398 (Biologic 2)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.12, df = 1 (P = 0.29); I2 =11%
Test for overall effect: Z = 1.36 (P = 0.17)
4 Secukinumab versus ustekinumab
Thaci CLEAR, 2015 215/337 196/339 100.0 % 1.10 [ 0.98, 1.25 ]
Subtotal (95% CI) 337 339 100.0 % 1.10 [ 0.98, 1.25 ]
Total events: 215 (Biologic 1), 196 (Biologic 2)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
5 Brodalumab versus ustekinumab
Lebwohl AMAGINE-2, 2015 719/1222 177/300 54.3 % 1.00 [ 0.90, 1.11 ]
0.01 0.1 1 10 100
Favours Biologic 1 Favours Biologic 2
(Continued . . . )
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(. . . Continued)
Study or subgroup Biologic 1 Biologic 2 Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lebwohl AMAGINE-3, 2015 682/1253 168/313 45.7 % 1.01 [ 0.90, 1.14 ]
Subtotal (95% CI) 2475 613 100.0 % 1.00 [ 0.93, 1.09 ]
Total events: 1401 (Biologic 1), 345 (Biologic 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
6 Guselkumab versus adalimumab
Blauvelt VOYAGE-1, 2016 170/334 170/329 47.1 % 0.99 [ 0.85, 1.14 ]
Gordon X-PLORE, 2015 103/208 24/43 11.6 % 0.89 [ 0.66, 1.20 ]
Reich VOYAGE-2, 2017 235/496 120/248 41.3 % 0.98 [ 0.84, 1.15 ]
Subtotal (95% CI) 1038 620 100.0 % 0.97 [ 0.88, 1.07 ]
Total events: 508 (Biologic 1), 314 (Biologic 2)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
Test for subgroup differences: Chi2 = 4.69, df = 5 (P = 0.46), I2 =0.0%
0.01 0.1 1 10 100
Favours Biologic 1 Favours Biologic 2
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Analysis 6.9. Comparison 6 Secondary outcome - adverse events, Outcome 9 Small molecules versus
placebo.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 9 Small molecules versus placebo
Study or subgroup Small molecules Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Apremilast versus placebo
Papp 2012b 142/264 35/88 14.2 % 1.35 [ 1.02, 1.79 ]
Papp 2013b 97/173 47/87 18.1 % 1.04 [ 0.82, 1.31 ]
Papp ESTEEM-1, 2015 248/562 85/282 21.7 % 1.46 [ 1.20, 1.79 ]
Paul ESTEEM-2, 2015 185/275 82/138 27.1 % 1.13 [ 0.96, 1.33 ]
Reich LIBERATE, 2017 58/83 50/84 18.9 % 1.17 [ 0.94, 1.47 ]
Subtotal (95% CI) 1357 679 100.0 % 1.22 [ 1.07, 1.38 ]
Total events: 730 (Small molecules), 299 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.84, df = 4 (P = 0.14); I2 =42%
Test for overall effect: Z = 3.07 (P = 0.0022)
2 Tofacitinib versus placebo
Bachelez 2015 378/662 55/108 24.9 % 1.12 [ 0.92, 1.36 ]
Krueger 2016 2/9 1/3 0.2 % 0.67 [ 0.09, 4.99 ]
Papp OPT Pivotal-1, 2015 405/723 89/177 37.5 % 1.11 [ 0.95, 1.31 ]
Papp OPT Pivotal-2, 2015 425/763 93/196 37.4 % 1.17 [ 1.00, 1.38 ]
Subtotal (95% CI) 2157 484 100.0 % 1.14 [ 1.03, 1.25 ]
Total events: 1210 (Small molecules), 238 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.011)
3 Ponesimod versus placebo
Vaclavkova 2014 172/259 34/67 100.0 % 1.31 [ 1.02, 1.68 ]
Subtotal (95% CI) 259 67 100.0 % 1.31 [ 1.02, 1.68 ]
Total events: 172 (Small molecules), 34 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Chi2 = 1.45, df = 2 (P = 0.49), I2 =0.0%
0.01 0.1 1 10 100
Favours Small molecules Favours Placebo
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Analysis 6.10. Comparison 6 Secondary outcome - adverse events, Outcome 10 Biologic versus small
molecules.
Review: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis
Comparison: 6 Secondary outcome - adverse events
Outcome: 10 Biologic versus small molecules
Study or subgroup Biologic Small molecules Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Etanercept versus tofacitinib
Bachelez 2015 192/336 378/662 100.0 % 1.00 [ 0.89, 1.12 ]
Subtotal (95% CI) 336 662 100.0 % 1.00 [ 0.89, 1.12 ]
Total events: 192 (Biologic), 378 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
2 Etanercept versus apremilast
Reich LIBERATE, 2017 58/83 44/83 100.0 % 1.32 [ 1.03, 1.69 ]
Subtotal (95% CI) 83 83 100.0 % 1.32 [ 1.03, 1.69 ]
Total events: 58 (Biologic), 44 (Small molecules)
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Chi2 = 3.94, df = 1 (P = 0.05), I2 =75%
0.01 0.1 1 10 100
Favours Biologic Favours Small molecules
A D D I T I O N A L T A B L E S
Table 1. Glossary
Term Definition
Antagonist A substance that interferes with or inhibits the physiological action of another
Antigen A molecule capable of inducing an immune respons
Anti-TNF alpha A pharmaceutical drug that suppresses the physiologic response to tumor necorsis
factor (TNF)
Biological agent Therapeutic agents consisting of immune molecules such as soluble receptors, re-
combinant cytokines, and monoclonal antibodies that target effector molecules or
cells of the immune system
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Table 1. Glossary (Continued)
CD6 Cluster of differentiation (CD) 6 is a protein encoded by the CD6 gene
Cheilitis An inflammation of the lips
Chimeric protein A chimeric protein can be made by combining two different genes
Complex cyclophilin-ciclosporin Cyclophilins are a family of proteins that bind to ciclosporin, an immunosuppres-
sant agent
Creatinine A compound that is produced by metabolism of creatine and excreted in the urine
Cyclic adenosine monophosphate It is a second messenger important in many biological processes
Cytokines Small proteins produced by a broad range of cells that are important in cell signaling;
they are immunomodulating agents
Dendritic cells Antigen-presenting cells of the immune system
Dermis It is a layer of the skin
Epitope It is a part of an antigen
Erythematous Redness of the skin
Folic acid B vitamin
Humanised antibody Antibodies from non-human species whose protein sequences have been modified
to increase their similarity to antibody variants produced naturally in humans
IL-17A A pro-inflammatory cytokine
IL-23R A cytokine receptor
Immune-mediated A group of diseases that are characterised by common inflammatory pathways
leading to inflammation, and which may result from a dysregulation of the normal
immune response
Immunogenicity This is the ability of a particular substance, such as an antigen or epitope, to provoke
an immune response in the body of a human or animal
Immunoglobulin 1 Fc An antibody
Interferon (IFN)-c A protein released by cells, usually in response to a pathogen
Interleukin A kind of cytokine
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Table 1. Glossary (Continued)
Janus kinase (JAK) inhibitors A pharmaceutical drug that inhibits the activity of one or more of the Janus kinase
family of enzymes
Keratinocytes Epidermal cells that constitute 95% of the epidermis
Lymphocyte A subtype of a white blood cell
Lymphoid organ Part of the body that defends the body against invading pathogens that cause
infections or the spread of tumours
Metalloproteinases A protease enzyme
Monoclonal antibodies Antibodies that are made by identical immune cells that are all clones of a unique
parent cell
Murine sequence Mouse genomic sequencing
Neutrophils Type of white blood cell involved in the innate immune system
p40 Subunit beta of interleukin 12 and 23
Periumbilical Around the navel
Pharmacological treatments Drugs
Phase I First-in-man studies
Phase II Studies to assess how well the drug works, as well as to continue phase I safety
assessments in a larger group of volunteers and participants
Phase III Randomised controlled multicenter trials on large patient groups and are aimed at
being the definitive assessment of how effective the drug is
Phase IV Post-marketing trials involve the safety surveillance
Phosphodiesterase 4 inhibitors A pharmaceutical drug used to block the degradative action of phosphodiesterase 4
Progressive multifocal leukoencephalopathy A rare viral neurological disease characterised by progressive damage of the white
matter of the brain at multiple locations
Receptor A protein molecule that receives chemical signals from outside a cell
Small molecules Chemically manufactured molecules (or SMOLs for short)
Sphingosine 1-phosphate receptor agonists A class of protein-coupled receptors that are targets of the lipid signalling molecule
Sphingosine-1-phosphate
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Table 1. Glossary (Continued)
T cells/CD4 T cells A type of white blood cell that is of key importance to the immune system
Th1 and Tc1 cells A type of T cell
Th17 and Tc17 cells A type of T cell
TNF-alpha A protein that is part of the inflammatory response
Tumour necrosis factor antagonists Class of biological agents
Umbilic Navel
Xerosis Dry skin
Table 2. Investigators contacted
Contact Requested Information Contacted Reply (last check 1/03/
2017)
Missing data
Akcali 2014 Prof. Akcali Outcomes: PASI 90,
PASI 75, PGA 0/1, QoL
scale, AEs & SAEs
8 and 21 November
2016
No response
Al-Hamamy 2014 Prof. Al-Hamamy Outcomes:
PASI 75, PGA 0/1, QoL
scale, AEs & SAEs
8 and 21 November
2016
No response
Asahina 2010 Prof. Asahina Outcome: PASI 90 8 November 2016 Asahina 2010 detailed
report
Asahina 2016 Prof. Asahina Pfizer Outcomes: AEs & SAEs 3 and 12 January 2017 Additional data to the
publicationnot provided
Asawanonda 2006 Prof. Asawanonda Outcomes: PASI 75,
PGA 0/1, AEs & SAEs
21 November 2016
15 December 2016
Asawanonda 2006 sent
detailed report for PASI
75 and AEs. PGA was
not collected during this
study
Bissonnette 2015 Prof. Bisonnette Innova-
derm Recherches Inc.
Outcomes: PASI 90,
PGA 0/1, AEs
8 and 21 November
2016
Additional data to the
publicationnot provided
Blauvelt FEATURE,
2015
Dr Blauvelt
Novartis
Outcome: QoL scale 8 and 21 November
2016
Additional data to the
publicationnot provided
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Table 2. Investigators contacted (Continued)
Caproni 2009 Prof. Fabri Outcomes: PASI 90,
PASI 75, PGA 0/1, QoL
scale, AEs & SAEs
8 and 21 November
2016
Caproni 2009 sent de-
tailed report for PASI 90
and SAEs. Other out-
comes (PGA, QoL and
AEs) not collected dur-
ing this study
Dogra 2013 Prof. Dogra Outcomes: PGA 0/1,
QoL scale, AEs & SAEs
8 and 21 November
2016
No response
Dogra 2012 Prof. Dogra Outcomes: PGA 0/1,
QoL scale, AEs & SAEs
8 November 2016 PGA & QoL scale
not collected during this
study. AEs & SAEs not
provided per arm
Fallah Arani 2011 Dr Fallah Arani Outcomes: PASI 90,
PGA 0/1 and QoL scale
8 and 21 November
2016
Outcomes not collected
during this study
Flytström 2008 Prof. Flytstrom Outcomes: PGA 0/1 12 and 19 January 2017 Additional data to the
publicationnot provided
Gisondi 2008 Prof. Gisondi Outcomes:
PASI 90, PGA 0/1, QoL
scale, AEs & SAEs
8 November 2016 Gisondi 2008 sent de-
tailed report for the re-
quested outcomes except
for QoL (not assessed
during the study)
Gordon 2006 Prof. Gordon Outcomes: PGA0/1,
AEs
3 and 12 January 2017 No response
Gottlieb 2012 Prof. Gottlieb
Abbvie
Outcomes: PASI 90 &
QoL scale
8 November 2016 Gottlieb 2012 sent de-
tailed report for the re-
quested outcomes
Gottlieb 2011 Prof. Gottlieb
Amgen
Outcomes:
PASI 90, PGA 0/1, QoL
scale, AEs & SAEs
8 November 2016 Gottlieb 2011 sent de-
tailed report for the re-
quested outcomes
Griffiths ACCEPT,
2010
Prof. Griffiths
Janssen
Outcome: QoL scale 16 December 2016 QoL was not collected
during this study
Jacobe 2008 Prof. Jacobe Outcomes:
PASI 90, PGA 0/1, QoL
scale, AEs & SAEs
8 and 20 November
2016
No response
Krueger 2016 Pfizer Outcomes: PASI 90,
QoL scale
3 and 12 January 2017 No response
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Table 2. Investigators contacted (Continued)
Krupashankar 2014 Prof. Ganapathi
R&D, Biocon Research
Limited
Outcomes: QoL scale,
AEs & SAEs
8 and 21 November
2016
Krupashandar sent de-
tailed report for the re-
quested outcomes, how-
ever AEs and SAEs were
only available for the en-
tire trial and not at the
time of the major out-
come assessment
Lebwohl AMAGINE-2,
2015
Prof. Lebwohl
Valeant Pharmaceuticals
NA LLC
Outcomes: PASI 90 &
QoL scale
8 and 21 November
2016
Lebwohl AMAGINE-2,
2015 sent detailed report
for PASI 90, individual
scores and median dif-
ference from baseline of
QoL were not available
Lebwohl AMAGINE-3,
2015
Prof. Lebwohl
Valeant Pharmaceuticals
NA LLC
Outcomes: PASI 90 &
QoL scale
8 and 21 November
2016
Lebwohl AMAGINE-3,
2015 sent detailed report
for PASI 90, individual
scores and median dif-
ference from baseline of
QoL were not available
Leonardi 2012 Prof. Leonardi Outcomes: QoL scale &
AEs
8 and 21 November
2016
No response
Mahajan 2010 Prof. Kaur Outcomes:
PASI 90, PGA 0/1, QoL
scale, AEs & SAEs
8 and 21 November
2016
No response
Menter REVEAL, 2008 Prof. Menter Outcome: PGA 0/1 8 and 21 November
2016
No response
Menter EXPRESS-II,
2007
Prof. Menter Outcome: PGA 0/1 8 and 21 November
2016
No response
Mrowietz BRIDGE,
2016
Prof. Mrowietz Outcome: QoL scale 3 and 12 January 2017 Additional data to the
publicationnot provided
Ortonne 2013 Prof. Paul
Novartis
Outcome: PASI 90 3 January 2017 Additional data to the
publicationnot provided
Papp 2013a Prof. Papp Outcome: QoL scale 22 November 2016 13
December 2016
Additional data to the
publicationnot provided
Papp AMAGINE-1,
2016
Prof. Papp Outcome: QoL scale 22 November 2016 13
December 2016
Additional data to the
publicationnot provided
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Table 2. Investigators contacted (Continued)
Papp 2005 Prof. Papp Outcome: QoL scale,
AEs & SAEs
22 November 2016 13
December 2016
Additional data to the
publicationnot provided
Papp 2012a Prof. Papp Outcome: QoL scale 22 November 2016 13
December 2016
Additional data to the
publicationnot provided
Papp 2013b Prof. Papp Outcome: PASI 90,
PGA0/1, QoL scale
3 January 2017 Additional data to the
publicationnot provided
Paul JUNCTURE, 2015 Prof. Paul
Novartis
Outcome: QoL scale 15 December 2016, 2
January 2017
Additional data to the
publicationnot provided
Reich 2015 Prof. Reich
Novartis
Outcomes: PGA 0/1 &
QoL scale
8 November 2016, 16
December 2016
Additional data to the
publicationnot provided
Reich LIBERATE, 2017 Prof. Reich PelotonAd-
vantage
Outcome: QoL scale 4 January 2017 Additional data to the
publicationnot provided
Rich 2013 Prof. Rich Outcome: QoL scale 22 November 2016, 13
December 2016
No response
Sterry PRESTA, 2010 Prof. Sterry Outcomes: PASI 90 &
QoL scale
8 and 21 November
2016
No response
Strober 2011 Prof. Strober
Abbvie
Outcome: QoL scale 8 November 2016 Strober sent detailed re-
port for the requested
outcomes
Thaci CLEAR, 2015 Prof. Thaçi
Novartis
Outcome: QoL scale 8 and 21 November
2016
Additional data to the
publicationnot provided
Torii 2010 Prof. Torii Outcomes: PASI 90 &
PGA0/1
21 November 2016 Torii sent detailed report
for the requested out-
comes
Tyring 2006 Prof. Tyring Outcomes: PGA 0/1 &
QoL scale
8 and 21 November
2016
No response
Van Bezooijen 2016 Dr van Bezooijen Outcomes: PASI 90, ad-
verse effects
4 and 12 January 2017 Additional data to the
publicationnot provided
Van de Kerkhof 2008 Prof. van der Kherkhof
Pfizer
Outcome: AEs 8 and 21 November
2016
Additional data to the
publicationnot provided
Yan 2011 No contact Outcomes: AEs and
SAEs
No Authors’ email not
found
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Table 2. Investigators contacted (Continued)
Zhu LOTUS, 2013 No contact Outcome: PASI 90 No Authors’ email not
found
Awaiting classification studies
Elewski 2016 Prof. Elewski Abbvie Study’s protocol andout-
comes: PASI 90, PASI
75, PGA 0/1, QoL scale,
AEs & SAEs
3 and 12 January 2017 Will be included when
published
Khatri 2016 Prof. Khattri Study’s protocol andout-
comes: PASI 90, PASI
75, PGA 0/1, QoL scale,
AEs & SAEs
3 and 12 January 2017 No response
Lee 2016 Prof. Lee Study’s protocol andout-
comes: PASI 90, PASI
75, PGA 0/1, QoL scale,
AEs & SAEs
3 and 12 January 2017 No response
Reich 2016 Prof. Reich Study’s protocol andout-
comes: PASI 90, PASI
75, PGA 0/1, QoL scale,
AEs & SAEs
3 January 2017 Will be included when
published
Chow 2015 Prof. Chow outcomes: PASI 90,
PASI 75, PGA 0/1, QoL
scale, AEs & SAEs
8 November 2016, 16
December 2016
No response
Gurel 2015 Prof. Gurel Study’s protocol andout-
comes: PASI 90, PASI
75, PGA 0/1, QoL scale,
AEs & SAEs
17 and 24 January 2017 Gurel 2015 sent detailed
report for the requested
outcomes. Finally Gurel
studywas classified in the
included studies section
Han 2007 No contact Outcomes: PASI 90,
PASI 75, PGA 0/1, QoL
scale, AEs & SAEs
No Authors’ email not
found
NCT01988103 Dr Nogarales, MD Cel-
gene Corporation
Asking for study proto-
col and efficacy/safety re-
sults
12 and 19 January 2017 Email response: ”Thank
you very much for your
email and your interest
in our study in Japanese
subjects.May I please en-
quire as to the planned
timing for publication
for your meta-analysis
as we have just recently
submitted our primary
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Table 2. Investigators contacted (Continued)
manuscript?“ Will be in-
cluded when published
NCT02248792 Prof. Krishna Asking for study proto-
col and efficacy/safety re-
sults
5 and 12 January 2017 No response
DRKS00000716 Prof. Jacobi Asking for study proto-
col and efficacy/safety re-
sults
12 and 19 January 2017 No response
CTRI/2015/05/005830 Prof. Shah Asking for study proto-
col and efficacy/safety re-
sults
12 and 19 January 2017
Abstracts
Yilmaz 2002 Prof. Yilmaz Outcomes: PASI 90,
PASI 75, PGA 0/1, QoL
scale, AEs & SAEs
16 December 2016 Yilmaz 2002 sent de-
tailed report for the re-
quested outcomes. Fi-
nally Yilmaz 2002 study
was classified in the in-
cluded studies section.
Mrowietz 2005 Prof. Mrowietz Study’s protocol andout-
comes: PASI 90, PASI
75, PGA 0/1, QoL scale,
AEs & SAEs
16 December 2016, 3
January 2017
Additional data to
the publication not pro-
vided. Finally Mrowietz
study was classified in
the awaiting classifica-
tion section
Reich 2004 Prof. Reich Study’s protocol andout-
comes: PASI 90, PASI
75, PGA 0/1, QoL scale,
AEs & SAEs
16 December 2016 Additional data to the
publication not
provided. Finally Reich
2004 study was classified
in the awaiting classifica-
tion section
Ongoing studies
NCT01558310 Dr Yamauchi Dr Pat-
naik, Director, Clinical
Science Institute
Asking for study proto-
col and efficacy/safety re-
sults
5 January 2017 Email response: Dear Dr
Sbidian,
Thank you for your kind
email, forwarded to me
by Dr Paul Yamauchi,
MD,PhD. Our ” Study
to Evaluate the Effec-
tiveness of STELARA
™ (USTEKINUMAB)
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Table 2. Investigators contacted (Continued)
in the Treatment of
Scalp Psoriasis (NCT
01558310)” completed
enrolment in December
2016 and the last subject
will complete in Decem-
ber 2017, as such we do
not have the final data
analysis. What is you ab-
solute cut- off for publi-
cation data ? Would an
interim analysis report
be acceptable ? Best re-
gards, Rickie Patnaik Di-
rector, Clinical Science
Institute
Will be included when
published
EUCTR2013-004918-
18-NL
Prof. Spuls Asking for study proto-
col and efficacy/safety re-
sults
5 January 2017 Email response “The
study is currently ongo-
ing and has not yet been
analysed. Therefore, we
are not able to provide
data on efficacy or safety.
We can provide you with
the study protocol. Will
this be helpful?
Kind regards, Phyllis
Spuls and Celine Busard
”
Will be included when
published
AE: adverse events; PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment; QoL: quality of life; SAE: serious
adverse events
Table 3. Direct and indirect evidences and network meta-analysis results summary table for PASI 90 at 12 to 16 weeks
Network meta-analysis Direct evidence Indirect evidence
Compar-
isons*
RR LCI UCI RR LCI UCI RR LCI UCI
FAEs vs
placebo
4.09 1.88 8.88 4.47 1.97 10.14 1.86 0.16 21.16
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Table 3. Direct and indirect evidences and network meta-analysis results summary table for PASI 90 at 12 to 16 weeks
(Continued)
Methotrex-
ate vs
placebo
3.91 2.16 7.08 1.53 0.66 3.53 17.16 5.69 51.75
Adal-
imumab vs
placebo
14.87 10.45 21.14 14.42 10.08 20.64 108.8 2.24 5287.86
Etanercept
vs placebo
10.79 8.47 13.73 10.62 7.52 15.01 11.21 7.26 17.32
Ustek-
inumab vs
placebo
19.91 15.11 26.23 22.7 15.46 33.34 17.91 12.71 25.24
Secuk-
inumab vs
placebo
26.55 20.32 34.69 24.53 14.93 40.32 28.25 19.1 41.78
Ixek-
izumab vs
placebo
32.45 23.61 44.60 39.46 20.64 75.44 24.51 10.05 59.77
Bro-
dalumabvs
placebo
25.45 18.74 34.57 26.58 16.65 42.41 23.74 10.09 55.86
Apremilast
vs placebo
7.66 4.30 13.66 6.72 3.07 14.69 10.83 2.43 48.31
Tofacitinib
vs placebo
8.50 6.23 11.60 6.3 4.14 9.56 17.91 8.3 38.62
Guselkumab
vs placebo
21.03 14.56 30.38 26.1 14.71 46.3 12.7 4.28 37.69
Methotrex-
ate vs FAEs
0.96 0.38 2.44 2 0.19 21.03 0.83 0.3 2.32
Alefacept
vs
methotrex-
ate
1.12 0.42 3.02 1.12 0.42 3.02
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Table 3. Direct and indirect evidences and network meta-analysis results summary table for PASI 90 at 12 to 16 weeks
(Continued)
Ci-
closporin
vs
methotrex-
ate
1.02 0.60 1.73 1.02 0.6 1.73
In-
fliximab vs
methotrex-
ate
2.86 2.06 3.97 2.86 2.06 3.97
Adal-
imumab vs
methotrex-
ate
3.80 2.26 6.39 3.35 2.02 5.57 13.2 3.4 51.32
Etanercept
vs acitretin
11.00 0.63 191.47 11 0.63 191.47
Guselkumab
vs adali-
mumab
1.41 1.21 1.65 1.4 1.18 1.66 2.88 0.68 12.21
Ustek-
inumab vs
etanercept
1.85 1.50 2.27 1.8 1.27 2.55 1.95 1.37 2.77
Secuk-
inumab vs
etanercept
2.46 2.01 3.02 2.33 1.66 3.28 2.62 1.82 3.77
Ixek-
izumab vs
etanercept
3.01 2.46 3.68 2.93 2.44 3.53 5.73 2.07 15.85
Apremi-
last vs etan-
ercept
0.71 0.40 1.25 0.72 0.36 1.45 0.69 0.26 1.81
To-
facitinib vs
etanercept
0.79 0.59 1.06 0.88 0.73 1.08 0.49 0.3 0.81
Secuk-
inumab vs
ustek-
inumab
1.33 1.11 1.61 1.38 1.03 1.84 1.19 0.79 1.81
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Table 3. Direct and indirect evidences and network meta-analysis results summary table for PASI 90 at 12 to 16 weeks
(Continued)
Bro-
dalumabvs
ustek-
inumab
1.28 1.10 1.48 1.27 1.1 1.46 1.64 0.69 3.89
FAES: fumaric acid esters; LCI: low confidence interval; RR: risk ratio; UCI: upper confidence interval; vs: versus,
*The comparisons listed in this table were included in at least one direct-evidence analysis.
Table 4. Ranking findings for all outcomes at class level
Class-
level
inter-
ven-
tions
SU-
CRA
PASI
90
Rank
PASI
90
SU-
CRA
SAE
Rank
SAE
SU-
CRA
PASI
75
Rank
PASI
75
SU-
CRA
AE
Rank
AE
SU-
CRA
PGA
Rank
PGA
SU-
CRA
QoL
Rank
QoL
Anti-
IL12/
23
85.7 2 53.9 3 85.0 2 57.0 3 83.8 2 75.7 3
Anti-
IL17
100.0 1 21.0 8 99.6 1 14.1 6 99.9 1 95.4 1
Anti-
IL23
71.3 3 39.6 5 72.2 3 78.7 2 73.1 3 83.4 2
Anti-
TNF
alpha
56.4 4 39.2 6 57.4 4 47.5 5 57.5 4 58.4 4
Other
biolog-
ics
26.3 6 68.2 2 17.0 7 16.6 7 15.5 7
Small
molecules
41.5 5 45.4 4 42.7 5 7.9 7 42.0 5 40.4 5
Con-
ven-
tional
sys-
temic
treat-
ments
18.7 7 94.8 1 26.0 6 50.8 4 27.1 6 30.8 6
Placebo 0 8 38.0 7 0 8 94.0 1 0 8 0.4 8
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AE: adverse events; FAEs: fumaric acid esters; PGA: Physician Global Assessment; QoL: Specific quality of life scale; SAE: serious
adverse events
Table 5. Ranking findings for all outcomes at drug level
Drug SU-
CRA
PASI
90
Rank
PASI
90
SU-
CRA
SAE
Rank
SAE
SU-
CRA
PASI
75
Rank
PASI
75
SU-
CRA
AE
Rank
AE
SU-
CRA
PGA
Rank
PGA
SU-
CRA
QoL
Rank
QoL
Ac-
itretin
9.9 19 46.9 9 26.0 15 - - - - - -
Adali-
mumab
63.1 8 40.4 14 60.2 9 70.1 5 56.9 8 57.6 7
Ale-
facept
25.3 15 62.6 5 12.6 18 - - 13.1 18 15.9 13
Apremi-
last
39.7 13 54.7 7 33.2 14 14.3 16 27.9 14 28.6 10
Bro-
dalumab
84.3 3 39.8 15 82.1 3 46.4 9 84.0 5 52.3 8
Cer-
tolizumab
75.7 5 70.9 3 71.6 6 78.0 4 90.1 1 - -
Ci-
closporin
21.3 17 78.2 2 33.2 13 36.8 12 24.0 16 - -
Etaner-
cept
52.6 11 43.6 11 57.7 10 45.9 10 51.7 10 67.6 5
FAEs 21.9 16 57.7 6 11.1 19 17.8 15 15.4 17 - -
Guselkumab
77.0 4 42.6 12 71.6 7 78.2 3 67.5 7 84.3 2
Inflix-
imab
53.2 10 64.4 4 48.0 11 40.1 11 52.4 9 - -
Itolizumab
56.0 9 - - 71.6 8 - - 29.4 13 16.0 12
Ixek-
izumab
94.3 1 33.7 17 91.8 1 18.1 14 85.9 3 99.2 1
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Table 5. Ranking findings for all outcomes at drug level (Continued)
Methotrex-
ate
20.2 18 90.7 1 21.3 16 68.4 6 24.9 15 31.5 9
Placebo 2.9 20 42.0 13 0.0 20 88.0 1 0.3 19 1.2 14
Ponesi-
mod
37.3 14 18.1 19 21.3 17 14.0 17 48.7 11 28.1 11
Secuk-
inumab
86.5 2 29.9 18 86.7 2 36.3 13 84.4 4 - -
Tildrak-
izumab
63.6 7 37.8 16 78.3 4 86.1 2 86.3 2 74.9 4
Tofaci-
tinib
42.5 12 44.0 10 46.2 12 47.3 8 36.6 12 65.1 6
Ustek-
inumab
72.6 6 52.0 8 75.2 5 64.3 7 70.4 6 77.4 3
AE: adverse events; FAEs: fumaric acid esters; PASI: Psoriasis Area and Severity Index; PGA: Physician Global Assessment; QoL:
specific quality of life scale; SAE: serious adverse events; SUCRA: Surface Under the Cumulative Ranking
Table 6. Total number of serious adverse events during the induction phase at class-level and most severe types
Number of
randomised partici-
pants
Number of serious
adverse events
Number of serious
infections
Number of malig-
nancies
Number of MACE
Drug Placebo Drug Placebo Drug Placebo Drug Placebo Drug Placebo
Conven-
tional sys-
temic
agents
767 220 19 10 0 0 0 0 0 0
Anti-
TNF
4508 2640 85 44 21 9 20 7 6 2
Anti-
IL12/23
2547 1607 38 23 7 5 4 1 4 3
Anti-
IL17
7551 2533 149 36 47 7 21 2 19 3
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Table 6. Total number of serious adverse events during the induction phase at class-level and most severe types (Continued)
Anti-
IL23
1347 510 23 7 4 1 0 0 1 0
Other bi-
ologics
509 227 15 10 - - 2 1 - -
Small
molecules
3920 1280 89 28 15 5 14 0 5 1
MACE: Major adverse cardiac events
Table 7. Direct and indirect evidence and network meta-analysis results summary table for serious adverse events at 12 to 16
weeks
Network meta-analysis Direct evidence Indirect evidence
Compar-
isons*
RR LCI UCI RR LCI UCI RR LCI UCI
FAEs vs
placebo
0.77 0.30 1.99 0.83 0.31 2.21 0.19 0 12.57
Methotrex-
ate vs
placebo
0.23 0.05 0.99 0.16 0.03 0.86 0.68 0.04 11.67
Adal-
imumab vs
placebo
1.02 0.61 1.73 1.05 0.62 1.78 0.07 0 26.92
Etanercept
vs placebo
0.99 0.65 1.51 1.09 0.65 1.84 0.76 0.31 1.89
Ustek-
inumab vs
placebo
0.89 0.57 1.39 0.74 0.44 1.26 1.36 0.61 2.99
Secuk-
inumab vs
placebo
1.19 0.69 2.03 1.61 0.78 3.33 0.75 0.3 1.87
Ixek-
izumab vs
placebo
1.12 0.66 1.90 1.16 0.62 2.16 0.97 0.18 5.12
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Table 7. Direct and indirect evidence and network meta-analysis results summary table for serious adverse events at 12 to 16
weeks (Continued)
Bro-
dalumabvs
placebo
1.04 0.62 1.73 0.92 0.53 1.62 2.77 0.38 20.28
Apremilast
vs placebo
0.84 0.47 1.52 0.78 0.42 1.44 4.33 0.09 201.27
Tofacitinib
vs placebo
0.98 0.55 1.76 1.05 0.53 2.06 0.67 0.08 5.35
Guselkumab
vs placebo
1.00 0.49 2.04 1.21 0.51 2.85 0.52 0.08 3.41
Methotrex-
ate vs FAEs
0.30 0.06 1.59 1 0.02 48.83 0.23 0.04 1.45
Ci-
closporin
vs
methotrex-
ate
0.98 0.06 15.38 0.98 0.06 15.38 - - -
In-
fliximab vs
methotrex-
ate
2.41 1.04 5.59 2.41 1.04 5.59 - - -
Adal-
imumab vs
methotrex-
ate
4.43 0.99 19.81 2.24 0.21 23.56 6.68 1.04 42.76
Etanercept
vs acitretin
1.00 0.02 48.82 1 0.02 48.83 - - -
Guselkumab
vs adali-
mumab
0.98 0.51 1.88 0.89 0.44 1.79 2.07 0.26 16.45
Ustek-
inumab vs
etanercept
0.90 0.52 1.57 1.25 0.38 4.11 0.83 0.44 1.54
Secuk-
inumab vs
etanercept
1.20 0.66 2.19 1.17 0.45 3.04 1.22 0.56 2.65
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Table 7. Direct and indirect evidence and network meta-analysis results summary table for serious adverse events at 12 to 16
weeks (Continued)
Ixek-
izumab vs
etanercept
1.14 0.66 1.94 1.02 0.53 1.95 1.47 0.53 4.09
Apremi-
last vs etan-
ercept
0.85 0.42 1.72 2.69 0.41 17.5 0.7 0.33 1.5
To-
facitinib vs
etanercept
0.99 0.53 1.87 0.87 0.35 2.19 1.12 0.47 2.7
Secuk-
inumab vs
ustek-
inumab
1.33 0.74 2.38 1.01 0.42 2.39 1.68 0.77 3.68
Bro-
dalumabvs
ustek-
inumab
1.16 0.64 2.11 1.32 0.59 2.98 0.95 0.33 2.71
FAES: fumaric acid esters; LCI: low confidence interval; RR: risk ratio; UCI: upper confidence interval
*The comparisons listed in this table were included in at least one direct-evidence analysis.
A P P E N D I C E S
Appendix 1. CRS/Cochrane Skin Group Specialised Register search strategy
(Psoria* or “palmoplantar* pustulosis” or “pustulosis palmaris et plantaris” or (pustulosis and palms and soles)) and (methotrexate*
or amethopterin or mtx or mexate or fumar* or dimethylfumarate or fae or dmf or fumaderm or acitretin or tegison or soriatane or
neotigason or ((oral or orally or systemic) and retinoid*) or isotretinoin or accutane or etretin* or ustekinumab or stelara or secukinumab
or “CNTO1275” or “cdp571” or etanercept* or enbrel or adalimumab* or d2e7 or humira or golimumab or simponi or briakinumab or
“ABT-874” or “psoralen uva” or ciclosporin or cyclosporine or cyclosporine or alefacept or brodalumab or ixekizumab or phototherap*
or ultraviolet or PUVA or photochemotherap* or photodynamic or “light therap*” or photoradiation or “broad band uvb” or “broad
band ultraviolet b” or “narrow band uvb” or “narrow band ultraviolet b” or BBUVB or NBUVB or BB-UVB or NB-UVB or infliximab*
or “monoclonal antibod*” or remicade or interleukin* or “anti tumour necrosis factor” or “anti tumor necrosis factor” or “tumour
necrosis factor antibod*” or “tumor necrosis factor antibod*” or “tnf antibod*” or “tnf alpha antibod*” or “anti tnf” or “immunoglobulin
fab fragment*” or “p40 subunit” or “tumor necrosis factor*” or tnf or “antitumor necrosis factor*” or “antitumour necrosis factor*” or
ampremilast or ponesimod or guselkumab or tofacitinib or itolizumab or certolizumab or tildrakizumab)
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Appendix 2. Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Library,
search strategy
#1MeSH descriptor: [Psoriasis] this term only
#2psoria*:ti,ab,kw
#3palmoplantar* pustulosis:ti,ab,kw
#4pustulosis palmaris et plantaris:ti,ab,kw
#5pustulosis and palms and soles:ti,ab,kw
#6#1 or #2 or #3 or #4 or #5
#7MeSH descriptor: [Methotrexate] explode all trees
#8MeSH descriptor: [Fumarates] explode all trees
#9MeSH descriptor: [Etretinate] explode all trees
#10MeSH descriptor: [Acitretin] explode all trees
#11MeSH descriptor: [Isotretinoin] explode all trees
#12MeSH descriptor: [Retinoids] explode all trees
#13MeSH descriptor: [Antibodies, Monoclonal] explode all trees
#14MeSH descriptor: [Interleukin-12] explode all trees
#15MeSH descriptor: [Interleukin-23] explode all trees
#16MeSH descriptor: [Interleukin-12 Subunit p40] explode all trees
#17MeSH descriptor: [Tumor Necrosis Factors] explode all trees
#18MeSH descriptor: [Tumor Necrosis Factor-alpha] explode all trees
#19MeSH descriptor: [Receptors, Tumor Necrosis Factor, Type II] explode all trees
#20MeSH descriptor: [Receptors, Tumor Necrosis Factor] explode all trees
#21MeSH descriptor: [Receptors, Tumor Necrosis Factor, Type I] explode all trees
#22MeSH descriptor: [TNF-Related Apoptosis-Inducing Ligand] explode all trees
#23MeSH descriptor: [Antibodies, Monoclonal] explode all trees
#24MeSH descriptor: [Immunoglobulin Fab Fragments] explode all trees
#25MeSH descriptor: [Phototherapy] explode all trees
#26MeSH descriptor: [Ultraviolet Therapy] explode all trees
#27MeSH descriptor: [PUVA Therapy] explode all trees
#28MeSH descriptor: [Photochemotherapy] explode all trees
#29MeSH descriptor: [Cyclosporine] explode all trees
#30(methotrexate* or amethopterin or mtx or mexate or fumar* or dimethylfumarate or fae or dmf or fumaderm or acitretin or tegison
or soriatane or neotigason or ((oral or orally or systemic) and retinoid*) or isotretinoin or accutane or etretin* or ustekinumab or
stelara or secukinumab or “CNTO 1275” or “cdp571” or etanercept* or enbrel or adalimumab* or “d2e7” or humira or golimumab
or simponi or briakinumab or “ABT-874” or “psoralen uva” or ciclosporin or cyclosporine or cyclosporine or alefacept or brodalumab
or ixekizumab or phototherap* or ultraviolet or PUVA or photochemotherap* or photodynamic or “light therap*” or photoradiation
or “broad band uvb” or “broad band ultraviolet b” or “narrow band uvb” or “narrow band ultraviolet b” or BBUVB or NBUVB or BB-
UVB or NB-UVB or infliximab* or “monoclonal antibod*” or remicade or interleukin* or “anti tumour necrosis factor” or “anti tumor
necrosis factor” or “tumour necrosis factor antibod*” or “tumor necrosis factor antibod*” or “tnf antibod*” or “tnf alpha antibod*” or
“anti tnf” or “immunoglobulin fab fragment*” or “p40 subunit” or “tumor necrosis factor*” or tnf or “antitumor necrosis factor*” or
“antitumour necrosis factor*” or ampremilast or ponesimod or guselkumab or tofacitinib or itolizumab certolizumab or tildrakizumab):
ti,ab,kw
#31{or #7-#30}
#32#6 and #31
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Appendix 3. MEDLINE (Ovid) search strategy
1. exp Psoriasis/ or psoria$.ti,ab.
2. palmoplantar$ pustulosis.ti,ab.
3. pustulosis palmaris et plantaris.ti,ab.
4. (pustulosis and palms and soles).ti,ab.
5. 1 or 2 or 3 or 4
6. exp Methotrexate/
7. methotrexate$.mp.
8. amethopterin.mp.
9. mtx.ti,ab.
10. mexate.mp.
11. exp Fumarates/
12. (fumar$ and esters).mp.
13. dimethylfumarate.mp.
14. fae.ti,ab.
15. dmf.ti,ab.
16. fumarate$1.mp.
17. fumaderm.mp.
18. Etretinate/
19. Acitretin/
20. Tegison.mp.
21. (Soriatane or Neotigason).mp.
22. ((oral or orally or systemic) and retinoid$).ti,ab.
23. Isotretinoin/
24. Accutane.mp.
25. isotretinoin.ti,ab.
26. etretin$.mp.
27. acitretin.mp.
28. Retinoids/
29. Ustekinumab.mp.
30. stelara.mp.
31. secukinumab.mp.
32. apremilast.mp.
33. ponesimod.mp.
34. guselkumab.mp.
35. tofacitinib.mp.
36. itolizumab.mp.
37. CNTO 1275.mp.
38. exp antibodies, monoclonal/
39. monoclonal antibod$.mp.
40. exp Interleukin-23/ or exp Interleukin-12/
41. exp Interleukin-12 Subunit p40/ or p40 subunit.mp.
42. exp Tumor Necrosis Factors/ or exp Tumor Necrosis Factor-alpha/ or exp Receptors, Tumor Necrosis Factor, Type II/ or exp
Receptors, Tumor Necrosis Factor/ or exp Receptors, Tumor Necrosis Factor, Type I/ or exp TNF-Related Apoptosis-Inducing Ligand/
43. (anti tumour necrosis factor or anti tumor necrosis factor).mp.
44. (tumor necrosis factor-alpha or tumour necrosis factor-alpha).mp.
45. anti tnf.mp.
46. (tnf antibod$ or tnf alpha antibod$).mp.
47. (tumour necrosis factor antibod$ or tumor necrosis factor antibod$).mp.
48. (antitumor necrosis factor or antitumour necrosis factor).mp.
49. exp Immunoglobulin Fab Fragments/
50. (infliximab$ or monoclonal antibody cA2 or remicade).mp.
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51. cdp571.mp.
52. (etanercept$ or enbrel).mp.
53. (adalimumab$ or d2e7 or humira).mp.
54. (golimumab or simponi).mp.
55. (Briakinumab or ABT-874).mp.
56. exp Phototherapy/
57. exp Ultraviolet Therapy/
58. exp PUVA Therapy/
59. exp Photochemotherapy/
60. photodynamic therap$.mp.
61. phototherap$.mp.
62. photochemotherap$.mp.
63. puva.mp.
64. ultraviolet.mp.
65. light therap$.mp.
66. photoradiation therap$.mp.
67. BBUVB.mp.
68. NBUVB.mp.
69. BB-UVB.mp.
70. NB-UVB.mp.
71. broad band uvb.mp.
72. broad band ultraviolet b.mp.
73. narrow band uvb.mp.
74. narrow band ultraviolet b.mp.
75. psoralen ultraviolet a.mp.
76. psoralen uva.mp.
77. Cyclosporine/
78. (Ciclosporin or cyclosporine or cyclosporin).mp.
79. alefacept.mp.
80. brodalumab.mp.
81. ixekizumab.mp.
82. certolizumab.mp.
83. tildrakizumab.mp.
84. or/6-83
85. randomized controlled trial.pt.
86. controlled clinical trial.pt.
87. randomized.ab.
88. placebo.ab.
89. clinical trials as topic.sh.
90. randomly.ab.
91. trial.ti.
92. 85 or 86 or 87 or 88 or 89 or 90 or 91
93. exp animals/ not humans.sh.
94. 92 not 93
95. 5 and 84 and 94
[Lines 85-94: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-
maximizing version (2008 revision)]
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Appendix 4. Embase (Ovid) search strategy
1. exp PSORIASIS/
2. psoria$.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade
name, keyword, floating subheading]
3. palmoplantar$ pustulosis.mp.
4. pustulosis palmaris et plantaris.mp.
5. (pustulosis and palms and soles).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug
manufacturer, device trade name, keyword, floating subheading]
6. 1 or 2 or 3 or 4 or 5
7. methotrexate/
8. methotrexate$.ti,ab.
9. amethopterin.ti,ab.
10. mtx.ti,ab.
11. mexate.ti,ab.
12. fumaric acid derivative/
13. (fumar$ and esters).ti,ab.
14. dimethylfumarate.ti,ab.
15. fae.ti,ab.
16. dmf.ti,ab.
17. fumarate$1.ti,ab.
18. fumaderm.ti,ab.
19. etretinate/
20. acitretin.ti,ab.
21. tegison.ti,ab.
22. (Soriatane or Neotigason).ti,ab.
23. ((oral or orally or systemic) and retinoid$).ti,ab.
24. isotretinoin/
25. isotretinoin.ti,ab.
26. Accutane.ti,ab.
27. etretin$.ti,ab.
28. retinoid/
29. ustekinumab.ti,ab.
30. ustekinumab/
31. stelara.ti,ab.
32. secukinumab/
33. secukinumab.ti,ab.
34. ampremilast.ti,ab.
35. ponesimod/
36. ponesimod.ti,ab.
37. guselkumab/
38. guselkumab.ti,ab.
39. tofacitinib/
40. tofacitinib.ti,ab.
41. itolizumab/
42. itolizumab.ti,ab.
43. “CNTO 1275”.ti,ab.
44. monoclonal antibod$.ti,ab.
45. exp monoclonal antibody/
46. interleukin 23/
47. interleukin 12/
48. interleukin 12p40/
49. p40 subunit.ti,ab.
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50. exp tumor necrosis factor/
51. tumor necrosis factor alpha/
52. tumor necrosis factor receptor 2/
53. tumor necrosis factor receptor/
54. tumor necrosis factor related apoptosis inducing ligand/
55. (anti tumour necrosis factor or anti tumor necrosis factor).ti,ab.
56. (tumor necrosis factor-alpha or tumour necrosis factor-alpha).ti,ab.
57. anti tnf.ti,ab.
58. (tnf antibod$ or tnf alpha antibod$).ti,ab.
59. (tumour necrosis factor antibod$ or tumor necrosis factor antibod$).ti,ab.
60. (antitumor necrosis factor or antitumour necrosis factor).ti,ab.
61. “immunoglobulin F(ab) fragment”/
62. (infliximab$ or monoclonal antibody cA2 or remicade).ti,ab.
63. cdp571.ti,ab.
64. (etanercept$ or enbrel).ti,ab.
65. (adalimumab$ or d2e7 or humira).ti,ab.
66. (golimumab or simponi).ti,ab.
67. (Briakinumab or ABT-874).ti,ab.
68. exp phototherapy/
69. PUVA/
70. photochemotherapy/
71. photodynamic therap$.ti,ab.
72. phototherap$.ti,ab.
73. photochemotherap$.ti,ab.
74. puva.ti,ab.
75. ultraviolet.ti,ab.
76. light therap$.ti,ab.
77. photoradiation therap$.ti,ab.
78. BBUVB.ti,ab.
79. NBUVB.ti,ab.
80. BB-UVB.ti,ab.
81. NB-UVB.ti,ab.
82. broad band uvb.ti,ab.
83. broad band ultraviolet b.ti,ab.
84. narrow band uvb.ti,ab.
85. narrow band ultraviolet b.ti,ab.
86. psoralen ultraviolet a.ti,ab.
87. psoralen uva.ti,ab.
88. cyclosporin/
89. (Ciclosporin or cyclosporine or cyclosporin).ti,ab.
90. alefacept/
91. alefacept.ti,ab.
92. brodalumab.ti,ab.
93. ixekizumab.ti,ab.
94. ixekizumab/
95. brodalumab/
96. certolizumab.mp.
97. tildrakizumab.mp.
98. or/7-97
99. crossover procedure.sh.
100. double-blind procedure.sh.
101. single-blind procedure.sh.
102. (crossover$ or cross over$).tw.
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103. placebo$.tw.
104. (doubl$ adj blind$).tw.
105. allocat$.tw.
106. trial.ti.
107. randomized controlled trial.sh.
108. random$.tw.
109. or/99-108
110. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
111. human/ or normal human/
112. 110 and 111
113. 110 not 112
114. 109 not 113
115. 6 and 98 and 114
Appendix 5. LILACS search strategy
psoria$
We searched using the term above and the Controlled clinical trials topic-specific query filter.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. Between the first protocol submission (January 2014) and the first search (February 2015), we identified and added in the
protocol new systemic therapeutics for psoriasis.
• Background > Description of the intervention
◦ Oral systemic treatment
◦ Biological therapies
• Background > How the intervention might work?
◦ Oral systemic treatment
◦ Biological therapies
• Objectives
We expanded our objectives to clarify the types of systemic treatments for psoriasis. We changed: “To assess the effects of systemic
pharmacological treatments for chronic plaque psoriasis” to “To compare the efficacy and safety of conventional systemic agents (acitretin,
ciclosporin, fumaric acid esters, methotrexate), small molecules (apremilast, tofacitinib, ponesimod), anti-TNF alpha (etanercept,
infliximab, adalimumab, certolizumab), anti-IL12/23 (ustekinumab), anti-IL17 (secukinumab, ixekizumab, brodalumab), anti-IL23
(guselkumab, tildrakizumab), and other biologics (alefacept, itolizumab) for patients with moderate to severe psoriasis and to provide
a ranking of these treatments according to their efficacy and safety.”
• Methods > Types of intervention
We changed: “Systemic and biological treatments include the following: fumaric acid esters, retinoids (acitretin), ciclosporin, methotrex-
ate, infliximab, etanercept, adalimumab, ustekinumab, briakinumab, alefacept, brodalumab, ixekizumab” to the following:
“Systemic and biological treatments included the following:
• Systemic conventional treatments:
◦ Fumaric acid esters
◦ Acitretin
◦ Ciclosporin
◦ Methotrexate
• Small molecules
◦ Apremilast
◦ Tofacitinib
◦ Ponesimod
• Anti-TNF alpha
◦ Infliximab
◦ Etanercept
◦ Adalimumab
◦ Certolizumab
• Anti-IL12/23
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◦ Ustekinumab
• Anti-IL17
◦ Secukinumab
◦ Brodalumab
◦ Ixekizumab
• Anti-IL23
◦ Tildrakizumab
◦ Guselkumab
• Other biologic treatment
◦ Itolizumab
◦ Alefacept
A new anti-IL23 molecule (BI 655066, risankizumab) appeared after we began this review and was not included in this systematic
review. However, the ongoing studies of risankizumab have been reported in this review.”
2. Background > Why it is important to do this review?
We updated the published literature regarding other systemic reviews and meta-analyses.
3. Methods > Criteria for considering studies for this review
Selection of trials
We added: “Phase I trials were not eligible because participants, outcomes, dosages, and schema of administration of interventions are
too different from phase II, III, and IV studies.”
Outcomes
Primary outcome 1
In the Protocol, we wrote, “The proportion of participants who achieved clear or almost clear skin. (By clear or almost clear, we mean
a Physician Global Assessment (PGA) value of 0 or 1 or a 90/100 PASI.)”
In the review, we changed this sentence to “The proportion of participants who achieved clear or almost clear skin, that is, at least PASI
90”.
As PASI and PGA are two different scales, we preferred to assess them separately and added as a secondary outcome “Proportion of
participants who achieve a Physician Global Assessment (PGA) value of 0 or 1”.
Primary outcome 1
We also modified the sentence about serious adverse effects (SAEs) (in the protocol we said we would use the FDA’s definition): “The
proportion of participants with serious adverse effects (SAE). We used the definition of severe adverse effects from the International
Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, which includes death,
life-threatening events, initial or prolonged hospitalisation, and adverse events requiring intervention to prevent permanent impairment
or damage.” The definition remains the same.
Secondary outcome 3
For’Quality of life measured by a specific scale’, we listed Dermatology Life Quality Index (DLQI), Skindex, Psoriasis Disability Index
(PDI), or Psoriasis Symptom Inventory (PSI). It is not an exhaustive list. Moreover, we had PSI as a validated scale because it was used
by some study authors.
496Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Timings
Wemodified the period of the induction therapy assessment to less than 24 weeks after randomisation instead of 12 to 24 weeks because
Nast et al defined the induction period as being with a duration less than 24 weeks (Nast 2015b).
To avoid duplicating text, we removed the text discussing timing for remission, as published in the protocol, and edited the timings for
induction and maintenance therapy to include the relevant short- or long-term remission classification. We also removed the timings
given in the protocol for the quality of life outcome for the same reason (we felt the text was duplicative).
We clarified that our inclusion criteria was to only include studies that reported our timings of interest by editing as follows: “We did
not include studies that had timings outside of these time ranges in our analyses” to “We did not include studies that had timings
outside of these time ranges in our review.”
4. Methods > Search methods for identification of studies
We removed the following two sentences from the review:
“We contacted key investigators and experts in the field to identify further published or unpublished data.”
“We contacted pharmaceuticals companies producing fumaric acid esters, and retinoids (fumaric acid esters, retinoids (acitretin), ci-
closporin, methotrexate, alefacept, infliximab, etanercept, adalimumab, certolizumab, ustekinumab, secukinumab, brodalumab, ixek-
izumab, tildrakizumab, guselkumab, Itolizumab, apremilast, tofacitinib, ponesimod.”
We replaced them with the following:
“We searched in the trial results databases of each company to identify ongoing and unpublished trials.”
5. Methods > Data extraction and management
We added some details regarding the data extraction (outcome data, other data) for greater clarity and added the sentence, “We extracted
the data from the reports of the U.S. Food and Drug Administration (FDA) when available, if not from the US National Institutes of
Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov), and finally from the published reports.”
6. Methods > Assessment of risk of bias in included studies
We added information regarding the network meta-analysis ’Risk of bias’ assessment (under “overall risk of bias”).
Network meta-analysis
“To summarise the quality of evidence and to interpret the network results, we used these six RoB criteria (random sequence generation,
allocation concealment, blinding of participants, blinding of outcome assessor, incomplete outcome data, and selective outcome
reporting) in order to classify each trial.
We would classify the trial as having low risk of bias if we rated none of the domains above as high risk of bias and two or less as unclear
risk.
We would classify the trial as having moderate risk of bias if we rated one domain as high risk of bias, one or less domains as unclear
risk, or no domains as high risk of bias but three or less were rated as unclear risk.
All other cases were assumed to pertain to high risk of bias.”
7. Methods > Measure of treatment effect
We added an explanation related to relative treatment ranking.
8. Methods > Dealing with missing data
We clarified who the authors or sponsors we contacted were: “We contacted trial authors or sponsors by email to request missing
outcome data (numbers of events and numbers of participants for important dichotomous clinical outcomes) when these were not
available in study reports that were less than 10 years old.”
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9. Methods > Assessment of reporting bias and Assessment of heterogeneity
We added an explanation regarding the network meta-analysis:
“We undertookmeta-analyses only if we judged participants, interventions, comparisons, and outcomes to be sufficiently similar (section
9.5.2 of the Cochrane Handbook for Systematic Reviews of Interventions) (Higgins 2011). Potential sources of heterogeneity included
participants’ baseline characteristics (weight, the duration of previous treatment, treatment doses, co-interventions, and duration of
treatment). When enough data were available, we investigated the distributions of these characteristics across studies and treatment
comparisons. The latter allows assessing transitivity, i.e. whether there were important differences between the trials evaluating different
comparisons other than the treatments being compared (Salanti 2014). To further reassure the plausibility of the transitivity assumption,
we only included in our analyses trials not involving co-interventions and with a timing of outcome assessment from 12 to 16 weeks.
In the classical meta-analyses, we assessed statistical heterogeneity by visual inspection of the forest plots and using the Q-test and the
I² statistic. We interpreted the I² statistic according to the following thresholds (section 9.5.2 of the Cochrane Handbook for Systematic
Reviews of Interventions; Higgins 2011): 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50%
to 90% may represent substantial heterogeneity; 75% to 100% represents considerable heterogeneity.
In the network meta-analysis, the assessment of statistical heterogeneity in the entire network was based on the estimated heterogeneity
standard deviation parameter (τ ) estimated from the network meta-analysis models (Jackson 2014). We inferred on the presence or
absence of important heterogeneity by comparing the magnitude of τ with the empirical distributions provided in Turner et al and
Rhodes et al (Rhodes 2015; Turner 2012). We also estimated the prediction intervals to assess how much the estimated heterogeneity
affects the relative effects with respect to the additional uncertainly anticipated in future studies (Riley 2011). Where feasible, we would
have investigated the possible sources of heterogeneity in subgroup analyses and meta-regression.
Although we restricted the risk of important heterogeneity in our data by considering eligible only studies with a follow-up period
between 12 and 16 weeks and without co-interventions, we investigated differences in heterogeneity across the different analyses.
Specifically, we observed whether splitting the nodes of the network and analysing each drug separately reduced the heterogeneity
estimate. We also ran a series of sensitivity analyses (see Sensitivity analysis), and we monitored whether heterogeneity became smaller
or larger compared to the primary analysis.”
Assessment of reporting biases
To assess reporting biases, we used an adaptation of the funnel plot by subtracting from each study-specific effect size the mean of
meta-analysis of the study-specific comparison, which we plotted against the study standard error (Chaimani 2013). We employed this
’comparison-adjusted funnel plot’ for all comparisons of an active treatment against placebo. When we detected funnel plot asymmetry
for the two primary outcomes, we investigated the presence of small-study effects in the network meta-regression (Chaimani 2012).
10. Methods > Data synthesis
We added the software used for the review: “We conducted pair-wise meta-analyses using Review Manager 5 (RevMan 5) (Revman
2014), and we performed all other analyses in Stata 14 using the ’network’ (www.stata-journal.com/article.html?article=st0410) and
’network graphs’ packages (www.stata-journal.com/article.html?article=st0411).”
11. Methods > Sensitivity analysis
We added “To assess the robustness of our results, we performed the following sensitivity analyses for the two primary outcomes:
(1) running the analysis at dose-level considering that each different drug dose is a different intervention; (2) excluding trials at high
risk of bias; (3) excluding trials with a total sample size smaller than 50 randomised participants; and (4) analysing only the observed
participants assuming that missing participants are missing at random.”
12. Methods > ’Summary of findings’ table
We added a section detailing the methods used to create the ’Summary of findings’ tables; we also explained how we used GRADE to
assess the certainty (quality/confidence) of the evidence.
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13. Contributions of authors
We changed or added authors’ contributions:
LLC, GD, IGD, and ES screened papers against eligibility criteria.
LLC, GD, IGD, CH, CM, CD, and ES appraised the quality of papers.
LLC, GD, IGD, CH, CM, CD, and ES extracted data for the review and sought additional information about papers.
AC responded to the methodological and statistical comments of the referees instead of LT (Ludovic Trinquard was no longer available
and was replaced by Anna Chaimani).
AC, LLC, and ES worked on the methods sections instead of LT, ES, and LLC (Ludovic Trinquard was no longer available and was
replaced by Anna Chaimani).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Network Meta-Analysis; Antibodies, Monoclonal [adverse effects; ∗therapeutic use]; Chronic Disease; Immunosuppressive Agents
[adverse effects; ∗therapeutic use]; Psoriasis [∗drug therapy; pathology]; Randomized Controlled Trials as Topic; Remission Induction;
Tumor Necrosis Factor-alpha [antagonists & inhibitors]
MeSH check words
Adult; Humans
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